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The inflammatory bowel diseases (IBD), encompassing Crohn’s disease (CD) and 
ulcerative colitis (UC), are chronic inflammatory disorders of the gastrointestinal 
tract.  Their aetiology is not fully understood but is thought to be a combination of 
the effect of environmental factors in a genetically susceptible person. The work 
presented is an examination of the phenotypic characteristics of CD in the Scottish 
population, and an investigation into genetic factors that may influence susceptibility 
and progression. 
An IBD cohort from Dundee was recruited (CD=367, UC=265), and extensive 
phenotypic information collected from these patients together with genomic DNA.  
Together with the Edinburgh CD cohort already established, the total CD population 
(n=1155) was examined for time to disease progression (stricturing and/or 
penetrating disease, according to the Montreal classification) and first resection; a 
multivariate analysis was performed for factors influencing these outcomes.  In this 
Scottish CD population, the median time to disease progression and first resection 
was 14.2 years and 8.9 years respectively.  The major factor influencing risk of 
resection and disease progression was disease location, with patients having pure 
ileal (L1) disease or ileocolonic (L3) disease being more susceptible than those with 
pure colonic (L2) disease.  Compared with L2 disease, the hazards ratios (HR) for 
disease progression were 4.7 and 2.8, and risk of resection 5.2 and 2.6 for L1 and L3 
disease respectively. 
Disease progression and risk of resection are surrogate markers of disease severity.  
To try to better understand the determinants of severe disease, a novel score for 
disease severity was developed and applied to the Dundee CD cohort.  This 
composite score encompassed the variables of medical and surgical management, 
disease behaviour and location, nutritional status as well as hospitalisations, with a 
total score that could range from 1 to 16.  A score of 7 or more was found to define 
the 50% of patients with the most severe disease.  This cut-off was used to divide 
patients into less severe and more severe categories; phenotypic and genetic factors 
were examined for correlation with more severe disease.  Genetic factors examined 
were the 32 most significant CD susceptibility single nucleotide polymorphisms 
 
 
(SNPs) uncovered by recent genome-wide association scans (GWAS).  Factors 
correlated with more severe disease included disease location (L1, odds ratio (OR) 
2.20, p=0.0025), age group at diagnosis (p=0.0004) and two CD susceptibility SNPs 
(rs9286879 and rs17582416; p=0.0085 and p=0.045 respectively).   
NOD2 was the first IBD susceptibility gene identified.  In order to further define 
pathways involving NOD2, a yeast two-hybrid screen in our laboratory using NOD2 
cDNA as the bait had already identified an interaction between NOD2 and UDP-N-
acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 
(GALNT2).  This enzyme is involved in O-glycosylation, important in the post 
translational modification of mucins.  A GALNT2 genotype/phenotype analysis on 
the Edinburgh IBD population was completed, with the Dundee IBD population used 
as a replication cohort.  In the Edinburgh IBD population, the GALNT2 tagging SNP 
rs7536663 was associated with CD susceptibility (OR 1.38, p=0.0008 vs controls), 
but replication was not achieved in the Dundee cohort (p=0.469).  There was no 
association of any of the GALNT2 SNPs with UC. 
The GALNT2/NOD2 interaction was further investigated by completing co-
immunoprecipitation between the two genes to characterise the level and type of 
interaction.  An interaction between GALNT2 and NOD2 was confirmed in 
mammalian cells, with the interaction being at the N-terminal end of the NOD2 
protein.  GALNT2 expression in a cell line and biopsies was investigated by 
quantitative polymerase chain reaction and immunohistochemistry respectively.  
There were no statistically significant changes in GALNT2 or NOD2 mRNA 
expression in the LS174T cell line after stimulation with specific ligands for NOD2 
and GALNT2.  GALNT2 protein expression was characterised in intestinal biopsy 
samples to be predominantly in the lamina propria, with some expression in the 
enterocytes.   
To further define the contribution of mucin genes to IBD susceptibility, tagging 
SNPs across the MUC2, MUC3A and MUC19 genes were genotyped in the 
Edinburgh IBD cohort and examined for a link with IBD, CD and UC susceptibility, 
but associations were not found.  In view of the strong association with CD 
susceptibility of a SNP near the MUC19 locus in a recent GWAS, tagging SNPs 
 
 
across the leucine rich repeat kinase-2 (LRRK2) gene, near the MUC19 gene, were 
also genotyped and examined in the Dundee cohort for an association with IBD, CD 
and UC susceptibility, but was also negative when corrected for multiple testing. 
The studies presented allow an improved understanding of the influence of 
phenotypic characteristics on disease progression, need for surgery and severity in 
CD.  The role of disease location has been determined to be particularly critical, in 
keeping with other published studies.  A detailed examination of the influence of 
specific genes on disease susceptibility has failed to definitely demonstrate an 
association between germline variation in GALNT2, MUC2, MUC3A, MUC19 or 
LRRK2 and IBD, CD or UC susceptibility.  An interaction in mammalian cells 
between NOD2 and GALNT2 has been shown, but further work is required to 
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1.1 The inflammatory bowel diseases 
Crohn’s disease (CD; MIM 266600) and ulcerative colitis (UC; MIM 191390) are 
chronic inflammatory disorders of the gastrointestinal tract of incompletely 
understood aetiology and for which there are no known cures.  
1.1.1 Pathology and presentation 
CD is characterised by patchy transmural inflammation that can affect any part of the 
gastrointestinal tract from the mouth to the anus, but most commonly affects the 
ileocaecal region.   There is a tendency to develop inflammatory or fibrotic strictures 
as well as fistulae, both internal and perianal.  The presentation of the disease can be 
rather heterogeneous due to the variety of locations that can be affected.  Typically, 
symptoms can include weight loss, abdominal pain, diarrhoea, vomiting and systemic 
upset. 
UC is characterised by a transmucosal inflammation that is continuous from the 
rectum to the extent of the disease, but classically only affects the colon, although the 
terminal ileum can be affected by a backwash ileitis, and in very rare cases a more 
diffuse small bowel inflammation can result.  The predominant symptom tends to be 
bloody diarrhoea.   
There is a multitude of extraintestinal manifestations affecting both CD and UC 
patients, including uveitis, erythema nodosum, primary sclerosing cholangitis, and in 
patients with colonic disease, a long-term increased risk of colon cancers.1  
1.1.2 Diagnosis 
The diagnosis of inflammatory bowel disease (IBD) is by the Lennard-Jones 
criteria2, which states exclusion and inclusion criteria for both CD and UC.  UC 
inclusion is continuous mucosal inflammation without granulomata affecting the 
rectum and some or the entire colon in continuity with the rectum, with specific 
exclusion criteria including infective colitis, ischaemic colitis and abnormalities 
suggesting CD (e.g. small bowel disease).  CD inclusion is discontinuous 
inflammation in areas from the mouth to the anus, with transmural inflammation with 
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granulomata, having the potential for fibrosis, abscesses, fistulae and fissuring ulcers.  
Exclusion criteria for CD include infection and ischaemia.  
1.1.3 Incidence and Prevalence 
The incidence of IBD has been widely studied, with age-adjusted incidence rates 
varying from 5-20 people/100,000/year for CD, and 3-20 people/100,000/year for 
UC, as shown in Table 1-1.  Point prevalence of CD is around 150/100,000 and UC 
200/100,000, as shown in Table 1-1.  There has been debate as to whether the 
incidence and prevalence is rising, and whether these rates are higher in countries 
with more northerly latitude.  A study in Europe3 looking at new diagnoses with IBD 
between 1991 and 1993 at 20 European centres found that there was a higher 
incidence in northern compared with southern centres.  Through the middle of the 
20th century the incidence of IBD was rising, but it is now thought to have 
plateaued.4;5  Whether the rise was due to better diagnosis of the diseases or a rise in 
incidence is not clear.   
 













Canada  Bernstein6 1998-2000 8.8-20.2 9.9-19.5 161-319 162-249 
USA 
Olmsted, 
Minnesota Loftus5 1990-2000 7.9 8.8 174 214 
UK Derby Fellows4 1976-1985 6.67 NS 85 NS 
Sweden Örebro Lindberg7 1963-1987 6.1 NS 146 NS 






Rousseau9 1988-1990 4.9 3.2 NS NS 
Table 1-1 IBD incidence and prevalence, NS= not studied 
1.1.3.1 Age at incidence 
The peak age of incidence of IBD is universally recognised to be between 20 and 30 
years, when the age-specific incidence of the disease is 10-40/100,0006;9-12, with a 
possible second peak between 60-70 years.5;13  Thus IBD is predominantly a disease 
that begins in early adulthood. 
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1.1.4 Classification 
1.1.4.1 Crohn’s disease 
Due to its heterogeneous nature, it is important to subclassify CD into disease types 
for research and clinical purposes.  Initial attempts to classify CD were on the basis 
of location of disease14, but it was later recognised that disease behaviour was also an 
important variable, as patients with penetrating disease appeared to have a different 
disease course to those who did not.15  The resulting ‘Rome classification’ had 
disease location variables (stomach/duodenum, jejunum, ileum, colon, rectum, 
anal/perianal) along with behaviour variables (primarily inflammatory, fistulating or 
fibrostenotic), disease extent (localised or diffuse) and operative history (primary or 
recurrent)16, but was not widely adopted because of its complexity.  The Vienna 
classification17 simplified this classification, using 3 variables: age at diagnosis 
(below 40 years old: A1, or 40 and above: A2), location (terminal ileum: L1, colon: 
L2, ileocolon: L3 and upper GI: L4) and behaviour (non stricturing non penetrating: 
B1, stricturing: B2, penetrating: B3).  The location variable was the maximum extent 
before the first resection, and the 4 locations were mutually exclusive; thus patients 
with upper GI disease and disease elsewhere were classified as being in the L4 
category.  As only a small proportion of L4 patients have disease localised only to 
the upper GI tract, valuable phenotypic information was lost.  In addition, the age 
classification cut-off of 40 years old at diagnosis did not take full account of the peak 
age of onset of disease, meaning that the majority of patients were in the A1 age 
category.  In the behaviour category, no time limit was put on the behaviour variable.  
In addition, perianal disease was counted as penetrating disease; evidence 
subsequently emerged that perianal disease was phenotypically quite different from 
internally penetrating disease.18;19 
These shortcomings were addressed in the Montreal classification20, which 
reclassified B3 disease as referring only to internally penetrating disease, but allowed 
any of the B1-B3 disease behaviour variables to be suffixed by ‘p’ to indicate that 
perianal disease was present.  It suggested that the behaviour variable should be 
assessed at the 5 year time point.  The classification also allowed L4 to be classified 
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along with other locations, and replaced the two age categories with three: less than 
17 years old at diagnosis, 17-40 at diagnosis and more than 40 at diagnosis. 
Recently, a modification of the Montreal classification (‘Paris classification’) has 
been agreed for paediatric patients.21  The A1 age group for paediatric onset patients 
has been further subdivided into A1a (age of onset less than 10 years old) and A1b 
(age of onset between 10 and 17 years old).  In addition, the L4 location has been 
subdivided into proximal upper GI, L4a (oesophageal, gastric or duodenal disease) 
and distal upper GI, L4b (jejunal, proximal and mid ileal disease).  Finally, the Paris 
classification has also added a B2B3 category to note when stricturing and 
penetrating disease co-exist.  At present these modifications apply to paediatric-onset 
disease only. 
1.1.4.2 Ulcerative colitis 
UC was first formally classified in the Montreal classification20 by extent (proctitis 
E1; left sided disease E2; and disease proximal to the splenic flexure E3)  and current 
severity (S0 asymptomatic; S1 mild; S2 moderate and S3 severe ulcerative colitis).  
The recent Paris classification of paediatric inflammatory bowel disease21 has 
modified the E3 category to disease extending past the splenic flexure but no further 
than the hepatic flexure, with a new E4 category denoting disease proximal to the 
hepatic flexure.  At present this modification applies to paediatric-onset disease only. 
1.2 Management of IBD 
The general aims of treatment for IBD are to alleviate symptoms and to improve or 
remove inflammation, strictures and fistulae.  Whether early medical therapy in the 
form of thiopurines or biological therapy can prevent or delay long term disease 
progression, rather than just prevent relapse, is a subject of ongoing debate. 
1.2.1 Medical management 
1.2.1.1 Corticosteroids 
One of the first ever double-blind placebo controlled trials in medicine proved the 
benefit of steroids in UC in the acute setting.22;23  Since then, steroids, both systemic 
 
Introduction    41   
(oral and intravenous) and topical, have been the mainstay of treatment in IBD, and 
in the past they have been used as maintenance therapy.  In more recent years there 
has been recognition of their long term risks and the need to use other ‘steroid-
sparing’ therapies in the medium to long term.  However, they still have a place in 
IBD management on a short term basis in order to induce remission in patients with 
active disease. 
1.2.1.2 5-Aminosalicylates 
The mechanism of action of 5-aminosalicylates (5-ASA) in IBD is thought to be 
through activation of the γ-form of the peroxisome proliferator-activated receptors 
(PPAR-γ) which are highly expressed in the colon and cause modulation of cytokine 
production.24 
The 5ASA compounds have a well-established role in the maintenance of remission 
in UC25, and may help to prevent development of colorectal cancers in this 
population.26  5ASA compounds are also important in the induction of remission in 
UC, both systemically27 and topically.28  A recent Cochrane meta-analysis found that 
there was no benefit of 5ASA compounds over placebo in the maintenance of 
remission of CD29, although they are still frequently prescribed to patients with 
colonic disease. 
1.2.1.3 Thiopurines 
The prodrug azathioprine and its active metabolite 6-mercaptopurine are purine 
antagonists that compete in biochemical processes requiring purines (e.g. DNA and 
RNA synthesis).  The exact mechanisms whereby thiopurines exert their 
immunosuppressive effect in IBD are poorly understood, but include promotion of 
the apoptosis of activated T lymphocytes.30  Thiopurines have a well established role 
in the induction of remission of CD, with an odds ratio (OR) of 2.43 compared with 
placebo for induction of remission.31   They are also known to be beneficial in the 
maintenance of remission, with an OR of 2.32 compared with placebo.  Their role in 
UC is less clear.  Although they are of benefit in the maintenance of remission, with 
an OR of 0.41 vs. placebo for failure to maintain remission32, there are conflicting 
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data as to the benefit of thiopurines in the induction of remission, with a meta-
analysis not conclusively proving their benefit.33 
1.2.1.4 Anti-TNFα therapies 
Tumour necrosis factor alpha (TNFα) is a key cytokine involved in stimulating the 
acute phase reaction, and is involved in the pathogenesis of many inflammatory 
diseases.  Serum TNFα levels have been shown to be elevated in IBD patients.34  
Infliximab is a chimeric human-murine monoclonal antibody which inhibits TNFα 
activity.  Initial studies focused on its use in CD patients.  Following a series of small 
studies showing benefit35-37, a larger trial involving over 500 patients (ACCENT–I) 
demonstrated that patients with poorly controlled CD were more likely to achieve 
clinical remission than patients who had placebo, and that it was effective at 
maintaining remission.38  More recently, studies in patients with acute severe UC 
have also shown benefit.39  However, up to a third of patients fail to respond and in 
many of those who do, the effect can be short-lived.  There is evidence to suggest 
that the formation of antibodies against infliximab is correlated with an increased 
risk of infusion reactions and reduced duration of response to treatment.40  
Theoretically adalimumab, as a fully humanized anti-TNFα antibody, should offer a 
reduced risk of infusion reactions and delayed hypersensitivity reactions.  Compared 
to infliximab, very similar remission rates were seen with adalimumab in the 
CLASSIC-I trial in patients naïve to anti TNF therapy.41  The rate of antibody 
formation was low (0.04%) but as the study was only 4 weeks long this figure is 
likely to be an underestimate.  A follow-on study, CLASSIC-II, compared 
adalimumab and placebo in the maintenance of remission42 and again produced 
comparable results to infliximab, with an antibody rate of 2.6%, compared to 14% 
with infliximab in ACCENT-I.  A larger study, CHARM, supported these remission 
rates but did not look at immunogenicity.43  Only one study so far has looked 
specifically at the use of adalimumab in patients who have had infusion reactions 
with infliximab, or have lost response to it.44  Adalimumab has the added benefit 
over infliximab of being given subcutaneously rather than intravenously, allowing 
home self-administration. 
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Apart from the short term problems of infusion reactions and hypersensitivity 
reactions with biologicals, other side effects can be more serious.  The risk of 
infection may be increased with patients who receive anti-TNFα therapies45 and 
previous tuberculosis is a relative contraindication due to risk of reactivation of the 
disease.  Case reports of patients developing haemopoetic cancers46 and solid 
tumours47-49 following anti TNFα therapies have rightly raised concerns about the 
long term risks of anti TNF agents, especially when used in combination with 
immunosuppressants including azathioprine.  However, more recent evidence from 
the SONIC trial has indicated that in moderate-to-severe CD, combination therapy 
with thiopurines and infliximab is more likely to bring patients into, and maintain 
them in, steroid-free remission.50  The long term safety of this strategy is unclear. 
1.2.1.5 Novel therapies 
There is a clinical need to develop novel therapies to complement the existing 
repertoire.  However, such advances have been slow.  A clinical trial of intravenous 
alicaforsen, an antisense inhibitor of intercellular adhesion molecule 1 (ICAM-1), 
failed to demonstrate any clinical benefit in patients with CD.51  An anti-p40 
antibody (ABT-894) against the common p40 subunit of IL12 and IL23 has shown 
promise in a small clinical trial in 79 patients with active CD.52  Another anti-p40 
monoclonal antibody, ustekinumab, was used in 104 CD patients and showed an 
early benefit from the treatment53; a larger trial is underway. 
Autologous stem cell transplantation, which in theory could ‘reset’ the immune 
system has shown promise in a non-randomised study in 12 patients with refractory 
CD54; further randomised trials are ongoing. 
1.2.2 Surgical management 
1.2.2.1 Ulcerative colitis 
Colectomy can be indicated for acute severe disease, low grade continuous 
inflammation refractory to medical therapy, or development of colorectal cancer or 
colonic high grade dysplasia.  In one study the proportion of patients who had 
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required colectomy was 20% at 5 years after diagnosis and 45% by 25 years; the 
main factor affecting need for colectomy was disease extent.55 
In patients admitted with acute severe disease (as defined by the Truelove-Witts 
criteria23), 30-40% will require colectomy on that admission56;57, with, on day 3, a 
stool frequency of >8/day, or CRP>45mg/l and stool frequency of 3-8, having a 85% 
risk of colectomy on that admission.57  An alternative risk score56 cites colonic 
dilatation and/or a mean stool frequency >9 within the first 3 days of hospital 
admission for acute severe UC as conferring a 85% risk of colectomy on that 
admission. 
1.2.2.2 Crohn’s disease 
Depending on the disease phenotype displayed, different forms of surgical options 
are available.  Patients with perianal disease often need multiple operations to 
promote abscess drainage and help fistula tract healing.  In other cases defunctioning 
procedures, by diverting faecal flow, can improve inflammation and give extra time 
for medical therapies to reach therapeutic levels.  Finally, many patients, especially 
those with ileal disease, will require an intestinal resection at some point in their 
disease course.  This is discussed in more detail in Chapter 3.   
1.3 Genetics of IBD  
The biological pathways underpinning the development of CD and UC are complex 
and poorly understood.  Increasing our understanding of the genetic architecture of 
IBD will assist scientists in delineating IBD pathways. This will advance our 
understanding of IBD aetiology and also focus attempts on developing new 
therapies. 
1.3.1 History of the genetics of IBD 
1.3.1.1 Twin studies 
Although the increased risk of disease development for relatives of IBD patients had 
already been noted58, the first definitive evidence of a genetic contribution to the 
development of IBD was from studies demonstrating a discordance in the incidence 
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of IBD between monozygotic (MZ) and same-sex dizygotic (DZ) twins.59-61  In these 
studies, the risk of development of CD in both MZ twins where one had already 
developed CD was 33-50% whereas in DZ twins it was less than 10%.  The genetic 
contribution to UC development was less as MZ twins showed a concordance of 15-
20% compared with about 5% in DZ twins.  However, unlike a Mendelian inherited 
disorder, the concordance was much less than 100% for both diseases in MZ twins, 
indicating that other determinants (most likely environmental factors) must also have 
an important role in disease susceptibility.  
1.3.1.2 The Early Years 
Studies to elucidate genetic susceptibility loci have evolved rapidly in the last 10-20 
years with improving technology and knowledge of the human genome.  The 
evolution of technology for genotyping from restriction fragment length 
polymorphisms (RFLP) to microsatellites to SNPs has catalysed gene discovery.  
Studies have used either a candidate gene approach, looking at potential genes that 
have a plausible link with disease pathogenesis and the segregation of markers in 
genes between patients and their unaffected family members, or a genome-wide 
approach.  Before high resolution sequencing of the human genome had been 
completed, the genome-wide approach could only identify large segments of the 
human genome associated with disease in patients compared with their unaffected 
family members, without being able to identify the actual susceptibility gene(s) 
within the area.  In the 1990s and early 21st century, family linkage studies 
demonstrated linkage in IBD at various loci in the human genome.  They included 
the IBD362;63 around the Human Leukocyte Antigen (HLA) Complex on 
chromosome 6, and IBD5 containing the OCTN gene on chromosome 5.64  However, 
narrowing down the signal to a single gene was extremely difficult with the 
technology available at the time.  The only success story was the positional cloning 
of NOD2, which was confirmed independently by two groups to be the CD 
susceptibility gene at the IBD1 locus on chromosome 16.65;66   
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1.3.1.3 Genome-wide association studies 
Even with improved technology, the ability of family linkage studies to find the 
common but small-effect polymorphisms that are important in complex diseases like 
IBD was limited.  This was due to the fact that when the effect size is small, some 
relatives in family studies will be affected because of other causes, and also because 
of the limited ability to recruit enough families for adequately powered 
experiments.67 
With improved resolution of the human genome, genome-wide association studies 
(GWAS) was the next step, using cases and unrelated controls from the same 
population and genotyping known SNPs across the genome.  Because of linkage 
disequilibrium (LD) - the tendency of certain areas of the gene to be inherited 
together - not every variation in the human genome needs to be genotyped.  This has 
heralded a revolution in the genetics of complex diseases.  A candidate gene 
approach requires a hypothesis–driven basis for the selection of genes to be 
genotyped, whereas GWAS is genome-wide and therefore can be without bias.   
These studies have significantly progressed the understanding of the biology 
underlying complex diseases.  The first published GWAS in IBD in 2006 genotyped 
over 300,000 SNPs in 567 patients with ileal CD and a similar number of controls68; 
since then a large number of Caucasian CD susceptibility loci have been uncovered.  
The most recent international meta-analysis analysed 5 separate GWAS in CD69-73, 
and highlighted 71 susceptibility loci.74  This paper utilised 6333 CD cases and 
15056 controls, with a replication cohort of 15694 cases and 14026 controls, and thus 
had the power to detect susceptibility loci with low odds ratios (OR); the lowest OR 
detected was 1.04.   
Reflecting the lower heritability of UC compared with CD, GWAS in UC did not 
start for several years after CD GWAS began.  McGovern et al75 did a meta-analysis 
with two datasets from Los Angeles (USA) and Sweden, and combined them with an 
existing published study using US-wide cases76.  A German GWAS77 and a British 
GWAS78 and copy number variation study79 have been performed.  A study in 
paediatric UC has also been completed.69  An international UC meta-analysis has 
recently been completed80 utilising 6687 cases and 19718 controls, with a replication 
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cohort of 9628 cases and 12917 controls.  Overall, 47 loci have a confirmed 
association with UC susceptibility, conferring OR 1.05-1.74. 
Although a lot of work has been done to reveal susceptibility loci, more effort is 
required: many of the significant tagging SNPs are in intergenic areas, with several 
plausible genes in the vicinity.  Fine mapping is required to identify the candidate 
gene, and to find the disease susceptibility mutations within the gene.  Functional 
work is then required to identify how changes in the identified gene affect the 
biological pathways underlying disease. 
1.3.2 NOD2 
Following the initial genome-wide study in CD in 1996, the first IBD susceptibility 
locus was identified on chromosome 16, around loci D16S409 and D16S419.81  
Positional cloning identified an association between the candidate gene NOD2 
(nucleotide-binding oligomerization domain containing 2) and CD, the variants being 
a frameshift mutation (1007fs) and two missense mutations (R702W, G908R) in the 
leucine rich repeat domain82 which is thought to be involved in the intracellular 
sensing of bacterial components.65;66  Further mutational analyses in 612 patients 
with IBD confirmed that these three mutations were independently associated with 
susceptibility to CD83 and accounted for about 80% of the CD-associated mutations 
in this gene.   
Amongst CD patients the overall prevalence of NOD2 mutations is around 30-45%84-
86, but there is both ethnic and geographical variation in this prevalence, with an 
absence of the mutations in Asian populations87 and a lower contribution to the 
genetic susceptibility in northern Europe compared with southern European 
countries.88  NOD2 mutations are correlated with susceptibility to ileal disease84 and 
stenosing disease.85 
The ligand of the NOD2 protein is muramyl dipeptide (MDP),89 which is a 
component of peptidoglycan present in Gram-positive and Gram-negative bacterial 
cell walls.  The NOD2 protein is located in the cytoplasm and plasma membrane of 
mammalian cells90 and appears to act as an intracellular sensor of MDP and therefore 
of bacteria.82  NOD2 consists of the LRR domain, involved in bacterial sensing, an 
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NBD domain and two CARD domains.  In the inactive state the LRR domain is 
folded back on the NBD domain.  When a ligand (e.g. MDP) binds to the LRR 
domain, it induces a conformational change in the NOD2 protein.  This allows self-
oligomerization between the NBD domains which thereafter causes signal 
transduction through interaction with RIP2, a CARD containing protein kinase via a 
CARD-CARD interaction.  This complex interacts with NF-κB and causes its 
activation and relocation to the nucleus to initiate the transcription of inflammatory 
cytokines (Figure 1-1). 
NOD2 is predominantly expressed in Paneth cells in the small bowel91 as well as 
monocytes.92  Paneth cells constitutively produce the antimicrobial peptides α-
defensins HD5 and HD6, and reduced defensin production has been shown to occur 
in ileal CD.93 
 




The membrane targeting of NOD2 appears to be mediated by 2 leucine residues and 
a tryptophan-containing motif in the COOH-terminal domain of the protein.90  Of the 
three common CD NOD2 mutations, the 1007fs NOD2 variant is the only one that is 
not expressed on the plasma membrane90 and is unresponsive to MDP.82  The 
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R702W and G908R mutations show membrane association, but have reduced levels 
of NF-κB activation after MDP stimulation compared with the NOD2 wildtype.90  
Even with targeting of the 1007fs to the cell membrane, responsiveness of MDP is 
not restored.95  The importance of the membrane localization of NOD2 may be in the 
recruitment of RICK (RIP2) through a CARD-CARD interaction with subsequent 
NF-κB activation.95  
Thus the common NOD2 mutations fit the concept of a defect in innate immunity, 
which is counter-intuitive in an inflammatory disease.  This paradox was addressed 
in a study96 which appeared to confirm that there is a weaker immune response to 
acute insults in patients with CD (though it was not correlated with the NOD2 
genotype), with a secondary exaggerated immune response causing the 
inflammation.  This ‘three-stage model’ of the imunopathogenesis of CD (initial 
penetration of foreign material, impaired clearance of this material due to reduced 
response and then a compensatory adaptive response)97 has not yet been conclusively 
proven, but remains an attractive hypothesis.  
1.3.3 Autophagy 
ATG16L1 is encoded by a gene on chromosome 2q37.1.  A non synonymous SNP 
GWAS98 first demonstrated an association with the ATG16L1 SNP rs2241880 and 
CD susceptibility.  The association of ATG16L1 with CD has been confirmed by 
several GWAS as well as other genotyping studies, culminating in the international 
CD GWAS meta-analysis74 which demonstrated an OR of 1.34 (95% CI 1.29-1.40, 
p=6.79 x 10-41) for the ATG16L1 SNP rs3792109, which is in LD with rs2241880.  
There may also be a weaker association with UC as a recent meta-analysis of all 
studies published on ATG16L1 (GWAS as well as individual genotyping studies) 
suggested an OR of 1.06 (95% CI 1.01-1.1, p=0.02)99 for UC, although the recent 
UC GWAS meta-analysis80 has not shown ATG16L1 to be associated with UC 
susceptibility.  The functional implications of the threonine to alanine substitution of 
the rs2241880 (T300A) mutation are not fully understood, although in human 
epithelial cell lines the alanine substitution impairs capture of internalised 
Salmonella within autophagosomes.100 
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IRGM (immunity-related p47 guanosine triphosphatase family, M) appears to be 
important in the regulation of autophagy and the elimination of intracellular 
bacteria.101  Following the association of SNPs in IRGM and CD susceptibility, the 
recent CD meta-analysis74 confirmed that the IRGM SNP rs7714584 confers an OR 
of 1.37 (95% CI 1.28-1.47, p-value 7.76 x 10-19) for disease susceptibility.  Exonic 
sequencing of the gene in 248 individuals failed to demonstrate any protein altering 
mutations.102  However, the non-functional mutations associated with CD are in LD 
with a 20kb deletion polymorphism immediately upstream of the gene.103  This 
deletion polymorphism is associated with reduced IRGM expression, which in turn 
significantly impairs autophagy in Salmonella infected epithelial cell lines.103  
Autophagy is a well conserved cytoplasmic mechanism which serves both as the way 
that damaged intracellular organelles are eliminated or recycled and also as a key 
mechanism for the removal of intracellular bacteria and viruses.104;105  It is a 
catabolic process which degrades these items through the lysosomal machinery.  
There are a number of autophagic processes but the most important one involves the 
formation of a membrane (the autophagosome) around the targeted area which then 
fuses with the lysosome.  
As shown in Figure 1-2, manufacture of the autophagosome is initiated by starvation 
or various growth factors.  ATG16L1 forms a complex with an ATG5-12 conjugate 
which drives the autophagocytic process.  An LC3 protein complex also promotes 
the process.  The final stages of autophagy, culminating with fusion with the 
lysosome, are less well characterised but appear to involve LC3. 
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Figure 1-2 The autophagocytic pathway, from Heath and Xavier
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Defective removal of intracellular bacteria in the autophagy process provides a 
plausible link with the pathogenesis of CD, as well as future therapeutic possibilities 
if autophagy can be upregulated pharmacologically. 
Several recent studies have highlighted a functional link between NOD2 and 
autophagy.  Signalling through toll-like receptors (TLRs) has been shown to lead to 
autophagosome formation.107;108  NOD1 and NOD2 interact with and recruit 
ATG16L1 to the plasma membrane to initiate autophagy, with the 1007fs NOD2 
mutation impairing this recruitment.109 
1.3.4 Th17 pathway 
Conventional wisdom of CD being predominantly a Th1 mediated disease and UC 
being predominantly a Th2 mediated disease has been re-evaluated in the light of the 
recent discovery of the Th17 pathway.110  The Th17 pathway is the production of 
IL17 from CD4+ T lymphocytes, and is antagonised by key cytokines from the Th1 
and Th2 pathways (IFNγ and IL4).110  IL23 is an important cytokine in the induction 
of the Th17 pathway.  The IL23 cytokine is made up of p19 and p40 subunits, with 
the p40 subunit being identical to the p40 subunit of IL12.  Transgenic mice with 
ubiquitous expression of IL23 show severe systemic inflammation111, and IL23 p19 
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knockout mice show impaired humoral and delayed type hypersensitivity 
reactions.112   
Engagement of IL23 in the IL23 receptor complex causes activation of the JAK-
STAT signalling pathway, as shown in Figure 1-3.  Tyrosine phosphorylation 
activates STAT which translocates to the nucleus to trigger the expression of 
cytokines, including IL17A, IL22 and IL21113.  IL17F and IL22 mRNA expression, 
induced via IL23 signalling, are increased in inflamed intestinal tissue compared to 
uninflamed tissue and increased IL22 serum levels have been reported in CD 
patients114, suggesting increased activity of this pathway in IBD.    
 
Figure 1-3 Proteins involved in IL23R signalling and Th17 cell development, from Brand
115
 
The recent advances in IBD genetics have provided further corroborative evidence of 
the importance of the Th17 pathway in disease pathogenesis.  Multiple genes within 
the pathway, including IL23R, TNFSF15, STAT3, IL12B, CCR6 and JAK2 
(demonstrated in Figure 1-3) show evidence of a link with IBD susceptibility, as 
shown in Table 1-2.  
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Gene/ 
locus SNP Disease Study  Paper P-value OR 95% CI 
IL23R rs11465804 IBD Paediatric 
Imielinski 
et al.
69 1.03 x 10-15 0.39 0.29–0.52 





74 1.00 × 10−64 2.66 2.36-3.00 




et al.80  5.12 × 10-28 1.74 1.57-1.92 





116 2.2 x 10-4 1.24 1.10-1.39 
TNFSF15 rs6478108 IBD Paediatric 
Imielinski 
et al.
69  5.06 x 10-10 0.74 0.67–0.83 





74 1.00 × 10−15 1.21 1.15-1.27 




et al.80  6.5 x 10-13 1.13 1.07-1.18 





117 6.82 x 10-12 1.18   





74 4.37 × 10−8 1.18 1.13-1.24 





116 6.8 x 10-4 0.84 0.73-0.97 





80  4.5 x 10-20 1.18 1.13-1.24 





74 2.51 × 10−12 1.17 1.12-1.22 
JAK2 rs10758669 IBD Paediatric 
Imielinski 
et al.
69  5.11 x 10-7     





74 1.00 × 10−13 1.18 1.13-1.23 





78 1.5 × 10−5     
Table 1-2 Synopsis of Th17 genes associated with IBD susceptibility 
The best elucidated of these genes and most strongly associated with CD is IL23R.  It 
was first associated with CD susceptibility in the first published GWAS in IBD68, 
and has since been replicated in other populations.  IL23R is expressed most highly 
on activated T cells, especially Th17 cells as well as natural killer cells.118  The only 
functional variant identified by GWAS, rs11209026, confers an OR of 0.45 for CD 
(minor allele frequency (MAF) 1.9% in CD, 7% in controls) and an OR of 0.55 for 
UC development (MAF 3.7% in UC, 7% in controls), implying a protective effect in 
both CD and UC.  More functional work is required, but preliminary data suggests 
that the rs11209026 ‘protective’ mutation reduces STAT phosphorylation in cell 
lines which are responsive to IL23 (Dr Pidasheva, personal communication), thus 
preventing normal signalling of the IL23 pathway. 
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1.3.5 Major histocompatibility complex 
In humans the major histocompatibility complex (MHC) is known as the human 
leukocyte antigen (HLA) complex.  The HLA region (Figure 1-4) encodes a number 
of proteins that are displayed on the outer surface of cells and are important in the 
differentiation between self and non-self.  The region (6p21.1-23) is the most gene-






Figure 1-4 Genetic map of the human leukocyte antigen region from Mehra and Kaur
119
 
IBD3 was one of the first areas linked with IBD susceptibility and includes the area 
encoding the major histocompatibility complex.  Early studies prior to the days of 
GWAS linked IBD3 to both CD and UC62;63, though more so with UC.120  Most work 
has concentrated on the Class II MHC, with different alleles providing either risk or 
protection.  A meta-analysis of the relationship between HLA class II phenotypes 
and IBD in 1999 confirmed this link.121  Identifying the relevant gene in the area has 
proved problematic due to the large number of genes and strong LD across the area, 
and GWAS has not been able to find the causative gene.  Multiple alleles within the 
region have been associated with IBD in recent GWAS, as shown in Table 1-3.   
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SNP Postiton Disease Study   P-value OR 95% CI 





74 3.98 x 10-11 1.19 1.13-1.25 





74 1.4 x 10-8 1.17 1.11-1.23 





80  1.4 x 10-9 1.15 1.07 - 1.24 





80  1.35 x 10-55 1.4 1.34 - 1.47 
rs9268480 6p21.32 UC 
Non-syn 
SNP UC  
Fisher et 
al.
116 7.2 x10-6   
rs660895 6p21.32 UC 
Non-syn 
SNP UC  
Fisher et 
al.
116 2.8 x 10-8   





122 1.02 x 10–8 0.724 0.65–0.81 





122 2.95 x 10–8 0.724 0.65–0.81 
Table 1-3 IBD3 alleles associated with IBD in recent GWAS 
1.3.6 Barrier function susceptibility genes 
1.3.6.1 MDR1 
The multidrug resistance gene 1(ABCB1/MDR1) on chromosome 7q, has been of 
interest since the first suggestions of association with IBD.123  A mouse knock-out 
model (mdr1a-/-) develops spontaneous colitis when kept in a pathogen free 
environment and shows dysregulated epithelial growth.124  The gene encodes for a 
transmembrane protein (P-glycoprotein 170) that functions as chloride channel pump 
across epithelial cells, and belongs to the ATP binding cassette superfamily.  P-
glycoprotein 170 is highly expressed in the human gastrointestinal tract125 and on the 
surface of peripheral blood lymphocytes.126  Two SNPs correlate with P-glycoprotein 
170 expression and activity: C3435T and G2677T/A.127  Conflicting data surround 
these two SNPs in CD and UC.  An association of the C3435T allele with was shown 
IBD, particularly UC128;128-130, but was not found in other studies.131-133  The 
G2677T/A allele has been shown to be associated with refractory CD.129  Given that 
the 2 alleles are in tight LD, 2-locus haplotype association tests have shown 
increased susceptibility to UC with the 3435T/G2677 haplotype.130  A more recent 
meta-analysis134 showed a significant association of the 3435T allele with UC but not 
with CD.  However, this allele could lie in LD with the causal variant.  This 
hypothesis is supported by a gene wide haplotype tagging approach that has provided 
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robust evidence for the involvement of the MDR1 gene in susceptibility to UC.135  
However, a later functional study suggested an alternative explanation, as the 
C3435T polymorphism, despite being ‘silent’, seems to affect P-glycoprotein 
function and substrate specificity.136   
1.3.6.2 DLG5 
DLG5 is on chromosome 10q23.  The DLG5 protein is a member of the membrane 
associated guanylate kinase family that appears to be involved in protein-protein 
interactions and is likely to be a scaffold protein involved in the maintenance of 
epithelial integrity.137 
Positional cloning identified genetic variants in the gene associated with IBD in 
German and British populations.138  The DLG5 gene is in an area of strong LD, and 
the extended DLG5 haplotype has 4 common haplotypes with haplotype A being 
under-transmitted and haplotype D being over-transmitted in IBD.  One of the main 
SNPs in haplotype D is the SNP 113G→A, causing an amino acid substitution 
R30Q, which may disrupt binding to a Rab GTPase and therefore is likely to have 
functional implications.  Though this finding has been replicated in Canadian and 
British populations139, and in a Scottish early-onset population140, it has not been 
replicated in other cohorts: Scottish adults141, German 142 and English patients.143;144  
In addition, a meta-analysis of published studies failed to demonstrate an 
association.145  This variability in association may be due to population 
heterogeneity, gender or gene-gene interactions. 
1.3.7 Other genes 
Recent GWAS have implicated multiple other SNPs in IBD susceptibility.  However, 
as most of these SNPs are in intergenic areas, defining the exact gene responsible for 
the association is not straightforward. 
1.3.7.1 IBD5 
It was a genome wide scan that suggested linkage in the 5q31-33 region, with higher 
density mapping further pinpointing a locus contributing to CD susceptibility in 
patients with early onset disease.63  This association has been confirmed in multiple 
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independent panels of patients.146-149  Within this area a 250Kbp haplotype has been 
shown to be associated with CD.150  However, localising the causal variant has 
proved problematic, due to tight LD and the large number of candidate genes in the 
area.  One of the candidate genes is OCTN1/2.  This was first reported in a study 
where two variants (a missense substitution in SLC22A4 and a G to C transversion in 
the SLC22A5 promoter) in the OCTN cluster (now known as OCTN1 and OCTN2 
respectively) formed a haplotype associated with susceptibility to CD in Canadian 
patients of European origin, independently of the full IBD5 haplotype.151  However, 
further studies amongst Scottish patients152, Caucasian children153 and North 
American patients154 found that the association with OCTN1/2 and susceptibility to 
CD was only in the context of the IBD5 risk haplotype.  Even more conflicting was 
data from a Belgian cohort that found no association between the OCTN1/2 variants 
and susceptibility to CD.155  Controversy continues as to the phenotype displayed by 
the IBD5 genotype and whether there is epistasis between IBD5 and NOD2.  
1.3.8 Missing heritability 
Even with the current 71 CD susceptibility loci, it has been stated that only 23.2% of 
the heritability of CD can be explained.74  However, the majority of the loci 
uncovered by GWAS are unlikely to be the causal allele for disease susceptibility.  It 
has therefore been argued that as ‘imperfect proxies’ for the causal allele, the true 
heritability at any loci is underestimated, so in fact the proportion of heritability 
explained by these 71 loci may be much higher.74  In addition, current heritability 
estimates may not be accurate as new updated twin data suggests lower disease 
concurrence than previously thought.156  Twin studies also use the ‘equal 
environments assumption’: that dizygotic twins have an equally shared environment 
compared with monozygotic twins.  If this is not the case, then heritability will be 
overestimated. 
It is a matter of debate whether any remaining heritability is explained by many 
thousands of alleles of very marginal OR, or whether, by pooling populations, we are 
diluting out population-specific loci with much higher OR.  Population mixing is 
necessitated by GWAS studies in order to have sufficient power for genome-wide 
statistical significance.  As the SNPs that are genotyped in GWAS are present in 5% 
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or more of the population, other SNPs of lower prevalence may also be important in 
disease susceptibility.  In addition, there are likely to be many ‘private mutations’ 
that are family-specific and may involve deletions, duplications and inversions.  
Structural variation, for example copy number variation (CNV), may also contribute 
to disease susceptibility, something that is only beginning to be explored. 
As next generation sequencing technologies are now becoming cheaper, it will soon 
be possible to sequence individuals, facilitated by the 1000 genomes project which is 
providing a comprehensive list of variants with MAF ≥1%.  This is the most likely 
method whereby rare SNPs will be identified.  However, identifying causal alleles 
will be difficult due to the large volume of data that will be generated.   
1.4 Environmental factors in IBD 
There is increasing recognition of the role of environmental factors in changing 
genetic phenotype without causing germline genetic mutations (termed 
‘epigenetics’).  This phenomenon uses various mechanisms including DNA 
methylation and histone acetylation to change gene expression.  It is possible that 
some of the environmental factors in IBD may act through epigenetic mechanisms; 
this is likely to be an increasingly important area for research in the future. 
1.4.1 Smoking 
Smoking is known to increase the risk of developing CD, and reduce the risk of UC. 
A recent meta-analysis157 comparing current and never smokers demonstrated an OR 
of 1.79 (95% CI 1.4-2.22) and 0.58 (95% CI 0.45-0.75) for development of CD and 
UC development.  A study looking at sibling pairs discordant for both smoking and 
IBD type (UC or CD) showed that smokers developed CD and non-smokers 
developed UC, suggesting a gene-environment interaction contributing to disease 
development in genetically susceptible people.158 
Smoking appears to affect the disease course for both CD and UC.  In CD, smokers 
tend to develop small bowel rather than colonic disease.159  There is evidence that 
those who quit during their disease have a lower risk of subsequent flare-up than 
those who continue smoking.160  With UC, there are anecdotal reports of patients 
who have flare-ups on attempting to stop smoking, with improvement of disease 
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activity course when they start to smoke again, but this association has not been 
proven conclusively.   
The active ingredient in cigarette smoke is unknown.  With over 4000 compounds, 
many of which are carcinogenic, definitive studies to find the agent are unlikely in 
the near future.  Studies trialling nicotine transdermal patches showed no benefit in 
the maintenance of remission in UC161, but a modest benefit in active disease.162  An 
open label pilot study of nicotine enemas in colonic CD suggested some benefit163, 
although a randomised trial in active UC failed to show any benefit.164  
1.4.2 Previous appendectomy 
Previous appendectomy reduces the subsequent risk of UC development (OR 0.307 
(95% CI 0.249-0.377).165  For CD there appears to be an increased risk of disease 
development following appendectomy166, although as the increased risk is 
predominantly in the first year after appendectomy it is unclear whether the 
symptoms that led to appendectomy were actually unrecognised symptoms of CD. 
1.4.3 Diet 
Ongoing controversy is provided by the role of diet in disease susceptibility, and 
further studies are required in this area.  The importance of diet in the modulation of 
CD is demonstrated by the fact that exclusive enteral feeding can induce remission in 
active disease (reviewed by O’Sullivan167).  In a Japanese case-control cohort with 
both UC and CD patients, the risk of IBD development was higher with increased 
refined sugar consumption, although this was a retrospective study and may suffer 
from recall bias.168  In North American children a case-control study demonstrated 
that low fruit and vegetable consumption was associated with CD development.169  
High levels of arachidonic acid, present in red meat as well as some oils and 
margarines have been found in the adipose tissues of patients who subsequently went 
on to develop UC compared to those that did not170, and increased consumption of 
arachidonic acid is linked with an increased incidence of the disease.171   
1.4.4 Hygiene hypothesis 
The hygiene hypothesis, first formally proposed in 1989172, is the theory that lack of 
early exposure to microbes leads to an increased susceptibility to allergic diseases 
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later in life.  This could explain the increasing incidence of allergic diseases in the 
Western world, and their continued low incidence in the developing world.  However 
whether CD and UC also fit the hygiene hypothesis is unclear.  Certainly, 
observational studies have linked IBD susceptibility with affluence173 although not 
with urban living.174 
1.4.5 Microbes 
The gastrointestinal tract is the most heavily colonised area of the human body with 
the number of bacteria estimated at 1014 composed of at least 400 species.  
Commensal bacterial communities in the gut have a symbiotic relationship with the 
host, helping to metabolise otherwise indigestible complex carbohydrates, 
challenging and promoting immune system development and regulating gut 
development.  These bacteria have evolved metabolic mechanisms to acquire 
nutrition from the host diet, unlike pathogenic bacteria which have virulence factors 
to enable them to access the tissues of the host.175 The large number of symbiotic 
bacteria make it more difficult for pathogenic bacteria to gain access to the host.  
Whether the host immune system is tolerant or ignorant of symbiotic bacteria is 
unclear, but it would appear that commensals reside in the lumen and the outer 
mucus layer, rather than the deep mucus layers and epithelial cells.  Evidence would 
suggest that minimising host recognition of commensals by keeping them within the 
intestinal microenvironment is important.  Innate and adaptive immunity 
complement each other in protecting the host, as shown by work in MyD88-/-   
Ticam-/- mice (deficient in the toll-like receptor adaptor molecules MyD88 and 
Ticam, important in innate immunity) reared in germ-free environments but then 
challenged with commensal bacteria.  These mice produce high titres of serum 
antibodies against commensal bacteria unlike their control wild type counterparts, 
who are able to maintain the bacteria within the mucosal immune compartment.176  
The mechanisms underlying this are unclear, but it does not appear to be due solely 
to increased intestinal permeability.176  Certainly it would appear that abnormal host 
responses, in particular in innate immunity, may contribute to bacteria gaining access 
to compartments beyond the gut mucosa.  This could be particularly pertinent in 
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IBD, where defects in innate immunity appear to be important in disease 
pathogenesis (see sections 1.3.2 and 1.3.3). 
There are many reasons to suspect microbial involvement in disease development 
and/or perpetuation.  As already described, many of the susceptibility genes in IBD 
are important in innate and adaptive immunity.  In animal models, disease does not 
occur in animals reared in a germ-free environment, unlike those that have been 
colonized by bacteria.177  Prolonged courses of antibiotics can improve CD 
symptoms in some patients.178  Diversion of faecal stream has been shown to 
improve inflammation in CD, with re-exposure to luminal contents in an excluded 
ileum causing recurrent inflammation.179  In addition, there is evidence to suggest 
that an episode of infectious gastroenteritis increases subsequent risk of IBD.180;181   
Whether microbe involvement in IBD pathogenesis is due to an abnormal immune 
response to gut commensals, or whether there are specific pathogens is unclear;  
although several microbes have been implicated in IBD, none have been 
conclusively proved to be causative in disease development. 
1.4.5.1 Adherent-invasive Escherichia coli 
Escherichia coli is a Gram-negative rod and many strains are important commensal 
bacteria in the gastrointestinal tract, colonizing the neonatal gut within hours of birth 
and helping to maintain intestinal homeostasis; other strains are recognised to cause 
gastroenteritis, usually through food poisoning.182  Adherent-invasive Escherichia 
coli (AIEC), unlike other pathogenic strains of E. coli, lack conventional genes 
conferring invasiveness, and have been isolated from the mucosa of patients with 
ileal CD undergoing resection183 and CD biopsy samples.184  E. coli antibody titres 
are higher in CD patients than in healthy controls185 and high numbers (37-56%) of 
CD patients have antibodies to OmpC (E. coli outer membrane porin C).186-188  
OmpC is thought to play a critical role in bacterial adhesion and invasion.189  AIEC 
have been shown to survive and replicate within macrophages, producing large 
amounts of TNFα.190  This is thought to be secondary to impaired autophagy, a key 
mechanism in the clearance of intracellular bacteria191, thus linking key CD 
susceptibility genes directly to a bacterial aetiology for CD. 
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1.4.5.2 Mycobacteria 
The similarity between the granulomas of CD and Mycobacterium species has long 
been recognised.  Johne’s disease, caused by Mycobacterium avium subspecies 
paratuberculosis (MAP) has manifestations similar to CD in ruminants: predominant 
ileal disease, weight loss and diarrhoea.192  When Chiodini and colleagues cultured 
MAP species from 3 patients with CD193, scientific plausibility was given to the 
controversial theory that MAP may be the cause of CD in humans.  MAP has been 
detected in milk194 and water supplies.195  Further evidence has been provided by 
various studies detecting MAP-specific DNA in CD tissues by PCR196;197 and in-situ 
hybridization198, although more recently MAP-specific DNA was not found in CD 
patients.199  However, CD improves rather than deteriorates with 
immunosuppression, and whilst MAP has been detected more frequently in CD 
patients than controls, it is unclear if it causes disease in a subset of patients, or 
whether it has a propensity to selectively colonise the diseased gastrointestinal tract 
of patients who have already developed CD, thus acting as an innocent bystander.  
Moreover, a double blind placebo controlled trial of two years of therapy with 
clarithromysin, rifabutin and clofazamine (to eliminate MAP) in CD patients with 
active disease failed to demonstrate a sustained benefit.200 
Leprosy is a chronic granulomatous disease caused by Mycobacterium leprae and 
Mycobacterium lepromatosis.  A GWAS of leprosy susceptibility in a Chinese 
population, comparing patients with leprosy to controls who had not developed 
disease despite living in the same area, demonstrated a number of susceptibility loci 
shared with CD.201  This confirms that susceptibility to some microbial infections can 
be affected by a person’s genetics.  As there are similarities in the pathology of some 
leprosy cases and CD, it remains possible that Mycobacteria species, either MAP or a 
strain as yet unidentified, could be responsible for at least a subset of CD. 
1.4.5.3 Faecalibacterium prausnitzii 
Intriguing data have emerged of the association of the Firmicute Faecalibacterium 
prausnitzii with CD: a reduced presence in the gut microbiota has been found to be 
associated particularly with post operative and endoscopic recurrence of ileal 
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disease.202  This study also found that F. prausnitzii has anti inflammatory effects in 
cellular and mouse models.  A further study has shown that UC patients also have 
reduced F. prausnitzii counts.203   
1.4.5.4 Other microbiota - the human microbiome 
Many of the human intestinal commensal bacteria have not been isolated and 
cultured.204  Various methods, including 16S rRNA technology, have been used to 
detect and identify unculturable organisms in the human gastrointestinal tract.  
Patients with CD have been shown to have a reduced diversity of faecal 
microbiota205, and a microarray analysis has demonstrated reduced abundance of 
Bacteroides sp. and increased Enterococcus sp. in CD patients compared with 
controls.206  Investigating the human microbiome is an exciting future prospect in 
IBD. 
1.5 Barrier protection 
Mucosal integrity is important for protecting the gut against intraluminal material, 
especially microbes.  In the three stage model of the immunopathogenesis of CD 
referred to in section 1.3.2, the initial beginning of the process of disease 
development is penetration of foreign material into the bowel wall.  Thus barrier 
protection is a key area for investigation in IBD.   
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Figure 1-5 Barrier protection of the gastrointestinal tract, from Hooper
207
 
Appropriate protection is important to allow essential functions like nutrient and 
water absorption whilst preventing penetration by luminal pathogens.  There are 
three layers that serve this purpose in the gastrointestinal tract, as shown in Figure 
1-5.  The outermost layer is a secreted loosely bound mucus gel layer which traps 
bacteria and pathogens, and contains commensal bacteria.  This layer is composed of 
secretory mucins produced by goblet cells.  As shown in Figure 1-6, the thickness of 
this layer varies through the gastrointestinal tract, from 715µm in the colon to 108µm 
in the jejunum in rats.208  Beneath that there is a mucus layer more tightly bound to 
the luminal cell surface, largely devoid of bacteria, termed the glycocalyx.  It 
consists predominantly of membrane-bound mucins, and also contains 
immunoglobulins IgA and antimicrobial peptides, e.g. defensins.  The depth of this 
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layer in rats varies between minimal or none in the small intestine to 154µm in the 
gastric antrum.208 
 
Figure 1-6 A schematic figure showing the thicknesses of the 2 mucus gel layers in vivo in the rat 
gastrointestinal tract, from Atuma et al.
208
 
The epithelial cell layer of the mucosa forms the deepest layer providing barrier 
protection.  Epithelial cells, including intestinal enterocytes, secretory Goblet cells, 
Paneth cells and enteroendocrine cells are all connected to each other by epithelial 
tight junctions.  There is evidence to suggest that CD patients and their unaffected 
first degree relatives have increased intestinal permeability.209 
1.5.1 Mucins 
Mucins, as already mentioned, can be either membrane bound or secretory.  They are 
heavily glycosylated molecules, resistant to proteases as well as having high water 
holding capabilities.  They are secreted as glycoprotein aggregates of very large 
molecular masses with the individual molecules linked to one another by non-
covalent interactions.  By being heavily glycosylated they form the major part of 
secretions to protect epithelial surfaces and thus appear to be important in the 
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maintenance of mucosal integrity.  The secretory mucin MUC2 and the membrane 
bound MUC3 are the commonest mucins expressed in the gastrointestinal tract.210 
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1.6 Thesis plan 
The first aim of the thesis was to define the Scottish CD phenotype according to the 
Montreal classification, the results of which are presented in Chapter 3.  The newly 
recruited Dundee CD cohort is compared with the more established Edinburgh CD 
cohort.  Characteristics affecting time to development of disease progression 
(stricturing and/or internally penetrating disease) and time to first resection are 
examined in univariate and multivariate analyses of the Scottish cohort.  Multiple 
resection data on the Scottish cohort are explored including time between resection 
with respect to disease location. The accepted convention that CD progresses from 
inflammatory to stricturing/penetrating, or inflammatory to stricturing to penetrating 
is examined in the Dundee cohort.   Finally, the development of disease progression, 
time to first resection and multiple resection data results in the Scottish cohort are 
compared to other published cohorts. 
In Chapter 4, the problems with existing definitions of severe CD are explored.  A 
novel score for defining severe CD is introduced, and the results of its application to 
the Dundee cohort presented.  It is compared to the most widely accepted current 
definition of disease severity.  A comparison of clinical and genetic characteristics 
present at diagnosis between more severe and less severe CD patients is shown, 
including a model for calculating the probability of more severe disease that could be 
used at diagnosis.  The results of a case-control analysis of 32 CD susceptibility 
SNPs are also presented. 
Having discussed clinical and genetic factors affecting the CD phenotype, the thesis 
moves on to discuss GALNT2, one of the NOD2-interacting proteins uncovered by 
the yeast two-hybrid screen.  Its role in Scottish IBD susceptibility is explored in 
Chapter 5, including sub phenotypic analyses in both CD and UC.  The results of 
sequencing the exons of GALNT2 are also presented in the search for a potentially 
causative mutation.   
Further, more functional, analyses of the interaction between GALNT2 and NOD2 
are presented in Chapter 6, including the examination of the level of the interaction, 
and the examination of how the most common CD NOD2 variants affect the 
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interaction between the two proteins.  The results of GALNT2 and NOD2 expression 
analyses by both immunohistochemistry and quantitative PCR are presented. 
In Chapter 7, a case-control susceptibility analysis of the MUC2 and MUC3 genes, 
the commonest mucins in the gastrointestinal tract, is presented.  Chapter 8 presents 
the results of the search in the Scottish IBD cohort for the gene representing the CD 
GWAS meta-analysis signal on chromosome 12q12 with the results of haplotype-
tagging studies of both MUC19 and LRRK2.   
Finally, in Chapter 9, the overall implications of the work presented in the thesis are 
discussed and suggestions made for future research. 
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Chapter 2 Materials and Methods 
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2.1 Reagents 
All reagents were from Sigma-Aldrich unless otherwise stated. 
2.2 Patients 
2.2.1 Dundee ethics 
The study had the full ethics approval of the Tayside Local Research Ethics 
Committee (LREC), approval number 226/02. 
2.2.2 Dundee recruitment 
Inclusion critera:  Consenting adult patients of >18 years old with a proven diagnosis 
of IBD.  Patients attending the weekly IBD clinic in Ninewells Hospital were sent a 
letter by Mrs Shirley Cleary RN at least 1 week prior to clinic appointment inviting 
them to participate (Appendices 10.1 and 10.2).  At clinic, these patients were asked 
whether they wished to participate and signed a consent form to formally document 
their agreement to the terms of the study.  Patients filled in a questionnaire 
(Appendix 10.3) and a 15ml sample of blood was obtained in EDTA tubes, or a 5ml 
sample of saliva into an Oragene® saliva kit (DNA Genotek, Ontario, Canada) for 
DNA extraction.  This clinic recruitment was done with Mrs Shirley Cleary RN, 
recruiting equal numbers of patients each.  
2.2.3 Edinburgh ethics and recruitment 
Patients living in the Edinburgh area were recruited at the Western General Hospital.  
This study had the full approval of the Lothian LREC (2000/4/192).  These patients 
were recruited by Mrs Linda Smith and Mrs Hazel Drummond in the same manner as 
described for the Dundee recruitment.  
2.2.4 Controls 
Controls were obtained from several sources.  Scottish Central and Tayside region 
controls for the Dundee cohort were obtained from the Generation Scotland 3D 
project, as previously described.211  Controls for the Edinburgh cohort were locally 
recruited controls who were friends and non-blood relatives of the Edinburgh IBD 
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cohort (recruited by Mrs Linda Smith, RN); additional controls were obtained from 
the 1958 birth cohort.  
2.2.5 Phenotyping 
Following clinic attendance, each patient’s notes were scrutinised retrospectively to 
extract details about their disease phenotype, which was documented on a paper 
proforma developed by Mrs Hazel Drummond (Appendices 10.5 and 10.6).  All 
phenotyping of the Dundee patients was done by myself whereas the Edinburgh 
patients were phenotyped by Mrs Hazel Drummond and other medical professionals 
and scientists.  The initial diagnosis of IBD was according to the Lennard-Jones 
criteria2 (Table 2-1), and subsequent disease location and behaviour were 
documented carefully according to the Montreal classification20 (Table 2-2 and Table 
2-3).  By convention, the CD location was taken to be the maximum extent of 
macroscopic disease prior to first resection.  For patients who had not had a resection 
by the time of phenotyping, it was the maximum extent during follow up.  CD 
behaviour was taken to be the disease behaviour at 5 years after diagnosis, or at last 
diagnosis for those who had not yet been diagnosed for 5 years.  The UC disease 
extent was the maximum extent of macroscopic disease at any point during follow 
up.   Patients with IBD-U (unclassified IBD) were included for overall IBD analyses 
but excluded from CD and UC analyses. 
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Ulcerative colitis criteria 
Exclusion Infective colitis 
 Ischaemic colitis 
 Irradiation colitis 
 Solitary ulcer 
 Abnormalities suggesting CD 
 Complex anal lesion 
 Granulomata 
Inclusion Continuous mucoscal inflammation without granulomata 
 Affecting the rectum and some or all of the colon in continuity with the rectum 





Inclusion Mouth to anus: Chronic granulomatous lesion of the lip or buccal mucosa 
  Pyelo-duodenal disease 
  Small bowel disease 
  Chronic anal lesion 
 Discontinuous  
 Transmural: Fissuring ulcers 
  Abscess 
  Fistula 
 Fibrosis Stricture 
 Lymphoid aggregates present 
 Mucin retention in the presence of active inflammation 
 Non caseating granulomata 
Table 2-1 Lennard-Jones criteria for IBD diagnosis 
Age at diagnosis A1 <17 years 
 A2 17-40 years 
 A3 >40 years 
Disease location L1 Ileal +/- caecal overspill 
 L2 Colonic 
 L3 Ileocolonic 
 L4 UGI (+ L1-L3 if both UGI disease and elsewhere) 
Disease behaviour B1 Inflammatory 
 B2 Stricturing 
 B3 Internally penetrating 
 p Perianal modifier 
Table 2-2 Montreal classification – Crohn’s disease 
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E1 Rectal  
E2 Distal to splenic flexure 
E3  Proximal to splenic flexure 
Table 2-3 Montreal classification - Ulcerative colitis 
Additional information was also recorded for each CD patient including drug history, 
number of hospital admissions and BMI in the first 5 years in order to calculate a 
severity score (Table 2-4).  Further details of the development of this score are given 
in section 4.2.1. 
2.2.6 Databases  
A custom-designed Microsoft Access™ database was used for the storage of the 
phenotypic information from the paper proforma on computer.  This database had 
been developed some years ago in Edinburgh and was used for the storage of data 
from the Edinburgh cohort.  It was adapted with the help of Mrs Maureen Edwards 
(Database Manager, Clinical Genetics, Western General Hospital, Edinburgh) for the 
Dundee IBD cohort.  All phenotypic information was entered onto this database. 
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 Severe: Score 4 for each Moderate: Score 2 for each Mild: Score 1 for each Score 0 
Disease 
extent/behaviour 
Panenteric disease  
OR Complex perianal 
disease requiring 3 or more 
operations 
OR Fistulating disease   
 
Stricturing but not 
fistulation  
Perianal disease requiring 1 
or 2 operations 
Single site involvement 
No evidence of 
stricturing/fistulation 






OR Need for 2 or more 
immunomodulatory drugs  
OR 2 Surgical resections 
OR Use of biological therapy 
 
More than 4 steroid 
courses, but none >4 
months 
OR 1 immunomodulator 
OR 1 surgical resection 
 
1-3 courses of steroids, 







BMI <15 at any point in the 5 
years 
BMI 15-18.5 at any point in 
the 5 years 
 BMI >18.5 at all 
times in the 5 years 
Socio-economic 
impact 
5 or more hospitalizations 
for management of active 
disease  
 
2-4 hospitalizations for 
active disease 
 
1 hospitalization for 
active disease 
No hospitalizations 
for active disease 
Table 2-4 Severity score, calculated for the first 5 years after diagnosis 
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2.3 DNA 
2.3.1 DNA extraction 
DNA extraction from blood and saliva was outsourced to the Medical Research 
Council (MRC) Human Genetics Unit, Western General Hospital, Edinburgh.  They 
used the Nucleon DNA extraction kit (Gen-Probe, Manchester, UK), using 
chloroform and Nucleon resin for DNA extraction and ethanol for DNA 
precipitation.  DNA concentrations were quantified at the MRC by Picogreen® 
(Molecular Probes, Oregon, USA). 
In the GI Unit the sample concentrations were confirmed using a Nanodrop 1000 
machine (Thermo Sciences, UK) and each sample made up to 150ng/µl using 1xTE 
(10mM Tris pH8 and 1mM EDTA).  Those with initial concentrations significantly 
below this value were re-precipitated and resuspended in a smaller volume to 
concentrate them.  DNA samples were stored at -80°C. 
2.3.2 SNP selection 
SNPs were selected in two different ways.  Tagging SNPs were chosen for a gene of 
interest to perform fine mapping of genetic variation.  To choose tagging SNPs for a 
gene of interest, the genetic variation for the gene was downloaded from 
www.hapmap.com212, allowing for 15kbp at either end of the gene.  This information 
was run in Haploview 4.1 and haplotype blocks defined according to solid spine of 
linkage disequilibrium.  The SNPs were chosen to tag haplotypic variation (>5%) of 
the gene of interest.  In other experiments SNPs were chosen to try to replicate other 
people’s results.   
2.3.3 Taqman® genotyping 
Taqman® genotyping (Applied Biosystems, Life Technologies) was completed at 
the Wellcome Trust Clinical Research Facility, Western General Hospital, Edinburgh 
on the ABI PRISM 7900HT machine.  Taqman® genotyping involved the design of 
nucleotide probes – one each for each of the variants of the SNP being examined.  
Each probe was tagged at the 5’ end with a different fluorophore and had a quencher 
at the 3’ end.  When still in close proximity to the quencher, the fluorophore was 
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prevented from emitting any fluorescence.  During real time polymerase chain 
reaction (RT-PCR) amplification of the target sequence, when the probe annealed to 
the genomic DNA, the 5’-3’ exonuclease activity of the DNA Taq Polymerase 
degraded the probe, thus releasing the fluorophore from the blocking of the 
quencher. The amplification conditions were: 50°C for 2 minutes, 95°C for 10 
minutes then 40 cycles of 95°C for 15 seconds and 60°C for 1 minute.  As both 
probes had different fluorophores attached to them, comparing the fluorescence of 
the emissions from the samples showed clustering according to the genotype of the 
SNP in question (AA, AB, BB).  This was visualised on an allelic discrimination 
assay plot where the fluorophores were plotted on opposing axes (Figure 2-1).  In 
circumstances where the genotype could be confidently called the sample was 
dropped from the analysis.   
 
Figure 2-1 Example of Taqman® clustering 
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2.3.4 Sequenom® genotyping 
Sequenom® sequencing was completed at the Genomics Core of the University of 
California, San Francisco.  Rather than using fluoroscent probes, SNPs were detected 
using MALDI-TOF to calculate the mass of the PCR extension product and hence 
the genotype of the SNP in question. 
2.3.5 Illumina Goldengate® genotyping 
With the Goldengate® platform (Illumina, SanDiego, CA), three oligonucleotides 
were designed for each SNP: two allele specific oligonucleotides (ASO) and a 
downstream locus specific oligonucleotide (LSO).  All three of these also had 
sequences complementary to universal primers – P1, P2 and P3, with each allele of 
the SNP of interest being specific to P1 or P2.  The oligonucleotides were allowed to 
hybridise to the genomic DNA being analysed.  Extension of the ASO to the LSO 
joined information about the SNP allele present and the SNP location.  The three 
universal primers were then used to amplify the product.  P1 and P2 were Cy3- and 
Cy5-labelled respectively, and the dye-labelled PCR products were allowed to anneal 
to a bead containing a complementary sequence to the LSO.  Thus, by analysing the 
fluorescence of that bead, the genotype (AA, AB or BB) was determined in a similar 
way to Taqman®.  As a chip could contain many beads and the universal primers 
were not specific to each reaction, many SNPs could be multiplexed. 
2.3.6 Data quality control 
For all three methods of genotyping, similar methods for ensuring the quality of the 
data were employed.  Initially the control samples were analysed using Haploview 
and samples not in Hardy-Weinberg (HW) equilibrium were discarded (HW p-
value<0.05, corrected appropriately for multiple testing).  SNPs with less than 90% 
genotyping were also removed from the analysis.  Where multiple SNPs were 
investigated (eg the work using the Illumina and Sequenom®), individual DNAs 
with <90% successful calling on the remaining SNPs were not used in analyses. 
2.3.7 Analysis of genotyping 
SNP genotyping was analysed using Haploview version 4.2.  For tagging SNP data, 
haplotypes were defined and analysis performed according to the initial haplotypes 
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on which the SNPs had been selected.  P-values of <0.05 were considered 
significant, and corrected for multiple testing as appropriate. 
2.3.8 Polymerase Chain Reaction (PCR) 
The sequence of the area of interest was downloaded from www.ensembl.org.  Pairs 
of primers were designed to cover the relevant SNP according to the criteria: 20-22 
base pairs long, an approximate GC content of 50%, the 3’ end being a G or a C, and 
not overlying a known SNP.  The primers were selected to be at least 60 base pairs 
away from the 5’ and 3’ of the sequence to be analysed.  Using the Sigma website 
(www.sigmaaldrich.com) the sequences were checked for the melting temperature of 
the primer, aiming for about 60°C and preferably for the absence of a secondary 
structure. 
For the PCR, each primer was used at a working concentration of 1mM, with NH4 
buffer (Bioline, London, UK, containing at working concentration 16mM (NH4)2SO4, 
67mM Tris HCl at pH 8.8 and 0.01% Tween 20), MgCl2 (working concentration 
1.5mM), dNTP (Bioline, London, UK, working concentration 1mM) and 0.2µl Taq 
polymerase (working concentration 0.05U/µl, gift of Dr Elaine Nimmo), and the 
appropriate DNA (final concentration 2.5-5ng/µl).  
The optimal temperature at which to run the PCR was checked using a temperature 
gradient range of 55-65°C, as shown in Table 2-5. 
 
94°C for 2 minutes (initial denaturation) 
92°C for 30 sec (denaturation) } 
Target temp for 30 sec (annealing) } repeated 
72°C for 45 sec (extension)  } 31 more times 
72°C for 5 minutes to complete the PCR 
Table 2-5 PCR conditions 
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2.3.9 PCR product gel electrophoresis 
The samples were run on a 1% agarose gel (agarose in 0.5xTBE) .  The 10xTBE 
stock solution used contained 106g Tris base, 55g boric acid and 40ml 0.5M EDTA.  
The agarose and 0.5xTBE were heated in a microwave to dissolve the agarose. 
Fifteen microlitres of SYBRsafe® DNA stain (Invitrogen, Life Technologies) was 
added to the agar solution after it was cooled slightly.  The agar solution was poured 
into a gel tray and left to set with combs to demarcate the lanes. 
Five microlitres of each of the PCR products were mixed with 5µl Cresol dye (0.25% 
Cresol red, 40% sucrose) and loaded onto each lane.  The molecular size marker 
loaded was a 100bp DNA ladder (Biolab, London, UK).  The gel was run for 30-45 
minutes (depending on the expected size of the PCR product) at 150V (400mA) and 
imaged by the GeneGenius Bioimaging system (Syngene, Cambridge, UK).  The 
annealing temperature that gave the strongest single band of the correct size was 
ascertained and used as the annealing temperature in all subsequent PCRs with that 
primer set.  Subsequent PCRs were run as above, except that the programme used 
was specific to the target temperature required.  To ensure that the PCR had worked 
before sending the samples for sequencing, several of the PCR products were 
sampled by agarose gel electrophoresis as above to check that a single product of the 
expected size was obtained. 
2.3.10 Sequencing 
Post PCR, samples were sequenced at the MRC Human Genetics Unit (Western 
General Hospital, Edinburgh), using the ABI 3730 Sanger sequencing machine 
(Applied Biosystems, Life Technologies).   A single primer was used to synthesis 
new DNA fragments, but with specific fluorescent dyes attached to each nucleotide 
of the DNA strand of interest.  A different dye was used for each of the four 
nucleotides: adenine, cytosine, guanine and thymine.  The samples were run by 
capillary action through a gel matrix, so that there was a correlation between the 
length of the DNA and the time at the sensor, and this was used to determine the 
DNA sequence. The sequencing machine could detect the wavelength of each 
fluorescent dye using optical sensors.   
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2.3.11 Analysis of sequencing 
Sequencing was analysed using Sequencher® 4.8-4.10 (Gene Codes Corporation, 
Ann Arbor, MI).  The known sequence was downloaded from www.ensembl.org and 
the sequencing results were compared to this.  The results were documented on a 
Microsoft® Excel spreadsheet.   
2.3.12 Phylogenetic analysis of conservation 
An analysis of conservation across species is helpful when considering a gene in 
which there may be an intronic mutation producing disease susceptibility, as areas 
that have been conserved across species are more likely to contain important 
regulatory non-coding areas.213  Sequences of the gene of interest from different 
species were downloaded from www.ensembl.org in the FastA format and uploaded 
to PIPmaker (pipmaker.bx.psu.edu/pipmaker/), and percentage of identity plots (PIP) 
calculated.  The multiple alignment programme of Vista was also used to complete a 
species alignment (pipeline.lbl.gov/cgi-bin/gateway2).   
2.4 Cell culture 
Unless otherwise stated, all plastic-ware was obtained from Greiner UK and cell 
culture reagents were obtained from Gibco, Life Technologies, UK.  LS174T cells 
were used for gene expression analyses (section 2.5) whereas the SW480 cells were 
used for protein work (section 2.6) 
2.4.1 Cell culture conditions 
Both the SW480 and the LS174T colonic cell lines were obtained from the European 
Collection of Cell Cultures (Health Protection Agency, Salisbury, UK).  The SW480 
cells were grown in unvented flasks in L-15 Leibovitz medium supplemented with 
10% foetal calf serum (FCS), 2mM glutamine, 100U/ml penicillin and 0.1mg/ml 
streptomycin.  The LS174T cells were grown in vented flasks in minimum essential 
medium eagle (MEM) (Sigma-Aldrich) supplemented with 10% FCS, 1% non 
essential amino acids, 2mM glutamine, 100U/ml penicillin and 0.1mg/ml 
streptomycin.  All cell lines were incubated at 37oC in humidified air containing 5% 
CO2. 
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2.4.2  Cell Passage 
Cells were passaged by washing the cells several times with phosphate buffered 
saline (PBS) and incubating with 0.25% trypsin/EDTA for several minutes.  The 
flask was then vigorously agitated to release the adherent cells.  These cells were 
pooled in a falcon tube, spun down to a pellet and resuspended in fresh medium.  For 
the LS174T cells, the cells were passed through a fine needle to ensure a single cell 
suspension.  The cells were cut back in a ratio between 1:2 and 1:8 depending on 
when and how many flasks of cells were needed for forthcoming experiments.   
2.5 Gene expression analyses 
2.5.1 Transfection 
Harvested LS174T cells of low passage number (<10) were counted using a 
haemocytometer and 1x106 cells plated out into each cell of a 6 well plate, and 
medium added to give a total volume of 2ml.  They were incubated to achieve 80-
90% confluence at the start of the transfection.  For each well to be transfected, 10µl 
lipofectamine™ 2000 (Invitrogen, Life Technologies) was diluted into 250µl Opti-
MEM® (Invitrogen, Life Technologies) without serum and incubated for 5 minutes 
at room temperature.  Then 2.5µg of the DNA to be transfected was added to 250µl 
Opti-MEM® and this mixture added to the lipofectamine™/Opti-MEM® that had 
already been made up.  This was incubated at room temperature for 20 minutes to 
allow the DNA-lipofectamine™ complexes to form.  After the above incubation, the 
mixture was added to wells already containing 1ml Opti-MEM®.  The cells were 
incubated at 37°C for 5-6 hours and the complexes were removed and complete 
medium, as defined in 2.4.1, was added.     
2.5.2 Time courses 
Time courses were carried out with LS174T cells to examine the effects of different 
compounds on the cells.  If a transfection was required (see above) the cells were 
allowed to recover for about 12 hours. Using cells in 6-well plates at 80-90% 
confluence, the medium was changed.  Cells were stimulated with: TNFα (final 
concentration 50ng/ml), LPS (final concentration 1µg/ml), MDP (final concentration 
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1µg/ml), monensin (final concentration 1µM) and carbachol (final concentration 
1mM) with a further well left unstimulated.  The cells were incubated at 37°C for 8, 
24 or 48 hours .  To harvest, the cells were washed twice with 1ml PBS and then 
scraped in 1ml PBS and recovered into a 1.5ml tube.  This was spun at 13,500rpm 
for 5 minutes, the supernatant removed and discarded, and the cell pellet stored at     
-80°C. 
2.5.3 RNA extraction  
RNA extraction was completed with the Qiagen RNeasy Mini kit (Qiagen, Crawley, 
UK), according to standard protocols.  Briefly, cells were lysed with 350µl lysis 
buffer (RLT containing 10µl β-mercaptoethanol per ml) and mixed well.  The lysate 
was pipetted onto a QIAshredder spin column in a 2ml collection column and 
centrifuged for 3 minutes at >8000g to homogenise the lysate.  350µl of 100% 
ethanol was added to the lysate and transferred to an RNeasy mini spin column 
placed in a 2ml collection tube.  This was centrifuged for 15 sec at >8000g to allow 
the RNA to adsorb to the silica-gel membrane, and the liquid from the column 
(follow through) was discarded. 
350µl Buffer RW1 was added to the column and centrifuged for 15s at >8000g, with 
the follow through being discarded. 80µl DNase (made up of 10µl DNase I stock 
solution with 70µl DNA digest buffer RDD) was added directly onto the column 
membrane and incubated at room temperature for 30-45 minutes to ensure removal 
of any remaining DNA.   
Following this incubation a further wash was performed with 350µl Buffer RW1 and 
centrifuged for 15s at >10000rpm.  500µl Buffer RPE was added to the column and 
this was centrifuged for 2 min at >8000g to wash spin column membrane.  The 
column was then removed into a new 1.5ml collection tube.  50µl RNase-free water 
was added directly onto the membrane and the spin column centrifuged for 1 min at 
>8000g to elute the RNA into the collection tube.  The RNA was quantified on the 
Nanodrop and stored at -80°C. 
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2.5.4 cDNA synthesis 
cDNA was made using the Invitrogen Superscript® III First-strand synthesis 
protocols and reagents (Invitrogen, Life Technologies).  1µg RNA was added to 1µl 
10mM dNTP mix and 50ng random hexamers, and the total volume made up to 10µl 
with DEPC-treated water.  This mixture was incubated at 65°C for 5 minutes to 
denature the RNA and primers, and then placed on ice for at least 1 minute.  The 
cDNA synthesis mix was added to the mixture (2µl 10X RT Buffer, 4µl 25mM 
MgCl2, 2µl 0.1M DTT, 1µl RNase OUT and 1µl Superscript® III reverse 
transcriptase and incubated at 25°C for 10 minutes to allow annealing.  cDNA 
synthesis was promoted by incubating at 50°C for 50 minutes.  The reaction was 
terminated by heating to 85°C for 5 minutes.  The cDNA was stored at -80°C. 
2.5.5 qPCR 
Real-time or quantitative (q)PCR is a method of not only detecting, but also 
quantifying the amount of specific nucleotide sequences.  A probe that preferentially 
binds to dsDNA and only fluoresces when bound to DNA was used in the PCR.  The 
fluorescence intensity was measured at each PCR cycle allowing DNA 
concentrations to be quantified by comparing to a standard dilution of DNA.   
2.5.5.1 SYBR® Green qPCR 
Appropriate primers for each gene of interest were designed by Ms Kimberley Soo 
using the Primer3 programme (http://frodo.wi.mit.edu/primer3).  An initial standard 
curve PCR was run to check that the primers were working and to calculate the 
cDNA optimal concentration for those primers.  Serial cDNA dilutions were made:  
1:5   1:10 
1:50   1:100 
1:500   1:1000 
1:5000   1:10000 
0 
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RotorGene-specific 0.1ml strip tubes (Qiagen) were used to add 2µl of the relevant 
cDNA dilution, 10µl SYBR® Green EXPRESS (Invitrogen, Life Technologies), 
primer pairs at a working concentration of 1mM each and the mixture made up to 
20µl with deionised water .  Each sample was done in duplicate.  The samples were 
loading into a 72-well rotor in the Rotor-Gene 6000 qPCR machine (Qiagen) and run 
in the conditions in Table 2-6. 
 
Hold at 90°C for 2 minutes 
95°C for 15 seconds }Repeated 40 times 
60°C for 60 seconds } 
Table 2-6 qPCR conditions 
The optimal concentration to run further qPCRs was calculated by choosing the 
concentration of cDNA which was within the exponential doubling phase of the 
qPCR.  For each qPCR run, the R2 was checked.   R2 is the percentage of the data 
which is consistent with the hypothesis that the given standards form a standard 
curve, and ideally should be around 0.99.  The reaction efficiency is a mark of how 
efficient each cycle of amplification is (i.e. does the fluorescent signal double with 
each cycle), and if it is 100% efficient the value is 1.   
Following the calculation of the optimal concentration for the qPCR, time course 
cDNAs at the appropriate optimal concentration were run with the same master mix 
as already listed.  Each PCR also had 5 standards run as a control.  For each set of 
cDNAs, the gene of interest was normalised to a glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) qPCR.   
2.5.5.2 Taqman® qPCR 
Previous work in the GI Unit by Ms Kimberley Soo had established that NOD2 
qPCR was best achieved using the Taqman® system (Applied Biosystems, Life 
Technologies) rather than the SYBR® Green system.  This involved the use of 
Taqman®’s inventoried, commercially available NOD2 and GAPDH assays.  Serial 
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dilutions of the cDNA were made to calculate the optimal concentration to run the 
qPCR: 
Neat   1:5 
1:10   1:50 
1:100   1:500 
1:1000   1: 5000 
1:10000  1:50000 
In addition, a Myc-tagged plasmid containing NOD2 (pCMV-Myc, BD Bioscience) 
was also used in serial dilutions for the standard curve: 
1:1000000  1:5000000 
1:10000000  1:50000000 
1:100000000  1:500000000 
1:1000000000 
RotorGene-specific 0.1ml strip tubes (Qiagen) were used to add 2µl of the relevant 
cDNA dilution, 5µl Taqman® Gene Expression master mix (Applied Biosystems, 
Life Technologies), 0.5µl primer mix (premixed assay of the relevant primers with 
the FAM reporter dye label, Applied Biosystems, Life Technologies) and deionised 
water to make up to 10µl.  Each sample was done in duplicate.  The samples were 
loading into a 72-well rotor in the Rotor-Gene 600 qPCR machine (Qiagen) and run 
on the programme shown in Table 2-7. 
 
Hold at 50°C for 2 minutes 
Hold at 95°C for 10 minutes 
95°C for 15 seconds } Repeat 40 times 
60°C for 60 seconds } 
Table 2-7 Taqman® qPCR conditions 
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Following the calculation of the optimal concentration for the qPCR, time course 
cDNAs at the appropriate optimal concentration were run with the same master mix 
as already listed.  Each PCR also had 5 standards of NOD2 plasmid run as a control.  
For each set of cDNAs, the gene of interest was normalised to a GAPDH Taqman® 
qPCR.   
2.6 Protein work 
2.6.1 Transfection 
SW480 cell transfections for western blotting and co-immunoprecipitation (Co-IP) 
were completed in T25 flasks incubated to achieve 80-90% confluence at the start of 
the transfection.  For each well to be transfected, 20µl lipofectamine™ 2000 
(Invitrogen, Life Technologies) was diluted into 500µl Opti-MEM® (Invitrogen, 
Life Technologies) without serum and incubated for 5 minutes at room temperature.  
Then 5µg of the DNA to be transfected was added to 500µl Opti-MEM® and this 
mixture added to the lipofectamine™/Opti-MEM® that had already been made up.  
This was incubated at room temperature for 20 minutes to allow the DNA-
lipofectamine™ complexes to form.  After the above incubation, the mixture was 
added to wells already containing 1.5ml Opti-MEM®.  The cells were incubated at 
37°C for 5-6 hours and the complexes were removed and complete medium, as 
defined in 2.4.1, was added.  After further incubation for at least 12 hours, the cells 
were harvested by being washed twice with 1ml PBS, scraped in 1ml fresh PBS and 
recovered into a 1.5ml tube.  This was spun at 13,500rpm for 5 minutes, the 
supernatant removed and discarded, and the cell pellet stored at -80°C. 
2.6.2 Cell lysate preparation 
Protein lysate for western blotting was produced by lysing the cell pellet with 500µl 
NP40 lysis buffer (master mix containing 16ml water, 1ml 2M NaCl, 1ml 10% NP-
40 (Calbiochem®, Merck, UK), 1ml 1M Hepes Buffer, 400µl 0.5M EDTA and 800µl 
complete protein inhibitor mix (Roche, UK)).   The solution was incubated on ice for 
20 minutes and spun at 13,000g at 4°C for 15 minutes.  The supernatant was 
transferred to a fresh tube ready for western blotting or co-immunoprecipitation, and 
stored at -80°C if not immediately needed. 
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2.6.3 Protein level quantification 
Protein lysate protein levels were quantified using the Qubit™ protein assay kit 
(Invitrogen, Life Technologies). 
2.6.4 Gel electrophoresis and western blotting 
Gel electophoresis used the NuPAGE® gel electrophoresis system (Invitrogen, Life 
Technologies).  For western blotting with protein lysates, 20µg protein lysate was 
added to 5µl 4x NuPAGE® LDS sample buffer, 2µl 10x NuPAGE® reducing agent 
along with sufficient deionised water to give a final volume of 20µl.  This sample 
was heated to 70°C for 10 minutes to denature the protein. 
1x NuPAGE® MOPS SDS running buffer was made up with the 20x solution 
provided and deionised water.  A NuPAGE® 4-12% Bis-Tris gel was mounted in the 
XCell Surelock™ Minicell system and the running buffer added into both chambers.  
500µl NuPAGE® antioxidant was added to the inner buffer chamber.  The denatured 
protein lysate samples were loaded onto the gel, with protein markers (a mixture of 
10µl Magic Marker and 5µl See Blue, both from Invitrogen, Life Technologies) in 
one lane.  The samples were run at 200V for 50 minutes.   
Following electrophoresis, western blotting was immediately started.  1x NuPAGE® 
Transfer buffer was made up with the 20x solution provided, deionised water, 10% 
methanol (20% if transferring 2 gels) and 0.1% NuPAGE® antioxidant.  The transfer 
pads and the filter paper were soaked in this buffer.  The PVDF membrane was 
presoaked in methanol for 30 seconds before being soaked in the transfer buffer.  The 
membrane was placed on the post electrophoresis gel and this was sandwiched 
between the filter paper.  This was put into the blot module surrounded by the 
transfer pads, according to Invitrogen’s protocols, and the transfer run for 1 hour at 
30V.  Following transfer the membrane was blocked in a milk solution (5% w/v 
Marvel (Premier Foods, UK) in PBS with 0.1% v/v Tween 20) for at least 1 hour at 
room temperature. 
2.6.5 Co-immunoprecipitation  
For each co-immunoprecipitation (CoIP) reaction, identical amounts of protein lysate 
were used.  In order to achieve this, 400µl of the lowest protein level sample was 
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used as the quantity of protein to be used in each reaction.  Appropriately calculated 
amounts of the other samples were used and each diluted with deionised water to 
achieve identical final concentrations and volumes. 
Protein G agarose beads (Roche, UK) were washed twice with PBS and centrifuged 
after each wash at 13000g for 30 seconds.  An equal volume of PBS was added to the 
agarose beads, and 20-30µl of the bead slurry pipetted out for each CoIP.  An 
appropriate amount of antibody (usually 2µg) and 400µl protein lysate was added to 
the bead slurry.  The mixture was incubated overnight on an orbital shaker at 4°C. 
The agarose beads were collected by short pulses of centrifugation and the beads 
washed twice with PBS.  PBS was added and incubated at 4°C for 10 minutes on an 
orbital shaker, and the beads centrifuged for 30 seconds.  The agarose beads were 
resuspended in 20µl 2x sample buffer, made up of 250µl 4x NuPAGE® LDS sample 
buffer, 200µl PBS and 50µl β mercaptoethanol.  The agarose beads were boiled for 3 
minutes to dissociate the immunocomplexes from the beads and denature the protein.  
After centrifugation at 13000g for 2 minutes the supernatant was collected and used 
to proceed directly to loading on the gel for gel electrophoresis and western blotting 
as described in section 2.6.4.  Protein lysate samples were also loaded onto the gel as 
described in section 2.6.4 to demonstrate that the initial transfection had been 
successful. 
2.6.6 Protein probing 
The transfer membrane from the western blotting was incubated overnight with the 
appropriate primary antibody at a concentration of 1µg/ml in 5% w/v Marvel in PBS 
with 0.1% v/v Tween 20 and constant agitation.  The membrane was washed 3 times 
for 10 minutes each in PBS/0.1% v/v Tween for 10 minutes and the appropriate 
secondary antibody applied in a concentration of 1:1000 in 5% w/v Marvel in PBS 
with 0.1% v/v Tween 20 (eg goat anti-rabbit IgG-HRP (Santa Cruz Biotech, Santa 
Cruz, CA) if a rabbit primary had been used) and incubated for 2 hours at room 
temperature before washing.   Finally the membrane was incubated in Immobilon™ 
Western Chemiluminescent HRP substrate (Millipore, Billerica, MA) for 5 minutes.  
X-ray film (Z370371, Sigma) was placed over the membrane for 10 seconds - 2 
minutes in a darkroom and the film passed through an X-ray developer to view the 
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luminescence of the membrane, seen as bands.  The markers were used to check that 
the bands seen were the correct size for the protein of interest. 
2.7 Expression studies on human intestinal tissue 
2.7.1 Recruitment of patients 
Patients attending for routine colonoscopy were approached to give consent for their  
participation in the study using a standard letter sent to them 1-2 weeks before their 
appointment (Appendices 10.7 and 10.8).  Patients with IBD were defined according 
to the standard criteria given in section 2.2.5.  Controls were recruited from the 
patient population attending for surveillance for bowel cancer or colonic polyps. 
2.7.2 Ethics 
The study had the full approval of the Lothian LREC (2001/4/72). 
2.7.3 Biopsy protocol 
Two biopsies were taken from each of: terminal ileum (if reached), ascending colon, 
transverse colon, descending colon, sigmoid colon and rectum.  Biopsies were 
collected and fixed in formaldehyde, mounted in paraffin blocks and sectioned onto 
Superfrost® Plus slides (Menzel Glaser, Germany).  The fixing, mounting and 
sectioning were done either in the Pathology Department, Western General Hospital, 
or at the Breakthrough Research Unit, Western General Hospital.    
2.7.4 Immunohistochemistry protocol 
Sections were deparaffinised in xylene (2 incubations of 5 minutes each), rehydrated 
in graded ethanol washes (2 x 5 minute washes in 100% ethanol then 2 x 5 minute 
washes in 70% ethanol) and finally washed in running water for 5 minutes.  Heat 
Induced Epitope retrieval (HIER) was performed in 500ml citrate buffer (10mM 
citric acid, pH adjusted to 6.0 with 1M NaOH, then 0.25ml Tween-20 added) in a 
pressure cooker for 5 minutes.  After a further wash for 5 minutes the slides were 
loaded into a Sequenza® (Thermo Scientific, UK) and washed in PBS for 5 minutes.  
The Envision™ system (Dako, Ely, UK) was used according to their protocols.  
Briefly, the dual endogenous enzyme block was applied for 5 minutes to block 
endogenous peroxidase activity.  After a 5 minute wash with PBS, 100µl of the 
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appropriately diluted primary antibody was applied and left to incubate for at least 30 
minutes.  After a further wash in PBS for 5 minutes the slides were incubated for 30 
minutes in 3 drops of labelled polymer HRP (horseradish peroxidase) – the 
secondary antibody.  The slides had a further wash in PBS for 5 minutes and were 
unloaded from the Sequenza®.  3,3'-diaminobenzidine (DAB) was made up using 
1ml of substrate buffer and 20µl DAB chromogen; 3 x 2 minute treatments were 
applied of the DAB with a brief wash in running water in between.  The slides were 
washed in running water, counterstained with filtered Mayer’s haematoxylin for 5 
minutes and dipped 3 times very briefly into 1% HCl in 70% ethanol to remove 
excess haematoxylin.   The slides were put in 0.2M lithium carbonate to ‘blue’ the 
slides, following a quick wash they were dehydrated in graded ethanol (2 x 5 minute 
washes in 70% ethanol then 2 x 5 minute washes in 100% ethanol) and mounted with 
pertex mounting medium.  Slides were visualized and imaged on an Olympus 
microscope. 
2.8 Site Directed Mutagenesis 
2.8.1 Initial PCR 
The Quikchange® site-directed mutagenesis kit (Stratagene®, La Jolla, CA) was 
used to attempt to introduce the 908 and 1007fs mutations into the NOD2 gene.  
Wild-type NOD2 had previously been cloned into a pCMV-Myc vector (BD 
Bioscience, gift of Dr Elaine Nimmo), and appropriate primers for the site-directed 
mutagenesis NOD2 mutations had already been designed by Dr Elaine Nimmo.  A 
PCR was run with 5µl 10x reaction buffer, 1µl dNTP mix, 2-10µl pCMV-Myc 
vector with NOD2wt, 125ng of each of the primers, 1µl PfuTurbo DNA polymerase 
(2.5U/µl) and made up to 50µl with ultra-pure water.  A control PCR was also set up 
with 5µl 10x reaction buffer, 1µl dNTP mix, 2µl (10ng) pWhitescript™ control 
plasmid, 1.25µl of each of the control primers, 1µl PfuTurbo DNA polymerase 
(2.5U/µl) and sufficient double distilled water to give a reaction volume of 50µl.  All 
the standard reagents were from the Quikchange® kit.  A PCR was performed with  
NOD2wt DNA according to the conditions in Table 2-8.  The control plasmid PCR 
was run according to the conditions in Table 2-9. 
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95°C for 30 seconds 
95°C for 30 seconds      } Repeated 16 times 
55°C for 1 minute     } 
68°C for 4 minutes (1minute/Kbp plasmid length)    } 
Table 2-8 Site-directed mutagenesis PCR for NOD2wt DNA 
95°C for 30 seconds 
95°C for 30 seconds      } Repeated 18 times 
55°C for 1 minute     } 
68°C for 5 minutes (1minute/Kbp plasmid length) } 
Table 2-9 Site-directed mutagenesis PCR from control plasmid 
Following PCR both reactions were placed on ice for 2 minutes to cool the reaction 
to <37°C.  1µl Dpn I restriction enzyme (10U/µl) was added to each reaction, mixed 
well and incubated at 37°C for 1 hour.  This enzyme is specific for methylated and 
hemi-methylated DNA and thus digests the parental DNA template whilst leaving the 
mutation-containing synthesised DNA intact, which contains staggered nicks due to 
incorporation of the primers.  
2.8.2 Transformation of XL-1 Supercompetent cells 
The XL1-blue E.Coli cells were gently thawed on ice.  For each control and sample 
transformation, 50µl of the cells were aliquoted into a prechilled 14ml polypropylene 
round-bottom tube (BD Biosciences), and 1µl of the appropriate post-PCR Dpn I 
treated DNA added to the tube.  As a control for this step, the transformation 
efficiency of the XL-1 cells was checked by adding 1µl of the pUC18 control 
plasmid (concentration 0.1ng/µl) to a further 50µl aliquot of the supercompetent 
cells.  The transformation reactions were gently mixed and incubated on ice for 30 
minutes.  The transformation reactions were heat pulsed for 45 seconds at 42°C and 
then put on ice for 2 minutes.  500µl NZY+ broth, having been preheated to 42°C, 
 
Materials and Methods   92   
was added to each reaction and the mixture incubated at 37°C for 1 hour with 
shaking at 225-250 rpm.   
The NZY+ broth was made as follows.  10g NZ amine (casein hydrolysate), 5g yeast 
extract, 5g NaCl were mixed and the solution made up to 1 litre with deionised 
water.  After adjusting the pH to 7.5 with NaOH and autoclaving the solution, 12.5ml 
1M MgCl2, 12.5ml 1M MgSO4 and 20ml 20% (w/v) glucose was added. 
Following incubation, 250µl aliquots of the cells were individually spread on 
Lysogeny broth (LB)-ampicillin (0.1mg/ml ampicillin) agar plates containing 
80µg/ml 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside (X-gal) and 20mM 
isopropyl-1-thio-β-D-galactopyranoside (IPTG).  For each of the sample mutagenesis 
reactions, 2 aliquots of the cells were individually plated out so that the whole of the 
500µl transformation reaction was used.  Only 5µl of the pUC18 control mixture was 
plated out using a further 200µl NZY+ broth.  The plates were incubated at 37°C 
overnight. 
2.8.3 Mutagenesis efficiency 
The pWhitescript™ control plasmid contains a stop codon (TAA) at the position 
where a CAA codon (coding for glutamine) would normally appear in the β 
galactosidase gene of the plasmid.  XL1-blue supercompetent cells transformed with 
this control plasmid appear as white colonies on LB-ampicillin plates containing 
IPTG and X-gal, as the β galactosidase activity has been removed.  However the 
point mutation introduced by the control primers revert the stop codon back to CAA 
and thus colonies can be screened for the β galactosidase (β gal+, blue) phenotype.  
The expected colony number from the transformation of the pWhitescript™ control 
mutagenesis reaction was 50-800 colonies.  More than 80% of the mutagenesis 
control colonies needed to contain the mutation for the site-directed mutagenesis 
control PCR to have been successful, and this was gauged by the number of blue 
colonies on the mutagenesis control agar plates containing IPTG and X-gal.   
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2.8.4 Transformation efficiency 
The transformation efficiency was calculated using the pUC18 control plasmid 
which was expected to give >250 colonies, with >98% having the blue phenotype, 
meaning that the transformation efficiency was >108cfu/µg.    
2.8.5 NOD2 mutagenesis analysis 
Individual colonies were streaked out onto an agar plate (with 100µg/ml ampicillin) 
using a pipette tip, and the pipette tip was dipped afterwards into the pre-prepared 
PCR mix to provide the DNA template for a PCR reaction to amplify the area of the 
expected mutagenesis, which was sequenced to check for successful introduction of 
the mutation.  Where the mutation appeared to have been introduced, the entire 
NOD2 gene was sequenced (using the methods detailed in sections 2.3.10 and 
2.3.11), to check that no other mutations had been introduced in the process. 
2.8.6 Plasmid DNA generation 
Colonies containing the introduced mutation were inoculated into 5ml LB culture 
medium (made by suspending 10g tryptone, 5g yeast extract and 10g NaCl in a total 
volume of 1 litre made up with water) with 0.1mg/ml ampicillin and incubated for 
about 7 hours at 37°C with gentle agitation.  10µl of this solution was inoculated into 
3ml LB medium with 0.1mg/ml ampicillin and the solution incubated overnight at 
37°C. 
2.8.7 Plasmid DNA purification 
Plasmid purification was performed according to the Qiagen Plasmid Purification 
Midi kit protocols (Qiagen).  After overnight culture, 25ml bacterial cell suspension 
was centrifuged at 6,000g for 15 minutes at 4°C, and the supernatant discarded.  The 
resulting pellet was resuspended in 4ml buffer P1 (resuspension buffer), and 4ml 
buffer P2 (lysis buffer) added and mixed well.  4ml buffer P3 (neutralisation buffer) 
was added and mixed well, and the mixture incubated on ice for 15 minutes.  This 
solution was centrifuged at >20,000g for 30 minutes at 4°C and the supernatant 
centrifuged again at >20,000g for 15 minutes at 4°C.  A Qiagen–tip 100 was 
equilibrated by adding 4ml buffer QBT (equilibration buffer) and allowing the 
column to empty by gravity flow.   The centrifuged supernatant was applied to the 
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Qiagen-tip and allowed to enter the resin by gravity flow.  Following this the Qiagen-
tip was washed twice with 10ml Buffer QC (wash buffer), which was also allowed to 
move through the tip by gravity flow.  The DNA was eluted using 5ml Buffer QF 
(elution buffer) into a 15ml tube.  The eluted DNA was precipitated by adding 3.5ml 
room temperature isopropanol and mixing, with subsequent centrifugation at 
>15,000g for 30 minutes at 4°C.  The supernatant was decanted, and the resulting 
DNA pellet washed with 2ml room temperature 70% ethanol and centrifuged at 
>15000g for 10 minutes, and the supernatant removed again.  The pellet was air 
dried for 10 minutes and the DNA redissolved in an appropriate volume of 1x TE.   
2.8.8 Plasmid DNA glycerol stock production 
100µl E.Coli K-12 cells (known competency 1x108cells/ml) and approximately 
100ng plasmid DNA were mixed in a 1.5ml tube and incubated on ice for 30 
minutes.  This was heated to 42°C for 2 minutes and then incubated on ice for 1 
minute.  500µl LB culture medium with 0.1mg/ml ampicillin was added and 
incubated at 37°C for 1 hour.  100µl of this solution was spread onto an Agar plate 
(containing 100µg/ml ampicillin) and incubated overnight at 37°C.  Single colonies 
were picked from each plate, put into 2ml LB culture medium with 100µg/ml 
ampicillin, and incubated at 37°C for 8 hours.  The samples were spun for 2 minutes 
at >20000g and the supernatant removed.  700µl LB culture medium with 25% 
glycerol was added to the pellet and the stocks stored at -20°C. 
2.9 Statistics 
2.9.1 Individual SNPs 
Individual SNPs were analysed through Haploview Version 4.2 or with the JMP 8.0 
(SAS) statistical package using the chi-squared or Fisher’s exact test, as appropriate.  
A significant p-value was considered to be <0.05, but where many SNPs were 
genotyped, a simple Bonferroni correction214 was made for multiple testing.   
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2.9.2 Gene-wide haplotype tagging methodology 
Multiple tagging SNPs were selected for genes based on HapMap data loaded onto 
Haploview and analysed according to the tagger algorithm embedded in Haploview 
version 4.2.215 
2.9.3 Haplotype analysis 
Haplotypic analyses were completed in Haploview version 4.2.   
2.9.4 Power calculations 
Power calculations for genetic studies were completed using Quanto216 
(http://hydra.usc.edu/GxE/). 
2.9.5 Kaplan-Meier survival analyses 
Kaplan-Meier analysis is a method of estimating survival function from patient data, 
and when the patient population is large enough, approximates the true survival 
function for that population.217  In the context of this thesis it was used to estimate 
the proportion of patients who had had a progression of their disease or had required 
an operation at any particular time point in disease course, bearing in mind ‘right 
censoring’ (patients not followed up long enough to have developed the 
complication).  Analyses of the Dundee and Edinburgh cohorts were performed 
using Microsoft Excel™ and GraphPad Prism version 4.00 (GraphPad Software, San 
Diego California USA), with the help of Dr Nicholas Lewin-Koh. 
2.9.6 Tests of correlation 
Tests of correlation were completed using GraphPad Prism version 4.00 for 
Windows (GraphPad Software, San Diego California USA). 
2.9.7 Chi-squared test 
Comparisons between groups were made using the chi-squared test, or Fisher’s exact 
test where appropriate, using using GraphPad Prism version 4.00 for Windows 
(GraphPad Software, San Diego California USA). 
2.9.8 Odds ratios 
All odds ratios are presented with 95% confidence intervals. 
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2.9.9 Receiver operating characteristic curve 
The receiver operating characteristic (ROC) curve is a method for displaying the 
relationship between the sensitivity and specificity of a continuous variable to predict 
another binary variable.  ROC curve analyses were completed using both GraphPad 
Prism version 4.00 for Windows (GraphPad Software, San Diego California USA) 
and JMP version 8.0.2 (SAS, Cary, NC, USA). 
2.9.10 Multivariate analyses 
Multivariate analyses on survival function were completed at Genentech, San 
Francisco by Nicholas Lewin-Koh using a Cox Proportional Hazards model designed 
in the R programme (version 2.10.1). 
The multivariate analyses on the severity data were completed using the statistical 
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Chapter 3 Analysis of disease progression and 
need for surgery in a Scottish Crohn’s Disease 
cohort  
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Summary 
Aim: To define the CD phenotype in Scottish patients according to the Montreal 
classification by examining the risk of disease progression and risk of surgery, 
including the need for multiple surgical resections. 
Methods: A total of 1155 patients recruited from Edinburgh and Dundee were 
examined.  Time to disease progression (development of stricturing and/or 
penetrating disease) and time to first resection were examined by Kaplan-Meier 
analyses.  Univariate analyses were completed on these factors with respect to 
disease location, age at diagnosis, smoking at diagnosis, perianal disease, and, for 
time to first resection, decade at diagnosis. Multivariate analyses of time to disease 
progression and time to first resection were also completed using a Cox Proportional 
Hazards model.  Kaplan-Meier analysis was used to examine the need for multiple 
resections with respect to disease location.   Patients who had developed stricturing 
disease as their first evidence of disease progression were examined for their 
subsequent risk of developing penetrating disease, and those with penetrating disease 
as their first evidence of disease progression were examined for their subsequent risk 
of stricturing disease.  
Results: Median time to disease progression was 14.5 years (95% CI 10.5-18.6).  On 
univariate analyses L2 disease had a longer median time to disease progression than 
other disease locations.  Age at diagnosis, smoking at diagnosis and presence of 
perianal disease were not important on univariate analyses.  This was confirmed on a 
multivariate analysis where the only significant factor was disease location, with L1 
disease conferring a HR of 4.7 (95% CI 3.6-6.1) and L3 disease HR 2.8 (95% CI 2.1-
3.8) compared with L2 disease.  The median time to first resection was 8.9 years 
(95% CI 7.5-10.0).  On univariate analyses L2 disease and those diagnosed in a later 
decade had a longer median time to first resection.  Age at diagnosis, smoking at 
diagnosis and presence of perianal disease were not important on univariate analyses.  
On a multivariate analysis (which excluded decade at diagnosis) the only significant 
factor for risk of first resection was disease location with L1 disease conferring a HR 
of 5.2 (95% CI 4.1-6.5) and L3 disease HR 2.6 (95% CI 2.1-3.3) compared with L2 
disease.  On Kaplan-Meier analysis of time to subsequent resections, there was a 
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statistically significant trend to increasing time between subsequent operations 
(p<0.0001).  This appeared to be primarily driven by patients with L2 disease.  Risk 
of stricturing disease in those with penetrating disease was similar to the penetrating 
disease in those with stricturing disease (p 0.843 on log rank test) 
Conclusions:  This study confirms the findings of previous studies that disease 
location is an important factor in determining risk of disease progression and risk of 
resection.  It also demonstrates that disease location is important in determining the 
need for multiple resections.  The data on disease behaviour would suggest that the 
stricturing and penetrating categories of disease behaviour should be considered as 
separate variables. 
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3.1 Introduction 
Crohn’s disease (CD) is an incurable inflammatory disease characterised by the 
tendency to progress to stricturing and/or penetrating disease.  Stricturing and 
penetrating disease can be major causes of morbidity for patients, with the need for 
intestinal resections as well as other surgical procedures such as stricturoplasties and 
incision and drainage of abscesses. 
The Montreal classification20, a modification of the Vienna classification17 is a 
method of classifying CD into meaningful categories, useful in research studies to 
provide uniformity of definitions across different clinicians and research groups.  A 
summary of the Montreal classification is shown in Table 3-1.  In particular, disease 
behaviour is commonly defined at a particular time point, usually 5 years after 
diagnosis, although in the analysis presented in this chapter a defined time point was 
not used because time to change in behaviour was examined. 
 
Age at diagnosis 
A1 <17 years old 
A2 17-40 years old 
A3 >40 years old 
Disease location (max extent before 1st resection) 









B3 Internally penetrating 
 +/- perianal modifier 'p'  
Table 3-1 Montreal classification of Crohn's disease
20
 
The problem with attempting to classify any disease as heterogeneous as CD is that a 
balance needs to be found between adequately describing disease variables and 
making the classification too complex to apply consistently.  Therefore, by necessity, 
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the Montreal classification can only be considered to give an outline of disease 
phenotype.   
One major area for debate is the behaviour variable, where penetrating disease (B3) 
overrides stricturing disease (B2).  This is based on the theory that increased 
intraluminal pressure (such as can occur in stricturing disease) helps to promote 
fistulae formation, reinforced by a small study of 42 consecutive CD intestinal 
resection samples in an Austrian hospital.218  Of these patients, 27 had internal 
fistulae, 26 of which had co-existent stricturing in the surgical specimen.   A bigger 
study of 236 resection specimens found 60 specimens with fistula formation of 
which only 4 did not have stricturing within the surgical specimen.219  Neither of 
these studies gives any details of the age at diagnosis of the patients in the study, 
although it seems likely that the majority of patients had adult onset disease.  Thus it 
is generally been assumed that patients with penetrating disease will have co-existent 
stricturing disease.  In contrast, however, a study of 55 paediatric CD resection 
specimens demonstrated that only 16 of the 28 specimens with fistulae formation 
also had evidence of stenosis in the surgical specimen.220  Whether this represents a 
difference between the paediatric and adult CD phenotype is unclear, but it certainly 
merits further investigation.  As discussed in the introduction, the recently published 
Paris classification21, a paediatric modification of the Montreal classification, has 
introduced a separate B2B3 disease behaviour category in recognition of the fact that 
in paediatric patients, stricturing and penetrating behaviours may be not be linked.   
Other factors not accounted for in the Montreal classification and purposely omitted 
from the preceding Vienna classification in the interests of simplicity17 include 
extraintestinal manifestations and family history, as well as a code for the oral 
disease location.  Furthermore there are additional factors that may be important in 
defining severe disease: nutritional status, drug response, socio-economic impact of 
disease and the need for multiple resections that are not within the Montreal 
classification.  Debate continues as to what classifies ‘severe’ disease, with no 
overriding consensus, but this will be addressed in more detail in the next chapter.   
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The aim of this chapter was to define the CD phenotype in Scottish patients 
according to the Montreal classification by examining the risk of disease progression 
and risk of surgery, alongside the risk of multiple resections. 
3.2 Patient recruitment 
Patients were recruited and phenotyped as detailed in Chapter 2.  The majority of 
patients were recruited some time after their disease had been initially diagnosed 
(median time from diagnosis to recruitment 9.4 years, interquartile range 3.2-18.8 
years).   
3.3 Definitions 
3.3.1 Stricturing disease 
The definition of stricturing disease was according to the Vienna17 and Montreal20 
classifications: ‘The occurrence of constant luminal narrowing demonstrated by 
radiologic, endoscopic, or surgical examination combined with prestenotic dilation 
and/or obstructive symptoms’. 
3.3.2 Penetrating disease 
The definition of penetrating disease was according to the Montreal classification: 
‘The occurrence of intra-abdominal fistulas, inflammatory masses and/or abscesses 
at any time in the course of disease’.20  Perianal fistulating disease was considered 
separately. 
3.3.3 Disease location 
As per the Montreal classification, disease location was defined as the maximum 
extent prior to the first resection.  For patients who had not had a resection, it was 
defined as the maximum extent during follow up.  The maximum extent was defined 
as the sum of all the areas affected at any point prior to the first resection, even if 
different areas had been affected at different times. 
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3.3.4 Time to last follow up 
Time to last follow up was the time from diagnosis of CD to the last investigation 
(for example radiological or endoscopic examination) rather than the time to the last 
clinic appointment.  
3.3.5 Time to disease progression 
Time to disease progression was defined as the time from diagnosis to the first 
stricturing or internally penetrating complication.   
3.3.6 Time to stricturing and penetrating disease 
Patients developing stricturing disease as their first evidence of disease progression 
could subsequently develop penetrating disease; patients developing primarily 
penetrating disease were assumed to also have stricturing disease, as discussed in 
section 1.1. 
3.3.7 Time to first surgical resection 
Time to first surgical resection was defined as the time from diagnosis to the first 
intestinal resection, no matter how much intestine was resected.  It excluded simple 
appendicectomies (even if CD was found in the resected specimen), defunctioning 
procedures and stricturoplasties.  
3.4 Patient demographics  
Basic patient demographics and comparisons (using chi-squared test) between the 
cohorts are shown in Table 3-2.  Most patients (68%) were recruited in Edinburgh.  
There was a significant difference in the proportions of males in the two cohorts, 
(44.7% in the Dundee cohort vs. 37.3%, p=0.02).  The median age at diagnosis was 
greater in the Dundee cohort, with more patients diagnosed at >40 years (35.7% vs. 
26.0%, p=0.0007), and fewer patients diagnosed at <17 years old (A1, 7.4% vs. 
11.7%, p=0.0246).  Both cohorts had similar durations of follow-up.  There was no 
significant difference in the proportions of current and non–smokers at diagnosis, but 
a higher proportion of the Dundee cohort were ex-smokers (17.2% vs. 11.2%, 
p=0.0049).  The proportion of patients with L1 disease was lower in the Dundee 
cohort (19.6%  vs. 30.6%, p<0.0001); the opposite was the case for L3 disease 
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(31.3% vs. 19.9%, p<0.0001).  Although similar proportions of patients in both 
cohorts had inflammatory disease at 5 years, more patients had stricturing disease 
and fewer had internally penetrating disease in the Dundee cohort (stricturing disease 
18.1% vs. 12.3%, p=0.0262); internally penetrating disease 10.8% vs. 16.4%, 
p=0.0345).  The large percentage of ‘not knowns’ for disease behaviour was either 
due to records having been destroyed or because patients had been managed 
elsewhere and their full investigation profile was not available at 5 years. 
 
Variable Dundee cohort Edinburgh cohort Combined 
Chi sq p-
value 
Total number of 
patients (% of total) 367 (32%) 788 (68%) 1155 NA 
Sex (% male) 164 (44.7%) 294 (37.3%) 458 (39.7%) 0.02 








Age group at diagnosis (% of total) 
A1 27 (7.4%) 92 (11.7%) 119 (10.3%) 0.0246 
A2 209 (56.9%) 491 (62.3%) 700 (60.6%) 0.0825 
A3 131 (35.7%) 205 (26.0%) 336 (29.1%) 0.0007 







(IQR 4.1-19.7)  
Smoking at diagnosis (% of total)  
Current 150 (40.9%) 317 (40.2%) 467 (40.4%) 0.2466 
Ex 63 (17.2%) 88 (11.2%) 151 (13.1%) 0.0049 
Non smoker 152 (41.4%) 355 (45.0%) 507 (43.9%)  0.8356 
Not known 2 (0.5%) 28 (3.5%) 30 (2.6%)  
Disease location (% of total)  
L1 Ileal 72 (19.6%) 241 (30.6%) 313 (27.1%) <0.0001 
L2 Colonic 118 (32.2%) 279 (35.4%) 397 (34.4%) 0.2784 
L3 Ileocolonic 115 (31.3%) 157 (19.9%) 272 (23.5%) <0.0001 
L4 Upper GI 4 (1.1%) 24 (3.0%) 28 (2.4%) 0.0442 
L4+another location 51 (13.9%) 69 (8.8%) 120 (10.4%) 0.0077 
Not known 7 (1.9%) 18 (2.3%) 25 (2.2%)  
Disease behaviour at 5 years (259 Dundee patients and 560 Edinburgh patients) (% of total) 
B1 Inflammatory 165 (63.7%) 356 (63.6%) 521 (63.6%) 0.9702 
B2 Stricturing 47 (18.1%) 69 (12.3%) 116 (14.2%) 0.0262 
B3 Penetrating 28 (10.8%) 92 (16.4%) 120 (14.7%) 0.0345 
Not known 19 (7.3%) 43 (7.7%) 62 (7.6%)  
Table 3-2 Dundee and Edinburgh basic demographics 
 
 
Disease progression and surgery   105   
Variable Males  Female  Chi sq p-value 
A1 57 (12.5%) 61 (8.8%) 0.047 
A2 269 (58.7%) 434 (62.2%) 0.229 
A3 132 (28.8%) 202 (29.0%) 0.953 
    
L1 107 (23.3%) 206 (29.6%) 0.022 
L2 168 (36.7%) 229 (32.9%) 0.184 
L3 107 (23.4%) 165 (23.7%) 0.944 
L4 16 (3.5%) 12 (1.7%) 0.077 
L4+ another 
location 50 (10.9%) 70 (10.0%) 
0.694 
Unknown 10 (2.2%) 15 (2.1%)  
Table 3-3 Age group at diagnosis and Montreal locations according to sex 
The analysis of age group at diagnosis and disease location according to sex is shown 
in Table 3-3.  The only statistically significant differences between the sexes were 
with age at diagnosis and L1 disease. 
 
Variable Non Ex Current Chi Sq p-value 
L1 119 (23.4%) 39 (25.8%) 144 (30.9%) 0.032 
L2 189 (37.3%) 68 (45.1%) 128 (27.5%) <0.0001 
L3 114 (22.4%) 26 (17.2%) 128 (27.5%) 0.023 
L4 16 (3.2%) 5 (3.3%) 6 (1.3%) 0.119 
L4+another 
location 60 (11.8%) 12 (7.9%) 46 (9.8%) 0.332 
Unknown 9 (1.8%) 1 (0.7%) 14 (3.0%)  
Table 3-4 Analysis of disease location with respect to smoking status  
The analysis of disease location with respect to smoking status at diagnosis (Table 
3-4) demonstrated that L2 disease was more common in non- and ex-smokers than 
with current smokers, with the opposite being true for L1 and L3 disease. 
3.5 Disease progression data 
3.5.1 Time to disease progression 
Including patients who had stricturing or penetrating disease at diagnosis, the median 
time to disease progression for the cohort was 14.5 years (95% confidence interval 
(CI) 10.5-18.6 years).  The Kaplan-Meier graph of progression-free proportion is 
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shown in Figure 3-1.  At one year after diagnosis, most of the patients with 
stricturing or penetrating disease had already had this phenotype at diagnosis: 18% of 
patients had stricturing or penetrating disease at diagnosis, whereas at one year 
follow-up, 20.5% of patients had stricturing or internally penetrating disease.  By 5 
years this percentage was 32.6% and then increased to 45% at 10 years and 54.5% at 
20 years, as shown in Table 3-5.      
































Figure 3-1 Kaplan-Meier of development of stricturing or penetrating disease 
 
Time/years 








Table 3-5 Percentages of patients with development of stricturing or penetrating disease, 
including those with disease progression at diagnosis 
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This analysis was repeated having excluded patients who had stricturing or 
penetrating disease at diagnosis; the Kaplan-Meier curve is shown in Figure 3-2.  
The median time to disease progression was 26.5 years.  At one year after diagnosis, 
of those still under follow up, only 3.1% of patients with inflammatory disease at 
diagnosis had developed stricturing or penetrating disease.  By 5 years, 17.8% of 
patients still under follow up had developed stricturing or penetrating disease, as 
shown in Table 3-6. 
































Figure 3-2 Kaplan-Meier of development of stricturing or penetrating disease, excluding those 
with disease progression at diagnosis 
 
Time/years 







Table 3-6 Percentages of patients with development of stricturing or penetrating disease, 
excluding those with disease progression at diagnosis 
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Rather than just plotting disease complications as a whole, the development of 
stricturing and penetrating disease was separated out (Figure 1-3).  Patients who 
developed penetrating disease directly from inflammatory disease were assumed to 
have stricturing disease at the time of development of penetrating disease, as per the 
Montreal classification and as discussed in section 3.1.  The median time to 
development of stricturing disease was 14.5 years whereas for penetrating disease 
this time was much higher at 52.2 years.  At diagnosis, 18.0% and 8.9% of patients 
had already developed stricturing and penetrating disease respectively, and by 5 
years these figures were 32.6% and 17.8% respectively (Table 3-7).  Over time, the 
proportion of patients with disease progression increased: at 20 years 54.5% and 
31.0% had developed stricturing and penetrating disease respectively. 


































Figure 3-3 Kaplan-Meier curve of development of stricturing and penetrating disease 
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% with progression 
Time/years Stricturing Penetrating 
0 18.0 8.9 
1 20.5 11.3 
3 26.5 14.2 
5 32.6 17.8 
10 45.0 24.9 
20 54.5 31.0 
Table 3-7 Percentages of patients with development of stricturing and penetrating disease, 
including those with disease progression at diagnosis 
3.5.2 Comparison of time to disease progression in Dundee and 
Edinburgh cohorts 
Given the phenotypic differences in the Dundee and Edinburgh cohorts (Table 3-2) 
the time to disease progression was compared between the two cohorts.  There was 
no statistically significant difference between the cohorts (log rank test p=0.378).  
The median time to disease progression for the Dundee and Edinburgh cohorts was 
18.6 and 12.7 years respectively. 
3.5.3 Time to disease progression according to disease location 
To determine whether disease location affected time to progression, Kaplan-Meier 
survival analysis was used to compare disease progression in patients with different 
disease locations. 
The initial analysis included all patients who had stricturing or penetrating disease at 
diagnosis (Figure 3-4).  The median time to disease progression for L1, L2, L3 and 
L4 disease was 3.3 years, 36.9 years, 10.4 years and 5 years respectively (log rank 
test p <0.0001).  As shown in Table 3-8, at 5 years 53.9% of L1 patients and 53.6% 
of L4 patients, compared with 11.5% of L2 and 33.3% of L3 patients had 
demonstrated disease progression.  At 20 years the difference between L3 and L1/L4 
disease was less marked, as 75% of L1, 84.9% of L4 and 65.7% of L3 patients had 
disease progression, although there was a clear difference between all of these and 
L2 disease in whom 20.4% of patients had progressed. 
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Figure 3-4 Kaplan-Meier of disease progression by disease location 
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% with progression 
Time/years L1 L2 L3 L4 
0 36.5 4.2 13.9 32.4 
1 40.9 4.8 16.9 33.8 
3 48.3 7.3 24.7 41.6 
5 53.9 11.5 33.3 51.6 
10 67.8 18.3 48.9 68.9 
20 75.0 20.4 65.7 84.9 
Table 3-8 Percentages of patients with disease progression by disease location, including those 
with disease progression at diagnosis 
As Table 3-8 shows, different proportions of L1 (36.5%) and L2 (4.2%) patients had 
disease progression at diagnosis.  To determine the time to development of 
penetrating or stricturing disease for patients with inflammatory disease at diagnosis, 
all patients with stricturing or internally penetrating disease at diagnosis were 
removed and the analysis repeated (Figure 3-5).  The median time to disease 
progression for L1, L2, L3 and L4 disease was 10.3 years, 36.9 years, 14.5 years and 
9.3 years respectively (log rank test p<0.0001).  As shown in Table 3-9, similar 
proportions of L1, L3 and L4 patients had disease progression at 5, 10 and 20 years, 
with L2 disease being markedly lower.  When L2 disease was excluded there was no 
difference between the other groups (log rank test p=0.121). 
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Figure 3-5 Kaplan-Meier curve of disease progression by disease location, excluding those with 
disease progression at diagnosis 
 
% with progression 
Time/years L1 L2 L3 L4 
1 7.0 0.5 3.5 2.2 
3 18.6 3.0 12.5 3.7 
5 27.4 7.6 22.5 28.4 
10 49.3 14.6 40.6 54.0 
20 59.0 16.9 60.2 77.6 
Table 3-9 Percentages of patients with disease progression by disease location, excluding those 
with disease progression at diagnosis 
3.5.4 Time to disease progression according to age at diagnosis 
A Kaplan-Meier survival analysis was used to examine whether time to disease 
progression differed according to the Montreal age group at diagnosis.  Although the 
median time to disease progression did increase across the age groups (A1, A2 and 
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A3 median times to disease progression 11.1, 14.2 and 16.7 years respectively), this 
did not reach statistical significance (log rank test p=0.8114). 
3.5.5 Time to disease progression according to smoking at 
diagnosis 
Kaplan-Meier survival analysis was used to examine whether time to disease 
progression differed according to smoking status at diagnosis (non-smoker, ex-
smoker, current smoker).  There was a statistically significant difference between the 
curves (log rank test p=0.011; median times to disease progression 18.2, 19.5 and 
10.3 years for non-, ex- and current smokers respectively).  This difference can be 
explained by the higher rate of disease progression at diagnosis (15.4%, 13.7% and 
21.8% for non-, ex-, and current smokers respectively); when these patients were 
excluded from the analysis, there was no difference in median times to disease 
progression (29.8, 35.4 and 21.2 years for non-, ex- and current smokers 
respectively, log rank test p=0.1883). 
3.5.6 Time to disease progression according to presence of 
perianal disease 
Kaplan-Meier analysis was used to examine whether time to disease progression 
differed according to the presence of perianal disease at any point in disease course.  
There was no difference in median time to disease progression between patients with 
and without perianal disease (14.5 years for both groups, log rank test p=0.6544). 
3.5.7 Time to disease progression - multivariate analysis  
To determine the relative contribution of different factors to the risk of disease 
progression, a multivariate analysis was completed by Dr Nicholas Lewin-Koh at 
Genentech, SF using the R programme (version 2.10.1).  A Cox proportional hazards 
model was used to examine the factors that significantly affect time to disease 
progression.  The model included disease location, gender, age at diagnosis (as a 
continuous variable), smoking at diagnosis and the presence of perianal disease.  
Results showed that disease progression was not associated with gender, age at 
diagnosis, smoking at diagnosis or perianal disease.  When compared to the risk of 
disease progression in patients with L2 disease, L1 disease conferred a hazards ratio 
(HR) of 4.7 (95% CI 3.6-6.1) and L3 disease conferred a HR of 2.8 (95% CI 2.1-3.8). 
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3.6 Surgical resection data 
3.6.1 Time to first resection 
The median time to first resection was 8.9 years (95% CI 7.5-10.0 years, Figure 3-6).  
A substantial proportion (12.7%) required a resection at diagnosis, as shown in Table 
3-10.  By 3 years, 32.8% of patients had required at least one resection, rising to 
53.3% at 10 years and 68.9% at 20 years. 



































Figure 3-6 Kaplan-Meier curve of time to first surgical resection 
 
Time/years 








Table 3-10 Time to first resection 
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3.6.2 Comparison of time to first resection in Dundee and 
Edinburgh cohorts 
The time to first resection was compared between the two cohorts.  There was no 
significant difference between the cohorts, but there was a trend for the time to first 
resection to be shorter in the Edinburgh cohort than the Dundee cohort (median times 
8.0 and 10.8 years respectively, log rank test p=0.0714).    
3.6.3 Time to first resection according to disease location 
Kaplan-Meier analysis was completed for time to first resection according to disease 
location (Figure 3-7).  The median time to 1st resection for L1, L2, L3 and L4 disease 
was 1.3 years, 30.0 years, 7.8 years and 7.0 years respectively (log rank test 
p<0.0001).  As shown in Table 3-11, patients with L1 disease were particularly likely 
to have a resection at diagnosis, with 26.9% of L1 patients falling into this category, 
as opposed to 3.4%, 6.8% and 9.5% for L2, L3 and L4 disease respectively.  The L1 
disease location category had the lowest resection-free proportion at all points during 
follow up.  Patients with L2 disease had a much lower risk of a resection than any of 
the other locations, and even at 20 years only 39.7% had needed at least one 
resection.
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Figure 3-7 Time to first resection according to disease location, including those operated on at 
diagnosis 
 
% required first resection 
Time/years L1 L2 L3 L4 
0 26.9 3.4 6.8 9.5 
1 46.6 6.9 15.9 23.3 
3 57.9 12.5 29.6 36.6 
5 65.4 16.3 37.4 49.9 
10 76.4 26.8 59.1 66.5 
20 87.6 39.7 78.3 85.5 
Table 3-11 Percentages of patients needing resection by disease location, including patients 
operated on at diagnosis 
The Kaplan-Meier analysis was repeated excluding patients who were operated on at 
diagnosis, and the statistically significant difference between the groups remained 
(log rank p<0.0001, Figure 1-8), even when L2 patients were not included in the 
analysis (p=0.0002).  The median times to first resection for L1, L2, L3 and L4 
disease were 4.5 years, 30.0 years, 8.9 years and 7.3 years respectively.  As shown in 
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Table 3-12, the L1 disease location had the largest proportion of patients requiring 
resection within the first 5 years (52.7%), but by 10 and 20 years the differences 
between patients with L1, L3 and L4 disease were much less marked.  L2 disease 
continued to have a lower risk of resection, with only 37.9% of patients followed up 
at 20 years having needed a resection. 




































Figure 3-8 Time to first resection, excluding patients operated on at diagnosis 
 
% required first resection 
Time/years L1 L2 L3 L4 
1 27.0 3.6 9.8 15.3 
3 42.3 9.5 24.5 29.9 
5 52.7 13.4 32.8 36.9 
10 67.6 24.2 56.1 63.0 
20 83.0 37.9 76.7 84.0 
Table 3-12 Percentages of patients needing resection by disease location, excluding patients 
operated on at diagnosis 
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3.6.4 Time to first resection according to age at diagnosis 
Kaplan-Meier survival analysis was used to examine time to first resection according 
to the Montreal age group at diagnosis.  There was no significant difference in the 
median time to first resection between the age groups (A1, A2 and A3: 9.0, 8.2 and 
16.2 years respectively, log rank test p=0.228). 
3.6.5 Time to first resection according to smoking at diagnosis 
Kaplan-Meier survival analysis was used to examine time to first resection according 
to the smoking status at diagnosis (non-smoker, ex-smoker, current smoker).  The 
median times to resection were significantly different (9.6, 19.1 and 6.5 years for 
non, ex and current smokers at diagnosis respectively, log rank test p<0.0001).  This 
significance remained even when those operated on at diagnosis were excluded 
(p=0.0018, median times to resection 11.0, 20.9 and 9.7 years for non, ex and current 
smokers at diagnosis respectively, Figure 3-9).  When ex-smokers were excluded, the 
differences between non- smoker and current smoker Kaplan-Meier curves did not 
quite attain significance (log rank test p=0.0537).  The difference is not explained by 
disease location, as ex smokers had a statistically significant excess of L2 disease. 


































Figure 3-9 Time to first resection according to smoking status at diagnosis 
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3.6.6 Time to first resection according to presence of perianal 
disease 
Kaplan-Meier survival analysis was used to examine whether time to first resection 
differed according to the presence of perianal disease at any point in the disease 
course.  The median times to first resection for patients with and without perianal 
disease were 7.0 years and 9.4 years respectively but this was not significantly 
different (log rank test p=0.4185). 
3.6.7 Time to first resection according to decade at diagnosis 
As surgical practices have changed over the last few decades, a Kaplan-Meier 
analysis was completed comparing decade of diagnosis and risk of surgery.  The 
numbers of patients diagnosed in each decade is shown in Table 3-13.  The Kaplan-
Meier graph is shown in Figure 3-10.  The median times for those diagnosed in the 
1950-60s, 1970s and 1980s were similar at 6.0, 6.9 and 7.1 years respectively, but for 
those diagnosed in the 1990s the median time to first resection was 10.1 years.  For 
those patients diagnosed in the 2000s the median time could not be defined due to 
insufficient follow up.  On a log rank test there was a statistically significant 
difference in the Kaplan-Meier curves between the groups (p=0.008) which became 
stronger on a log rank test for trend across the decades (p-value 0.0004), indicating 
an increase in the median time to first resection across the decades. 
 









Excluded as surgical information not known  3 
Total 1155 
Table 3-13 Number of patients diagnosed in each decade 
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Figure 3-10 Kaplan-Meier curve of time to 1st resection by decade at diagnosis 
3.6.8 Time to first resection - multivariate analysis  
A Cox proportional hazards model was generated by Dr Nicholas Lewin-Koh to 
determine the factors that are independently associated with the risk of 1st resection.  
The model included gender, age at diagnosis (as a continuous variable), smoking at 
diagnosis and the presence of perianal disease.  There was no association with age at 
diagnosis, gender, smoking at diagnosis or perianal disease.  When compared with 
the risk of first resection for patients with L2 disease, L1 location conferred a HR of 
5.2 (95% CI 4.1-6.5) and L3 disease conferred a HR of 2.6 (95% CI 2.1-3.3). 
3.6.9 Multiple resections 
The notes from the Scottish cohort were examined and information about dates of 
operations extracted.  The maximum number of resections in any patient was seven.  
This multiple resection data was plotted on a Kaplan-Meier curve (Figure 3-11).  For 
the total population the median time from diagnosis to the 2nd resection was 40.1 
years, but for the 3rd-7th resections could not be defined as the majority of patients 
were not at risk, having not having had a 2nd resection.   
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Figure 3-11 Kaplan-Meier curve of time to resection from diagnosis 
The median time from diagnosis to the ‘n’th resection was calculated by considering 
only those at risk (Table 3-14).  The median time from diagnosis to 2nd resection was 
long at 25.7 years and thereafter was above 30 years with 34.5 years being the 
median time from diagnosis to the 4th resection.  Beyond the 4th resection the number 
of patients at risk was substantially reduced, making meaningful comparisons more 
difficult.
 



























1st resection 1155 589 1 565 8.9  
2nd resection 590 204 6 380 25.7 18.4 
3rd resection 210 75 5 130 32.6 16.8 
4th resection 80 31 4 45 34.5 9.2 
5th resection 35 11 1 23 Undefined Undefined 
6th resection 12 4 1 7 37.8 16.8 
7th resection 5 2 0 3 38.0 26.6 
Table 3-14 Population at risk and median times to resection 
The data were also analysed according to time from previous resection, arguably a 
more clinically relevant comparison.  The median times from previous resection to 
the next resection are shown in Table 3-14.  The Kaplan-Meier curve is shown in 
Figure 3-12. There was a statistically significant difference between the curves (log 
rank test, p<0.0001) and in addition the log rank test for trend between the 1st and 7th 
resection was also statistically significant (p-value <0.0001) indicating a trend for an 
increasing time between subsequent resections. 
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Figure 3-12 Kaplan-Meier curve of time from previous resection to next resection 
3.6.9.1 Multiple resection data according to disease location 
The multiple resection data were subdivided according to disease location.  Only the 
first four resections were considered as subsequent resections had insufficient 
patients at risk in each disease location for the analysis to be meaningful.  Times 
from each resection to subsequent resection were compared across each disease 
location in a Kaplan-Meier analysis; the results are shown in Table 3-15.  L1, L3 and 
L4 locations all showed significant differences between times to subsequent 
resections, which was not seen in L2 disease.  For L1 and L3 disease there was a 
significant decrease in the time intervals between subsequent resections, shown by 
the log rank test for trend (<0.0001 and 0.0097 respectively). 
 















Number at risk 360 264 86 25 L1 
Median time to 
resection/years 1.3 17.4 16.8 6.8 <0.0001 <0.0001 
Number at risk 416 101 22 6 L2 
Median time to 
resection/years 30 Undefined Undefined 12.3 0.6021 0.9667 
Number at risk 325 186 75 32 L3 
Median time to 
resection/years 7.8 18.4 11.7 6.1 <0.0001 0.0097 
Number at risk 147 101 52 22 L4 
Median time to 
resection/years 7 10.7 7.2 6.8 0.0022 0.0580 
Table 3-15 Disease location number at risk, median time to resection from previous resection 
and log rank test results 
3.7 Detailed analysis of disease progression in the Dundee 
cohort  
The Dundee cohort was examined in more detail to determine whether stricturing 
and internally penetrating disease are linked and should be considered sequential, or 
if they should be considered as completely separate markers of disease progression. 
The aim was to examine the patients who developed stricturing disease to determine 
whether they ever developed penetrating disease, and those who went from 
inflammatory to penetrating disease without an intermediate diagnosis of stricturing 
disease to determine whether any of them did have strictures at the time of diagnosis 
of penetrating disease, or if they subsequently developed strictures. 
The patients from the Dundee cohort who had complete follow up documented 
throughout their disease course were considered (n=345 patients).  There were 17 
patients who had both stricturing and penetrating disease together as the first 
evidence of disease progression and were excluded from the following analyses.  
Patients who developed stricturing disease as the first evidence of disease 
progression were examined (n=84) using Kaplan-Meier analysis.  The median time 
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to development of penetrating disease was 32.4 years (Figure 3-13).  

































Figure 3-13 Kaplan-Meier curve of time to development of penetrating disease from time of 
diagnosis of stricturing disease   
Similarly, patients who developed penetrating disease as the first evidence of disease 
progression were examined for development of stricturing disease (n=32, Figure 
3-14).  The median time to development of stricturing disease could not be defined, 
as 50% of patients had not developed stricturing disease during the follow-up period.  
A table showing the percentages of patients developing a different type of disease 
progression is shown in Table 3-16.  Although the numbers of patients at risk is 
lower in patients with B3 disease as their first evidence of disease progression, very 
similar proportions of patients subsequently develop a different type of disease 
progression. At 10 years 25.9% of stricturing patients have penetrating disease, 
compared with 28.2% of penetrating patients have stricturing disease.  On a log rank 
test there was no statistically significant difference between the two groups (p 0.843). 
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Figure 3-14 Kaplan-Meier curve of time to development of stricturing disease from time of 
diagnosis of penetrating disease  
 





% with B2 disease 
developing B3 disease 
Penetrating-Stricturing (B3-
B2) 
% with B3 disease 
developing B2 disease 
5 18.7 14.1 
10 25.9 28.2 
20 40.1 42.4 
Table 3-16 Disease progression changes in the Dundee cohort 
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3.8 Discussion 
3.8.1 Patient demographics  
There were statistically significant differences in demographics and phenotype 
between the Dundee and Edinburgh cohorts.  Whether there really are differences 
between cohorts which are geographically so close is unlikely.  The higher 
proportion of young onset patients in the Edinburgh cohort is likely to reflect its 
position as a tertiary referral centre.  The differences in disease location between the 
cohorts, especially in the proportions of L1 and L3 disease, as shown in Table 3-2, 
could possibly be because the two centres have different investigation algorithms; for 
example the Dundee cohort could do more routine colonoscopies of patients with 
ileal CD, thus finding more colonic disease or completing more small bowel 
investigations in those with colonic disease.   Although there was a statistically 
significant difference in disease behaviour at 5 years between the two cohorts, as 
shown in Table 3-2, this was not reflected in differences in disease progression when 
the two cohorts were compared in a Kaplan-Meier analysis in section 3.5.2, and is 
therefore unlikely to be a real difference.   
Smoking status markedly affected disease location, with patients who were smoking 
at diagnosis much more likely to have ileal disease and less likely to have pure 
colonic disease than non- or ex-smokers.  This is in keeping other published 
cohorts.221;222 
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3.8.2 Comparison of disease progression in Scotland with other 
cohorts 
Two of the largest patient cohorts studied for disease progression are from France223 
(Cosnes et al.) and New Zealand224 (Tarrant et al.).  A table comparing the basic 
characteristics of the cohorts is shown in Table 3-17.   
 
Age at diagnosis 
(%) 
Location (according to Vienna 
classification17) 
% of patients in each group 
Country Pt no. Follow up 
A1 A2 A3 Time of 
assessment 
L1 L2 L3 L4 
Scotland 1155 Median 10.3 
yrs (IQR 
4.1-19.7) 
10 61 29 Maximum 
extent  
27 34 24 13 
France223 2002 Mean   
8.6 +/-7.9 
years 





715 Median  
6.5 years 
12  58  30  At 
diagnosis  
32 49 19 1 
Table 3-17 Comparison of basic demographics 
The French dataset, although much bigger than the Scottish cohort (2002 patients 
compared with 1155), had similar numbers of patients still under follow up at 20 
years: approximately 300 (15%) compared with 283 patients (24.5%) in the Scottish 
cohort.  The French data were analysed according to the Vienna classification; thus 
the definitions of location were slightly different and perianal fistulae counted as 
penetrating disease.  Due to the way the data were collected in the Scottish cohort, it 
was not possible to analyse the data according to the Vienna classification of disease 
behaviour, making a direct comparison difficult.  In the French cohort, perianal 
disease accounted for 540 (57%) of the 945 penetrating disease progressions.  Of 
these, in 433 (80%) no internally penetrating behaviour was ever observed; it was 
only in the remaining 107 patients (20%) that an internally penetrating complication 
followed.  This indicates that out of the total population, although there were 945 
penetrating disease complications, only 512 (54%) ever developed internally 
penetrating disease.   Therefore it is not surprising that the figures for development of 
disease progression were much higher compared with the Scottish cohort (Table 
3-18), with the risk at 20 years of having stricturing or penetrating disease being 88% 
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in the French cohort, compared with 54.5% in the Scottish cohort.  Risk factors for 
penetrating disease in the French cohort were age at diagnosis <40 (HR 1.4, 95% CI 
1-1.5), being non Causcasian (HR 1.3, 95% CI 1.1-1.6), anoperianal lesions (HR 2.6, 
95% CI 2.3-3.0) and lack of oesophagogastroduodenal involvement (HR 1.4, 95% CI 
1.1-1.9).  Risk factors for stricturing disease included ileal or jejunal involvement 
and lack of colonic involvement (HR 2.5, 3.2 and 2.0 respectively) as well as lack of 
anoperineal involvement (HR 1.4).  For the disease location variable it is not clear 
what the reference was for the hazard ratios.  The multivariate analysis data 
presented in this chapter was on the basis of time to first evidence of disease 
progression, rather than considering stricturing and penetrating disease separately; 
disease location also came out strongly, but age at diagnosis was not significant, nor 
was perianal disease.  Perianal (‘anoperineal’) being a risk factor for penetrating 
disease yet protective against stricturing in the French dataset can be explained by 
their data collection.  In their population, 46% of the patients who developed 
penetrating disease only ever had perianal disease as their manifestation of 
penetrating disease; this would explain why perianal disease was a risk factor for 
penetrating disease.   Anoperineal disease ‘protecting’ against stricturing disease 
would have been because patients directly developing penetrating disease were 
excluded from further analyses of stricturing disease, having been ‘censored’ for 
stricturing disease at the time of penetrating disease development.  
In the New Zealand cohort, where disease behaviour was phenotyped according to 
the Montreal classification, the risk of disease progression was much higher than in 
the Scottish cohort (45% vs. 17.8% at 5 years in those patients with inflammatory 
disease at diagnosis), as shown in Table 3-18.  The median time to disease 
progression was also shorter (21.2 years compared with 26.5 years in the Scottish 
cohort, only considering those with B1 disease at diagnosis). The presence of 
perianal disease was predictive of disease progression (HR 1.62, 95% CI 1.28-2.05), 
as was L3 and L1 disease (HR not stated in the paper). 
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% Risk of progression 
at different time points 
Cohort  
0 5yrs 10yrs 20yrs Risk factors for disease progression 
Including 
B2/B3 at 








Dx NG 52.0 NG 88.0 






Dx 0 45.0 56.0 NG 
Ileal/Ileocolonic disease, Perianal disease 
Table 3-18 Risk of disease progression in the different cohorts, NG= Not given 
The comparisons suggest that the Scottish phenotype is less severe than that in New 
Zealand.  This is especially surprising because the New Zealand cohort was 
population-based, as opposed to the clinic-based Scottish cohort: it is normally 
expected that a clinic-based study has a greater chance of being skewed in the 
direction of those with more severe disease.  It is possible that CD is managed more 
aggressively in Scotland, which may prevent disease progression.  It is also possible 
that Scottish patients were diagnosed earlier in the course of their symptoms.  
However, the differences in disease progression are so large that it seems unlikely 
that either of these two possibilities could adequately explain them.  Alternatively 
there could be due to differences in interpretation of the Montreal classification, e.g. 
a mild inflammatory stricture without prestenotic dilatation and without obstructive 
symptoms could have been interpreted as B2 in the New Zealand cohort, whereas in 
the Scottish cohort this would be interpreted as B1.  Without cross-validation of the 
New Zealand phenotyping this question is impossible to answer.   
The consistent risk factor for disease progression across all three cohorts was disease 
location, especially L1 disease.  In the French cohort L1 disease conferred a HR of 
2.5 (95% CI 1.9-3.3) for B2 disease, compared to 5.2 (95% CI 4.1-6.5) for disease 
progression (either B2 or B3 disease) in the Scottish cohort.  Unfortunately the New 
Zealand paper did not state HR for L1 and L3 disease.  It is not understood why ileal 
disease is such a risk factor for disease progression.  It has previously been argued 
that the narrow ileal lumen compared with the colon might predispose to the 
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development of ‘functionally significant’ strictures.225   The reduced mobility of the 
colon compared with the small bowel could result in fewer opportunities for serosal 
surfaces to stick together.  Alternatively, the larger surface area of the small bowel 
compared with the colon could increase the chances of fibrosis and fistulae 
formation, despite similar cell turnover times.  Further work is required in this 
interesting area. 
Perianal disease, both on univariate and multivariate analyses, was not associated 
with disease progression in the Scottish cohort, unlike the New Zealand cohort, 
despite both cohorts being phenotyped according to the Montreal classification.  In 
the New Zealand cohort 27% of patients had perianal disease; this figure in the 
Scottish cohort was 22.5%.  It is possible that the shorter follow up period in the 
New Zealand cohort could skew the data in favour of patients with perianal disease.  
3.8.3 Risk of resection 
The median time to first resection in the Scottish cohort was 8.9 years, with an 
association with disease location and risk of resection (HR 5.2 for L1 disease 
compared with L2 disease and 2.6 for L3 disease compared with L2 disease).  It is 
unfortunate that the multivariate analysis did not take account of decade at diagnosis, 
as this was the only other variable associated with risk of surgery on univariate 
analyses, and earlier decade at diagnosis has been associated with a shorter time to  
operation in another cohort.226 
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Age at Diagnosis 











A1 A2 A3 
Time point 
of 
assessment L1 L2 L3 L4 
Scotland 1155 10.3  30.8 10 61 29 
Vienna 
Max 
extent 27 34 24 13 









diagnosis 36 33 30 5 
Norway 237 Not given 
Not 
given 70 30 
Vienna at 
diagnosis 27 49 23 1 
Wales 341 7.7 30 9 57 34 
Montreal 
at 
diagnosis 38 45 14 4 
Table 3-19 Basic demographics   
 
Cohort Definition of surgery 
Scotland Intestinal resection, excluded simple appendicectomies and defunctioning procedures 
USA 
Any intra-abdominal surgical procedure performed for treatment of CD or its 
complications 
Norway Any intra-abdominal surgical procedure for active CD 
Wales Resection of bowel, stricturoplasty or defunctioning stoma formation 
Table 3-20 Definitions of surgery in different studies 
Relatively few cohorts have examined the variables associated with risk of resection.  
Three cohorts compared here to the Scottish data are from USA227, Norway228 and  
Wales.226  The basic demographics of the cohorts are compared in Table 3-19. 
In the US cohort of 345 patients227 diagnosed between 1991 and 1997 in New 
England, 24% of patients required ‘major surgery’ within 3 years of diagnosis, as 
shown in Table 3-21.  The US definition of major surgery, as shown in Table 3-20, 
was less stringent than that applied in the Scottish study.  Despite the less stringent 
definition, the risk of surgery in the US cohort was less than that in the Scottish 
cohort (24% vs 33% at 3 years).  On univariate analysis, risk factors for major 
surgery within 3 years included being a current smoker (HR 3.1, 95% CI 1.47-6.51, 
compared with non-smokers) and L1 location (HR 2.22, 95% CI 1.30-3.81, 
compared with all other locations).  L2 location was found to be protective against 
surgery (HR 0.27, 95% CI 0.13-0.56, compared with all other locations). 
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A smaller Norwegian cohort of 237 Crohn’s patients228 examined risk of surgery, 
with the definition similar to the US study detailed above, as shown in Table 3-20.  
By 5 years, 27% of patients had required surgery, compared with 39% in the Scottish 
cohort, as shown in Table 3-21.  
  
% Risk of surgery 
 0 3 5 10 20 Risk factors 
Scotland 12.7 32.8 38.6 53.3 68.9 Ileal/ileocolonic location 
USA 4.1 24.2 NG NG NG 
Smoking, Ileal location, non 
colonic disease 
Norway 0 NG 27 37.9 NG 
Ileal location, stricturing or 
penetrating disease 
Wales 7 NG 39 NG NG 
Year at diagnosis, colonic 
location (protective), early oral 
steroid therapy, early thiopurines 
use (proective) 
Table 3-21 Risk of surgery in the different cohorts, NG= Not given 
Both cohorts showed a lower rate of surgery compared with the Scottish cohort.  
Even if only those people diagnosed more recently in the Scottish cohort were 
considered, the risk of surgery was still substantially higher than in the other studies 
(37.9% and 34.2% of patients diagnosed in the 1990s and 2000s respectively in the 
Scottish cohort at 5 years, compared with 27% in the Norwegian study overall at 5 
years, all of whom were diagnosed 1990-1994).   
This is in contrast to the Welsh study226, which, unlike the US and Norwegian 
studies, showed similar rates of surgery to the Scottish cohort.  The Welsh study also 
noted a greater risk of surgery with those diagnosed in earlier decades (HR 1.7 95% 
CI 1.1-2.5 for those diagnosed 1986-1991 compared with those diagnosed 1998-
2003), confirmed the finding of the other studies that colonic disease was protective 
(HR 0.39 (95% CI 0.26-0.56 compared with ileal disease), but also found that early 
oral steroids and early thiopurines use were also associated (HR 1.7 and 0.47 
respectively). 
The reasons behind the differences in risk of surgery between the US/Norway and 
the UK are not clear.  One possibility is that the Scottish/Welsh CD phenotype is 
more severe although the risk of disease progression (a surrogate marker for severe 
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disease) is lower in the Scottish cohort than in other cohorts.  As will be discussed in 
Chapter 4, there is some evidence to suggest that when other criteria are used to 
assess severity of disease the Scottish phenotype does appear to behave in a more 
severe manner than some other cohorts.   Patient recruitment (clinic-based system vs. 
population-based) could also account for the differences, skewing the data towards 
people who required more hospital intervention.  As L1 disease is a risk factor for 
need for surgery, the higher rate of surgical intervention in the Scottish cohort could 
be explained if there was a higher rate of L1 disease, but this was not the case.  
Another possibility is a difference in surgical practices in Scotland compared with 
other countries, although this would be difficult to investigate or prove. 
In conclusion, the higher rate of surgery in the Scottish and Welsh cohorts may be a 
reflection of a more severe disease phenotype, the clinic based nature of recruitment, 
and possibly a difference in surgical practices in the UK compared with other 
centres. 
3.8.4 Multiple resection data 
There was a trend for time from one resection to the next to lengthen gradually, with 
the median time to 1st resection being 8.9 years, compared with median times of 18.4  
and 16.8 years between 1st and 2nd resections and 2nd and 3rd resections respectively.  
When this was broken down into disease locations, comparisons became more 
difficult because of smaller patient numbers.  Patients with L4 disease appeared to 
have the shortest intervals between resections with little evidence for an increase in 
time to the next resection.  Similarly with L1 and L3 disease there was also a trend 
for lengthening times between resections.  Conversely, a trend was not proven for 
patients with L2 disease, who appear to have very long intervals between successive 
resections.  It is to be expected that patients with L2 disease would have long 
intervals between operations: disease location tends to remain static over time224, 
therefore patients requiring colectomy for L2 disease are much less likely to need a 
further resection than patients with other disease locations.  Conversely, operations 
for L1 and L4 disease are likely to remove the minimum amount possible, meaning a 
greater chance of needing a further operation. 
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It would be interesting to analyse the data further to examine factors that may be 
important in the early need for re-operation.  This was studied in a cohort of 432 CD 
patients in Milwaukee recruited 1998-2004229, of whom 65 patients required more 
than 1 surgical intervention.  Of these 65 patients, 32 (49%) required ‘rapid 
reoperation’ (i.e. repeat intestinal surgery, including stricturoplasty and resection, 
within 2 years of the previous operation.  However, no significant differences were 
found between the rapid and non-rapid reoperation groups in terms of disease 
location, disease behaviour or age at onset. Another study in Pennsylvania examined 
88 patients who had had at least 2 resections for CD, and whose last resection had 
been between the years of 1988 and 1993.230  Risk factors for early post operative 
recurrence of CD after the 1st resection were ‘perforating’ disease (HR 2.33, 95% CI 
1.47-3.57, compared with ‘non perforating’ disease) and a period of >8.9 years from 
the diagnosis of CD to the 1st resection (HR 1.96, 95% CI 1.06-3.61) compared with 
a preoperative period of <8.9 years).  Disease location, age group at diagnosis and 
smoking history were not found to be significant.  An earlier study in New York 
examining 164 patients who had an intestinal resection 1976-1989, had found that 
early symptomatic recurrence occurred in 40% of patients and was not associated 
with age at onset, or location of disease, but did appear to be associated with 
histological evidence of CD in the resection margins and the number of anastomoses 
(HR not given).   
These studies suggest that disease location and age at diagnosis are not important 
factors in early reoperation, and that disease behaviour is important.  Other factors 
must therefore be important, which merits further investigation. 
3.8.5 Disease behaviour 
Although the numbers of patients developing B3 disease as their first manifestation 
of disease progression (‘primary B3 disease’) is less than the numbers developing B2 
disease as their first manifestation of disease progression (‘primary B2 disease’), it is 
interesting to note that patients with primary B3 disease have an equal risk of 
subsequently developing stricturing disease as the risk of patients with primary B2 
disease have of developing B3 disease.  It would be helpful to extend this 
examination to the full Scottish cohort. 
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It must be noted, however, that this was a retrospective study and that detailed 
pathological examination of resection specimens, over and above what is routine 
clinical practice, was not completed.  Decisions about B2 and B3 disease were made 
on the basis of what was documented in the clinical notes, including radiological, 
pathology and endoscopy reports, as ascertained by a clinician.  Therefore it is hard 
to prove one way or another in this cohort whether B3 disease really does always 
coexist with B2 disease or not.  A further prospective study examining pathology 
resection specimens to further elucidate the pattern of disease behaviour in CD 
would be necessary.  Certainly, considering B2 and B3 as entirely separate entities 
would seem to be appropriate in the interim. 
3.8.6 Conclusions 
This study of disease behaviour, using carefully and consistently obtained phenotypic 
data, is one of the largest cohorts examined to date for disease progression and is the 
largest study examining risk of surgery in CD.  It provides further confirmation of 
the importance of disease location in determining disease behaviour and the need for 
surgery.  It also confirms that surgical practices have changed over the years, with 
patients being at a lower risk of surgery now compared with previous decades.  The 
study provides novel perspectives on the need for multiple resections, showing that 
disease location affects the need for subsequent operations.  It provides data on 
disease progression, suggesting that B2 and B3 behaviour should be considered as 
separate entities, something that has important implications for the Montreal 
classification and disease phenotype in general. 
The limitations of the current study include the fact that it is a clinic-based rather 
than a population-based cohort study.  In addition, it was retrospective rather than 
prospective.  Prospective cohort studies are an important ‘gold standard’ in research 
methodology but have the limitation of taking many years to generate appropriate 
data.  Further studies examining the effect of drug therapy on disease progression 
and need for surgery are necessary, especially to examine the hypothesis that early 
biological and immunosuppressive therapies change long term disease course rather 
than just preventing relapse.  
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However, despite these limitations, the results presented in this chapter demonstrate 
that important research can still be generated with retrospective studies which have 
important implications for the future management of patients with CD.  As risk of 
disease progression and the need for surgery are surrogate markers for disease 
severity, alternative methods of defining disease severity are required.  This concept 
is explored in more detail in the next chapter.
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Chapter 4 Crohn’s disease severity prediction 
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Summary 
Aims: To construct a multi-faceted composite score that could be used to define a 
proportion of the population with severe disease, and to find clinical and genetic 
factors that correlated with more severe disease. 
Methods: A novel severity score assessed over the first 5 years after diagnosis was 
constructed based on physician consensus, with a possible score that ranged from 1 
to 16.  This was applied to 366 CD patients recruited in Dundee.  Univariate and 
multivariate analyses (using the chi squared test and logistic regression with 
backward elimination respectively) were completed to examine for factors present at 
diagnosis (clinical and genetic) that correlated with more severe disease, defined as a 
score >6.  The 30 top susceptibility loci uncovered by a recent CD GWAS were 
genotyped in the Dundee cohort of 366 CD, 261 UC patients and 539 controls using 
the Sequenom® platform at the University of California, San Francisco.  A case-
control analysis was completed for these SNPs in both CD and UC. 
Results: 249 CD patients had full severity data available for the first 5 years after 
diagnosis.  The mean score was 6.3.  Association with long term disease progression 
was demonstrated for a subset of the score.  A statistically significant correlation 
between the proportion of risk alleles present and severity score was not found 
(R2=0.012, p=0.078).  On univariate analyses, age <17 at diagnosis (OR 0.23 
compared with patients 17-40 at diagnosis, p-value 0.0004), ileal disease at diagnosis 
(OR 2.2, p-value 0.0025) and upper GI disease at diagnosis (OR 5.3, p-value 0.0008) 
correlated with more severe disease.  Using logistic regression these three factors 
along with 2 SNPs (rs13361189 and rs9286879) were found to have an independent 
correlation with more severe disease, and were built into a model to define the 
probability of more severe disease.  On a case-control analysis 8 SNPs (representing 
loci at or near IL23R, ATG16L1, PTGER4, IRGM, ZNF365, NOD2 1007fs, ORMDL3 
and the SNP rs1736135) showed association with CD susceptibility with similar OR 
to those in the original GWAS meta-analysis.  Three meta-analysis SNPs 
(representing loci at or near IL12B, STAT3 and IL23R) were associated with UC 
susceptibility.  There was a statistically significant difference in the mean proportion 
of risk alleles present in CD compared with controls. 
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Conclusion: This study has demonstrated that it is possible to construct a composite 
severity score that is correlated with long term outcomes and which is more 
discriminant than existing definitions of CD severity.  In addition, it has been used to 
build a model for predicting severe disease that could be useful in clinical practice.  
Further validation in a separate cohort is required. 
 
 
Disease severity   141  
4.1 Introduction 
Recent treatment algorithms for CD are increasingly advocating a ‘top down’ 
approach to the management of the disease.231  That is, giving immunosuppressant 
therapy with thiopurines and biologicals at an early stage with the hope of preventing 
the development of strictures and fistulae.  However, long term immunosuppression 
is not without its risks, including infections, blood dyscrasias, and, with biologicals, 
possibly the development of autoimmune phenomenon, e.g. demyelination and lupus, 
as well as solid cancers.232;233  Therefore it is important to select patients carefully on 
the basis of long-term risk of severe disease, to prevent giving people strong 
immunosuppression unnecessarily.  Unfortunately there is no test or objective way to 
identify those who would benefit most from early therapy in CD.  Ideally, the best 
criteria should be apparent at diagnosis so that an informed decision can be made 
about the patient’s long term risk of having severe disease at an early stage. 
Currently there is no universally recognised definition of what constitutes severe or 
disabling disease.  The ‘behaviour’ variable of the Montreal classification20 is the 
closest to approximating the development of disabling disease, as people with 
penetrating disease are at higher risk for operations than those with inflammatory 
disease.228  In addition, there is a clear progression over time from inflammatory 
disease to the development of stricturing and/or penetrating disease as demonstrated 
by other authors223 and in the previous chapter.   
The only current classification of severe disease is by Beaugerie et al.234; their 
criteria for severe disease are given in Table 4-1.   
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Within the 5 year period following diagnosis, at least one of:  
1. More than 2 steroid courses required and/or dependence on steroids 
2. Further hospitalization after diagnosis for flare-up or complication of the disease 
3. 
Presence of a cumulative time of more than 12 months within the 5 year study period of 
disabling chronic symptoms, this being defined as including: 
 -Diarrhoea with nocturnal and or urgent stools 
 -Intense abdominal pain because of intestinal obstruction 
 -Fever or fatigue attributable to the disease 
 -Joint pain 
 -Painful uveitis or pyoderma gangrenosum 
4. Need for immunosuppressive therapy 
5. Intestinal resection 
6. Surgical operation for perianal disease 
Table 4-1 Beaugerie criteria for disabling Crohn's disease 
In their cohort 85.2% of patients fitted this definition of disabling disease.  In a 
cohort of Scandinavian patients235, 60% fitted the criteria for ‘disabling’ disease.  
Thus it could be argued that this description is not very discriminating.  The other 
issue with the Beaugerie criteria is the description of disabling disease itself.  The 
need for surgical operation for perianal disease is the criterion that is the easiest to 
fulfill, as almost all patients who have perianal disease will need a minor operation, 
e.g. incision and drainage, or seton placement.  It is therefore not surprising that on 
multivariate analyses perianal disease comes out as a strongly positive predictor of 
‘disabling disease’.   
The hypotheses of this chapter were: 
1) That a multi-faceted composite score could be used to define a proportion of 
the population most at risk of severe disease.   
2) That phenotypic and genetic variants could be correlated with disease 
severity, based on the severity score, and that genetic variants, as an unchanging 
variable, could be used from the onset of disease to help predict disease severity, 
before complications developed.  
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4.2 Methods  
4.2.1 Severity score 
The severity score itself is detailed in the Chapter 2, and again in Table 4-2.  It was 
developed in consultation with various members of the gastroenterology unit at the 
Western General Hospital, Edinburgh (Prof Jack Satsangi, Dr Gwo-Tzer Ho and Dr 
Ian Arnott) as well as Dr Craig Mowat at Ninewells Hospital, Dundee.   
Using the Beaugerie definition of ‘disabling disease’ as a starting point, an initial 
discussion was had with each Edinburgh-based clinician as to what they thought 
defined CD severity.  When it became apparent that there were several different 
aspects to defining severity, the consensus of opinion was that a composite score 
reflecting different disease parameters would be the best.  Discussion between 
clinicians was had as to what the disease parameters should be.  Disease phenotype 
and disease management encompassed disease progression and surgical management 
respectively; nutritional status accounted for poor nutrition as a result of more severe 
CD and hospitalisations reflected the social-economic impact, as well as recognising 
the fact that more difficult-to-manage CD is more likely to result in a hospital 
admission.  Within each parameter, consensus was reached as to what severe, 
moderate and mild disease should be.  Once overall consensus was reached between 
Edinburgh clinicians, it was sent to a clinician in another hospital (Dr Craig Mowat,  
Ninewells Hospital, Dundee) for independent verification that this score accurately 
reflected an expert’s opinion as to what constituted severe disease.  Dr Mowat 
suggested some minor refinements, and these were accepted by all Edinburgh 
clinician.  Following this, no further modifications were forthcoming from any of the 
Scottish IBD experts.  Of note, BMI was used as the indicator of nutritional status 
and was not corrected for BMI percentile in those aged less than 17 at diagnosis.  
Although recognising that this was not optimal for those yet to finish puberty with 
epiphyseal fusion, patients less than 14 at diagnosis (an age at which 50% of children 
will have completed puberty) accounted for less than 5.7% of the cohort. 
A time point of the first 5 years after diagnosis was chosen to assess this score which 
was felt to give the best balance of maximising patient numbers yet assessing 
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severity on a sufficiently long timescale.  The minimum total possible score was 1 
with a maximum of 16. 
The information was collected from all previously recruited Dundee CD patients by 
retrospective case note review, with the help of Dr Tim Heron in Ninewells Hospital, 
Dundee.   
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 Severe: Score 4 for each Moderate: Score 2 for each Mild: Score 1 for each Score 0 
Disease extent/behaviour Panenteric disease  
OR Complex perianal 
disease requiring 3 or more 
operations 
OR Fistulating disease   
 
Stricturing but not 
fistulation  
Perianal disease requiring 
1 or 2 operations 
Single site involvement 
No evidence of 
stricturing/fistulation 






OR Need for 2 or more 
immunomodulatory drugs  
OR 2 Surgical resections 
OR Use of biological 
therapy 
 
More than 4 steroid 
courses, but none >4 
months 
OR 1 immunomodulator 
OR 1 surgical resection 
 
1-3 courses of steroids, 





Nutritional status BMI<15 at any point in the 
5 years 
BMI=15-18.5 at any point 
in the 5 years 
 BMI >18.5 at all 
times in the 5 years 
Socio-economic impact 5 or more hospitalizations 
for management of active 
disease  
 
2-4 hospitalizations for 
active disease 
 
1 hospitalization for active 
disease 
No hospitalizations 
for active disease 
Table 4-2 Severity score, calculated for the first 5 years after diagnosis 
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4.2.2 SNP selection 
Thought was given to the best SNPs to select to genotype in the Dundee cohort.  
Most of the CD-related SNPs are associated with disease susceptibility rather than 
any other aspect of the disease, so it was thought that these would not be associated 
with disease severity in a given population.  The initial plan had been to genotype the 
top 50 SNPs from the WTCCC GWAS study73 that appeared to differentiate between 
B1 and B2/B3 disease at 5 years, and examine them with respect to the new severity 
score.  This was discussed in detail with Dr Carl Anderson of the WTCCC, who 
stated that the most significant SNPs differentiating B1 and B2/B3 disease at 5 years 
in the CD dataset had not been replicated in a separate cohort (unpublished data).  
Despite this lack of replication it was still felt to be the best strategy, as SNP 
selection was on the basis of a surrogate marker of disease severity rather than 
susceptibility.  The co-operation and permission of the UK IBD Genetics Consortium 
was obtained.  Unfortunately, due to computer server malfunction at WTCCC, access 
to the relevant data was not possible.  Therefore it was decided that alternative 
strategies should be used to select SNPs for genotyping in the cohort. 
In the absence of known SNPs that are correlated with disease severity (aside from 
NOD2 SNPs that correlate with stricturing ileal disease85), it was decided that the top 
susceptibility SNPs from a CD meta-analysis117 should be genotyped in the Dundee 
cohort.  CD and UC patients as well as controls were genotyped and examined for 
associations with disease severity to enable calculation of the odds ratios for 
susceptibility in the Dundee cohort.  In addition to the NOD2 1007fs mutation 
(rs2066847), the two other common NOD2 CD SNPs not in the meta-analysis were 
also genotyped.  A list of the SNPs genotyped is given in Table 4-3. 
 





OR Barrett et al. Gene of interest 
rs2476601 1p13.2 1.31 PTPN22 
rs11209026 1p31.3 2.50 IL23R 
rs2274910 1q23.3 1.14 ITLN1 
rs9286879 1q24.3 1.19 ? 
rs11584383 1q32.1 1.18 ? 
rs2241880 2q37.1 1.28 ATG16L1 
rs3197999 3p21.31 1.20 MST1 
rs4613763 5p13.1 1.32 PTGER4 
rs2188962 5q31.1 1.25 ? 
rs13361189 5q33.1 1.33 IRGM 
rs10045431 5q33.3 1.11 IL12B 
rs6908425 6p22.3 1.21 CDKAL1 
rs7746082 6q21 1.17 ? 
rs2301436 6q27 1.21 CCR6 
rs1456893 7p12.2 1.20 ? 
rs1551398 8q24.13 1.08 ? 
rs10758669 9p24.1 1.12 JAK2 
rs4263839 9q32 1.22 TNFSF15 
rs10995271 10q21.2 1.25 ZNF365 
rs11190140 10q24.2 1.20 NKX2-3 
rs7927894 11q13.5 1.16 C11ORF30 
rs11175593 12q12 1.54 LRRK2/MUC19 
rs3764147 13q14.11 1.25 ? 
rs2066844 16q12.1 Not studied NOD2 R702W 
rs2066845 16q12.1 Not studied NOD2 G908R 
rs2066847 16q12.1 3.99 NOD2 1007fs 
rs2872507 17q12 1.12 ORMDL3 
rs744166 17q21.2 1.18 STAT3 
rs2542151 18p11.21 1.35 PTPN2 
rs1736135 21q21.1 1.18 ? 
rs762421 21q22.3 1.13 ICOSLG 
Table 4-3 Selected SNPs for genotyping  ?=gene not known 
4.2.3 Genotyping methods 
Genotyping of the SNPs was completed on the Sequenom® platform at the 
Genomics Core of the University of California, San Francisco, as detailed in Chapter 
2.  DNA from 366 CD, 261 UC and 539 controls were genotyped. 
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4.2.3.1 Quality control 
The controls were examined for Hardy-Weinberg equilibrium (table 1-4).  The SNP 
rs3764147 was discounted because of a lack of Hardy-Weinberg equilibrium (p-
value 3x10-4). A further SNP, rs4263839, had a poor rate of successful genotyping 
(62.2% in controls) and was also discounted.   
 
SNP 
Gene of interest 
?=not known HW p-value %Geno MAF 
Maj:Min 
Alleles 
rs2476601 PTPN22 0.4282 100 0.087 G:A 
rs11209026 IL23R 0.6825 99.6 0.075 G:A 
rs2274910 ITLN1 0.2564 88.3 0.267 C:T 
rs9286879 ? 0.6135 99.8 0.264 A:G 
rs11584383 ? 0.8704 99.6 0.313 T:C 
rs2241880 ATG16L1 0.5327 99.1 0.492 C:T 
rs3197999 MST1 0.7265 97.8 0.283 C:T 
rs4613763 PTGER4 1 99.8 0.133 T:C 
rs2188962 ? 0.4915 98.5 0.475 C:T 
rs13361189 IRGM 0.6694 99.3 0.065 T:C 
rs10045431 IL12B 0.4013 80.3 0.328 C:A 
rs6908425 CDKAL1 0.0061 99.1 0.216 C:T 
rs7746082 ? 1 100 0.284 G:C 
rs2301436 CCR6 0.8572 92 0.465 G:A 
rs1456893 ? 0.1236 98.3 0.327 A:G 
rs1551398 ? 0.0839 99.8 0.372 T:C 
rs10758669 JAK2 0.7645 99.1 0.358 A:C 
rs4263839 TNFSF15 0.681 62.2 0.314 G:A 
rs17582416 ? 0.5913 99.3 0.343 T:G 
rs10995271 ZNF365 0.129 99.4 0.372 G:C 
rs11190140 NKX2-3 0.4776 98.9 0.476 C:T 
rs7927894 C11ORF30 0.1188 96.5 0.391 C:T 
rs11175593 LRRK2/MUC19 1 100 0.019 C:T 
rs3764147 ? 3.00E-04 19.9 0.182 A:G 
rs2066844 NOD2 702 0.9776 100 0.036 C:T 
rs2066845 NOD2 908 1 100 0.007 G:C 
rs2066847 NOD2 1007 1 100 0.019 Ins C 
rs2872507 ORMDL3 0.7651 97 0.482 G:A 
rs744166 STAT3 0.3781 98.9 0.46 T:C 
rs2542151 PTPN2 1 98.7 0.181 T:G 
rs1736135 ? 0.2852 99.3 0.447 T:C 
rs762421 ICOSLG 0.7548 99.3 0.393 A:G 
Table 4-4 Quality control on genotyped SNPs, controls only shown 
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4.3 Results 
4.3.1 Severity score  
Of the 366 CD patients in the Dundee cohort, 249 (68.3%) had complete sets of data 
available for the first 5 years after diagnosis.  These patients were used for analysis 
and validation of the severity score. 
4.3.1.1 Score distribution 
The graph showing the numbers of patients with each score is shown in Figure 4-1.  
The Kolmogorov-Smirnow test confirmed that the data approximated a normal 
distribution (p>0.10).  The mean severity score was 6.3 (95% CI 5.90-6.64).  A score 
of <3 encompassed the least severe 20.9% of the population, whereas a score >9 
identified the most severe 20.5% of the population. 



























Figure 4-1 Distribution of severity scores, ▬▬▬ line of best fit 
 
Disease severity   150  
4.3.1.2 Sub-score correlation with total score 
As the severity score used all important clinical criteria, there were no independent 
disease parameters with which to compare the scores with long term outcome.  
Therefore subsets of the score were examined for the best correlation with the total 
score. 
The Pearson correlation was used to examine how individual aspects of the score 
correlated with the total score, to determine which combination of the criteria had the 
strongest correlation with the total score.  As shown in Table 4-5, the single 
parameter with the highest correlation with total score was D, the number of 
hospitalizations.  Similarly the 2-parameter combination with the strongest 
correlation was B+D (medical/surgical management + number of hospitalizations) 
and the 3-parameter combination was A+B+C (disease extent/behaviour + 
medical/surgical management + nutritional status). 
 
Parameter Pearson r R squared 
A Disease extent/behaviour 0.624 0.390 
B Medical/surgical management 0.688 0.473 
C Nutritional status 0.563 0.317 
D Hospitalizations 0.734 0.538 
2 Parameters combined 
A+B 0.860 0.739 
B+C 0.821 0.674 
C+D 0.816 0.665 
A+C 0.797 0.635 
A+D 0.816 0.667 
B+D 0.870 0.756 
3 Parameters combined 
A+B+C 0.950 0.903 
B+C+D 0.934 0.873 
A+C+D 0.904 0.816 
A+B+D 0.943 0.889 
Table 4-5 Pearson's test for correlation results All p-values for correlation were <0.0001 
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4.3.1.3 Long term association 
Based on the two parts of the score that correlated best with the total score: 
medical/surgical management and hospitalizations, an abbreviated severity score was 
calculated (total score possible=8) and the patients divided according to their score 
(lower abbreviated score ≤4, higher abbreviated score >4).  A Kaplan-Meier curve 
was calculated with time to disease progression for each of these groups, as shown in 
Figure 4-2.  The median times to disease progression were 21.2 years and 9.1 years 
for the lower score and the higher abbreviated score respectively (log rank test 
p=0.02). 



































Figure 4-2 Kaplan-Meier: time to disease progression according to abbreviated severity score 
4.3.2 Genotyping correlation with severity score 
4.3.2.1 Scoring: total SNP score 
For each patient, all risk alleles were scored (risk allele=1, non-risk allele=0) and 
summated, and then divided by the total number of alleles genotyped successfully.  
This calculation gave the percentage of risk alleles present.  The scatter plot of this 
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analysis against the severity score is shown in Figure 4-3, which has the line of best 
fit.  A statistically significant correlation was not found between the severity score 
and the SNP score (two-tailed Pearson’s test of correlation, p = 0.078, R = 0.1106, 
R2= 0.012).   
 




































Figure 4-3 Scatter plot of severity score against SNP score. ▬▬▬ line of best fit  
4.3.2.2 Scoring: weighted total SNP score  
As different SNPs confer different ORs for disease susceptibility, the data was also 
analysed adding a weighting for the ORs for disease susceptibility from the GWAS 
meta-analysis.117  For each SNP, a risk allele homozygote had a score of 2xOR, a 
risk allele heterozygote had a score of 1xOR and a low risk homozygote had a score 
of 0.  This score was summated and divided by the total possible score if all the 
successfully genotyped SNPs had been risk allele homozygous.  The scatter plot is 
shown in Figure 4-4.  There was no correlation between the weighted SNP and 
severity scores (Pearson’s test of correlation p = 0.22).   
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Figure 4-4 Scatter plot of severity score against weighted SNP score, ▬▬▬ line of best fit 
4.3.3 Univariate analysis of factors correlating with more severe 
disease 
The aim of this investigation was to explore whether factors present at diagnosis 
could be used to predict risk of severe disease in the future and from the model 
decide at diagnosis the patients most suitable for ‘top-down’ therapy. 
As the mean severity score was 6.3, the 249 patients were subdivided according to 
severity score: lower score group (score ≤6) and higher score group (score >6).  
Various factors obtained at diagnosis were each examined for association with more 
severe disease using the chi-squared test.  The list of factors and the results are given 
in Table 4-6.  When corrected for multiple testing with a Bonferroni correction, a 
significant p-value was <0.005.  For smoking at diagnosis and Montreal age group at 
diagnosis, the p-value is for a chi-squared test for trend.  
The genotyping data for each SNP was also analysed using the chi-squared test.  For 
simplicity, SNPs were assumed to behave in a dominant fashion.  When corrected for 
multiple testing with a Bonferroni correction, a significant p-value was <0.002.  The 
results are shown in Table 4-7.   
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The data demonstrates that A1 age group at diagnosis (i.e.<17 years old at diagnosis) 
and ileal or Upper GI location at diagnosis had a statistically significant correlation 
with more severe disease. 
In addition, SNP data was analysed according to Montreal behaviour at 5 years.  
When corrected for multiple testing, none of the SNPs had a statistically significant 
correlation with B2 or B3 behaviour at 5 years (data not shown). 
 
Factor OR 95% CI 
Chi 
squared 
 p val 
Steroid treatment at diagnosis 1.12 0.677-2.12 0.50 
First degree relative with IBD 0.952 0.470-1.94 1.0  
Resection at diagnosis 1.53 0.732-3.19 0.300 
Sex 0.920 0.554-1.53 0.797 
Smoking at diagnosis (smoker, ex-smoker, non 
smoker) 
  0.405 
Perianal disease at diagnosis 2.23 0.978-5.10 0.065 
Montreal age group at diagnosis (A1, A2, A3)   0.0004 
A2 compared with A1  0.226 0.072-0.712  
A3 compared with A1 0.131 0.040-0.427  
Ileal location at diagnosis (includes those with 
ileocolonic disease) 
2.20 1.32-3.68 0.0025 
Colonic location at diagnosis (includes those with 
ileocolonic disease)   
  0.168 
Upper GI location at diagnosis 5.30 1.9-14.7 0.0008 
Table 4-6 Chi-squared test of clinical factors present at diagnosis and more severe disease 
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MAF OR CI p-value 
rs2476601 1p13.2 PTPN22 0.094 0.83 0.051 - 13.42 1 
rs11209026 1p31.3 IL23R 0.025 0.824 0.233 – 2.92 0.759 
rs2274910 1q23.3 ITLN1 0.25 0.461 0.107 - 1.97 0.306 
rs9286879 1q24.3 ? 0.25 1.77 1.070 - 2.94 0.03 
rs11584383 1q32.1 ? 0.286 1.51 0.608 - 3.73 0.502 
rs2241880 2q37.1 ATG16L1 0.429 1.01 0.517 - 1.96 1 
rs3197999 3p21.31 MST1 0.298 1.09 0.648  - 1.82 0.793 
rs4613763 5p13.1 PTGER4 0.168 1.27 0.746 - 2.16 0.416 
rs2188962 5q31.1 ? 0.482 0.934 0.522 - 1.67 0.882 
rs13361189 5q33.1 IRGM 0.093 2.09 1.07 - 4.09 0.042 
rs10045431 5q33.3 IL12B 0.309 1.36 0.369 - 5.00 0.751 
rs6908425 6p22.3 CDKAL1 0.183 1.67 0.409 - 6.86 0.519 
rs7746082 6q21 ? 0.316 1.20 0.728 - 1.99 0.523 
rs2301436 6q27 CCR6 0.47 1.38 0.736 - 2.57 0.346 
rs1456893 7p12.2 ? 0.317 0.741 0.314 - 1.75 0.517 
rs1551398 8q24.13 ? 0.351 0.980 0.421 - 2.28 1 
rs10758669 9p24.1 JAK2 0.372 1.36 0.806 - 2.31 0.287 
rs17582416 10p11.12 ? 0.374 1.54 0.921 - 2.57 0.12 
rs10995271 10q21.2 ZNF365 0.427 0.949 0.560 - 1.61 0.893 
rs11190140 10q24.2 NKX2-3 0.475 0.758 0.439 - 1.31 0.332 
rs7927894 11q13.5 C11ORF30 0.426 1.18 0.700 - 2.00 0.595 
rs11175593 12q12 LRRK2/MUC19 0.008 1.21 0.075 - 19.5 1 
rs2066844 16q12.1 NOD2 R702W 0.044 0.912 0.328 - 2.54 1 
rs2066845 16q12.1 NOD2 G908R 0.012 6.25 0.719 - 54.3 0.095 
rs2066847 16q12.1 NOD2 1007fs 0.046 1.05 0.477 - 2.31 1 
rs2872507 17q12 ORMDL3 0.468 1.24 0.695 - 2.21 0.559 
rs744166 17q21.2 STAT3 0.444 0.881 0.469 - 1.66 0.748 
rs2542151 18p11.21 PTPN2 0.186 1.03 0.604 - 1.74 1 
rs1736135 21q21.1 ? 0.372 1.37 0.689 - 2.71 0.396 
rs762421 21q22.3 ICOSLG 0.436 0.608 0.350 - 1.06 0.092 
Table 4-7 Chi-squared test: SNP genotype with more severe disease 
4.3.4 Correlation with Beaugerie severity score 
The Beaugerie definition of disabling CD was applied to the 249 patients with full 
data available.  Of these, 218 patients (87.5%) fitted the criteria for disabling disease.  
To compare the two scoring systems, the sensitivity and specificity of each level of 
the novel score was calculated (using GraphPad) for its ability to predict whether a 
patient fitted the Beaugerie disabling disease category or not, and is shown in Table 
4-8.  This was plotted on a Receiver Operating Characteristic (ROC) curve (Figure 
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4-5) in order to define the level of the novel score that fitted best with the Beaugerie 




Cutoff Sensitivity 95% CI Specificity 95% CI 
Likelihood 
ratio 
< 1.5 0.188 0.072 - 0.364 1 0.983 - 1.00  
< 2.5 0.656 0.468 - 0.814 0.982 0.954 - 0.995 35.6 
< 3.5 0.875 0.710 - 0.965 0.889 0.840 - 0.928 7.91 
< 4.5 0.969 0.838 - 0.999 0.816 0.758 - 0.865 5.26 
< 5.5 0.969 0.838 - 0.999 0.627 0.559 - 0.691 2.6 
< 6.5 0.969 0.838 - 0.999 0.516 0.448 - 0.584 2 
< 7.5 1 0.891 - 1.00 0.364 0.300 - 0.432 1.57 
< 8.5 1 0.891 - 1.00 0.235 0.180 - 0.297 1.31 
< 9.5 1 0.891 - 1.00 0.194 0.143 - 0.253 1.24 
< 10.5 1 0.891 - 1.00 0.106 0.068 - 0.155 1.12 
< 11.5 1 0.891 - 1.00 0.078 0.046 - 0.123 1.09 
< 13.0 1 0.891 - 1.00 0.018 0.005 - 0.047 1.02 
Table 4-8 Sensitivity and specificity for the novel score to predict Beaugerie disabling disease 






















Figure 4-5 ROC curve for Beaugerie severity score compared with the novel severity score 
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The area under the curve was high at 0.950 (0.912-0.989).  A cut-off of >3 in the 
novel severity score gave the best balance of sensitivity and specificity (sensitivity 
0.875, specificity 0.8894) and therefore fitted best with Beaugerie disabling disease.   
4.3.5 Multivariate analysis of factors correlating with more severe 
disease 
Factors with a univariate p-value of <0.1 for correlation with more severe disease 
(perianal disease, age group at diagnosis, ileal and upper GI locations) along with 
similarly significant SNPs (rs9286879, rs13361189, rs762421, rs17582416 and 
rs2066845) were tested in a logistic regression model with backward elimination 
using JMP 8.0.2.  As before, SNPs were assumed to behave in a dominant fashion.  
Independent factors retaining significance (p<0.05) are shown in Table 4-9, along 
with the OR, positive predictive value (PPV) and negative predictive value (NPV).  
Age <17 at diagnosis and UGI disease at diagnosis conferred particularly high OR 
for more severe disease (5.50 and 6.16 respectively).     
 
Factor OR PPV NPV p-value 
Age <17 at Dx 5.50 0.800 0.424 0.002 
Ileal at Dx 2.19 0.540 0.348 0.005 
Upper GI at Dx 6.16 0.792 0.418 0.0003 
rs13361189 2.17 0.605 0.422 0.035 
rs9286879 1.99 0.531 0.390 0.014 
Table 4-9 Independent factors retaining significance on logistic regression 
From this logistic regression, a model was formulated to calculate the probability, 
from these 5 parameters, of subsequently developing severe disease. (Table 4-10).   
 
Probability of severe disease = 1/(1+Exp[Z]) 
Z is calculated with the following formula: 
Z = 1.362    
 – 1.704 (if <17 at Dx) 
 – 0.786 (if ileal disease at Dx) 
 – 1.818 (if UGI disease at Dx) 
 – 0.776 (if 1-2 rs13361189C alleles) 
 – 0.688 (if 1-2 rs9286879G alleles) 
Table 4-10 Calculating the probability of predicting more severe disease 
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The ROC curve for this analysis is shown in Figure 4-6, and has an area under the 
curve of 0.725 signifying a reasonable correlation between the calculated probability 
of severe disease and the actual severe disease status (more severe vs. less severe).  
Assuming equal equivalence is given to a false positive and a false negative, the cut 
off in probability is 0.528, as shown by the yellow line in Figure 4-6, giving a 
sensitivity of 0.584 and a specificity of 0.75 for the prediction of a severity score of 
>6 at 5 years.   
 
Figure 4-6 ROC curve for the logistic regression model 
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4.3.6 Genotyping: case control analysis 
The results of a case-control analysis of the genotyped SNPs are shown in Table 
4-11.  As each of these genes had previously shown an association with CD, a 

















rs2476601 PTPN22 A 0.087 0.095 0.4517 0.094 0.5755 0.098 0.4674 
rs11209026 IL23R A 0.075 0.032 1.40E-06 0.025 3.97E-06 0.04 0.008 
rs2274910 ITLN1 T 0.267 0.252 0.4254 0.25 0.4414 0.264 0.914 
rs9286879 ? G 0.264 0.247 0.3519 0.25 0.5049 0.239 0.2923 
rs11584383 ? C 0.313 0.278 0.0613 0.286 0.2106 0.276 0.1285 
rs2241880 ATG16L1 T 0.492 0.439 0.0088 0.429 0.008 0.462 0.2488 
rs3197999 MST1 T 0.283 0.291 0.6641 0.298 0.5039 0.284 0.954 
rs4613763 PTGER4 C 0.133 0.148 0.3187 0.168 0.0416 0.13 0.8627 
rs2188962 ? T 0.475 0.476 0.9879 0.482 0.7783 0.469 0.82 
rs13361189 IRGM C 0.065 0.085 0.0596 0.093 0.027 0.08 0.2481 
rs10045431 IL12B A 0.328 0.288 0.0649 0.309 0.4611 0.259 0.0164 
rs6908425 CDKAL1 T 0.216 0.193 0.1556 0.183 0.0885 0.212 0.8332 
rs7746082 ? C 0.284 0.305 0.266 0.316 0.1491 0.287 0.8887 
rs2301436 CCR6 A 0.465 0.46 0.8249 0.47 0.8419 0.447 0.5579 
rs1456893 ? G 0.327 0.331 0.8183 0.317 0.6641 0.352 0.3073 
rs1551398 ? C 0.372 0.358 0.4562 0.351 0.3601 0.362 0.694 
rs10758669 JAK2 C 0.358 0.378 0.3149 0.372 0.5403 0.39 0.2242 
rs17582416 ? G 0.343 0.357 0.5005 0.374 0.1882 0.351 0.7707 
rs10995271 ZNF365 C 0.372 0.41 0.0581 0.427 0.0177 0.391 0.4612 
rs11190140 NKX2-3 T 0.476 0.499 0.2653 0.475 0.9629 0.517 0.127 
rs7927894 C11ORF30 T 0.391 0.416 0.2133 0.426 0.1443 0.397 0.821 
rs11175593 
LRRK2/ 
MUC19 T 0.019 0.014 0.3617 0.008 0.0678 0.015 0.6379 
rs2066844 
NOD2 
R702W T 0.036 0.033 0.7075 0.044 0.4269 0.022 0.1349 
rs2066845 
NOD2 
G908R C 0.007 0.01 0.5785 0.012 0.295 0.008 0.963 
rs2066847 NOD2 1007fs C 0.019 0.029 0.1105 0.046 7.00E-04 0.01 0.1723 
rs2872507 ORMDL3 A 0.482 0.526 0.0341 0.532 0.0373 0.52 0.1616 
rs744166 STAT3 C 0.46 0.427 0.1031 0.444 0.4912 0.393 0.0107 
rs2542151 PTPN2 G 0.181 0.2 0.2492 0.186 0.802 0.215 0.1126 
rs1736135 ? G 0.447 0.383 0.0014 0.372 0.0013 0.406 0.1185 
rs762421 ICOSLG G 0.393 0.417 0.2326 0.436 0.0703 0.402 0.7236 
Table 4-11 Case-control SNP analysis 
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4.3.6.1 Crohn’s disease  
The SNPs at or near IL23R, ATG16L1, IRGM, PTGER4, ZNF365, NOD2 (1007fs), 
ORMDL3 and rs1736135 (intergenic area) had a statistically significant association 
with CD susceptibility compared with controls.  The odds ratios (ORs) are shown in 
Table 4-12.  The IL23R wild-type allele of rs11209026 conferred the highest risk 
(OR=3.21), whereas the mutant allele conferred protection (OR=0.31); NOD2 1007fs 
mutations and the autophagy genes, ATG16L1 and IRGM, also were associated with 
CD susceptibility (ORs 2.57, 1.29 and 1.48 respectively).   
4.3.6.2 Ulcerative colitis  
The SNPs representing IL23R, IL12 and STAT3 had a statistically significant 
association with UC susceptibility compared with controls.  The ORs are given in 
Table 4-13.  Three of these SNPs are in the IL23 pathway (IL23R, IL12B and STAT3) 
although other IL23 pathway SNPs (JAK2 and CCR6) were not associated with UC 
susceptibility.  IL12B is also known as the p40 subunit of both IL12 (with p35) and 
IL23 (with p19).   
 
SNP Gene of interest CD OR 95% CI 
rs11209026 IL23R 0.31 0.18-0.52 
rs2241880 ATG16L1 1.29 1.07-1.56 
rs4613763 PTGER4 1.31 1.01-1.70 
rs13361189 IRGM 1.48 1.04-2.10 
rs10995271 ZNF365 1.26 1.04-1.53 
rs2066847 NOD2 1007fs 2.57 1.47-4.50 
rs2872507 ORMDL3 1.23 1.01-1.48 
rs1736135 Not known 1.37 1.13-1.66 
Table 4-12 Odds ratios of statistically significant SNPs in Crohn's disease   
 
SNP Gene of interest UC OR 95% CI 
rs10045431 IL12B 1.40 1.06-1.83 
rs744166 STAT3 1.32 1.07-1.63 
rs11209026 IL23R 0.52 0.32-0.85 
Table 4-13 Odds ratios of statistically significant SNPs in Ulcerative colitis 
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4.3.6.3 Percentage of risk alleles present: case/control 
comparison 
In order to examine whether CD patients had more risk alleles than controls, the two 
populations were compared.  For each patient, all risk alleles were scored (risk 
allele=1, non-risk allele=0) and summated, and then divided by the total number of 
alleles genotyped successfully.  This calculation gave the percentage of risk alleles 
present.  The 32 meta-analysis SNPs and the three NOD2 risk alleles were included 
in the calculation.  The risk allele proportions were compared between CD cases and 
controls (Figure 4-7).  There was a statistically significant difference in the means 



































Figure 4-7 Scatter dot plot comparing proportion of risk alleles present in CD and controls; 
bars represent the upper and lower data points, and thick central line represents mean. 
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4.4 Discussion 
4.4.1 Severity score 
The severity score was normally distributed amongst the Dundee CD cohort studied.  
When defined according to the Beaugerie criteria, a slightly higher proportion of 
these patients were classified as ‘disabling’ than in other populations (87.5% vs. 
85.2%234 and 60%235), suggesting that Dundee CD patients have a more severe 
phenotype.    
It is difficult to correlate a score that is the summation of the first 5 years of the 
disease course with long term outcomes, as the parameters which measure disease 
severity have been used already.  To account for this, correlations of subsets of the 
score with the total score were as examined.  The best subset (medical/surgical 
management and hospitalizations) did not include disease behaviour, and the rates of 
disease progression were compared between patients with lower and higher 
abbreviated scores.  The statistically significant difference between these 2 groups, 
strongly suggests that the total score was correlated with a long-term, more severe 
phenotype. 
There are ongoing international efforts to define a Crohn’s Disease Digestive 
Damage Score (the Lémann score).236  This will be a much more anatomically based 
score, defining amount of bowel affected by CD with weighting for different 
locations affected.  It will not account for the other aspects of disease severity which 
are utilised in the severity score detailed in this chapter, for example nutritional 
status and socio-economic impact:  
4.4.2 Severity score correlation with genotyping 
There was no correlation between the severity score and proportion of risk alleles 
present whether the SNPs were weighted or not.  With only 32 alleles being 
examined, this was not surprising, especially since the SNPs are disease 
susceptibility rather than severity SNPs.  It would have been better to have used the 
SNPs differentiating between B2 and B3 disease in the WTCCC, but these were not 
available.  It would be interesting to compare genome-wide polygenic scoring, as 
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previously analysed in schizophrenia237 against severity score.  It is possible that 
more severe cases would have more risk alleles.   
4.4.3 Univariate analysis of severe disease correlation 
A score of >6 was selected to differentiate between patients with more and less 
severe disease.  Choosing the score that separated the patients into halves increased 
the statistical power of any analyses as well as representing a realistic proportion of 
CD patients who might be deemed appropriate for top-down therapy.   However, the 
cut-off score could be set at whatever level is felt to represent the proportion of 
patients who would benefit from early aggressive therapy - this could be further 
delineated in confirmatory studies in other cohorts.   
The only factors examined for correlation with disease severity as a binary variable 
were those that could be obtained at diagnosis, in keeping with the ultimate aim: to 
be able to select patients at diagnosis who are at risk of more severe disease.  It was 
surprising that steroid treatment at diagnosis and resection at diagnosis, both clinical 
decisions, were not correlated with more severe disease.  This is in contrast with age 
group and location at diagnosis which were correlated with disease severity, which 
are factors that are not based on a clinical decision.  The correlation of ileal disease 
and upper GI disease with disease severity is not surprising considering their strong 
correlation with disease progression and surgery, as demonstrated in the previous 
chapter.  Perianal disease (p-value 0.052) did not approach statistical significance 
with Bonferroni correction.  The differences in relative contribution of the clinically 
defined and more objective factors are a reflection of the difficulties of identifying 
patients with a more severe disease phenotype at diagnosis.  
In the Beaugerie study234, univariate analyses demonstrated that age <40 at diagnosis, 
pure colonic disease at diagnosis, perianal disease at diagnosis, and steroids at 
diagnosis corresponded with disabling disease.  In contrast, steroids at diagnosis, 
perianal disease and colonic disease were not correlated with severe disease in the 
analyses presented here whereas ileal disease and upper GI disease were important in 
severe disease.  The Beaugerie definition encompasses a greater subset of patients, 
correlating with a novel severity score of ≥3, which may explain the differences in 
findings. 
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Although three of the SNPs showed a trend to association with more severe disease, 
on Bonferroni correction none of the SNPs reached statistical significance.   
4.4.4 Multivariate analysis of severe disease correlation 
The multivariate analysis confirmed age at diagnosis (especially those <17 at 
diagnosis) and disease location as important variables as in the univariate analysis.  It 
also confirmed that 2 of the SNPs were correlated with more severe disease: 
rs13361189 and rs9286878, neither of which had held up to Bonferroni correction on 
univariate analyses, as detailed in section 4.3.3.  The SNP rs13361189 is associated 
with the IRGM gene.  The SNP rs9286879 is on chromosome 1q24.3 in an area 
without identified genes, as yet.  Each one of the five factors is an important 
predictor of more severe disease if present, but lack of them does not definitely mean 
less severe disease, as shown by the high negative predictive values for each of the 
factors. 
The model allows direct calculation of the probability for more severe disease.  At 
what level the probability cut-off should be for identifying high risk patients can be 
debated.  In a situation where we did not wish patients to miss out on early 
aggressive therapy, and just wanted to identify the subset of patients with low risk of 
more severe disease, the probability of severe disease cut-off could be placed so that 
the sensitivity was high and the specificity low, for example 0.338 (sensitivity 0.938, 
specificity 0.257).  If we did not wish to unnecessarily give patients early aggressive 
therapy, the probability cut-off could be placed much higher, for example 0.756 
(sensitivity 0.230, specificity 0.963).  These cut-offs can be varied depending on 
clinician preferences as well as finances.  
4.4.5 Case-control genotyping 
In the case-control study, 8 of the loci were associated with susceptibility to CD (as 
shown in Table 4-12), and 3 associated with UC (as shown in Table 4-13); the only 
common risk allele that was significant in both UC and CD was IL23R.  Indeed, all 
the positive associations in UC were in the Th17 pathway, confirming its 
significance in UC pathogenesis, as discussed in Chapter 1.     
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There were broad similarities in the OR for the Dundee cohort significant CD 
susceptibility SNPs compared with the GWAS meta-analysis data.117  The SNPs at or 
near IL23R, IRGM and ORMDL3 had marginally higher OR than in the meta-
analysis; ATG16L1, ZNF365 and PTGER4 had similar OR to the meta-analysis with 
NOD2 1007fs demonstrating a lower OR than the meta-analysis, as shown in Table 
4-14.     
 
SNP Gene of interest CD OR 
Meta-analysis117 
OR 
rs11209026 IL23R 0.31 0.40 
rs2241880 ATG16L1 1.29 1.28 
rs4613763 PTGER4 1.31 1.32 
rs13361189 IRGM 1.48 1.33 
rs10995271 ZNF365 1.26 1.25 
rs2066847 NOD2 1007fs 2.57 3.99 
rs2872507 ORMDL3 1.23 1.12 
rs1736135 ? 1.37 1.18 
Table 4-14 CD SNP OR compared with meta-analysis
117
 OR 
The functional significance of IL23R and the Th17 pathway, NOD2, ATG16L1 and 
IRGM in IBD pathogenesis are in innate immunity and the recognition and 
destruction of intracellular microbes, as has already been discussed in the Chapter 1. 
Of the other loci associated with CD, the SNP rs10995271 lies about 7kbp from the 
3’ end of the ZNF365 gene and is in LD with it.  Mutations in the ZNF365 gene are 
known to be linked with uric acid nephrolithiasis238, but the function of the gene is 
poorly understood. 
PTGER4 (prostaglandin E receptor 4) on chromosome 5, has 3 exons with a gene 
structure resembling that of the thromboxane and prostacyclin receptors.  It was first 
associated with CD in a European GWAS in 2007.70   It is one of a family of 
prostaglandin E receptors (EP1-4).  Prostaglandin E (PGE), a prostanoid, acts on this 
receptor with cyclooxygenase (COX) enzymes catalysing PGE production.  It has 
long been recognised that non steroidal anti-inflammatory drugs (NSAIDs), which 
inhibit the COX enzymes, can have a deleterious effect on IBD.239  In a dextran 
sodium sulphate (DSS) induced mouse model of colitis using PTGER4-/- mice, 3% 
DSS was sufficient to produce a severe colitis, which only produced a mild colitis in 
 
Disease severity   166  
wild type mice or mice deficient in other prostaglandin receptors.  Histology of the 
colon demonstrated epithelial cell loss and crypt damage, suggesting a role in 
maintaining mucosal integrity.240 Therefore the role of PTGER4 appears to be 
protective in the context of gut inflammation, but further investigation is warranted.   
The SNP rs2872507 lies near ORMDL3 (ORM1-like protein) which is part of the 
ORM (orsomucoid) protein family, negative regulators of sphingolipid synthesis.241  
Sphingolipids protect cell surfaces by forming part of the plasma membrane lipid 
layer.242  They are also involved in cell recognition and signal transmission.242  
Genetic variants regulating its expression have been linked with susceptibility to 
childhood asthma.243  
The SNP rs1736135 is in an area where no genes have yet been identified.  Ongoing 
gene mapping may produce further answers in the future as to the functional 
significance of the area it represents. 
Given that this study had less than 400 patients, it is impressive that a quarter of the 
loci were replicated in the Dundee CD population.  It is impossible to tell whether 
the SNPs not showing association with CD susceptibility in the Dundee cohort were 
true or false negatives.  For a SNP with an allelic frequency >10%, confidently 
ruling-out an association with CD susceptibility would require 7000-10000 case-
control pairs (depending on the allelic frequency of the SNP in question) for an OR 
of 1.1.  As Edinburgh and Dundee are only 60 miles apart, the genetic architecture of 
cases and controls recruited is likely to be very similar between the two populations.  
To increase the power of the studies it would be useful to genotype CD patients from 
the Edinburgh cohort for all of the 32 SNPs.  However, as many of the GWAS meta-
analysis SNPs had an OR <1.1, even with the combined cohorts the study would 
remain underpowered. 
There was a difference in the means of the SNP risk allele score between CD cases 
and controls.  This has previously been noted in another study.244  There is evidence 
that for a large GWAS this sort of approach could be relevant.  In schizophrenia, a 
GWAS was completed on 3322 cases and 3587 controls237; individual SNPs were 
compared in the standard case/control way and the polygenic contribution was also 
examined.  This involved using a filtered proportion of the GWAS SNPs, and using 
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those with p-values of <0.5 to produce a SNP score in a discovery cohort.  This SNP 
score was tested in a further target cohort, and was found to be highly correlated with 
schizophrenia.  This approach takes into account the theory that the genetic 
association of polygenic diseases, including CD, is explained by large numbers of 
alleles, each of very small levels of significance.  It would be interesting to do this 
analysis on CD GWAS data.   
4.5 Conclusions 
The severity score is a novel way of considering disease severity.  As a summation of 
four different variables, it provides a unique way of assessing CD which has not been 
attempted before.  Validation of the long term outcome of the score in predicting 
more severe disease has been presented.  In this chapter, more severe disease has 
been defined as that which encompasses the most severe half of the patient set, 
making it more discriminant than the Beaugerie disabling disease definition.  
However, as it is assessed as a continuous variable, it allows a decision to be made as 
to where ‘more severe’ disease should be defined, depending on the study it is used 
in.   
Further studies with larger numbers of SNPs are required examining the hypothesis 
that more severe CD is correlated with more risk SNPs.  This would need to be 
completed on a genome-wide level on a large number of patients.  As genome-wide 
SNP analysis becomes cheaper in the future, if positive results are gained, it may 
prove to be a cost-effective method of identifying more severe patients. 
The multivariate analysis provides an equation for calculating the probability of 
severe disease.  Undoubtedly this model requires validation in a separate cohort, 
something that is currently being planned in the Edinburgh cohort.  However, if 
validation is obtained, it provides a potentially useful clinical tool in the treatment 
decision making process when a patient is first diagnosed.  From an extensive 
examination of the literature, this is the first time that a formal model has been used 
in a CD cohort for predicting disease severity.    
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Chapter 5 Germ-line variation in GALNT2 and 
association with IBD 
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Summary 
Aims: To examine for an association between GALNT2 and IBD susceptibility in a 
Scottish cohort, and search for a potentially causative mutation. 
Methods: Tagging SNPs across the GALNT2 gene were genotyped on the Illumina® 
platform in the Edinburgh cohort of 374 CD, 470 UC patients and 879 controls.  
WTCCC GWAS genotype data across the GALNT2 gene was examined for gene-
wide significance.  Replication, where relevant, was completed on the Dundee cohort 
of 300 CD, 211 UC and 682 controls using the Taqman® platform.  PCR 
amplification was used to sequence the 16 exons of the gene in patients with specific 
genotypes.   
Results: After initial problems with the genotyping on the Illumina® platform, the 
SNP rs7536663T demonstrated a statistically significant association with CD 
susceptibility in the Edinburgh cohort (MAF CD 0.351, controls 0.309, OR 1.38, p-
value 0.0008).  In addition, a four SNP haplotype containing rs7536663 was 
associated with CD (p-value 0.0017).  No other SNP or haplotype block 
demonstrated a statistically significant association with IBD, UC or CD; a CD and 
UC sub phenotypic analysis was also negative.  Replication at the rs7536663 locus in 
the Dundee cohort did not demonstrate a statistically significant association (MAF 
CD 0.326, controls 0.309, p-value 0.469), although the replication cohort was 
underpowered to rule out an association.  Exonic sequencing across the 16 exons 
failed to demonstrate any non-synonymous SNPs to be associated with the 
rs7536663T or four SNP haplotype containing rs7536663. 
Conclusion: A larger replication cohort is required to confirm or refute an 
association of rs7536663T with CD susceptibility.    
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5.1 Introduction  
Following translation of proteins from mRNA in the ribosomes, many proteins 
require post-translation modification.  The addition of sugar moieties to make 
glycoproteins is a modification particularly characteristic of secreted molecules and 
cell surface receptors.  One of the types of sugar modifications that can occur is O-
glycosylation: the attachment of N-acetyl-D-galactosamine (GalNAc) to the 
hydroxyl group of Ser/Thr side chains on protein substrates, as shown in Figure 5-1.  
This process occurs after transfer of the protein into the Golgi apparatus, thus is 
completed at a late stage of protein processing.  The addition of these sugar groups 
gives proteins the capacity to resist proteolysis alongside considerable water holding 
capacity, enabling them to form components of the extracellular matrix and mucosal 
secretions. 
 
Figure 5-1 O-glycosylation by GALNT enzymes 
The initial step in O-glycosylation is catalysed by a family of glycosyltransferases 
called GALNT (UDP-N-acetyl-α-D-galactosamine polypeptide N-
acetylgalactosaminyltransferase).245  To date 24 human isoforms have been 
isolated.246  GALNT12 SNPs are associated with colorectal cancer susceptibility.247  
Abnormal expression of GALNT3 is correlated with stage and grade of tumour in a 
variety of cancers including gastric248, oesophageal249, pancreatic250 and colorectal251 
cancers.  SNPs in GALNT3 contribute to genetic susceptibility to familial 
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hyperphosphataemic tumoral calcinosis (reviewed by Chefetz and Sprecher252).  The 
SNP rs4846914, within intron 1 of the GALNT2 gene, was associated with HDL 
cholesterol in a GWAS of lipid concentrations and risk of coronary artery disease, 
conferring an OR of 1.15.253  It has subsequently been speculated that GALNT2 is 
important in the O-glycosylation of proteins involved in lipid metabolism.254  The 
other GALNT genes have not been associated with other diseases in the literature to 
date. 
5.2 Yeast two-hybrid screen – uncovering protein-protein 
interactions 
The yeast two-hybrid screen is a method of studying protein-protein interactions by 
analysing the activation of one or more reporter genes in the budding yeast 
Saccharomyces cerevisiae.255  The protein of interest is cloned into a yeast 
expression vector and this bait protein used to probe a cDNA library in yeast cells.  
An interaction causes growth and expansion of the yeast cell population.  This 
method has been used successful to delineate protein interactions and pathways in a 
variety of conditions including cancer256, HIV257 and schizophrenia.258  Another 
research group used NOD2 as the bait protein in a yeast two-hybrid screen which 
suggested that CENTB1259 and GRIM19260 were interacting proteins.  In the 
Gastrointestinal laboratory at the University of Edinburgh a yeast two-hybrid screen 
was also completed by Dr Elaine Nimmo using NOD2 as the bait protein261, which 
identified six proteins that appeared to interact with NOD2, as shown in Table 5-1.  
 
Gene Chr Function 
GALNT2 1q41-42 O-linked glycosylation  
TLE1 9q21.32 Transcriptional corepressor - binds to a number of transcription 
factors 
Vimentin 10p12.33 Maintains cell shape in integrity, stabilises cytoskeleton 
interactions, involved in immune response, controls protein 
transport 
FIS1 7q22.1 Promotes the fragmentation of the mitochondrial network and its 
perinuclear clustering 
HTATIP 11q13 Catalytic subunit of NuA4 histone acetyltransferase complex,  
involved in transcriptional activation of select genes 
PPP2R5E 14q23.2 Belongs to the phosphatase 2A regulatory subunit B family, 
implicated in the negative control of cell growth and division 
Table 5-1 Yeast two-hybrid screen NOD2 interacting proteins 
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Thus GALNT2 (UDP-N-acetyl-α-D-galactosamine polypeptide N-
acetylgalactosaminyltransferase) appeared to be one of the interacting proteins.  The 
GALNT2 gene is located on chromosome 1q41-42.262  The coding sequence is 
1713bp arranged in 16 exons spanning 100Kbp, with the gene encoding a protein of 
571 amino acids (64.7 kDa).263  The protein structure is thought to consist of a large 
glycosyl transferase segment lying within the lumen of the Golgi apparatus, a 
transmembrane anchor and a short cytoplasmic domain.246 
In the event of an interaction of NOD2 with GALNT2, it follows that mutations in 
the GALNT2 gene may predispose to IBD susceptibility.  This chapter sets out the 
investigation of this hypothesis.  This hypothesis has plausibility because changes in 
mucus composition due to defective O-glycosylation could affect barrier protection 
of the gastrointestinal tract. 
5.3 Methods 
5.3.1 GALNT2 tagging SNP analysis 
Tagging SNPs across the GALNT2 gene had already been selected by Dr Elaine 
Nimmo.  The 27 SNPs chosen are given in Table 5-2.  These SNPs were genotyped 
on the Illumina® platform at the Wellcome Trust Clinical Research Facility 
(WTCRF) at the Western General Hospital in the Edinburgh cohort of 374 CD 
patients, 470 UC patients and 879 controls. 
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SNP Alleles 
Chr 1 position 
(B36) 
rs12135308 A:T 228253271 
rs7515331 T:C 228253467 
rs1474925 G:T 228274056 
rs910820 A:G 228280942 
rs11122300 G:A 228287788 
rs12029443 C:G 228293831 
rs7536663 A:T 228295422 
rs2057233 G:A 228299413 
rs868287 G:C 228307737 
rs1474839 G:A 228308023 
rs1884578 A:G 228333832 
rs1973943 C:T 228338686 
rs4846908 G:A 228351679 
rs1998064 A:C 228353751 
rs2281719 A:G 228364282 
rs4846919 G:A 228368074 
rs1264084/rs606587 A:G 228382812 
rs4846928 C:T 228408528 
rs7512360 G:A 228422806 
rs3811486 T:C 228438684 
rs901675 C:T 228456625 
rs1471915 C:T 228469247 
rs2273967 G:A 228481916 
rs16851339 A:T 228483455 
rs1043908 T:C 228483917 
rs1043909 G:A 228483994 
rs7022 G:C 228484287 
Table 5-2 GALNT2 SNP selection 
In addition, the genotyping across GALNT2 generated by the WTCCC GWAS73 in 
UK CD cases and controls was analysed looking at the p-values for the SNPs across 
the gene. 
5.3.2 PCR optimization for GALNT2 sequencing  
The PCR amplifications were optimized using gradient gels to check the working 
temperature for the PCR and the best quantities of reagents.  DNA from a patient 
(0309UC) was used as the DNA template for amplification.  Some of the gradient 
PCRs required increased amounts of Taq (806/807: failed PCR) or increased 
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magnesium (818/819: non specific product) as shown in Table 5-3, which also shows 
primer combinations.  
Exon 
Primer 






















716 CTTGCATCTTGACTCCCTAAC AAGTTTTAACTTGACCACCCAC 61⁰C  
3 
765/ 
766 TTCTGGAGTTAACACTTACTGCAG GCCAGTCACACAACTCTCTTTC 65⁰C  
4-6 
806/ 
807 CTCTGAAGGGCTAAACAAGC TTGAGCTAAAGCACTTCTTTATG 62⁰C 2xTaq 
7 
808 
/809 TGGAGCAGTTTTGATCTCATC ACTAATCAGGCTCTCACCAGC 65⁰C  
8 
810/ 
811 GTAGTAGGTAGTAAGGGCCAGTTG GAGGGCTTCATCATCTCTG 61⁰C  
9 
812/ 
813 AGTCCCCTTCTCTCTCCTCC CAACATACAGGAATGCACAGAC 65⁰C  
10 
814/ 
815 CACTGTGGGAACATCCAGG AAACACTTGGGTTCAGACGC 64⁰C  
11 
816/ 




819 CAAATGGAGTGATGCAGACAG ATTCTCAGCTCCACACCATG 65⁰C 2xMgCl2 
14 
820/ 
821 TGTGGTAGGAAGAGGCACG GTTGTATAGGCATACCAGGCAG 64⁰C  
15 
822/ 
823 TGAATCTAAGCTCCACCCC CACTTGCATTATGTATCGAGTACC 62⁰C  
16 
824/ 
825 TCCTGAATTCACACGAATCTG ATTTCAAGAGTTCTCCTCGCTC 60⁰C  
Table 5-3 GALNT2 primer sequences and conditions 
There were particular problems with the amplification of exon 1, which is discussed 
in 5.8.1.  Once PCRs were optimized, PCRs were completed on samples as discussed 
in Sections 5.8.2 and 5.8.3.   
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5.4 Initial Illumina® GALNT2 data analysis 
5.4.1 Quality control 
GALNT2 data from the Illumina® Goldengate platform were initially subject to 
quality control.  All the SNPs were in Hardy-Weinberg equilibrium in controls.  The 
SNP rs868287 was excluded due to the poor rate of genotyping (86% genotyping).  
When poorly genotyped DNA (5 samples) was also excluded, it left 371 CD, 470 UC 
and 879 controls for analysis across the 26 remaining SNPs.   
5.4.2 GALNT2 Single SNP analysis 
The initial results for the single SNP analysis are shown in Table 5-4.  After 
Bonferroni correction, a significant p-value was taken as <0.0019.  As can be seen, 
rs2281719 was the only significant CD SNP (p-value of 0.001 in IBD, 0.0002 in 
CD); it showed a non-significant p-value in UC.  The MAF was 0.474 in CD and 
0.394 in controls. 
 







MAF p-value CD MAF p-value UC MAF p-value 
rs12135308 T 0.107 0.111 0.739 0.125 0.2087 0.098 0.4503 
rs7515331 C 0.107 0.122 0.173 0.121 0.3355 0.119 0.3759 
rs1474925 T 0.213 0.209 0.781 0.207 0.7329 0.205 0.6354 
rs910820 G 0.209 0.219 0.501 0.23 0.2521 0.209 0.9949 
rs11122300 A 0.189 0.185 0.76 0.174 0.3764 0.195 0.7285 
rs12029443 G 0.162 0.168 0.627 0.148 0.3928 0.183 0.1699 
rs7536663 T 0.312 0.323 0.494 0.365 0.012 0.292 0.3201 
rs2057233 A 0.398 0.383 0.368 0.344 0.0112 0.416 0.3838 
rs1474839 A 0.179 0.179 0.951 0.155 0.1323 0.199 0.2111 
rs1884578 G 0.269 0.278 0.577 0.319 0.0128 0.247 0.2263 
rs1973943 T 0.448 0.418 0.087 0.456 0.7168 0.387 0.0038 
rs4846908 A 0.443 0.448 0.758 0.457 0.5104 0.446 0.8779 
rs1998064 C 0.219 0.232 0.361 0.263 0.0172 0.209 0.555 
rs2281719 G 0.394 0.449 0.001 0.474 0.0002 0.431 0.0661 
rs4846919 A 0.151 0.144 0.582 0.151 0.9818 0.14 0.4422 
rs1264084/rs606587 G 0.337 0.33 0.699 0.333 0.8585 0.333 0.852 
rs4846928 T 0.142 0.146 0.751 0.154 0.4253 0.14 0.8967 
rs7512360 A 0.441 0.424 0.34 0.435 0.7867 0.415 0.2125 
rs3811486 C 0.116 0.113 0.777 0.113 0.8175 0.113 0.7711 
rs901675 T 0.297 0.285 0.46 0.263 0.087 0.3 0.836 
rs1471915 T 0.114 0.117 0.726 0.106 0.5789 0.128 0.2644 
rs2273967 A 0.253 0.253 0.985 0.25 0.8697 0.255 0.9101 
rs16851339 T 0.021 0.016 0.28 0.015 0.3946 0.015 0.3103 
rs1043908 C 0.121 0.12 0.979 0.102 0.1893 0.131 0.4426 
rs1043909 A 0.188 0.202 0.3 0.193 0.7838 0.212 0.1414 
rs7022 C 0.325 0.319 0.708 0.314 0.5915 0.319 0.7575 
Table 5-4 GALNT2 Single SNP Analysis 
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5.4.3 GALNT2 Haplotype analysis 
Haplotypes were defined according to solid spine of LD on the control samples.  The 
LD plot is shown in Figure 5-2, and the analysis shown in Table 5-2.  The only 
significant haplotype was the GG in block 8, containing rs2281719 and rs4846919.  
On its own, rs2281719 had a CD p-value of 0.0002.  The p-value improved slightly 
to 8.9x10-5 in the GG haplotype block.   
 
 
Figure 5-2 GALNT2 LD plot: controls only 
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Block 1  Controls IBD p-value CD p-value UC p-value 
AT 0.785 0.771 0.3095 0.755 0.0963 0.784 0.9275 
TT 0.107 0.119 0.2653 0.124 0.2185 0.118 0.3878 
AC 0.107 0.11 0.8238 0.121 0.333 0.098 0.4433 
Block 2        
G 0.787 0.794 0.6141 0.793 0.7347 0.795 0.6385 
T 0.213 0.206 0.6141 0.207 0.7347 0.205 0.6385 
Block 3        
AG 0.602 0.597 0.7598 0.597 0.8101 0.597 0.802 
GG 0.21 0.219 0.5211 0.23 0.2453 0.209 0.9627 
AA 0.189 0.185 0.7712 0.173 0.3526 0.195 0.7181 
Block 4        
C 0.838 0.833 0.6747 0.852 0.3945 0.817 0.1731 
G 0.162 0.167 0.6747 0.148 0.3945 0.183 0.1731 
Block 5        
TGG 0.313 0.324 0.4713 0.365 0.0112 0.29 0.2587 
AGG 0.288 0.292 0.8439 0.289 0.986 0.295 0.7879 
AAG 0.219 0.205 0.3037 0.192 0.1218 0.217 0.8475 
AAA 0.178 0.178 0.9915 0.154 0.1496 0.198 0.2194 
Block 6        
AC 0.544 0.562 0.2949 0.523 0.34 0.593 0.0151 
GT 0.262 0.278 0.2892 0.316 0.0058 0.247 0.4068 
AT 0.19 0.158 0.0142 0.158 0.0571 0.159 0.0427 
Block 7        
GA 0.557 0.549 0.646 0.542 0.507 0.554 0.9044 
AC 0.22 0.233 0.3429 0.263 0.0203 0.236 0.456 
AA 0.223 0.218 0.6842 0.195 0.1129 0.209 0.5388 
Block 8        
AG 0.604 0.55 0.0013 0.527 3.00E-04 0.569 0.0794 
GG 0.245 0.303 1.00E-04 0.32 8.93E-05 0.29 0.0118 
GA 0.15 0.146 0.7406 0.152 0.8696 0.141 0.545 
Block 9        
A 0.663 0.667 0.8227 0.667 0.859 0.667 0.8527 
G 0.337 0.333 0.8227 0.333 0.859 0.333 0.8527 
Block 10        
CGTT 0.293 0.283 0.4674 0.261 0.1043 0.301 0.7292 
CGTC 0.268 0.294 0.0946 0.305 0.056 0.284 0.3849 
CATC 0.18 0.164 0.2083 0.163 0.2997 0.165 0.3086 
TATC 0.139 0.146 0.5539 0.155 0.2849 0.138 0.9616 
CACC 0.117 0.113 0.7481 0.113 0.7978 0.112 0.755 
Block 11        
CGA 0.643 0.64 0.8454 0.654 0.6142 0.628 0.4591 
CAA 0.222 0.226 0.7893 0.224 0.8989 0.228 0.7653 
TGA 0.104 0.108 0.7076 0.096 0.5621 0.118 0.2862 
CAT 0.021 0.016 0.2479 0.016 0.3934 0.016 0.3309 
Block 12        
TGG 0.486 0.478 0.6234 0.49 0.8671 0.467 0.3594 
TGC 0.205 0.201 0.7812 0.215 0.5615 0.19 0.3407 
TAG 0.187 0.201 0.3025 0.189 0.897 0.212 0.1408 
CGC 0.118 0.114 0.7306 0.097 0.1338 0.128 0.4596 
Table 5-5 GALNT2 Haplotype analysis 
 
GALNT2 genotype   179   
5.4.4 Sub phenotypic analysis - CD 
Results of a CD sub phenotypic analysis are shown in Table 5-6 and were negative 
after Bonferroni correction (p-value <0.0019).   A CD sub phenotypic haplotype 
analysis (Table 5-7 and Table 5-8) revealed that the GG haplotype in block 8 was 
significant in L2 disease with a p-value of 3x10-4.
 


















rs12135308 T 0.107 0.128 0.3444 0.12 0.3289 0.105 0.9402 0.13 0.0563 0.118 0.582 0.115 0.6088 
rs7515331 C 0.107 0.123 0.4891 0.129 0.2843 0.092 0.5594 0.116 0.5852 0.085 0.4565 0.182 0.0104 
rs1474925 T 0.213 0.214 0.9549 0.191 0.6081 0.169 0.2093 0.204 0.8143 0.204 0.9447 0.224 0.628 
rs910820 G 0.209 0.268 0.0464 0.236 0.2994 0.209 0.9993 0.221 0.5371 0.218 0.824 0.292 0.0263 
rs11122300 A 0.189 0.167 0.4165 0.176 0.6065 0.189 0.9985 0.16 0.1963 0.191 0.9673 0.188 0.9145 
rs12029443 G 0.162 0.152 0.698 0.156 0.7632 0.151 0.7335 0.133 0.3007 0.152 0.678 0.2 0.3198 
rs7536663 T 0.312 0.389 0.0227 0.357 0.165 0.356 0.2681 0.343 0.5051 0.361 0.2736 0.402 0.036 
rs2057233 A 0.398 0.314 0.0152 0.354 0.1689 0.388 0.8051 0.346 0.0558 0.33 0.1303 0.356 0.2811 
rs1474839 A 0.179 0.152 0.3067 0.16 0.4614 0.184 0.8829 0.137 0.074 0.152 0.443 0.209 0.4121 
rs1884578 G 0.269 0.33 0.0537 0.312 0.1852 0.322 0.157 0.302 0.3998 0.324 0.2251 0.364 0.0196 
rs1973943 T 0.448 0.445 0.9425 0.439 0.7507 0.486 0.3737 0.429 0.326 0.433 0.733 0.54 0.0514 
rs4846908 A 0.443 0.465 0.5347 0.457 0.6272 0.467 0.5723 0.468 0.1751 0.438 0.9975 0.417 0.634 
rs1998064 C 0.219 0.259 0.1737 0.271 0.0971 0.273 0.1231 0.266 0.0373 0.282 0.1144 0.227 0.8249 
rs2281719 G 0.394 0.527 0.0249 0.492 0.0038 0.447 0.1977 0.473 0.0122 0.429 0.5117 0.492 0.0344 
rs4846919 A 0.151 0.162 0.6591 0.134 0.5274 0.191 0.1912 0.138 0.4855 0.13 0.5679 0.205 0.083 
rs1264084/rs606587 G 0.337 0.353 0.6314 0.324 0.6707 0.327 0.8053 0.333 0.8075 0.339 0.9816 0.321 0.7001 
rs4846928 T 0.142 0.17 0.2638 0.15 0.9199 0.125 0.5703 0.155 0.6278 0.145 0.9937 0.154 0.8064 
rs7512360 A 0.441 0.441 0.9832 0.449 0.8129 0.39 0.2395 0.45 0.9867 0.409 0.5071 0.439 0.9428 
rs3811486 C 0.116 0.112 0.8316 0.102 0.5712 0.14 0.3911 0.121 0.8308 0.098 0.5962 0.106 0.7733 
rs901675 T 0.297 0.257 0.214 0.26 0.1797 0.293 0.9336 0.261 0.0905 0.268 0.4833 0.276 0.5595 
rs1471915 T 0.114 0.111 0.8965 0.109 0.5739 0.12 0.811 0.095 0.1296 0.116 0.9546 0.142 0.371 
rs2273967 A 0.253 0.239 0.6387 0.267 0.4908 0.274 0.5796 0.251 0.9105 0.208 0.3165 0.282 0.4735 
rs16851339 T 0.021 0.018 0.8019 0.008 0.3128 0.021 0.9995 0.021 0.6421 0.019 0.9822 0 0.1148 
rs1043908 C 0.121 0.098 0.3256 0.102 0.6305 0.097 0.4022 0.091 0.2003 0.111 0.8328 0.125 0.8361 
rs1043909 A 0.188 0.205 0.5626 0.168 0.4107 0.185 0.9206 0.189 0.922 0.213 0.541 0.18 0.791 
rs7022 C 0.325 0.306 0.5772 0.32 0.9609 0.284 0.3042 0.302 0.4892 0.33 0.9127 0.31 0.7133 
Table 5-6 GALNT2 CD sub phenotypic analysis
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Haplotype 
 Control 
freq L1 freq p-value L2 freq p-value L3 freq p-value 
Block 1        
AT 0.785 0.75 0.2285 0.751 0.1241 0.803 0.6174 
AC 0.107 0.123 0.4856 0.129 0.2847 0.092 0.5584 
TT 0.107 0.127 0.3695 0.12 0.3319 0.105 0.9371 
Block 2        
G 0.787 0.786 0.9551 0.809 0.6095 0.83 0.2151 
T 0.213 0.214 0.9551 0.191 0.6095 0.17 0.2151 
Block 3        
AG 0.602 0.567 0.3208 0.587 0.6396 0.602 0.9964 
GG 0.21 0.267 0.0486 0.236 0.2974 0.211 0.9706 
AA 0.189 0.166 0.4038 0.176 0.615 0.187 0.965 
Block 4        
C 0.838 0.848 0.6992 0.844 0.764 0.849 0.7336 
G 0.162 0.152 0.6992 0.156 0.764 0.151 0.7336 
Block 5        
TGG 0.313 0.387 0.0234 0.357 0.165 0.359 0.233 
AGG 0.289 0.294 0.873 0.287 0.9744 0.252 0.3381 
AAG 0.22 0.166 0.066 0.197 0.4092 0.204 0.6597 
AAA 0.178 0.152 0.3397 0.159 0.4413 0.184 0.8477 
Block 6        
AC 0.544 0.523 0.5609 0.54 0.9602 0.499 0.292 
GT 0.261 0.326 0.0404 0.31 0.1148 0.315 0.1511 
AT 0.191 0.149 0.1302 0.148 0.1034 0.179 0.701 
Block 7        
GA 0.557 0.535 0.5426 0.543 0.6233 0.531 0.5397 
AC 0.22 0.259 0.1856 0.271 0.1071 0.273 0.1312 
AA 0.223 0.206 0.5478 0.186 0.285 0.196 0.4343 
Block 8        
AG 0.604 0.531 0.036 0.509 0.0049 0.552 0.2086 
GG 0.244 0.304 0.0508 0.355 3.00E-04 0.257 0.7252 
GA 0.15 0.164 0.583 0.135 0.6149 0.19 0.1853 
Block 9        
A 0.663 0.647 0.6329 0.676 0.6719 0.673 0.8065 
G 0.337 0.353 0.6329 0.324 0.6719 0.327 0.8065 
Block 10        
CGTT 0.294 0.256 0.2407 0.255 0.1621 0.296 0.9616 
CGTC 0.268 0.304 0.2426 0.297 0.2596 0.314 0.2154 
CATC 0.181 0.158 0.4013 0.19 0.6487 0.127 0.0914 
TATC 0.139 0.17 0.2037 0.15 0.8022 0.125 0.6324 
CACC 0.117 0.111 0.7948 0.104 0.6274 0.138 0.4279 
Block 11        
CGA 0.644 0.667 0.5039 0.636 0.8493 0.611 0.45 
CAA 0.221 0.204 0.5618 0.246 0.3398 0.248 0.4737 
TGA 0.103 0.094 0.6854 0.099 0.5359 0.114 0.7078 
CAT 0.021 0.019 0.7884 0.01 0.3308 0.021 0.954 
Block 12        
TGG 0.486 0.488 0.9683 0.501 0.7118 0.531 0.286 
TGC 0.205 0.209 0.8676 0.228 0.4903 0.187 0.5991 
TAG 0.187 0.198 0.6854 0.168 0.4228 0.184 0.926 
CGC 0.118 0.094 0.28 0.094 0.4384 0.096 0.4185 
Table 5-7 GALNT2 CD sub phenotypic haplotype analysis – disease location 
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Haplotype 
 Control 
freq B1 freq p-value B2 freq p-value B3 freq p-value 
Block 1        
AT 0.785 0.755 0.0679 0.795 0.901 0.704 0.0202 
AC 0.107 0.116 0.5844 0.087 0.4809 0.181 0.0108 
TT 0.107 0.129 0.0594 0.118 0.5827 0.115 0.6291 
Block 2        
G 0.787 0.796 0.8153 0.796 0.9456 0.776 0.6281 
T 0.213 0.204 0.8153 0.204 0.9456 0.224 0.6281 
Block 3        
AG 0.602 0.618 0.6552 0.592 0.8817 0.529 0.1097 
GG 0.21 0.222 0.523 0.217 0.8543 0.292 0.0258 
AA 0.189 0.16 0.213 0.192 0.9963 0.179 0.7379 
Block 4        
C 0.838 0.867 0.3008 0.848 0.678 0.801 0.3266 
G 0.162 0.133 0.3008 0.152 0.678 0.199 0.3266 
Block 5        
TGG 0.313 0.344 0.5027 0.358 0.305 0.401 0.031 
AGG 0.289 0.307 0.2271 0.312 0.572 0.242 0.2717 
AAG 0.22 0.212 0.6361 0.179 0.281 0.148 0.043 
AAA 0.178 0.137 0.0727 0.152 0.4546 0.209 0.3987 
Block 6        
AC 0.544 0.55 0.5826 0.53 0.8149 0.438 0.0208 
GT 0.261 0.3 0.2872 0.317 0.1985 0.361 0.0114 
AT 0.191 0.149 0.0622 0.142 0.186 0.2 0.8709 
Block 7        
GA 0.557 0.532 0.1729 0.562 0.9903 0.58 0.6782 
AC 0.22 0.266 0.039 0.281 0.1194 0.228 0.8336 
AA 0.223 0.202 0.637 0.156 0.1123 0.192 0.477 
Block 8        
AG 0.604 0.529 0.0142 0.571 0.5303 0.513 0.0474 
GG 0.244 0.331 0.0013 0.297 0.253 0.28 0.4599 
GA 0.15 0.14 0.5275 0.131 0.6169 0.207 0.0636 
Block 9        
A 0.663 0.667 0.8083 0.661 0.9816 0.679 0.7001 
G 0.337 0.333 0.8083 0.339 0.9816 0.321 0.7001 
Block 10        
CGTT 0.294 0.26 0.0906 0.268 0.5182 0.276 0.5962 
CGTC 0.268 0.293 0.0987 0.323 0.1757 0.287 0.5388 
CATC 0.181 0.168 0.5072 0.16 0.5848 0.178 0.9347 
TATC 0.139 0.155 0.5761 0.151 0.7869 0.154 0.7037 
CACC 0.117 0.122 0.8259 0.098 0.595 0.104 0.7282 
Block 11        
CGA 0.644 0.66 0.4345 0.689 0.3459 0.592 0.261 
CAA 0.221 0.222 0.9006 0.175 0.258 0.265 0.2714 
TGA 0.103 0.088 0.163 0.102 0.954 0.127 0.4609 
CAT 0.021 0.022 0.671 0.02 0.9909 0.001 0.1206 
Block 12        
TGG 0.486 0.508 0.6241 0.457 0.5661 0.5 0.7317 
TGC 0.205 0.212 0.7684 0.219 0.7668 0.195 0.7375 
TAG 0.187 0.184 0.9973 0.202 0.6948 0.18 0.8119 
CGC 0.118 0.086 0.1419 0.101 0.6368 0.124 0.7941 
Table 5-8 GALNT2 CD sub phenotypic haplotype analysis - disease behaviour 
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5.4.5 Sub phenotypic analysis – UC 
Results of a UC sub phenotypic analysis of GALNT are shown in Table 5-9 and 






MAF E3 MAF p-value E2 MAF p-value E1 MAF p-value 
rs12135308 T 0.107 0.116 0.6379 0.083 0.1748 0.101 0.8242 
rs7515331 C 0.107 0.126 0.2877 0.117 0.6036 0.115 0.7759 
rs1474925 T 0.213 0.209 0.8701 0.203 0.6973 0.209 0.9276 
rs910820 G 0.209 0.264 0.0234 0.181 0.2227 0.171 0.2847 
rs11122300 A 0.189 0.196 0.762 0.201 0.6037 0.182 0.8388 
rs12029443 G 0.162 0.203 0.0552 0.169 0.7245 0.169 0.8241 
rs7536663 T 0.312 0.279 0.2186 0.305 0.8107 0.288 0.5497 
rs2057233 A 0.398 0.44 0.1418 0.414 0.5849 0.378 0.6333 
rs1474839 A 0.179 0.196 0.4458 0.207 0.225 0.182 0.9272 
rs1884578 G 0.269 0.244 0.3423 0.251 0.5035 0.246 0.5634 
rs1973943 T 0.448 0.41 0.1983 0.367 0.007 0.393 0.2096 
rs4846908 A 0.443 0.473 0.2889 0.422 0.4739 0.445 0.955 
rs1998064 C 0.219 0.23 0.6426 0.193 0.285 0.209 0.7935 
rs2281719 G 0.394 0.428 0.2264 0.436 0.1381 0.426 0.4501 
rs4846919 A 0.151 0.12 0.1309 0.158 0.7197 0.144 0.8194 
rs1264084/rs606587 G 0.337 0.328 0.7492 0.334 0.9332 0.349 0.7544 
rs4846928 T 0.142 0.128 0.5059 0.157 0.4457 0.134 0.7954 
rs7512360 A 0.441 0.419 0.4517 0.412 0.3102 0.432 0.8299 
rs3811486 C 0.116 0.106 0.5669 0.126 0.6233 0.099 0.5216 
rs901675 T 0.297 0.274 0.389 0.307 0.7034 0.351 0.1629 
rs1471915 T 0.114 0.12 0.7413 0.131 0.3403 0.142 0.3005 
rs2273967 A 0.253 0.247 0.8128 0.247 0.8125 0.283 0.4453 
rs16851339 T 0.021 0.02 0.9044 0.011 0.2414 0.015 0.6559 
rs1043908 C 0.121 0.138 0.3637 0.114 0.7081 0.142 0.4506 
rs1043909 A 0.188 0.215 0.2331 0.237 0.0358 0.149 0.2333 
rs7022 C 0.325 0.324 0.979 0.289 0.1835 0.362 0.3672 
Table 5-9 GALNT2 UC sub phenotypic analysis
 







freq p-value E1 freq p-value 
Block 1        
AT 0.785 0.759 0.2591 0.8 0.5311 0.784 0.9651 
AC 0.107 0.126 0.2968 0.116 0.6165 0.115 0.7773 
TT 0.107 0.115 0.6536 0.084 0.1757 0.101 0.8213 
Block 2        
G 0.787 0.791 0.8716 0.796 0.7002 0.791 0.9276 
T 0.213 0.209 0.8716 0.204 0.7002 0.209 0.9276 
Block 3        
AG 0.602 0.544 0.0386 0.617 0.5788 0.645 0.3007 
GG 0.21 0.261 0.0299 0.182 0.2339 0.172 0.2862 
AA 0.189 0.196 0.7605 0.201 0.5951 0.182 0.8496 
Block 4        
C 0.838 0.798 0.0581 0.831 0.727 0.831 0.8241 
G 0.162 0.202 0.0581 0.169 0.727 0.169 0.8241 
Block 5        
TGG 0.312 0.275 0.1623 0.303 0.7252 0.291 0.5962 
AGG 0.29 0.289 0.9912 0.283 0.7995 0.33 0.294 
AAG 0.22 0.241 0.3685 0.21 0.6968 0.196 0.5114 
AAA 0.178 0.194 0.4482 0.204 0.2374 0.182 0.8952 
Block 6        
AC 0.544 0.577 0.2406 0.608 0.0245 0.583 0.3488 
GT 0.261 0.246 0.5581 0.25 0.653 0.243 0.6327 
AT 0.191 0.175 0.4774 0.14 0.0231 0.172 0.5635 
Block 7        
GA 0.557 0.526 0.2801 0.579 0.4478 0.557 0.9971 
AA 0.223 0.243 0.4197 0.228 0.8475 0.234 0.7758 
AC 0.22 0.231 0.6315 0.193 0.2662 0.209 0.7707 
Block 8        
AG 0.604 0.572 0.2463 0.564 0.1589 0.574 0.4712 
GG 0.244 0.306 0.0137 0.276 0.2034 0.279 0.348 
GA 0.15 0.122 0.1675 0.159 0.654 0.147 0.9161 
Block 9        
A 0.663 0.672 0.7499 0.666 0.9337 0.651 0.7559 
G 0.337 0.328 0.7499 0.334 0.9337 0.349 0.7559 
Block 10        
CGTT 0.294 0.275 0.4645 0.306 0.6465 0.351 0.1471 
CGTC 0.268 0.305 0.1393 0.282 0.585 0.216 0.1734 
CATC 0.181 0.182 0.9694 0.136 0.0387 0.205 0.4825 
TATC 0.139 0.129 0.6214 0.154 0.4356 0.128 0.7245 
CACC 0.116 0.108 0.6575 0.122 0.7869 0.1 0.5418 
Block 11        
CGA 0.642 0.639 0.9143 0.633 0.7348 0.595 0.2418 
CAA 0.223 0.22 0.9023 0.224 0.9524 0.246 0.5046 
TGA 0.105 0.114 0.6022 0.121 0.3371 0.125 0.4202 
CAT 0.021 0.021 0.958 0.011 0.2142 0.017 0.7413 
Block 12        
TGG 0.486 0.46 0.3653 0.474 0.6849 0.486 0.9968 
TGC 0.205 0.187 0.4437 0.177 0.2138 0.223 0.5948 
TAG 0.188 0.214 0.23 0.234 0.0411 0.148 0.2365 
CGC 0.118 0.137 0.3226 0.111 0.6924 0.135 0.5564 
Table 5-10 GALNT2 UC sub phenotypic haplotype analysis 
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5.5 WTCCC analysis 
The publicly available WTCCC SNP data across the GALNT2 gene were 
downloaded from the WTCCC website by Dr Gail Davies.  As the Edinburgh cohort 
formed part of the WTCCC study these samples were excluded from this analysis in 
order to prevent some samples being in both the WTCCC analysis and the separate 
Edinburgh analysis of the Illumina® data.  Information downloaded included the p-
values for each SNP but not the minor allele frequencies.  The p-values were plotted 
against the SNP location.  There were 92 WTCCC SNPs, thus to correct for multiple 
testing across the gene a p-value <5x10-4 was required.  Gene-wide rather than 
genome-wide significance was considered appropriate for a gene which already had a 
hypothesis for CD susceptibility.  The results are shown in Figure 5-3.  Only one 
marker reached gene-wide significance: rs12751815 (p-value 1.85x10-4).  Two 
further SNPs, rs1358769 and rs7513659, approached significance (p-values 0.001 
each).  There was a cluster of SNPs between exons 1 and 2 that had smaller p-values 
than in other areas, giving the suggestion that it may be an area of significance. 
 
Figure 5-3 Non Scots WTCCC GALNT2 data and Haploview map of the region 
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5.6 Replication of findings 
Although the WTCCC data analysis was a reassuring ‘surrogate’ replication, it was 
necessary to try to get replication of the association between CD and rs2281719 in a 
separate cohort of Scottish patients.  At the time of requesting this genotyping, the 
Dundee cohort was incomplete and no controls were available, so the purpose of 
genotyping was to attempt replication of the MAF in cases.  In the Edinburgh cohort 
the MAF of rs2281719 was 0.45 in IBD and 0.47 in CD, with a control MAF of 0.39.  
However, in the limited Dundee cohort of 155 CD, 119 UC, the MAF was 0.38, with 
no difference between UC and CD.   
These results were puzzling and hard to explain.  The WTCCC dataset was re-
examined, and it appeared that rs2281719 had been genotyped in this population, but 
without showing any significant association when comparing WTCCC CD cases 
against controls (p-value 0.327, MAF not available).   
SNP calls on the Illumina® platform are automatically generated by the Beadstudio 
clustering algorithm.  The Illumina® cluster plot was examined (Figure 5-4) for 
suboptimal clustering of rs2281719, and it was felt that reclustering would be 
appropriate as there was poor separation between the wild type homozygotes (red) 
and the heterozygotes (purple) samples.    The reclustering was done manually by 
Angie Fawkes in the WTCRF, Edinburgh.  However, on reanalysis of the SNP, the 
MAF for cases remained 0.46 for IBD, and 0.39 for controls.
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Figure 5-4 rs2281719 before reclustering 
 
Figure 5-5 rs2281719 after reclustering 
The next step was to sequence across the SNP in specific patients to check the 
accuracy of the Illumina® calling.  The primers used were 
5’ATACATGAAGTCTCTGGGCC3’ (forward) and 
5’ATATGGTAGGTGATCAGATACAGG 3’(reverse) (primers 763/764), which 
were optimized for an annealing temperature of 62°C with an initial gradient PCR.  
A total of 63 DNAs were selected: 36 GA, 19 AA and 8 GG samples for sequencing 
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across the rs2281719 SNP.  The sequencing results matched the genotyping results in 
all of the AA cases.  Of the 8 GG genotyping, 7 were GG when sequenced, and one 
was AA.  Of the 36 supposed heterozygotes, 29 correlated with the sequencing, but 7 
did not, and appeared to be AA on the basis of the sequencing.  This low correlation 
of Illumina® genotyping with the sequencing data, particularly for the heterozygotes, 
was of major concern.  
The next step was to perform Taqman® genotyping for rs2281719, in order to clarify 
the situation for as many of the dataset as possible.  As the DNA plates that had been 
used for both Illumina® and Taqman® genotyping had run low, the DNA had been 
replated meaning that not all of the samples genotyped on the Illumina® platform 
were genotyped on Taqman®.  Of note, on Taqman® the MAF in both CD cases and 
controls was 0.37.  In total there were 995 samples with both Illumina® and 







called GG AG AA 
Not 
called 0 1 4 3 
GG 10 15 4 0 









AA 10 2 8 302 
Table 5-11 rs2281719 Illumina® and Taqman® sequencing compared 
In total there were 112 discrepancies between the datasets, representing 11.3% of the 
samples, including 2 samples that had been called on Illumina® as wild type 
homozygous which on Taqman® were called minor allele homozygous.  One or 
other of the genotyping platforms was seriously flawed for this genotyping. 
In order to clarify which one of the 2 genotyping platforms was incorrect for the 
genotyping of this SNP, as many as possible of the discrepant samples were 
sequenced using primers 763/764, as detailed earlier in this section.  In total it was 
possible to sequence 83 of these samples.  In all of these cases the sequencing 
correlated with Taqman® rather than Illumina®, including one of the samples that 
had been called on Illumina® as AA but was called as GG on Taqman®.  When 
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these samples were looked at on the Illumina® clustering, only 54 of the samples 
were in areas that could be no-calls if the clustering on Illumina® was made more 
stringent, as shown in Figure 5-6.   
 
Figure 5-6 rs2281719 Illumina® cluster plot with more stringent clustering 
The rest of the discrepant samples (29) fell within the centre of the clusters.  So not 
only were more than 10% of the samples not called on the more severe clustering 
(thus not attaining pre-determined quality control levels) but in addition some of the 
samples appeared to have been incorrectly called.  It was not clear whether this was a 
problem with the SNP genotyping or a problem with the plates on which the 
genotyping had been done.  Advice was taken from Dr Mark Gibbs, an Illumina® 
field application employee.  After looking at the data for rs2281719, his response 
was: 
‘The SNP itself is on the 1M chip, and is in dbSNP with quite a lot 
of data.  Allele frequencies for the SNP for Caucasians are 0.35, 
0.483 and 0.187.  Relative to these your data has an excess of AA 
and AG calls, and a lack of GG calls, and this is a significant 
difference (according to my back of envelope chi square test).  All 
in all it looks like this Goldengate assay is not resolving the 
genotypes, which can happen if there are additional 
polymorphisms, other similar sequences in the genome etc that 
either affect the binding of primers, amplification of alleles and so 
on creating null alleles or unusual, these kinds of things could also 
affect the Taqman® assay of course.  In this sense, Infinium is 
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more robust than Goldengate I think because it hinges on extension 
from a single long primer.  I don't know if this is significant, but 
the ASO sequence has two perfect matches in the genome, the 
correct on Chr 1, and another on chr12, even if the chr 12 match 
won't make a PCRable product because the LSO is a perfect match 
only to Chr1, perhaps there is some variation in signal introduced.’ 
 
In view of this knowledge, data from rs2281719 had to be discounted.  As a large 
number of the controls had not been sequenced on Taqman®, it was not possible to 
incorporate the Taqman® data with the remaining GALNT2 genotyping.  
This concern about rs2281719 led us to re-call and check all the data generated on 
the Illumina® platform.  A large number of SNPs (1536) had been genotyped 
covering not only the yeast-2 hybrid candidates but also fine mapping the IBD2 
region (25Mb) on chromosome 12.  Angie Fawkes at the Genetics Core of the 
WTCRF examined the other SNPs that had been genotyped on the Illumina® 
platform at the same time and on a number had similarly questionable clustering.  
One of the problems appeared to be differences in sample concentration between 
plates.  Angie Fawkes went through each SNP in the dataset and reclustered each one 
manually, calling every plate separately.  This generated a new set of GALNT2 data, 
which had to be completely reanalysed. 
A number of SNPs from the other genes that had been genotyped on the Illumina® 
platform were also genotyped on the Taqman® platform, and this genotyping 
correlated well with the reclustered data, giving us confidence in the Illumina® 
platform for the rest of the sequencing. 
5.7 GALNT2 reanalysis 
5.7.1 Quality control 
Initial quality control removed only one SNP in addition to rs2281719: rs16851339, 
due to poor genotyping (following reclustering of all the SNPs).  Interestingly, 
rs868287, despite having been excluded on the initial analysis (see section 5.4.1), 
was not removed on the reanalysis.  This was as a result of more DNA samples being 
excluded and the poor genotyping having been with those excluded samples.  The 
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numbers of samples analysed were: 351 CD, 434 UC and 841 controls as 23 CD, 36 
UC and 37 control samples were removed at the quality control stage. 
5.7.2 GALNT2 reanalysis - single SNP analysis 
When corrected for multiple testing (p-value<0.002), the SNP rs7536663 (located in 
intron 1) was the only single SNP demonstrating association (OR 1.38, 95% CI 1.14-







MAF p-value CD MAF p-value UC MAF p-value 
rs12135308 T 0.101 0.109 0.441 0.121 0.1633 0.1 0.9465 
rs7515331 C 0.106 0.117 0.3433 0.123 0.2299 0.111 0.7003 
rs1474925 T 0.213 0.205 0.5408 0.204 0.6031 0.205 0.6273 
rs910820 G 0.206 0.221 0.3322 0.233 0.1577 0.21 0.8319 
rs11122300 A 0.186 0.183 0.8225 0.176 0.6172 0.188 0.8873 
rs12029443 G 0.162 0.163 0.9078 0.148 0.4321 0.176 0.3629 
rs7536663 T 0.281 0.314 0.0407 0.351 8.00E-04 0.284 0.8629 
rs2057233 A 0.401 0.385 0.3714 0.351 0.0273 0.413 0.5517 
rs868287 C 0.283 0.296 0.395 0.293 0.6346 0.299 0.3843 
rs1474839 A 0.178 0.176 0.8682 0.154 0.1707 0.194 0.3319 
rs1884578 G 0.26 0.276 0.3039 0.311 0.0135 0.248 0.5198 
rs1973943 T 0.462 0.458 0.8558 0.501 0.0807 0.422 0.0634 
rs4846908 A 0.441 0.447 0.7419 0.461 0.3595 0.435 0.7592 
rs1998064 C 0.222 0.234 0.3819 0.267 0.0177 0.208 0.4201 
rs4846919 A 0.153 0.149 0.7562 0.156 0.8747 0.144 0.5311 
rs1264084/ 
rs606587 G 0.335 0.335 0.9825 0.337 0.9168 0.334 0.9598 
rs4846928 T 0.145 0.15 0.6677 0.157 0.4487 0.144 0.979 
rs7512360 A 0.447 0.427 0.257 0.436 0.6182 0.42 0.1963 
rs3811486 C 0.118 0.114 0.7436 0.117 0.9376 0.112 0.6598 
rs901675 T 0.291 0.288 0.8597 0.262 0.1457 0.31 0.3239 
rs1471915 T 0.115 0.12 0.6597 0.104 0.4382 0.133 0.1882 
rs2273967 A 0.257 0.258 0.9785 0.25 0.7283 0.264 0.7219 
rs1043908 C 0.121 0.122 0.9505 0.102 0.2007 0.138 0.2341 
rs1043909 A 0.186 0.199 0.3418 0.19 0.8164 0.207 0.2085 
rs7022 C 0.328 0.322 0.7374 0.32 0.7225 0.324 0.8494 
Table 5-12 GALNT2 reanalysis - single SNP analysis 
5.7.3 GALNT2 reanalysis - Haplotype analysis 
A haplotype analysis was completed, defining the haplotype block according to solid 
spine of LD on the control samples only (Figure 5-7).  The results are shown in Table 
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5-13.  Haplotypes in block 5 were associated with CD susceptibility: the TGGG 
haplotype in intron 1 showed association with CD (p = 0.0017).  The AGGG 
haplotype had a higher frequency in controls rather than cases, but the frequencies in 
the cohort were very low, meaning that it could represent an artifact. 
 
Figure 5-7 GALNT2 reanalysis haplotypes, controls only
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Haplotype  Controls IBD p-value CD p-value UC p-value 
Block 1        
AT 0.793 0.774 0.2031 0.757 0.0537 0.789 0.8186 
AC 0.106 0.116 0.3447 0.123 0.2314 0.111 0.7018 
TT 0.101 0.109 0.4593 0.12 0.1738 0.1 0.9325 
Block 2        
C 0.787 0.795 0.5433 0.796 0.6055 0.795 0.6293 
A 0.213 0.205 0.5433 0.204 0.6055 0.205 0.6293 
Block 3        
AG 0.608 0.597 0.5243 0.591 0.4239 0.602 0.7705 
GG 0.207 0.22 0.3346 0.233 0.1539 0.21 0.8434 
AA 0.185 0.182 0.8291 0.176 0.6146 0.188 0.8726 
Block 4        
C 0.838 0.837 0.9084 0.852 0.4348 0.824 0.3672 
G 0.162 0.163 0.9084 0.148 0.4348 0.176 0.3672 
Block 5        
TGGG 0.288 0.315 0.0873 0.352 0.0017 0.284 0.8901 
AGCG 0.281 0.295 0.3852 0.287 0.77 0.302 0.3057 
AAGG 0.223 0.208 0.2906 0.196 0.1406 0.218 0.7346 
AAGA 0.176 0.176 0.9829 0.153 0.1848 0.195 0.2671 
AGGG 0.029 0.003 1.39E-08 0.007 7.00E-04 0.001 1.07E-06 
Block 6        
TC 0.536 0.539 0.8627 0.498 0.0982 0.572 0.08 
CT 0.261 0.276 0.3157 0.312 0.0115 0.247 0.4774 
TT 0.201 0.184 0.2414 0.19 0.5318 0.18 0.2022 
Block 7        
GA 0.559 0.554 0.7899 0.54 0.3975 0.566 0.7354 
AC 0.221 0.235 0.3389 0.268 0.0141 0.208 0.4499 
AA 0.22 0.211 0.5137 0.192 0.1288 0.226 0.7301 
Block 8        
GA 0.656 0.658 0.8877 0.657 0.9678 0.659 0.8629 
GG 0.191 0.193 0.8448 0.188 0.916 0.198 0.6821 
AG 0.144 0.143 0.9191 0.15 0.7167 0.137 0.6231 
Block 9        
CGACC 0.267 0.285 0.2664 0.301 0.0894 0.271 0.8226 
CAACC 0.181 0.163 0.1882 0.163 0.2986 0.164 0.2817 
CGATC 0.176 0.168 0.5308 0.158 0.2725 0.176 0.9968 
TAACC 0.143 0.149 0.6267 0.157 0.3833 0.142 0.972 
CGATT 0.115 0.12 0.6125 0.105 0.4673 0.134 0.1692 
CAGCC 0.119 0.115 0.76 0.117 0.92 0.113 0.6977 
Block 10        
CT 0.735 0.736 0.9471 0.744 0.6685 0.73 0.7768 
TT 0.144 0.142 0.9274 0.155 0.5074 0.133 0.4588 
TC 0.113 0.115 0.8663 0.096 0.2424 0.131 0.2089 
Block 11        
GG 0.487 0.48 0.7144 0.493 0.7946 0.469 0.4044 
GC 0.327 0.32 0.6879 0.316 0.6263 0.324 0.8487 
AG 0.185 0.197 0.3722 0.186 0.8997 0.207 0.1994 
Table 5-13 GALNT2 reanalysis - haplotype analysis 
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5.7.4 Sub phenotypic reanalysis – CD 
Results of an analysis of genotype with CD sub phenotype are shown in Table 5-14.  
No values reached statistical significance, although rs7536663 had a borderline 
significant association with L1 disease (p-value of 0.0024).  On haplotypic analysis 
no values reached statistical significance (data not shown).  The TGGG haplotype in 
block 5 had a non significant p-value of 0.004 in L1 disease.
 






MAF L1 MAF p-value L2 MAF p-value L3 MAF p-value B3 MAF p-value B2 MAF p-value B1 MAF p-value 
rs12135308 T 0.101 0.12 0.3968 0.116 0.4887 0.093 0.7523 0.114 0.6618 0.123 0.4807 0.122 0.1973 
rs7515331 C 0.106 0.119 0.5713 0.138 0.1475 0.099 0.7768 0.184 0.0104 0.085 0.4877 0.117 0.4974 
rs1474925 T 0.214 0.21 0.9112 0.196 0.5286 0.152 0.0881 0.224 0.7891 0.208 0.8828 0.198 0.4712 
rs910820 G 0.207 0.274 0.0255 0.24 0.2406 0.214 0.8323 0.295 0.0276 0.222 0.7005 0.221 0.5039 
rs11122300 A 0.185 0.154 0.2774 0.183 0.9616 0.193 0.8098 0.175 0.8066 0.186 0.9668 0.174 0.5886 
rs12029443 G 0.161 0.15 0.6694 0.158 0.9198 0.143 0.5757 0.198 0.2921 0.142 0.5975 0.137 0.2079 
rs7536663 T 0.281 0.382 0.0024 0.344 0.0432 0.343 0.1269 0.377 0.0288 0.365 0.0659 0.342 0.0112 
rs2057233 A 0.4 0.311 0.0128 0.36 0.2302 0.407 0.8663 0.362 0.4212 0.324 0.1185 0.355 0.0773 
rs868287 C 0.283 0.294 0.727 0.298 0.639 0.254 0.4538 0.241 0.3352 0.306 0.6139 0.302 0.4147 
rs1474839 A 0.177 0.145 0.2361 0.154 0.3741 0.196 0.592 0.202 0.5127 0.144 0.3875 0.145 0.0961 
rs1884578 G 0.26 0.329 0.0362 0.298 0.2152 0.312 0.1896 0.351 0.0347 0.324 0.1599 0.299 0.0995 
rs1973943 T 0.462 0.486 0.1526 0.483 0.5374 0.521 0.1765 0.588 0.0093 0.481 0.6954 0.485 0.3711 
rs4846908 A 0.441 0.457 0.6551 0.459 0.5947 0.486 0.3001 0.412 0.5515 0.435 0.9078 0.479 0.1392 
rs1998064 C 0.222 0.262 0.1896 0.275 0.0667 0.286 0.0829 0.246 0.5551 0.288 0.1148 0.268 0.0359 
rs4846919 A 0.153 0.173 0.4531 0.127 0.2863 0.196 0.1867 0.211 0.1032 0.142 0.7466 0.146 0.694 
rs1264084/rs606587 G 0.335 0.36 0.4684 0.32 0.6367 0.338 0.9373 0.33 0.921 0.34 0.9208 0.338 0.894 
rs4846928 T 0.145 0.17 0.3376 0.145 0.989 0.134 0.7164 0.132 0.694 0.17 0.4833 0.16 0.4027 
rs7512360 A 0.447 0.435 0.733 0.446 0.9749 0.4 0.2837 0.431 0.7396 0.417 0.5403 0.441 0.8248 
rs3811486 C 0.118 0.118 0.988 0.103 0.4972 0.141 0.427 0.121 0.9381 0.104 0.6528 0.119 0.954 
rs901675 T 0.291 0.257 0.2945 0.25 0.1808 0.296 0.9137 0.293 0.9701 0.269 0.6106 0.253 0.0997 
rs1471915 T 0.115 0.113 0.9286 0.103 0.5831 0.121 0.8274 0.149 0.2777 0.12 0.8729 0.91 0.118 
rs2273967 A 0.257 0.233 0.4601 0.269 0.6862 0.269 0.7644 0.282 0.5629 0.212 0.3028 0.251 0.7992 
rs1043908 C 0.12 0.094 0.2676 0.095 0.2573 0.106 0.6256 0.118 0.9458 0.115 0.8796 0.095 0.127 
rs1043909 A 0.186 0.205 0.5069 0.158 0.3064 0.187 0.9821 0.182 0.9175 0.212 0.5136 0.187 0.9543 
rs7022 C 0.328 0.308 0.5702 0.321 0.8255 0.291 0.383 0.286 0.3581 0.346 0.698 0.323 0.8359 
Table 5-14 GALNT2 CD sub phenotypic reanalysis
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5.7.5 Sub phenotypic reanalysis – UC 
Results of a sub phenotypic analysis for GALNT2 in UC are not shown, but did not 
demonstrate any statistically significant association with UC susceptibility either 
with single markers or haplotypes. 
5.7.6 Replication 
The positive result for rs7536663 merited an attempt at replication and was 
genotyped on the Taqman® platform in the Dundee cohort of 300 CD, 211 UC 
patients and 682 controls.  The results are given in Table 5-15.  Although there was a 
trend towards a difference in allele frequencies in CD compared with controls, it was 
far from being statistically significant, unlike the Edinburgh MAF of 0.351 and 0.281 
in CD and controls respectively.   
 
  MAF 
p-value vs 
controls 
Controls rs7536663T 0.309  
IBD rs7536663T 0.312 0.874 
CD rs7536663T 0.326 0.469 
UC rs7536663T 0.293 0.5319 
Table 5-15 Dundee genotyping of rs7536663 
5.8 GALNT2 exonic sequencing 
At the point of finding the positive results for rs2281719 in CD patients and the 
WTCCC association in the same area of the gene (the intronic area between exons 1 
and 2) mentioned in sections 5.4 and 5.5, all 16 exons of the GALNT2 gene were 
sequenced in patients with specific haplotypes in an attempt to find potential 
causative mutations.  As the GG haplotype in block 8 in CD patients had 
demonstrated a lower p-value compared with rs2281719, DNA was selected 
according to this haplotype rather than solely on the basis of the rs2281719 genotype.  
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Numbers of DNAs sequenced are shown in Table 5-16.  By sequencing 25 of the 
GG/GG risk haplotype there was sufficient power to detect mutations occurring at a 
rate of at least 4%.  There were no patients with the AA/AA haplotype. 
 





1 AA GG 73 53 126 
2 GG AA 4 5 9 
3 GG GG 11 14 25 
Table 5-16 GALNT2 Exonic sequencing: DNA selection 
5.8.1 GALNT2 Exon 1 PCR 
GALNT2 exon 1 proved problematic to amplify.  An initial PCR with primers 
804/805 failed, and despite doubling the amount of Taq polymerase there was no 
band on the post-gradient PCR gel.  A further PCR with increased DNA, magnesium 
and Taq worked, and so the DNAs were taken to the HGU MRC Technical services 
department for sequencing.  However when the sequencing was analysed it was clear 
that, although the sequencing was clean, the post-PCR product was not GALNT2 
exon 1.  On review of the gradient PCR that had appeared to work it was clear that 
the product size was actually too small (Figure 5-8), with a product size of 300bp 
when the expected size was about 900bp.   
 
Figure 5-8 GALNT2 Exon 1 Gradient PCR E57D10 
A second set of primers were designed (853/854) but that PCR did not work: the 
post-PCR gel was blank despite several attempts with varying quantities of Taq, 
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of primers (804/854 and 853/805) were also attempted.  There was a band of the 
correct size on the post PCR gel with primer combinations 804/854 (Figure 5-9), but 
there were non specific DNA fragments present, which despite optimizing with 
varying Taq and magnesium, could not be improved.   
 
Figure 5-9 Gradient PCR E60D10 with 1 minute extension: A 804/854 with correct product size 
(1500bp) and non specific binding; B 853/854 expected product size 900bp - did not work; C 
853/805 expected product 700bp – did not work 
Before proceeding to full sequencing with this primer set and conditions, a small 
number of DNAs were sequenced with a nested PCR.  The optimized conditions 
were used with primers 804/854 for the PCR, and primers 853/805 were used for the 
sequencing reaction (Figure 5-10).  Unfortunately the resulting sequencing was 
extremely poor, with unreadable sequence in the centre (Figure 5-11).   
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Figure 5-11 Exon 1 Trial sequencing 
Due to the high GC content of the region with the resultant possibility of tight DNA 
folding preventing the primers from accessing the relevant DNA, a commercially 
available Taq polymerase, specific for high GC content PCRs was used (BioXAct 
Short, Bioline) at a working concentration of 0.08 units/µl, along with Polymate 
Additive (a melting agent to improve reaction specificity, Bioline) at the 
manufacturer’s recommended concentration.  Bioline’s 10x reaction buffer and 
MgCl2 were also used (Bioline).  The PCR run was according to Bioline’s protocols, 
and was different to the conditions used in standard PCRs, as shown in Table 5-17. 
 
95°C for 5 minutes (initial denaturation) 
Target temperature for 1 minute (annealing) 
70°C for 2 minutes (extension) }repeated  
95°C for 30 sec (denaturation) }30  
Target temp for 30 sec (annealing) }times 
70°C for 10 minutes (final elongation) 
Table 5-17 Bioline PCR conditions 
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Unfortunately the post PCR gels remained blank, despite trying different primer 
combinations (853/854, 804/854, 853/805) and varying the amounts of Taq, 
magnesium and DNA. 
Finally Betaine (trimethylglycine, Sigma) at a working concentration of 0.1M was 
used, and the resulting PCRs all worked, producing a product of the expected size 
(Figure 5-12).  Betaine, by mechanisms that are not understood, helps to prevent the 
formation of secondary structures in DNA.  The best primer combination (853/805) 
was repeated with several DNAs and the normal in-house Taq and conditions, but 
with 0.1M Betaine.  This PCR also worked well, and sequencing of 8 DNAs 
produced good quality sequencing (Figure 5-13).   
 
Figure 5-12 Gradient PCRs run on E60D10M2 programme 
 
Figure 5-13 Check sequencing 853/805; black line is at beginning of Exon 1 
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5.8.2 GALNT2 sequencing results 
Once the PCRs were optimized for exons 1-16, PCRs were completed on the DNAs 
as shown in Table 5-16.  The results were analysed according to genotype.  Each 
exon was examined, including, where possible, 50bp up and downstream of the exon 











Exon 1 73.8 39.3 39.3 
Exon 2 64.3 64.3 64.3 
Exon 3 65.5 72.6 71.4 
Exon 4 4.8 37.5 35.7 
Exon 5 36.3 36.3 36.3 
Exon 6 37.5 37.5 20.2 
Exon 7 57.7 56.5 56.5 
Exon 8 59.5 58.9 58.9 
Exon 9 39.9 39.9 39.9 
Exon 10 64.9 64.9 64.9 
Exon 11 50.6 50.6 50.6 
Exon 12 79.7 82.1 82.1 
Exon 13 81.5 81.5 81.5 
Exon 14 63.1 63.1 63.1 
Exon 15 67.2 66.6 66.6 
Exon 16 47.6 51.8 51.8 
Table 5-18 Percentage successful sequencing for each GALNT2 exon and immediately adjacent 
intronic areas 
There were problems with the quality of the sequencing of particular exons, 
especially exons 4-6.  However, there were still enough good sets of sequencing to 
allow a meaningful analysis of each area.  A summary of the analysis is shown in 
Table 5-19 which only lists the 15 samples in which mutations were found.  Within 
the areas in and around exons 1 and 2, ie around the areas of haplotype block 8, there 
was one intronic SNP (rs678050) about 50bp upstream of exon 2 which was 
homozygous for the rare allele in 2 DNAs: 040CD (case) and 204BT(control).  There 
were 2 synonymous coding SNPs in exon 9, rs3748006 and rs1923950.  One of the 
sequenced samples (340CD) was heterozygous for rs3748066 and homozygous for 
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the wild type genotype with rs1923950.  Another two samples (040CD and 306CD) 
were heterozygous for rs1923950 and wild type homozygous for rs3748006.  The 
only non synonymous SNP found was in Exon 16 (rs2273970) but the heterozygote 
was only found in one DNA (340CD), as all the other samples that were successfully 
sequenced were wild type homozygous.  In conclusion, the sequencing did not reveal 
any new non synonymous SNPs likely to be correlated with the genotype of 
haplotype block 8.
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      Exon 2 Exon 4 Exon 5 Exon 9   Exon 10   Exon 12 Exon 15 Exon 16     
SNP rs2281719 rs4846919 rs678050 rs3811488 rs3811486 rs3748006 rs1923950 rs2273965 rs2273966 rs3811485 rs12091838 rs6698963 rs2273970 rs2273969 
wt/minor 
allele A/G A/G T/C G/A A/G T/C G/A C/T T/A G/A C/T A/G G/A C/T 
SNP 




Coding Intronic Intronic Intronic Intronic Intronic Non Syn 3' UTR 
040CD AA GG CC - - wt GA wt TA wt CT AG wt wt 
215CD AA GG - GA AG - - - - GA - - - - 
264CD AA GG - AA wt - - wt wt wt - - - - 
280CD AA GG wt - - - - - - - wt AG wt wt 
296CD AA GG - - - - - - - wt - - - - 
306CD AA GG wt - - wt GA wt TA wt CT AG wt wt 
329CD AA GG wt - - - - - - - wt wt wt wt 
333CD AA GG wt - - - - wt TA wt wt wt wt wt 
340CD AA GG wt - - TC wt CT wt wt wt AG GA wt 
204BT GG GG CC - - - - wt AA AA wt - - - 
231BT GG GG wt - - - - - - wt wt - - - 
007HC GG GG - GA wt - - wt wt wt - - - - 
052HC GG GG wt wt wt wt wt wt wt wt wt AG wt CT 
084HC GG GG wt - - - - wt wt wt wt - - - 
121HC GG GG wt GA wt wt wt wt TA GA wt AG wt CT 
Table 5-19 GALNT2 exon sequencing, only samples that had mutations are listed here, wt=wild type, -=not sequenced 
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5.8.3 Further Sequencing 
The DNAs used in the sequencing across the GALNT2 gene detailed in section 5.8.2 
had been chosen on the basis of a haplotype that was subsequently found not to be 
valid.  Therefore further sequencing was completed on GALNT2 exons 1 and 2 on the 
basis of the TGGG haplotype detailed in section 5.7.3.  Only these exons were 
sequenced because the TGGG haplotype lay between these exons.  Twelve CD 
patients with the ‘at risk’ TGGG haplotype and twelve controls with at least one 
chromosome having the AGGG haplotype (the other chromosome having either the 
AAGG or the AGCG haplotype) were selected.  These samples were amplified by 
PCR with the primers and conditions for exons 1 and 2 listed in section 5.3.2, and 
sequenced at the MRC Human Genetics Unit, Edinburgh. 
5.8.3.1 Results 
Of the 12 CD samples, 9 produced good sequencing across the whole of exon 1, two 
samples completely failed and one other had poor sequencing for the 50bp upstream 
of the exon, but good sequencing otherwise.  Of the 12 control samples, 8 produced 
good sequencing, 3 completely failed and one sample had poor sequencing for the 
50bp upstream of the exon, but good sequencing otherwise.  No SNPs were found in 
this region in the samples that had been successfully sequenced. 
All 24 samples produced good sequencing for exon 2, and no SNPs were found in 
this exon and the regions 50bp upstream and downstream of the exon. 
5.9 Discussion 
This chapter has demonstrated that rs7536663 in the GALNT2 gene is associated with 
CD susceptibility in the Edinburgh cohort with an OR of 1.38.  There was a trend to 
a difference in the MAF in CD and controls in the Dundee replication cohort but the 
replication cohort was underpowered to rule out an association: with an OR of 1.38 a 
minimum of 695 CD cases in the replication cohort would be needed in order to 
confidently rule out an association with CD, and this number rises to 1035 with an 
OR of 1.3, and 2110 with an OR of 1.2.  Other CD cohorts from other groups could 
also be used for this purpose but then the population specific nature of the potential 
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genetic association would be lost.  Recent WTCCC immunochip genotyping has 
included the rs7536663 SNP; results are eagerly awaited.  Of course, the question of 
what is a significant p-value is a constant concern in hypothesis-driven genetic 
research.  There have been issues with replicated genetic loci from candidate gene 
studies not being uncovered in GWAS or meta-analyses; DLG5 is a good example of 
this.145  It is not clear whether this lack of association in GWAS is due to population 
pooling diluting out a population-specific gene or whether it was really a false 
positive. 
GWAS are an important tool in the search for susceptibility genes in complex 
diseases.  However, they have their limitations.  Not only are they unable to uncover 
genes which have low OR for susceptibility, but they are also not able to distinguish 
population specific susceptibility genes due to the need for large populations and the 
necessary pooling of cohorts.  The yeast two-hybrid screen was a plausible 
alternative to help negate the second problem of population specific susceptibility 
genes.  As NOD2 is a known susceptibility gene with a low rate of mutations in the 
Scottish cohort, it made a sensible bait protein for the screen, to try to find other 
genes in its pathways that may prove to be susceptibility genes as well.   
The amplification of the exons of GALNT2 for sequencing proved to be difficult.  
Getting good sequence data for exon 1 was a particular challenge although once 
betaine was used to relax the secondary structure of the area it was possible to get 
excellent quality sequencing data across that exon.  The sequencing that was 
completed was only exonic and the immediately adjacent intronic areas.  Other 
potential regulatory areas in intronic areas were not examined, which, if rs7536663 is 
associated with IBD susceptibility, may be important in the GALNT2 gene.  An 
attempt was made to do an analysis of conservation across species (data not shown) 
for the gene in order to select the best intronic areas for sequencing.  This 
concentrated particularly on intron 1, but the problems of defining the best regulatory 
regions over such a huge intronic area (about 25kbp) for the purposes of selected 
sequencing meant that large areas of the intron would have needed to have been 
sequenced, something that was not possible with the available finances.  With the 
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development of more cost-effective high-throughput sequencing, this may not be a 
problem in the future.   
This chapter also demonstrates the difficulties that can be encountered with 
genotyping on automated systems.  Our group were the first to have genotyping done 
on the Illumina® platform at the WTCRF, Edinburgh, which meant that knowledge 
of the pitfalls of this technology were limited.   Uncovering the problems proved 
difficult, and it was unfortunate that rs2281719 appeared to have such a good 
association initially.  The genotyping for this SNP had to be completely discounted, 
not only because a large number of the DNAs fell into the undetermined genotype on 
reclustering, but also because some of the genotyping was miscalled despite being 
clearly within the centre of a cluster, or gave a completely opposite genotype to the 
true genotype.  The fact that one of the ASOs (allele specific oligonucleotide) for that 
SNP has 2 perfect matches in the human genome may have been the problem, as 
suggested by Dr Gibbs at Illumina®.  The ASO, as described in the materials and 
methods chapter, hybridises to genomic DNA, with extension to the LSO (locus 
specific oligonucleotide) as the ‘tag’ for the location.  The subsequent PCR product 
has a complementary sequence to the LSO on the Illumina® bead to which it anneals 
and causes fluorescence of the bead.  It is possible that the alternative site ASO on 
the genome, despite not having an associated LSO, would also have produced a PCR 
product and provided noise in the interpretation of the real signal.  One of the other 
issues affecting the quality of the genotyping across all the Illumina® SNPs was 
DNA quality and concentration, which appears to be far more critical for Illumina® 
genotyping than for Taqman®.  This required careful calling at an individual plate 
level to ensure accuracy. 
Whether or not there is an association with the GALNT2 gene and CD susceptibility, 
the novel interaction between GALNT2 and NOD2 suggested by the yeast two-hybrid 
screen could still be a biologically important interaction in the complex biological 
pathways of IBD.  This interaction is investigated further in the next chapter. 
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Chapter 6 NOD2 and GALNT2 expression and 
interaction 
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Summary 
Aims: To test the hypothesis that GALNT2 and NOD2 interact in mammalian calls 
and that they are expressed in the same cell types in the gastrointestinal tract. 
Methods: Co-immunoprecipitation and western blotting in NOD2-transfected 
SW480 cells was used to investigate the interaction between NOD2 and GALNT2.  
Truncated NOD2 and the common NOD2 mutants were also transfected to 
investigate the position on the NOD2 protein with which GALNT2 interacted, and 
how the common NOD2 mutations affected the interaction.  Immunohistochemistry 
was used to investigate whether GALNT2 and NOD2 were co-expressed in 
gastrointestinal tissue biopsies. Quantitative PCR was used to investigate how NOD2 
and GALNT2 stimulators affected NOD2 and GALNT2 expression. 
Results: NOD2 and GALNT2 were shown to interact in a mammalian system, with 
an interaction at the level of the CARD domain of NOD2.  The common NOD2 
variants reduced the intensity of the interaction.  GALNT2 was shown to be 
expressed in enterocytes, goblet cells and the lamina propria, with the suggestion of a 
reduced expression in inflamed tissues.  Due to the lack of a functioning NOD2 
antibody, despite attempts to generate one, it was not possible to show that NOD2 
was co-expressed.  Quantitative RT-PCR did not show that NOD2 or GALNT2 
stimulators changed GALNT2 or NOD2 expression respectively. 
Conclusions: It has been proven that NOD2 and GALNT2 interact in a mammalian 
system, validating the yeast two-hybrid experiment that initially suggested the 
interaction.  Further work is required to investigate whether NOD2 and GALNT2 are 
expressed in the same cell types and cellular location.  Key to this is the development 
of a functioning NOD2 antibody.
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6.1 Introduction 
In Chapter 1 the yeast-two hybrid experiment and the interaction of GALNT2 with 
NOD2 in yeast cells was described.  Experiments examining germline variation in 
GALNT2 and association with IBD have also been described in Chapter 5.  The aim 
of this chapter was to test the hypothesis that GALNT2 and NOD2 interact in 
mammalian calls and that they are expressed in the same cell types in the 
gastrointestinal tract. 
6.2 Validation and preparation of reagents specific to the 
studies in this chapter 
Details of the standard cell culture, gel electrophoresis, western blotting, 
immunohistochemistry and PCR techniques are given in Chapter 2.  
6.2.1 Validation of the commercial GALNT2 antibody 
Protein lysate from SW480 cells was used in gel electrophoresis and blotted onto 
PVDF membrane.  The membrane was probed overnight with a 1:500 dilution of 
GALNT2 antibody (final concentration 500pg/µl, Sigma-Aldrich); the secondary 
antibody was goat anti-rabbit IgG-HRP (400µg/µl, SantaCruz Biotech, Santa Cruz, 
CA).  A single clean band of just over 60kDa, appropriate to the size of the GALNT2 
protein (64.4kDa) was obtained (Figure 6-1). 
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Figure 6-1 GALNT2 antibody Western blot with Magic Mark markings in kDa 
6.2.2 Validation of commercially available NOD2 antibody  
The most widely available NOD2 antibody in the literature is a mouse monoclonal 
antibody (clone 2D9) developed against the N-terminal end of the recombinant 
NOD2 protein (Cayman Chemicals, Ann Arbor, MI); this was used in a study 
demonstrating NOD2 protein in Paneth cells in the GI tract264 and showed clear 
staining in Paneth cells of the terminal ileum. 
Immunohistochemistry (IHC) was performed using this antibody.  Unfortunately, 
despite repeated attempts with varying conditions (citrate buffer pH 6.0 antigen 
retrieval, protein blocking, and varying concentrations of antibody), there was no 
apparent staining of Paneth cells, or of any other cells in the terminal ileum. 
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Figure 6-2 Terminal ileal biopsies using NOD2 Cayman Chemicals antibody, and stained with 
haemotoxylin.  A=CD patient with mild inflammatory cell infiltrate, arrow points to Paneth cell; 
B=CD patient with normal terminal ileum 
To determine whether the antibody recognised the denatured NOD2 protein, a 
western blot was completed by Dr Craig Stevens, using HCT116 cells that had 
transfected (or mock transfected) with an HA-tagged NOD2wt plasmid.  The 
antibody successfully detected HA-tagged NOD2, but not endogenous NOD2 
(Figure 6-3).   
 
Figure 6-3 Western blot of mock transfected (1) and HA-tagged NOD2 wt transfected (2) 
HCT116 cells probed with HA antibody (A) and Cayman Chemicals NOD2 antibody (B) 
6.2.3 Generation of a polyclonal NOD2 antibody 
An extensive search was made for other commercially available antibodies; however 
all of them appeared to have been generated from the 2D9 clone used above. As the 
NOD2 protein is not commercially available, any attempt at antibody generation 
needed to be on the basis of selecting and generating a peptide sequence in a larger 
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6.2.3.1 Peptide sequence selection 
As the antibody was needed for both IHC and western blotting it was important that 
the peptide sequence chosen was on the exposed region of the protein when normally 
folded: protein modelling was therefore required.  Dr Dinesh Soares (Medical 
Genetics group, Molecular Medicine Centre, University of Edinburgh), a 
bioinformatician specialising in using computer modelling, performed the protein 
structure prediction.  A hydropathy plot of full-length NOD2 predicted the secondary 
structure (Figure 6-4) and enabled the generated of an approximate 3D model (Figure 
6-5).   
 
Figure 6-4 NOD2 NBD domain - predicted secondary structure 
 
Figure 6-5 NOD2 NBD domain - predicted surface epitope 
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Several regions appeared to be suitable on the basis of their hydropathy scores and 
their exposure in the folded state of the protein. The amino acid sequence 435-454 
was chosen as one of the best regions (sequence RKYIRTEFNLKGFSEQGIEL).   
6.2.3.2 Antibody generation 
The antibody generation was carried out in rabbits.  To increase the immunogenicity 
of the peptide sequence, it was coupled to a large protein that would elicit a strong 
antibody response.  The choice was between coupling it to keyhole limpet 
haemocynin (KLH) or manufacturing it as an octomeric multiple antigenic peptide 
(OMAP).  The NOD2 peptide sequence was found to have 90% homology with 
rabbit NOD2.  In view of this, it was thought that coupling to KLH would be more 
immunogenic and would increase the chance of successful generation of a NOD2 
antibody.  The antibody generation was provided by Alta Bioscience (University of 
Birmingham, UK) who coupled the NOD2 peptide sequence to the carrier protein 
and injected it into a rabbit at monthly intervals for 3 months.  Three bleeds were 
undertaken at monthly intervals and the serum shipped to the GI laboratory, before a 
terminal bleed.  The resulting serum from the terminal bleed was affinity purified by 
Alta Biosciences using controlled pore glass to separate the specific antibody from 
the rest of the proteins in the rabbit serum.   
Each of the initial sera as well as the affinity purified terminal bleed serum were 
tested in western blots using protein lysates from SW480 cells that had been mock 
transfected, NOD2-transfected and left unstimulated, or NOD2 transfected with 
TNFα stimulation (to induce both endogenous and transfected NOD2).   
None of the blots probed with the unpurified sera from the 3 initial bleeds (either at a 
dilution of 1:25 or used neat, data not shown) or the affinity-purified serum (Figure 
6-6A) showed a band of the correct size.  The single band that was picked up with 
the affinity-purified serum was 30kDa, far below the expected NOD2 band size of 
115kDa.  The blots were incubated with an antibody against the plasmid vector 
which gave a band of a different size to that seen with the anti-NOD2 antibody, 
indicating that the NOD2 antibody was not detecting the NOD2 protein (Figure 
6-6B).   
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Figure 6-6 Western blots Probing with A: Alta generated NOD2 antibody 1:250; B: HA 
antibody 1:1000 1=Mock transfected cells, 2=Empty HA vector transfected, 3=NOD2 wt 
transfected.  Magic Mark used as markers, numbers are in kDa 
IHC was also performed with the Alta generated NOD2 antibody on ileal tissue.  
Three different sets of ileal tissue were used; all were from patients with UC and 
were reported to be within normal limits (i.e. without inflammation) when formally 
reported by consultant pathologists at the Western General Hospital, Edinburgh. 
Negative controls using PBS instead of antibody were completed as well as 
incubations with the antibody at 1:100 and 1:250 dilutions.  All samples were subject 
to antigen retrieval using a pH 6.0 Citrate buffer, as already described. 
There was a large amount of non-specific staining of the lamina propria and no 
Paneth cell staining in all three sample sets, as shown in Figure 6-7 (patient 1), 









GALNT2 and NOD2 expression   215   
 








GALNT2 and NOD2 expression   216   
 





GALNT2 and NOD2 expression   217   
 
Figure 6-9 IHC: Patient 3; A&B=Negative controls, C=1:100 Alta antibody, D=1:250 Alta 
antibody 
These experiments, along with the western blot of the purified antibody, indicated 
that it was unlikely that the antibody generation attempt had been successful.  
Thus it was decided that obtaining a functioning NOD2 antibody for use in IHC and 
western blotting was beyond the scope of this research project.  As an alternative 
approach for the co-immunoprecipitation (Co-IP) studies and western blotting, cells 
were used that had been transfected with tagged-NOD2 plasmids (containing wild 
type NOD2 or each of the three common variants) and antibodies to the plasmid tag 
were used for the western blot. 
6.2.4 Site-directed mutagenesis – NOD2 G908R mutant 
production 
As detailed in Chapter 2, the Quikchange® site-directed mutagenesis kit 
(Stratagene®, La Jolla, CA) was used to introduce the NOD2 G908R mutation into 
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Bioscience, gift of Dr Elaine Nimmo).  Primers were designed by Dr Elaine Nimmo 
using the primer design guidelines given in the Quikchange manual; both primers 
covered the SNP of interest and contained the complementary base to the mutation 
rather than to the wild type.  The primers chosen were 331/332: 
5’CCTGGGATTCTGGCGCAACAGAGTGGG3’ (forward), 
5’CCCACTCTGTTGCGCCAGAATCCCAGG3’ (reverse). In addition to a control 
reaction, two reactions with different quantities (2ng and 10ng) of the NOD2 wild 
type DNA template were used.  The PCR reaction extension phase of each cycle was 
3 minutes as the plasmid was approximate 3kbp in length. Following Dpn I 
restriction enzyme digest to remove the methylated strand, the PCR product was used 
to transform XL1-blue E.coli cells, with an overnight incubation at 37°C.  The 
mutagenesis efficiency was calculated for the pWhitescript control plasmid.  On this 
plate there were 418 blue colony forming units (cfu) and 66 white cfu, giving a 
mutagenesis efficiency of 86.4%.  The transformation efficiency was also calculated 
for the pUC18 control plate (with 671 cfu) to be >108 cfu/µg. 
To check whether the mutation had been introduced by the site directed mutagenesis, 
amplification was performed using primers 33/34: 
5’AGGCCACTCTGGGATTGAG3’ (forward), 
5’GTGATCACCCAAGGCTTCAG3’ (reverse) on DNA from 12 different colonies, 
2 positive controls with the G908R mutation and 2 negative controls with wildtype 
NOD2.  Sequencing of the PCR products was performed at the MRC Human 
Genetics Unit, Edinburgh.  The results showed that 11 of the 12 colonies selected 
appeared to have been successfully transformed from the wild-type to the G908R 
mutation (Figure 6-10, A-K).  The negative controls (N and O) were both wildtype; 
one of the positive controls was NOD2 G908R (M) and the other control sequence 
was too poor to interpret (not shown). 
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Figure 6-10 NOD2 G908R mutagenesis sequencing results, nucleotide in black is the 908 
position     A-K=successful mutagenesis, L=unsuccessful mutagenesis, M=positive control, 
N&O=negative control 
Having confirmed that the site-directed mutagenesis had been successful, full length 
NOD2 was sequenced in three of the colonies in which the mutation had been 
introduced to ensure that no other mutations had also been introduced.  Three sets of 
primers were required to sequence across the full length NOD2 (289/290, 291/32 and 
292/293, a gift of Dr Elaine Nimmo).  All primer sequences are given in Table 6-1.  
Gradient PCRs were set up to calculate the optimal annealing temperatures for each 
primer pair in the subsequent PCRs (Table 6-1).  PCRs were set up with DNA 
isolated from the three colonies and sequencing of the PCR products was done at the  
MRC Human Genetics Unit.  The primer combination 289/290 gave a PCR product 
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of the wrong size (400bp rather than 840bp).  The gradient PCR for these was 
repeated with double the normal amount of Taq (working concentration 1U/ml rather 
than 0.5U/ml), but the band size remained incorrect.   
As an alternative approach, two pCMV-vector primers were used that were near the 
two junction points with the cloned NOD2 gene (primers 398/399) and therefore 
amplified across the whole of the cloned NOD2 gene.  The optimal temperature for 
the annealing phase was 58°C, and as the PCR product was large (approximately 
4000bp), a 4 minute extension phase was used.  This amplification was performed 
with DNA from the 3 colonies and the PCR product sent for sequencing with a 
number of primers (as given in Table 6-1) to ensure that the entire gene was 
sequenced.  Figure 6-11 gives an overview of the sequencing strategy and is shown 
with the NOD2 exonic reference sequence.  From examination of the DNA sequence 
obtained from all 3 colonies it was determined that apart from the G908R mutations 
no other mutations had been introduced.  
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PCR primer set Forward primer 5’-3’ Reverse primer 5’-3’ 
Annealing 
temperature/°C 
289/290 CCTAATGGCATATGATGGGGGAAGAGGGTGGTTCAGCC CATGTGCCATGGGTGGCCAGGGGTGCTGAAGAGCTCC N/A 
291/32 CCCATGGCCATGGCCACATGCAAGAAGTATATGG GGATGGAGTGGAAGTGCTTG 61 
292/293 GCGCCCCTGGAATTCCTTCACATCAC CCGGGATCCTCAAAGCAAGAGTCTGGTGTCCCTG 64 
398/399, used with: GATCCGGTACTAGAGGAACTGAAAAAC TCATCAATGTATCTTATCATGTCTGG 58 (4 min extn) 
 63 
 TGGAAGTCTTGCCCTGCAG  
 109 
ATGGGGGAAGAGGGTGGTTC   
 111 
GCCACATGCAAGAAGTATATGG   
 112 
GAATTACCAGTCCCATTGGC   
 115 
 GCCTCCTGACAATGGCTG  
 118 
ATGTGCTCGCAGGAGGCTTTTCAGGCA   
 289 
CCTAATGGCATATGATGGGGGAAGAGGGTGGTTCAGCC   
 290 
 CATGTGCCATGGGTGGCCAGGGGTGCTGAAGAGCTCC  
 399 
 TCATCAATGTATCTTATCATGTCTGG  
 842 
GTCCTGTTAACCTTTGATGGC   
 843 
 TCAGCAGGTACATATCTGTAGTGG  
 844 
CAGATCACAGCAGCCTTCC   
 845 
 CTCGTCACCCACTCTGTTG  
35/846 
GGCAGAAGCCCTCCTGCAGGGCC TGAATGCAATTGTTGTTGTTAAC 62 
Table 6-1 Primer sequences for NOD2 PCRs and sequencing 
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Figure 6-11 NOD2 sequencing for 3 selected colonies, indicating which primers were used in the sequencing.  The NOD2 reference sequence is shown at the 




NOD2 reference sequence 
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6.3 Co-immunoprecipitation experiments – NOD2/GALNT2 
interaction in mammalian cells 
The SW480 cell line was used in the co-immunoprecipitation (CoIP) experiments.  
This cell line was chosen because it had been used to generate the cDNA library for 
the initial yeast-two hybrid screen.  Because endogenous NOD2 expression is low in 
SW480 cells, the cells were initially transfected with NOD2 cloned into the HA 
vector (gift of Dr Craig Stevens).  The transfection was completed by transfecting 
5µg of the appropriate DNA in Opti-MEM and lipofectamine into T25 flasks of 
SW480 cells at 80-90% confluence, and the cells incubated in Opti-MEM for 6 hours 
at 37°C before removing the complexes and medium and replacing it with complete 
medium.  Cell lysate was prepared and protein levels quantified.  In the Co-IP, 
GALNT2 was pulled down with the anti-mouse GALNT2 antibody (Sigma-Aldrich).  
As the antibody was relatively dilute and expensive, only 0.25µg was used rather 
than 2µg (the usual amount used in the GI laboratory).    After the Co-IP reaction had 
been completed, gel electrophoresis and western blotting was performed, using the 
Co-IP products.  To demonstrate that the initial transfections had been successful, 
20µg of each of the corresponding protein lysates were run in a 2nd gel.  The 
resulting membranes were probed with an antibody against HA (HA.11 Clone 
16B12, Covance, Princeton, NJ) in view of the lack of a functioning NOD2 antibody. 
The NOD2 transfection DNAs used in this section were: NOD2 wild type, NOD2 1-
247 (ie CARD domains of NOD2 only), NOD2 1-693 (ie CARD and NBD domains 
of NOD2 only), NOD2 R702W mutant, NOD2 G908R mutant and NOD2 1007fs 
mutant.  All of these DNAs had been cloned into the pCMV-HA expression vector 
(BD Bioscience) and were gifts of Dr Craig Stevens, although, as described in 
section 6.2.4, the NOD2 G908R had been initially cloned into the pCMV-Myc 
expression vector (BD Bioscience).  It was subsequently transferred into the HA 
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6.3.1 Interaction of NOD2 wild type and GALNT2 
The aim of this CoIP was to show that NOD2 and GALNT2 interact in mammalian 
cells and to discover which part of the NOD2 protein interacts with GALNT2.  
NOD2 wild type, NOD2 1-693, NOD2 1-247 and empty vector plasmids (all HA-
tagged) were transfected into the SW480 cells with a mock-transfected control 
(identical conditions except that PBS used instead of a plasmid).  The western blots 
of the whole cell protein lysates of the transfected cells (A) and pulled down with 
GALNT2 antibody (B) are shown in Figure 6-12.  The molecular weights of the 
products were: NOD2 wild type: 115.3kDa, NOD2 1-693: 77.2kDa and NOD2 1-
247: 27.8kDa.  Proteins of the correct sizes were seen from the transfected cells and 
the Co-IPs.  This demonstrates that GALNT2 and NOD2 interact in mammalian 
cells; moreover, there is an interaction with all lengths of the NOD2 protein.  This 
suggests that GALNT2 and NOD2 interact at the CARD domains, which lie at the N-
terminal end of the protein and were present in all 3 of the shortened NOD2 forms. 
 
Figure 6-12 Western blot from CoIP pulling down GALNT2 and probing with HA antibody 
A=Mock transfection, B=NOD2 wild type, C=NOD2 1-693, D=NOD2 1-247, E=Empty vector 
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6.3.2 Interaction of variant NOD2 and GALNT2   
The aim of these experiments was to investigate whether the NOD2 mutations 
affected the interaction with GALNT2.  NOD2 wild type, NOD2 R702W, NOD2 
G908R and NOD2 1007fs and an empty vector (all HA-tagged) were transfected into 
the SW480 cells.  A mock transfection was also completed, as before.  The expected 
molecular weights of the NOD2 wild type, NOD2 R702W and NOD2 G908R were 
115.3kDa, whereas for the NOD2 1007fs it was 111.4kDa.  The results are shown in 
Figure 6-13 (whole cell protein lysates) and Figure 6-14 (pulled down with GALNT2 
antibody).   The western blot of proteins in lysates of the transfected cells (Figure 
6-13) demonstrates that the transfections were successful. The Co-IP (Figure 6-14) 
shows that GALNT2 interacted with each of the NOD2 variants, but the strength of 
the interaction varied, as suggested by the intensity of the band.  The strength of the 
interaction was less with all the NOD2 variants compared with the wild type, but 
especially with the NOD2 R702W variant.
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Figure 6-13 Western blot of protein lysates probing with HA antibody A=Mock transfection, 
B=Empty vector, C=NOD2 wild type, D=NOD2 R702W, E=NOD2 G908R, F=NOD2 1007fs 
 
Figure 6-14 Western blot from CoIP pulling down GALNT2 and probing with HA antibody  
A=Mock transfection, B=Empty vector, C=NOD2 wild type, D=NOD2 R702W, E=NOD2 
G908R, F=NOD2 1007fs 
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6.4 GALNT2 protein expression in gut biopsies 
6.4.1 Methods 
IHC was carried out on intestinal biopsy samples from patients with IBD using the 
same GALNT2 antibody as used for western blotting according to the protocols 
detailed in section 2.7.3.  For this antibody, information was available on 
www.proteinatlas.org, including optimal concentrations and pictures of staining in 
normal and cancerous tissues.  Initial experiments defined optimal conditions as heat 
induced epitope retrieval (HIER) using a pH6.0 citrate buffer and an antibody 
dilution of 1:50 (0.025µg/ml).  Colonoscopic biopsies were used from patients with 
CD (n=7) and UC (n=2). 
6.4.2 Results 
In the uninflamed terminal ileal samples, there was some GALNT2 staining in the 
enterocytes and goblet cells, as well as in the lamina propria, as shown in Figure 
6-15.  GALNT2 appeared to be somewhat reduced in tissues that also had some 
inflammatory infiltrate (Figure 6-16).  There was no evidence of GALNT2 staining 
of Paneth cells in any of the sections examined.  In the colon, GALNT2 staining was 
predominantly in the lamina propria, with some on the enterocytes (Figure 6-17).  In 
the few sections that had evidence of inflammation, antibody staining for GALNT2 
appeared to be decreased (Figure 6-18).
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Figure 6-15 GALNT2 IHC of uninflamed terminal ileal tissue 
 
Figure 6-16 GALNT2 IHC of terminal ileal tissue having a patchy increase in chronic 
inflammatory cells. 
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Figure 6-17 GALNT2 immunohistochemistry A=Ascending colon, B=Transverse colon, 
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Figure 6-18 GALNT2 immunohistochemistry A&B=uninflamed rectum, C=rectum reported as 
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6.5 Messenger RNA expression studies with GALNT2 and 
NOD2 
GALNT2 and NOD2 expression was investigated using LS174T cells, a mucinous 
colon cancer cell line, which was thought to be most appropriate for investigating 
potential interactions between an enzyme involved in O-glycosylation and NOD2. 
6.5.1 Methods 
The primers used for qRT-PCR are listed in Table 6-2. 
 
 Forward primer 5’-3’ Reverse primer 5’-3’ 
GALNT2 ATGGGCCTTGACGAAGGAGAAG CCTCGATCTGTTCCCATTTCTGTC 
GAPDH TCATCTCTGCCCCCTCTGCT CGACGCCTGCTTCACCACCT 
NOD2 
Taqman® Taqman® inventoried assay: Hs00223394_m1 (ABI Biosystems) 
GAPDH 
Taqman® Taqman® inventoried assay: Hs99999905_m1 (ABI Biosystems) 
Table 6-2 qPCR primers 
6.5.2 PCR Optimization 
6.5.2.1 SYBRGreen®  
For each set of primers, amplification of serial dilutions of LS174T cDNA by PCR 
was set up as described in the Chapter 2.  A standard curve was produced and 
concentrations of cDNA within the exponential doubling phase of the qPCR were 
used for subsequent qPCRs.  From these experiments, it was determined that the best 
cDNA dilution was 1:100 for GALNT2 and for GAPDH. 
6.5.2.2 Taqman®  
The NOD2 Taqman® optimization PCR was run with several different sets of 
samples.  A NOD2 standard curve used dilutions of a pCMV-Myc plasmid 
containing NOD2 wt (gift of Dr Elaine Nimmo).  In addition, two standard curves of 
cDNA from two samples of LS174T cells were completed, one of which had been 
transfected with NOD2.  The qPCR with the non-transfected cells showed extremely 
low levels of NOD2 expression compared with the NOD2 plasmid controls and the 
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Ct values did not change in the expected way with serial dilution, as shown in Table 
6-3.  In the non-NOD2 transfected form, NOD2 mRNA expression levels were 
possibly too low to quantitate accurately by qPCR; therefore NOD2 expression was 
only examined in the time courses where NOD2 had been transfected.  In the NOD2 
transfected cells the optimal cDNA concentration for NOD2 qPCR was found to be 







(copies/ul) % Var 
1:1 31.13 500 194710 38842% 
1:1 31.03 500 201155 40131% 
1:5 33.4 100 897.49 797.50% 
1:5 33.34 100 1,442.78 1342.80% 
1:10 33.96 50 20.06 59.90% 
1:10 33.69 50 127.95 155.90% 
1:50 34.43 10 0.81 91.90% 
1:50 34.22 10 3.28 67.20% 
1:100 34.41 5 0.92 81.60% 
1:100 33.97 5 18.28 265.60% 
1:500 34.39 1 1.04 4.10% 
1:500 34.14 1 5.63 462.70% 
1:1000 34.88 0.5 0.04 92.80% 
1:1000 34.79 0.5 0.07 87.00% 
1:5000 34.91 0.1 0.03 71.00% 
1:5000 34.8 0.1 0.06 37.90% 
1:10000 34.98 0.05 0.02 63.40% 
1:10000 35 0.05 0.02 68.50% 
1:50000 34.62 0.01 0.22 2085.00% 
1:50000 34.66 0.01 0.17 1570.50% 
0 35.38  0  
0 35.9  0  
Table 6-3 NOD2 Taqman® qPCR, non-transfected cells 
6.5.3 Choice of stimulators 
In the absence of a known positive control for up- or down-regulating GALNT2 
expression, monensin was used.  Monensin is a carboxylic ionophore which acts as a 
Na+/H+ antiporter modifying Golgi pH and causing osmotic swelling of the Golgi 
cisternae, and thus inhibiting Golgi function.265;266  As it would appear that cis-Golgi, 
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where GALNT2 is thought to act267, is affected later than trans Golgi268, the 48 hour 
time point was examined.  In published studies monensin has been used in varying 
concentrations; 1µM was used in the experiments in this chapter as this was the 
concentration used in a MUC2 study in LS180 cells.269   
Carbachol, a cholinergic agonist which promotes mucin secretion from mucin 
producing cells, was used as a negative control as its promotion of mucin secretion is 
not through stimulation of the Golgi.270  It was used at a concentration of 1mM, 
which was the concentration used in the MUC2 study in LS180 cells.269  
In order to examine the effect of NOD2 on GALNT2 expression, a range of NOD2 
stimulators were chosen.  TNFα is a cytokine that upregulates NOD2 expression via 
NF-κB271, and was used at a final concentration of 50ng/ml.  Muramyl dipeptide 
(MDP), a peptidoglycan subunit which is a component of Gram positive and Gram 
negative bacteria, is a direct ligand of NOD289, and was used at a final concentration 
of 1µg/ml.  Lipopolysaccharide (LPS), an outer wall component of Gram negative 
bacterial cells, is an endotoxin that stimulates NOD2 via the toll-like receptors89, and 
was used at a final concentration of 1µg/ml. 
Time points chosen for cell harvest were 0, 8, 24 and 48 hours.  These were selected 
on the basis of previous experiments that showed TNFα-induced NOD2 expression 
in human epithelia cell lines272 and mice macrophage cell lines273 peaks at 6-8 and 24 
hours. 
Each set of time course experiments were triplicated for the untransfected time 
course and the NOD2wt transfected time course.   An HA-empty vector transfection 
and a mock transfection time course were also completed.  Each qPCR sample was 
run in duplicate. 
6.5.4 Quality control  
RNA samples were quantified by Nanodrop and quality checked by ensuring that the 
A260/280 was >1.8 and the A260/230 was >2.0.  cDNA was made from standard 
amounts of RNA, as detailed in Chapter 2.  Two negative template controls (NTC) 
were run for each qPCR run to ensure there was no DNA contamination in the 
primers or master mixes.  A standard curve was run for each reaction to allow R2 - 
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the correlation coefficient - to be calculated, as a measure of accuracy.  The reaction 
efficiency was calculated for each run for both the target gene and the housekeeping 
gene in order to ensure they were similar and to allow normalization as detailed in 
the section 6.5.5. 
6.5.5 Normalization 
The time courses were normalized to glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) which had previously been established to be stable in relevant cell lines 
(Dr Marian Aldhous, unpublished data).  As all the experiments were in the same cell 
line, variation in GAPDH expression levels between different cell populations was 
not an issue, so initial optimisation of qPCRs on a full panel of housekeeping genes 
was not required.  As absolute quantification of copy number was not required, 
relative quantification was completed using the 2∆∆Ct method274, as the reaction 
efficiencies for GAPDH and the target enzyme were almost identical with both the 
SYBRGreen® and the Taqman® qPCR methods. 
6.5.6 Statistical analysis 
The two tailed independent t-test was used to compare each set of stimulations to the 
unstimulated set at each time point.  A significant result was considered to be 
P<0.05. 
6.5.7 Results: GALNT2 expression in non-transfected cells 
Results were calculated as fold change from time point 0 and are shown in Figure 
6-19 and Figure 6-20.  No stimulator tested produced consistently statistically 
significant changes across the time points.  Monensin reduced GALNT2 expression 
compared with the unstimulated cells at 48 hours, but this did not quite reach 
statistical significance.  The p-values for the comparisons are given in Table 6-4. 
 
 













8 hours 0.464 0.388 0.723 0.992 0.280 
24 hours 0.599 0.879 0.907 0.293 0.696 
48 hours 0.688 0.270 0.210 0.051 0.690 
Table 6-4 GALNT2 expression Two-tailed independent t-test p-values for comparisons to the 
unstimulated time course 
6.5.8 Results: GALNT2 expression in NOD2-transfected cells 
For the NOD2 wild type transfection time courses, the graphs of results are shown in 
Figure 6-21 and Figure 6-22.  The p-values for the comparisons are given in Table 












8 hours 0.953 0.618 0.650 0.649 0.887 
24 hours 0.583 0.861 0.155 0.371 0.800 
48 hours 0.571 0.678 0.453 0.133 0.713 
Table 6-5 GALNT2 expression Two-tailed independent t-test p-values for comparisons to the 
unstimulated time course - NOD2 transfected time course 
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Figure 6-19 GALNT2 expression in unstimulated and TNF/LPS/MDP time courses.  Data points 
are mean ± standard error of the mean (SEM) 
 

















































Figure 6-20 GALNT2 expression in unstimulated and monensin/carbachol stimulated time 
courses.  Data points are mean ± SEM.
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Figure 6-21 GALNT2 expression in NOD2 wild type transfected unstimulated and 
TNF/LPS/MDP time courses.  Data points are mean ± SEM. 
 


















































Figure 6-22 GALNT2 expression in NOD2 wild type transfected unstimulated and 
monensin/carbachol time courses.  Data points are mean ± SEM. 
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6.5.9 Results: NOD2 expression in NOD2-transfected cells 
Results from two time courses could be used, as the third experiment qPCR had one 
very poor R2 value and differing reaction efficiencies between GAPDH and NOD2. 
For the NOD2 wild type transfection time courses, the graphs of results are shown in 
Figure 6-23 and Figure 6-24.  The p-values for the comparisons are given in Table 













8 hours 0.369 0.921 0.593 0.794 0.876 
24 hours 0.417 0.213 0.178 0.133 0.205 
48 hours 0.461 0.991 0.964 0.364 0.362 
Table 6-6 NOD2 expression Two-tailed independent t test p-values for comparisons to the 
unstimulated time course - NOD2 transfected time course
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Figure 6-23 NOD2 expression in NOD2 wild type transfected unstimulated and TNF/LPS/MDP 
time courses.  Data points are mean ± SEM. 















































Figure 6-24 NOD2 expression in NOD2 wild type transfected unstimulated and 
monensin/carbachol time courses.  Data points are mean ± SEM. 
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6.6 Discussion 
This chapter has demonstrated convincingly that NOD2 and GALNT2 interact in 
mammalian cells.  This validates the yeast two-hybrid experiment that showed an 
interaction in yeast cells.  Interestingly, although GALNT2 appears to interact with 
the CARD domains of NOD2 (at the N terminal end of the protein), the interaction is 
affected by the common NOD2 mutations, which are all in the LRR domain of the 
protein (at the C-terminal end of the protein).  The bands on the western blot were 
less intense from CoIP with the NOD2 variant compared with wild type suggesting 
that the interaction between NOD2 and GALNT2 is less strong with the variants.  
The R702W variant appeared to have the greatest effect on the interaction.  As these 
experiments were completed once each, further experiments are required to confirm 
the results.  In addition, densitometry on the western blot band intensities would be 
worth doing to quantitate the difference.   
It is likely that the NOD2 mutants cause a conformational change in the tertiary 
structure of the NOD2 protein, meaning that the GALNT2-NOD2 interacting area of 
NOD2 is less exposed.  Interestingly, the R702W mutant is a change from the 
hydrophilic, polar amino acid arginine to the non-polar tryptophan with a neutral 
hydropathy index.  However, the G908R mutation is a change from the non-polar 
glycine (with a neutral hydropathy index) to arginine.  Either of these changes could 
substantially change the tertiary structure of the protein, thus affecting the interaction 
of NOD2 with the other proteins and affecting downstream functions of NOD2.   
An alternative cell line with higher endogenous levels of NOD2 expression could be 
used to explore the interaction of NOD2 and GALNT2 by Co-IP which would be 
useful in case the artificially high level of NOD2 in transfected cells affected the 
nature of the interaction. 
Having shown that NOD2 and GALNT2 interact in mammalian cells, the next 
question was to address whether the two proteins are expressed in the same cellular 
compartments of the same cell types.  NOD2 is a cytosolic protein whereas GALNT2 
is located in the Golgi apparatus.  Because a NOD2 antibody was not available either 
commercially or in-house, it has not been possible to prove that these proteins are 
expressed in the same cells.  Certainly this chapter has shown that GALNT2 is 
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expressed in enterocytes, goblet cells and the lamina propria, with a possible 
reduction in GALNT2 expression in inflamed tissues.  The appropriate IHC with a 
functioning NOD2 antibody, when available, would be the next step.  To investigate 
whether they are both expressed in the same cellular compartments, 
immunofluorescence microscopy or immuno-electron microscopy could also be 
helpful, again, only if a functioning NOD2 antibody was available.  Co-IP after 
separating different cell fractions could also be an alternative method to investigate if 
NOD2 and GALNT2 are expressed in the same cellular compartments. 
The commercially available NOD2 antibody did not stain appropriately in the IHC 
presented in this chapter, despite there being clear pictures in the literature of 
beautiful staining of Paneth cells.  Why did it not work?  The lack of an appropriate 
band on the western blot - unless NOD2 transfected protein lysate is used - would 
suggest that there is a problem with the NOD2 antibody itself, as long as the 
HCT116 cells used in this experiment produced sufficient of endogenous NOD2.  It 
is possible that the endogenously produced NOD2 does not express the N-terminal 
end of the protein, thus, as the 2D9 clone is raised against the N-terminal end of the 
protein, it would not recognise the endogenous protein.  It would have been helpful 
to have contacted the authors of the paper264 which demonstrated the antibody 
staining Paneth cells in case there were further IHC conditions, not detailed in the 
paper, which may have worked. 
The attempt to raise a NOD2 antibody was also unsuccessful as it did not generate a 
band of the correct size on the western blot and it also failed to show appropriate 
staining on IHC.  It is likely that the initial antibody generation was unsuccessful. 
The fact that the amino acid sequence had 90% homology with rabbit should not 
have mattered, as it was coupled with KLH.  However, only a tiny proportion of the 
antibodies generated might have been against NOD2, with the rest of the antibodies 
against peptide sequences on KLH.  With the benefit of hindsight both methods of 
peptide conjugation should have been used to increase the chances of successful 
antibody production.  OMAP is a method of peptide antigen synthesis where the 
peptide is synthesised directly onto a branching lysine core, negating the need for a 
carrier protein and potentially producing a higher proportion of antibodies against the 
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target peptide sequence.  Whether the 90% homology of the peptide with rabbit 
sequence - the initial concern that led to the choice of KLH - would have been an 
issue with OMAP is not clear.  
The best way of successfully producing an antibody is to use the relevant purified 
protein as the immunogen, as this ensures that it is presented in its most biologically 
relevant state, with the outermost epitopes on display.  However, the anti-bacterial 
properties of NOD2 make bacterial-based protein production methods difficult.  If in 
the future it is possible to produce large amounts of NOD2 protein, this should be 
used in a further antibody generation attempt.  The fact that there is not a good 
commercially available antibody available, despite the scientific need, would suggest 
that biotechnology companies have also been unsuccessful in their NOD2 antibody 
generation attempts.    
Alternative ways needed to be found to examine for an interaction between GALNT2 
and NOD2.  Using qPCR with NOD2 and GALNT2 stimulators and investigating if 
mRNA levels of either increased was an appropriate alternative, with the caveat, of 
course, that proteins which affect the production of another protein do not necessarily 
interact: it could happen through a third protein.  The data presented here do not 
show that NOD2 stimulators change GALNT2 mRNA expression.  It would be 
worthwhile repeating the experiments with cells demonstrating a higher endogenous 
expression of NOD2 mRNA, as the low levels of NOD2 expression in the cells may 
mean that the interaction is not relevant in LS174T cells.  Ideally, a cell line with 
quantifiable NOD2 levels should be used. It would also be interesting to use cell lines 
which are known to have germline variation in the NOD2 gene, especially those with 
the 3 common NOD2 variants. 
Expression in cell lines is not necessarily an accurate reflection of what happens in 
vivo as cell lines are transformed and the cells could have different expression 
profiles compared with normal cells and be regulated differently.  Therefore, looking 
at mRNA expression in patient biopsies would also be useful, although that would 
require a different housekeeping gene for normalisation.  Many types of cells would 
be present which may introduce heterogeneity into the samples.  A way round this 
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would be to use microdissection prior to RNA extraction, although the problem 
would then be the small amounts of material available. 
In summary, this chapter has demonstrated that NOD2 and GALNT2 interact in a 
mammalian system.  Further work is required to investigate whether they are 
expressed in the same cell types and cellular location.  Key to these investigations is 
the manufacture of a functioning NOD2 antibody.  This is a problem that continues 
to hinder the scientific investigation of NOD2 in CD. 
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Chapter 7 Germline variation in MUC2 and MUC3A 
and association with IBD 
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Summary 
Aims: To investigate if germline variation of the main mucin genes expressed in the 
gastrointestinal tract (MUC2 and MUC3A) are associated with IBD susceptibility. 
Methods: Tagging SNPs across the MUC2 and MUC3A genes were selected and 
genotyped on the Taqman® platform in the Edinburgh IBD cohort of 446 CD, 452 
UC and 428 controls. 
Results:  In MUC2 the TG haplotype in block 1 (rs7942850T and rs11825977G) was 
significantly associated with controls compared with CD (haplotype frequency 0.469 
in controls and 0.388 in CD, OR 0.72, p-value 0.0007).  The SNP rs7942850C 
showed a statistically significant association with B2 disease (p=0.0027), with the 
TG haplotype including this SNP also demonstrating association with controls 
compared with B2 disease (p=0.0011).  An analysis of association of MUC2 and UC 
was negative.  The TG haplotype in block 1 of MUC2 was genotyped in the limited 
Dundee cohort of cases only, and demonstrated a haplotype frequency of 0.428.  The 
MUC3A study was negative in both CD and UC. 
Conclusion: Further genotyping of the rs7942850T and rs11825977G alleles in a 
larger cohort are required.  Emerging evidence of the importance of MUC2 in 
inflammation and colon cancer makes mucins an important topic for future studies in 
IBD.   
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7.1 Introduction 
The mucin genes are a family of related genes encoding apomucin proteins.   
Twenty-one mucins have been identified so far.  Secretory mucins are clustered 
around chromosome 11p15.5275 whereas membrane bound mucins are found over 3 
regions: 7q22276, 3q277 and 1q21.278  Following translation as apomucin proteins they 
are transferred to the Golgi apparatus where they undergo post translational 
modification in the form of O-glycosylation, involving many enzymes including 
those of the GALNT family.  O-glycosylation is the attachment of glycans to serine 
and threonine amino acids on the apomucin.  As the apomucins have serine and 
threonine rich amino acid sequence from DNA displaying variable number tandem 
repeats (VNTR), extensive O-glycosylation occurs (these areas are termed ‘mucin 
domains’).  This gives mucins high molecular weights and the ability to retain water 
and become more resistant to proteolysis. In addition to these highly O-glycosylated 
sequences the mucin glycoprotein also has cysteine rich peptide sequences that are 
involved in the disulphide bond linkage between mucin subunits.  As these areas are 
not O-glycosylated, they are susceptible to proteolytic attack. 
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Mucins occur in 2 forms, as illustrated in Figure 7-1:  
1) Secretory, where the glycoprotein product is secreted into the lumen and forms 
part of the loosely bound mucus layer and  
2) Membrane-bound: on the epithelial cell surface as part of the glycocalyx280 
Mucin production is either due to constitutive baseline secretion or compound 
exocytosis, the latter being promoted by a variety of secretogogues.281 
7.1.1 Mucins in the gastrointestinal tract 
As discussed in Chapter 1, the mucosal defensive barrier is a vital part of gut barrier 
protection, as shown in Figure 7-2.  Secreted mucins form an important part of the 
loosely adherent mucin layer protecting the gastrointestinal tract.  Membrane bound 
mucins form part of the deeper, more adherent mucus layer.  Mucins in the 
gastrointestinal tract are predominantly produced by goblet cells.  MUC2 and MUC5 
are the main secreted mucins expressed in the gastrointestinal tract, with MUC2 
predominant in the small and large intestines.210;282;283  Of the membrane associated 
mucins MUC1, MUC3A, MUC12, MUC13 and MUC17 appear to be expressed in 
the gastrointestinal tract280;283, with MUC3A being predominant.210  A study 
examining intestinal biopsies used real-time quantitative RT-PCR to look at mucin 
expression in the gut280  demonstrated that the predominant mucins in the ileum were 
MUC2, MUC13 and MUC17, whereas in the colon it was MUC2, MUC12, MUC13 
and MUC17.  MUC10 and MUC19 were not covered by probesets on the DNA 
microarray.  MUC3 was not mentioned in the paper for reasons that are not entirely 
clear. 
MUC2 is a secreted glycoprotein which is strongly expressed by goblet cells in the 
bowel.  The gene codes for a protein core of about 5100 amino acids.282  The MUC3 
glycoproteins are transmembrane mucins.284  They consist of 2 genes: MUC3A and 
MUC3B, both on chromosome 7q22285;286 which are expressed in the small intestine 
and colon.285  MUC12287, MUC13288 and MUC17289 are all transmembrane mucins 
encoded by genes on chromosome 7q22 which have expression in the GI tract.  
MUC19 is a secreted mucin with predominant expression in the submandibular 
gland290; it is not known to be expressed in the gastrointestinal tract. 
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Figure 7-2 Gut mucus layers and domain structures of MUC2 and MUC3.  TR=tandem repeat 
domain, D1-4=von Willebrand factor domain, CK=C-terminal cysteine knot domain, 
EGF=Epidermal growth factor-like domain, SEA=sperm protein, enterokinase and agrin 
domain.  From Kim and Ho
291
 
7.1.2 Mucins and association with cancer 
Changes in mucin expression have long been known to be associated with colonic 
adenocarcinomas.  Reduced MUC2 and MUC3 expression has been observed in 
human non-mucinous colon cancer specimens292;293 and Muc2 -/- mice have a 
tendency to develop small intestine and large intestine adenomas, suggesting that it 
may be involved in the suppression of colorectal cancers.294  MUC2 expression is 
correlated with less aggressive tumour behaviour.295 
7.1.3 Mucins and IBD 
In a dextran sodium sulfate (DSS) induced colitis mouse model, colonic Muc2 
mRNA expression is reduced in both acute and chronic colitis, whereas Muc3 mRNA 
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expression is increased in acute colitis but returns to basal levels in chronic colitis.296 
A similar rat model looking at small intestine and colonic mucin expression indicated 
that Muc2 mRNA expression was reduced in the ileum but unchanged in the colon in 
acute DSS induced colitis, whereas Muc2 mRNA expression was unchanged in the 
ileum and increased in the colon in acute colitis.297  Muc2 -/- mice - and even Muc2 +/- 
to an extent - are highly susceptible to DSS induced colitis compared with Muc2 
wild type mice.298   
IBD, particularly UC299;300, is characterised by a reduced layer of mucin in the areas 
of the bowel where there is inflammation, although whether this is cause or effect is 
not understood.    Goblet cell depletion is recognised as being one of the hallmarks of 
UC.301  There is evidence to suggest that mucin mRNA expression280 especially 
MUC2 mRNA210 and MUC2 secretion302 is down-regulated in the UC inflamed gut.  
7.1.4 MUC2 gene 
MUC2 is a gene on chromosome 11p15.5 spanning 30kbp.  It consists of 49 exons 
including a large central exon containing tandem repeat sequences and encodes an 
apomucin of 5100 amino acids282, the structure of which is shown in Figure 7-2.  
7.1.5 MUC3A gene 
MUC3A is located on chromosome 7q22 and consists of at least 12 exons. The gene 
encodes a transmembrane apoprotein containing a large extracellular domain, an 
epidermal growth factor-like transmembrane domain and a cytoplasmic tail303, as 
illustrated in Figure 7-2.  It contains a VNTR region that has been incompletely 
sequenced so far.  
Early studies, before the advent of GWAS, indicated linkage between MUC3 and 
IBD.  A linkage study using microsatellite markers in 186 sibling pairs had 
demonstrated a lod (logarithm of odds) score of 3.08 for RFLP marker D7S669, 
located within 25Mbp of the MUC3 gene locus.304  This was further examined in 
Japanese and Caucasian UC and control populations by using a Southern blot 
analysis of MUC3 alleles following restriction enzyme digestion.286  This indicated 
that rare VNTR MUC3 alleles were associated with IBD.  This study was 
subsequently expanded to include CD patients and it was discovered that in fact 
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MUC3 consisted of 2 transcripts, MUC3A and MUC3B, with rare MUC3A exonic 
variants being identified with IBD more often than in controls but no MUC3B 
variants showing association.303  However no individual alleles showed association 
with IBD overall or CD or UC separately.  This study was limited by the technology 
available at the time, and the small size of the cohorts. 
7.1.6 Hypothesis 
It was hypothesized that germ line changes in mucin genes expressed in the 
gastrointestinal tract may be associated with increased IBD susceptibility.  The 
MUC2 and MUC3A genes were examined as they are the major intestinal mucins. 
7.2 Methods 
7.2.1 MUC2 genotyping 
SNP data for MUC2 was downloaded from www.hapmap.org, including the 5Kbp 
regions upstream and downstream of the gene.  Tagging SNPs were selected across 
the gene (tagging for haplotype frequency >5%) as shown in Figure 7-3 and 
genotyped in the Edinburgh cohort of 446 CD, 452 UC and 428 controls on the 
Taqman® platform.  This required 12 SNPs, as listed in Table 7-1.   
 
 
Figure 7-3 MUC2 Haplotypes >5% 
 
 

















Table 7-1 MUC2 SNP selection 
7.2.2 MUC3A genotyping 
SNP data for MUC3A was downloaded from www.hapmap.org, covering the 3 
MUC3A transcripts and allowing for 15kbp each side.  When the data was run 
through Haploview, blocks defined according to solid spine of LD and haplotypes 
examined above 5%, there were a large number of variants, as shown in Figure 7-4.  
In order to adequately tag each block, a total of 13 SNPs would have been needed.  
  
 
Figure 7-4 MUC3A Haplotypes >5% frequency 
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In order to reduce the number of SNPs required, only haplotypes above 10% were 
examined.  This meant that blocks one and two could be joined, with the resultant 
blocks as shown in Figure 7-5.  This meant that only 3 SNPs were required to tag the 
gene adequately.   
 
 
Figure 7-5 MUC3A Haplotypes >10% frequency 
The 3 SNPs: rs4341099, rs11762787 and rs11765099, were genotyped on the 
Taqman® platform in the Edinburgh cohort of 446 CD, 452 UC and 428 controls. 
7.3 Results 
7.3.1 MUC2 genotyping 
7.3.1.1 Quality control 
All the SNPs were in Hardy-Weinberg equilibrium in controls.   
7.3.1.2 MUC2 single SNP and haplotype analysis 
When corrected for multiple testing across the 12 SNPs, a significant p-value was 
defined as <0.0042.  The LD plots for CD and UC are shown in Figure 7-6.  A single 
SNP analysis across MUC2 showed no association with CD or UC, as shown in 
Table 7-2.  Results of a haplotype analysis are shown in Table 7-3.  The haplotypes 
were defined based on the haplotypes on which the SNPs had initially been chosen.  
The TG haplotype in block 1 was significantly associated with controls, with a p-
value of 0.0007, and MAF of 0.469 in controls and 0.388 in CD.  This conferred an 
OR of 0.72 (95% CI 0.59-0.87).  No other haplotypes reached statistical significance 
after correction for multiple testing. 
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rs7942850 C 0.378 0.409 0.148 0.443 0.0081 0.375 0.8875 
rs11825977 A 0.176 0.211 0.0457 0.224 0.0171 0.198 0.2689 
rs11245936 A 0.106 0.1 0.6199 0.097 0.5073 0.103 0.8418 
rs10794288 C 0.212 0.19 0.1915 0.174 0.0489 0.206 0.7555 
rs7944723 C 0.208 0.194 0.4168 0.185 0.2471 0.203 0.7939 
rs6421972 T 0.409 0.423 0.5105 0.43 0.3952 0.416 0.7657 
rs10794293 T 0.362 0.373 0.607 0.377 0.5217 0.368 0.7966 
rs11245954 G 0.081 0.078 0.7719 0.073 0.5677 0.082 0.9502 
rs11245962 C 0.336 0.294 0.0389 0.276 0.0105 0.312 0.2997 
rs6597976 T 0.069 0.055 0.1649 0.049 0.0976 0.06 0.4646 
rs7479605 C 0.088 0.095 0.5711 0.1 0.3886 0.089 0.9023 
rs7105198 G 0.16 0.151 0.5767 0.138 0.2209 0.164 0.8284 
Table 7-2 MUC2 Single SNP analysis 
A B 
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  Controls IBD p-value CD p-value UC p-value 
Block 1        
TG 0.469 0.422 0.0246 0.388 7.00E-04 0.455 0.5982 
CG 0.353 0.368 0.4701 0.39 0.1137 0.347 0.7305 
TA 0.152 0.17 0.2262 0.171 0.2574 0.171 0.3341 
CA 0.027 0.04 0.0846 0.051 0.012 0.027 0.6539 
Block 2        
GTG 0.581 0.619 0.067 0.643 0.0091 0.594 0.554 
GTC 0.206 0.191 0.3737 0.183 0.2234 0.2 0.7308 
ACG 0.106 0.1 0.6196 0.097 0.5186 0.103 0.8287 
GCG 0.105 0.087 0.1357 0.075 0.0279 0.1 0.6687 
Block 3        
CCA 0.494 0.485 0.6861 0.488 0.7777 0.482 0.6835 
TTA 0.342 0.357 0.4422 0.368 0.2721 0.347 0.8053 
CCG 0.076 0.073 0.7845 0.07 0.6669 0.077 0.9512 
TCA 0.065 0.063 0.8323 0.06 0.6114 0.067 0.8927 
CTA 0.019 0.017 0.7392 0.012 0.3389 0.022 0.8553 
Block 4        
TCTC 0.586 0.617 0.1252 0.632 0.0586 0.602 0.4749 
CCTC 0.165 0.134 0.0376 0.13 0.0399 0.139 0.1314 
CCTG 0.091 0.093 0.8336 0.086 0.7308 0.101 0.4874 
TCCC 0.086 0.094 0.4887 0.099 0.291 0.089 0.7883 
CTTG 0.068 0.055 0.189 0.051 0.1252 0.059 0.4507 
Table 7-3 MUC2 Haplotype analysis 
7.3.1.3 MUC2 CD sub phenotypic analysis 
Results of a CD sub phenotypic analysis are shown in Table 7-4 and Table 7-5; no 
association was demonstrated when corrected for multiple testing.  The SNP 
rs7942850C showed a statistically significant association with B2 disease 
(p=0.0027), with the TG haplotype including this SNP also demonstrating 
association with controls compared with B2 disease (p=0.0011).  A haplotype 
analysis also showed no evidence of association (Table 7-6 and Table 7-7). 
 













rs7942850 C 0.378 0.454 0.0303 0.451 0.0406 0.447 0.1336 
rs11825977 A 0.176 0.203 0.331 0.228 0.0707 0.25 0.0436 
rs11245936 A 0.106 0.056 0.015 0.095 0.6088 0.12 0.6384 
rs10794288 C 0.212 0.136 0.0069 0.187 0.3836 0.203 0.811 
rs7944723 C 0.208 0.205 0.9058 0.194 0.6221 0.15 0.1126 
rs6421972 T 0.409 0.407 0.9571 0.451 0.2382 0.44 0.4936 
rs10794293 T 0.362 0.376 0.6864 0.393 0.3773 0.336 0.568 
rs11245954 G 0.081 0.057 0.2056 0.072 0.6466 0.079 0.9248 
rs11245962 C 0.336 0.278 0.0904 0.286 0.1477 0.25 0.0542 
rs6597976 T 0.069 0.038 0.0736 0.048 0.2429 0.082 0.5727 
rs7479605 C 0.088 0.117 0.1701 0.089 0.9307 0.116 0.2888 
rs7105198 G 0.16 0.142 0.4932 0.124 0.17 0.157 0.9327 














rs7942850 C 0.378 0.49 0.0275 0.527 0.0027 0.426 0.1079 
rs11825977 A 0.176 0.179 0.9379 0.222 0.2438 0.233 0.0193 
rs11245936 A 0.106 0.045 0.0398 0.045 0.0444 0.096 0.5541 
rs10794288 C 0.212 0.116 0.0175 0.094 0.0043 0.188 0.3143 
rs7944723 C 0.208 0.202 0.8787 0.191 0.6782 0.183 0.2999 
rs6421972 T 0.409 0.387 0.6634 0.443 0.4971 0.436 0.3598 
rs10794293 T 0.362 0.296 0.1804 0.441 0.1194 0.378 0.585 
rs11245954 G 0.081 0.045 0.1755 0.056 0.3552 0.075 0.7272 
rs11245962 C 0.336 0.192 0.0032 0.245 0.0657 0.295 0.1569 
rs6597976 T 0.069 0.037 0.2106 0.046 0.3798 0.051 0.2282 
rs7479605 C 0.088 0.111 0.4255 0.069 0.5186 0.11 0.2157 
rs7105198 G 0.16 0.074 0.0193 0.12 0.2902 0.151 0.6978 
Table 7-5 CD sub phenotypic analysis - disease behaviour
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  Controls L1 p-value L2 p-value L3 p-value 
Block 1        
TG 0.469 0.393 0.0295 0.379 0.0112 0.369 0.0289 
CG 0.353 0.405 0.1305 0.395 0.2181 0.387 0.4532 
TA 0.152 0.156 0.8706 0.172 0.4248 0.188 0.2786 
CA 0.027 0.047 0.0875 0.053 0.0328 0.056 0.0502 
Block 2        
GTG 0.581 0.657 0.0229 0.619 0.2542 0.65 0.1173 
GTC 0.206 0.205 0.9251 0.195 0.6543 0.144 0.0797 
GCG 0.106 0.08 0.2093 0.091 0.4692 0.08 0.3486 
ACG 0.105 0.057 0.0165 0.094 0.5988 0.119 0.6413 
Block 3        
CCA 0.494 0.516 0.5379 0.475 0.5824 0.485 0.8408 
TTA 0.342 0.361 0.5669 0.383 0.2284 0.341 0.9919 
CCG 0.076 0.056 0.2714 0.069 0.7101 0.076 0.9945 
TCA 0.065 0.052 0.4119 0.059 0.7161 0.093 0.2475 
CTA 0.019 0.014 0.6452 0.011 0.4844 0.003 0.1854 
Block 4        
TCTC 0.586 0.612 0.4807 0.633 0.1917 0.641 0.2185 
CCTC 0.165 0.135 0.2249 0.153 0.6176 0.083 0.0122 
CCTG 0.091 0.1 0.6593 0.073 0.3811 0.077 0.6003 
TCCC 0.086 0.112 0.1627 0.088 0.7918 0.115 0.2296 
CTTG 0.068 0.039 0.0848 0.051 0.301 0.076 0.7451 
Table 7-6 MUC2 Crohn’s sub phenotypic haplotype analysis – disease location 
 
  Controls B3 p-value B2 p-value B1 p-value 
Block 1        
TG 0.469 0.384 0.094 0.303 0.0011 0.4 0.0177 
CG 0.353 0.438 0.0879 0.476 0.0137 0.37 0.5286 
TA 0.152 0.134 0.6078 0.17 0.6513 0.175 0.2456 
CA 0.027 0.045 0.2275 0.052 0.102 0.055 0.0162 
Block 2        
GTG 0.581 0.682 0.036 0.713 0.0072 0.629 0.0952 
GTC 0.206 0.202 0.8766 0.191 0.6766 0.182 0.2914 
GCG 0.106 0.071 0.2401 0.051 0.0654 0.091 0.5594 
ACG 0.105 0.045 0.0404 0.045 0.0457 0.095 0.3988 
Block 3        
CCA 0.494 0.557 0.2112 0.48 0.7899 0.484 0.7249 
TTA 0.342 0.291 0.2846 0.419 0.1102 0.37 0.3197 
CCG 0.076 0.043 0.2095 0.056 0.4402 0.073 0.8414 
TCA 0.065 0.096 0.2429 0.024 0.0865 0.063 0.8447 
CTA 0.019 0.012 0.6366 0.021 0.8651 0.008 0.1704 
Block 4        
TCTC 0.586 0.702 0.0202 0.687 0.049 0.604 0.5236 
CCTC 0.165 0.114 0.1628 0.125 0.2897 0.135 0.1608 
CCTG 0.091 0.037 0.057 0.069 0.4556 0.098 0.6826 
TCCC 0.086 0.107 0.3692 0.063 0.5152 0.109 0.1812 
CTTG 0.068 0.037 0.1965 0.049 0.4448 0.051 0.2288 
Table 7-7 MUC2 Crohn’s sub phenotypic haplotypic analysis - disease behaviour 
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7.3.1.4 UC sub phenotypic analysis 
Results of a UC sub phenotypic analysis are shown in Table 7-8 and Table 7-9, and 

















rs7942850 C 0.378 0.36 0.5367 0.396 0.5937 0.355 0.614 
rs11825977 A 0.176 0.178 0.9269 0.194 0.4803 0.262 0.0231 
rs11245936 A 0.106 0.104 0.8984 0.092 0.4659 0.117 0.7156 
rs10794288 C 0.212 0.213 0.9593 0.202 0.7081 0.192 0.6103 
rs7944723 C 0.208 0.199 0.7174 0.191 0.5294 0.219 0.7795 
rs6421972 T 0.409 0.378 0.3117 0.425 0.6197 0.492 0.0783 
rs10794293 T 0.362 0.329 0.2655 0.383 0.5153 0.444 0.0757 
rs11245954 G 0.081 0.092 0.5161 0.069 0.4894 0.077 0.8762 
rs11245962 C 0.336 0.317 0.5245 0.322 0.6509 0.254 0.0728 
rs6597976 T 0.069 0.058 0.4706 0.07 0.9528 0.04 0.2332 
rs7479605 C 0.088 0.08 0.6731 0.086 0.9307 0.119 0.2578 
rs7105198 G 0.16 0.173 0.567 0.169 0.7067 0.133 0.4379 
Table 7-8 MUC2 UC sub phenotypic analysis 
 
  Controls E3 p-value E2 p-value E1 p-value 
Block 1        
TG 0.469 0.482 0.6319 0.436 0.3449 0.427 0.3913 
CG 0.353 0.339 0.5691 0.368 0.695 0.314 0.3632 
TA 0.152 0.157 0.8627 0.169 0.5159 0.22 0.0559 
CA 0.027 0.022 0.8405 0.026 0.7683 0.039 0.3283 
Block 2        
GTG 0.581 0.594 0.6634 0.607 0.3757 0.588 0.8431 
GTC 0.206 0.192 0.5674 0.192 0.5455 0.219 0.7671 
ACG 0.105 0.104 0.9035 0.092 0.4746 0.115 0.7465 
GCG 0.106 0.103 0.9004 0.109 0.9392 0.077 0.295 
Block 3        
CCA 0.494 0.509 0.6078 0.485 0.8061 0.414 0.092 
TTA 0.342 0.304 0.2048 0.364 0.4799 0.426 0.0604 
CCG 0.076 0.084 0.6498 0.066 0.5193 0.077 0.9935 
TCA 0.065 0.07 0.7761 0.062 0.8081 0.066 0.9904 
CTA 0.019 0.025 0.564 0.021 0.8724 0.017 0.9261 
Block 4        
TCTC 0.586 0.608 0.4541 0.595 0.7745 0.633 0.3314 
CCTC 0.165 0.133 0.1362 0.147 0.442 0.114 0.1404 
CCTG 0.091 0.114 0.1986 0.092 0.9318 0.092 0.9556 
TCCC 0.086 0.082 0.8465 0.082 0.9361 0.108 0.334 
CTTG 0.068 0.057 0.4859 0.07 0.8919 0.034 0.1335 
Table 7-9 MUC2 UC sub phenotypic haplotype analysis 
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7.3.1.5 Replication  
As the TG haplotype in block 1 of the MUC2 genotyping demonstrated a positive p-
value in CD when compared with controls, it merited an attempt to confirm the 
findings in a separate cohort of patients.  Unfortunately, we were only able to attempt 
to replicate the CD MAF in the small Dundee cohort of 299 CD and 213 UC 
samples.  The comparisons of haplotype frequency are shown in Table 7-10.  When 
the Dundee samples were compared directly with the Edinburgh controls, there was 









TG 0.428 0.388 0.469 
CG 0.371 0.39 0.353 
TA 0.184 0.171 0.152 
CA 0.017 0.051 0.027 
Table 7-10 Haplotype frequency in different cohorts 
7.3.2 MUC3A genotype 
The 3 SNPs were in Hardy Weinberg equilibrium in controls.  A significant p-value 
was defined as <0.016 when corrected for multiple testing.  Results of a MUC3A 
single SNP and haplotype analysis are shown in Table 7-11 and Table 7-12, and were 
negative.  The study had approximately 70% power to detect OR>1.4, and >99% 
power to detect OR of 2.6 (OR given in the previous MUC3A study286)  Given the 














rs11762787 C 0.26 0.257 0.8585 0.264 0.8331 0.25 0.6323 
rs4341099 C 0.259 0.281 0.2424 0.298 0.0828 0.268 0.6889 
rs11765099 C 0.463 0.455 0.7332 0.465 0.9289 0.448 0.5253 
Table 7-11 MUC3A Single SNP analysis 
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  Controls IBD p-value CD p-value UC p-value 
Block 1        
GT 0.479 0.461 0.4005 0.437 0.0883 0.482 0.9162 
GC 0.26 0.282 0.2388 0.299 0.0784 0.268 0.6932 
CT 0.262 0.257 0.8076 0.265 0.8925 0.251 0.6036 
Block 2        
A 0.537 0.544 0.737 0.535 0.9299 0.552 0.5312 
C 0.463 0.456 0.737 0.465 0.9299 0.448 0.5312 
Table 7-12 MUC3A Haplotype analysis 
7.4 Discussion 
A definite link between the MUC2/MUC3A genes and IBD susceptibility has not 
been demonstrated by the data presented in this chapter.   
7.4.1 Mucins and genetics 
With the SNP rs7942850 and its two-marker associated haplotype showing 
association in the Edinburgh CD cohort, it is certainly possible that MUC2 is indeed 
an IBD susceptibility gene.  The replication study did not have a control group that 
was genotyped to make it a formal replication cohort.  With the bigger Dundee 
cohort now available, including controls, there is a plan to complete genotyping on 
the full Dundee cohort.  However, if there is lack of an association in this cohort, it 
will still not be possible to refute the association, as it would be underpowered for 
the OR in the discovery cohort.  For an OR of 1.39 and an allelic frequency of 0.40, 
at least 650 case-control pairs would be required to rule-out an association with 80% 
power. 
The MUC3A case-control study was negative.  Limitations of the study include the 
small cohort size, the tagging SNPs being chosen on the basis of a haplotype 
frequency of >10% (rather than 5%) as well as the fact that there is incomplete data 
on the correct MUC3A sequence (due to the VNTR region being incompletely 
sequenced).  The initial interest in MUC3A was due to the finding that a lod score of 
3.08 for the D7S669 RFLP marker (‘IBD11’). However, in the era of more detailed 
chromosomal mapping, this area is actually more than 20Mbp upstream of the 
MUC3A gene.  A more recent large UC GWAS has re-awakened interest in the area 
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with a SNP (rs7809799) 2Mbp upstream of MUC3A, in between the SMURF1 and 
KPNA7 genes, conferring an OR of 1.56 for UC susceptibility.77  This area, rather 
than MUC3A, appears more likely to be responsible for the signal at this locus. 
The traditional candidate gene approach to gene discovery has been superseded by 
GWAS which reduce the risk of false positive gene susceptibility studies but may 
increase the rate of false negatives due to population pooling.  It would be useful to 
download the relevant WTCCC GWAS data to analyse for gene-wide significance 
for any SNPs within these genes.  Certainly there is no genome-wide significance 
between MUC2 or MUC3A and IBD susceptibility on any recent GWAS. 
Even when studies are negative overall for CD, UC and IBD, sub phenotypic studies 
are still worthwhile as a gene may be solely associated with a subtype of disease (for 
example, L1 disease).  This is why the relevant analyses are detailed in this chapter. 
7.4.2 Cause or effect? 
Another consideration is whether the reduced mucin layer and goblet cell reduction 
in UC is the cause or the effect of the disease.  The mucin layer could be reduced or 
functioning abnormally contributing to bacterial damage to the epithelial layer.  Or it 
could be that the inflammation and damage to goblet cells is causing reduced mucin 
production. 
Even given the former possibility, there are a number of ways that reduced 
mucin/abnormal mucin function could occur, aside from germline variation in the 
apomucin gene itself, as detailed in section 7.4.3. 
7.4.3 Alternative causes for mucin abnormalities  
Epigenetic changes in the mucin genes could change their expression.  MUC2305 and  
MUC3A
306 expression in colon cancer cell lines has been shown to be highly 
controlled by methylation and histone deacetylation.  A recent study with the 
LS174T cell line has indicated that MUC2 expression is regulated in part by short-
chain fatty acids (SCFA), with butyrate and propionate inducing an increase in 
MUC2 mRNA levels via histone acetylation/methylation and butyrate-responsive 
regions in the promoter area of the gene.307  This is especially interesting as SCFA 
are the fermentation products of bacteria, so changes in intraluminal bacteria, by 
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changing the SCFA composition of the luminal contents, may affect mucin gene 
expression.  Of course, cancer cell lines can function very differently to their non-
cancerous counterparts, but it still shows the potential importance of epigenetics in 
mucin regulation. 
Bacteria affect mucin expression in other ways.  MUC2 has NF-kappaβ binding sites 
in its promoter region308 and it has been demonstrated that TNFα309;310and LPS308 
activate MUC2 transcription via NF-kappaβ in colonic cell lines.  
A further mechanism for changes in mucin production could be in the post-
translational processing of mucins, in particular O-glycosylation.  The GALNT 
family of enzymes catalyse the first step in O-glycosylation in the Golgi apparatus - 
in Chapter 5, germline variation in GALNT2 and the possible linkage with IBD 
susceptibility has been discussed.  However, there are numerous other genes 
encoding enzymes and other regulators of O-glycosylation; germline variation or 
changes in expression in any one of them could affect the quality or quantity of 
mucin produced by the cell.  
Mucin sialylation and sulfonation (addition of sialyl and sulfonyl groups 
respectively) are further post translational modifications that help to protect mucins 
from degradation, and changes or abnormalities in these processes could render 
mucins to be less effective in their role as protection against the luminal contents.  In 
UC, there is evidence for reduced sulfation311, although evidence for reduced 
sialylation is less clear-cut. 
Mucolytics (eg bacterial glycosidases) produced by luminal bacteria themselves 
could also cause a reduction or change in the mucin layer, and increased ability to 
damage the underlying structures (reviewed by Deplancke and Gaskins281).  A recent 
study had used 16S RNA technology to demonstrate that there are increased 
mucolytic bacteria in the mucin of IBD patients, but especially in CD patients.312 
7.4.4 Conclusion 
Despite the lack of definite evidence linking germline variation of IBD with MUC2 
and MUC3A, mucins in IBD still appears to be a highly relevant topic for further 
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research, not only for the reasons given above, but also the fact that mucins could be 
a common link between IBD and colon cancer. 
It would be interesting to study the epigenetics of MUC2 and MUC3A in IBD 
patients and compare them with controls.  Further bacterial studies examining in 
more detail the effects of specific bacteria – for example, adherent-invasive E. Coli – 
on mucin expression and production, would also be useful. 
Much of the data on mucins and O-glycosylation in IBD is more than 10 years old; 
with increasing recognition not only of the part that luminal bacteria have to play in 
the pathogenesis of IBD but also of the role of the mucosal barrier in the defence 
against these bacteria, this topic is likely to be extensively studied in the future
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Chapter 8 Germline variation in MUC19 and 
LRRK2 and association with IBD
 
MUC19 and LRRK2 genotype   264   
Summary 
Aims: To investigate whether either MUC19 or LRRK2 was responsible for the CD 
susceptibility signal at the rs11175593 locus. 
Methods: MUC19 tagging SNPs were genotyped on the Taqman® platform in the 
Edinburgh cohort of 437CD, 451 UC and 428 controls.  LRRK2 tagging SNPs were 
genotyped on the Sequenom® platform in the Dundee cohort of 366 CD, 261 UC 
and 539 controls. 
Results: Genotyping across the MUC19 gene was negative in IBD overall, and CD 
and UC separately, including appropriate sub phenotypic analyses of association.  
There were no statistically significant associations of LRRK2 and IBD when 
corrected for multiple testing but there were multiple SNPs and haplotypes that 
demonstrated a trend to statistical significance.  
Conclusion: LRRK2 is most likely to represent the CD susceptibility gene at the 
rs11175593 locus, but larger adequately powered replication studies are required. 
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8.1 Introduction 
As already described, GWAS in IBD have uncovered a large number of potential 
susceptibility genes.  Combining cohorts of patients provides increased power to 
detect susceptibility genes conferring lower odds ratios (ORs), but potentially loses 
any population specific loci.  The meta-analysis combining British, North American, 
Belgian-French CD GWAS117 and the subsequent larger CD GWAS meta-analysis74, 
has led to the discovery of several novel SNPs linked with CD susceptibility 
conferring ORs of 1.04 – 1.5.  Many of these novel loci lie near rather than within 
genes of interest.  This is the case for the strongest novel locus identified in the 
Barrett meta-analysis117 which was tagged by the rs11175593T variant and estimated 
to confer an OR of 1.54 for CD susceptibility.  This variant lies within the 
chromosome 12q12 region and is within 40Kbp (kilo base pairs) of the leucine-rich 
repeat kinase 2 (LRRK2) gene and 360Kbp of the MUC19 gene (Figure 8-1).   
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Figure 8-1 Haploview diagram of rs11175593 (green box) relative to LRRK2 & MUC19 (selected SNPs only shown) 
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8.1.1 MUC19 
The family of MUC genes encode apoproteins that undergo post translational 
modification to become glycoproteins forming an important part of the barrier 
protection of epithelial cell surfaces.313  MUC19 is a secreted mucin; it is the largest 
mucin gene identified to date290 spanning more than 180kbp, with a deduced peptide 
sequence of >7000 amino acids.  Although mRNA MUC19 expression has been 
characterised in the mucous cells of human submandibular gland290 and other species 
have demonstrated MUC19 glycoprotein in saliva, the MUC19 glycoprotein has not 
been isolated from human saliva.314  MUC19 mRNA transcripts and MUC19 
expression on IHC have also been noted in the human cornea, conjunctiva and 
lacrimal gland315 and mRNA transcripts found in the human middle ear.316  There are 
no published data on MUC19 expression in the gastrointestinal tract or in immune 
cells.   
8.1.2 LRRK2 
The LRRK2 gene encodes a protein of almost 2500 amino acids317 which is 
ubiquitously expressed.318  It was first cloned in studies of familial Parkinson’s 
disease (PD) where the signal at the PD susceptibility locus PARK8 was linked with 
mutations in this gene.317;318  As these cases of familial PD are inherited in an 
autosomal dominant pattern, it appears that the mutations cause a gain in function.  
LRRK2 is a cytoplasmic protein kinase that also associates with the mitochondria.319  
The gene contains a Ras of Complex Proteins (ROC) domain which acts as a GTPase 
to regulate its protein kinase activity.  Most of the research in LRRK2 has been in the 
context of PD, where the mutant form of the protein increased apoptotic cell death 
and reduced neuronal cell viability in cell lines.319  A neuroblastoma cell line 
transfected with LRRK2 cDNA containing the most common PARK8 mutation, 
G2019S, resulted in significant reduction in neurite length compared with cells 
transfected with wild-type LRRK2, and these G2019S-transfected cells showed 
markedly increased autophagic vacuoles.320  These effects were reversed when LC3 
and Atg7, two important components of autophagy, were knocked down by RNA 
interference in the G2019S LRRK2 transfected cell line.320  A further study suggested 
that LRRK2 is a negative regulator of autophagy activity, with LRRK2 knockdown 
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increasing autophagic activity and impaired autophagic balance with a mutant 
LRRK2 form.321 
LRRK2 has been detected in immune cells and expression is upregulated by IFNγ322, 
a cytokine implicated in CD pathogenesis.  In CD intestinal biopsy specimens, 
LRRK2 mRNA expression is upregulated in inflamed tissues compared with 
uninflamed.322  The same study also showed that LRRK2 activates NF-kappaB 
pathways, and that LRRK2 knock-down reduces killing of intracellular bacteria.322   
8.1.3 Study aim 
The aim of this study was to investigate whether either MUC19 or LRRK2 was 
responsible for the CD susceptibility signal at the rs11175593 locus.     
8.2 Methods 
8.2.1 MUC19  
MUC19 SNPs were chosen using solid spine of linkage disequilibrium (LD) to tag 
haplotypic variation of the MUC19 gene including the extended 5’ and 3’ regions 
(haplotype frequency >5%), and required three SNPs.  These SNPs were genotyped 
on the Taqman® genotyping platform in the Edinburgh cohort of 437CD, 451 UC 
and 428 controls.  Given that the case-control OR of association of rs11175593 with 
CD was 1.54, the study had more than 85% power to detect an association with CD 
for each of the 3 tagging variants. 
8.2.2 LRRK2 SNP selection and genotyping 
LRRK2 SNPs were chosen using solid spine of LD to tag haplotypic variation of the 
LRRK2 gene, including the extended 5’ and 3’ regions, and genotyped on the 
Sequenom® platform at University of California, San Francisco in collaboration with 
Genentech, Inc.  The haplotypic structure of the gene is shown in Figure 8-2.  Due to 
the large number of combinations of SNP variants in the gene, the haplotype blocks 
were joined to tag for >5% variation.  However this resulted in the SNP selection 
encompassing less variation of the gene.  Thus an increased number of haplotype 
blocks, and therefore SNPs, were chosen (Figure 8-3, table 1-1).  These 36 SNPs 
were genotyped in the Dundee cohort of 366 CD, 261 UC and 539 controls. 
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Figure 8-2 Haplotypic structure of LRRK2, with the haplotype blocks marked 
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Figure 8-3 LRRK2 haplotypes on which SNP selection was made 
 
 





MAF in CEU 
HapMap 
population 
rs7973254 38894033  0.35 
rs12230685 38909057  0.175 
rs10878246 38918366  0.183 
rs6581622 38920425  0.3 
rs10878258 38927959  0.292 
rs7955902 38931524  0.383 
rs2723264 38938787  0.25 
rs17465912 38942662  0.133 
rs10784462 38944038  0.442 
rs11175784 38945801  0.492 
rs10784470 38949863  0.383 
rs7308193 38951494  0.317 
rs10506150 38953027  0.15 
rs10506151 38957265  0.158 
rs7309197 38959527  0.458 
rs17491061 38980285  0.133 
rs10784499 38984757  0.283 
rs10878343 38986851  0.233 
rs11175958 38987655  0.233 
rs11564128 38992102 0.125  
rs2896975 38992642  0.325 
rs10467144 38993468  0.383 
rs11175985 38993545  0.225 
rs4768230 39001569  0.392 
rs10878371 39002527  0.383 
rs11176030 39004720  0.392 
rs2404832 39008719  0.283 
rs17444124 39010761  0.475 
rs6581667 39017773  0.433 
rs10506155 39022206  0.317 
rs2162471 39024099  0.217 
rs10459265 39024570  0.433 
rs4767973 39042515  0.325 
rs11835105 39044312  0.2 
rs17466605 39046247  0.333 
rs17520676 39048180  0.206 
Table 8-1 SNP selection for LRRK2   
8.3 MUC19 Results 
All three SNPs were in Hardy-Weinberg equilibrium in controls, and had >90% 
genotyping rates.  After Bonferroni correction for multiple testing for the 3 SNPs at a 
p-value of 0.05, a significant p-value was <0.017.  Single marker and haplotype 
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susceptibility analyses did not show an association with any of the MUC19 
haplotype-tagging variants in IBD overall, nor in CD or UC separately (Table 8-2).  
A detailed genotype-phenotype analysis for both CD and UC according to the 
Montreal classification found no associations in CD (Table 8-3: only L1, L2 and B3 
comparisons with controls shown) and UC (Table 8-4: only E3 comparison with 
controls shown). 
 







MAF p-value UC MAF p-value 
rs4768291 C 0.156 0.143 0.487 0.155 0.968 
rs1352938 A 0.320 0.328 0.736 0.345 0.296 
rs17128462 C 0.215 0.195 0.322 0.185 0.129 




allele Controls L1 p-value L2 
p-
value B3 p-value 
rs4768291 C 0.156 0.159 0.880 0.137 0.353 0.143 0.711 
rs1352938 A 0.320 0.307 0.625 0.320 0.990 0.347 0.560 
rs17128462 C 0.215 0.197 0.434 0.194 0.373 0.172 0.265 




allele Controls E3 p-value 
rs4768291 C 0.156 0.185 0.202 
rs1352938 A 0.320 0.325 0.869 
rs17128462 C 0.215 0.182 0.191 
Table 8-4 Allelic freq UC sub phenotypic analysis 
Further detailed analysis of available HapMap data showed a complete lack of LD 
between rs11175593 and the three MUC19 tagging variants (r2=0). 
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8.4 LRRK2 results 
8.4.1 Quality control 
Two SNPs were discounted:  rs11175958 (successful genotyping of < 90%) and 
rs10506151 (due to lack of Hardy-Weinberg equilibrium in the controls).  Nineteen 
controls and three IBD DNAs were excluded due to unsuccessful genotyping 
(<90%). 
8.4.2 Single SNP analysis 
Single SNP marker analysis for association with IBD, CD or UC is shown in Table 
8-5.  When corrected for multiple testing, the level of significance was p<0.0015, 
which was not attained by any of the SNPs in IBD, CD or UC compared with 
controls.  However, both rs10878246 and rs7955902 had borderline significance in 
IBD and UC (rs10878246: IBD p=0.0175, UC p=0.0018; rs7955902: IBD p=0.0061, 
UC p=0.0164).  In CD patients none of the SNPs approached statistical significance.  
Results of a sub phenotypic analysis for the single SNPs in CD are shown in Table 
8-6 and Table 8-7.  The SNP rs7955902 had a borderline significant association with 
L1 disease location (p =0.004).  However, 13 of the 34 SNPs were associated with 
B3 internal penetrating disease compared with controls at a p <0.05 (Table 8-7), 
although none of the associations reached statistical significance overall.   
Results of a sub phenotypic analysis for the single SNPs in UC are shown in Table 
8-8.  Five SNPs across the gene were associated with E3 disease (pancolitis) 
compared with controls (p<0.05).  However, none reached statistical significance 
overall when corrected for multiple testing. 
 






MAF IBD MAF p-value CD MAF p-value UC MAF p-value 
rs7973254 C 0.315 0.316 0.9756 0.31 0.805 0.323 0.7646 
rs12230685 T 0.119 0.123 0.7343 0.129 0.5142 0.12 0.958 
rs10878246 G 0.185 0.225 0.0175 0.203 0.3329 0.253 0.0018 
rs6581622 C 0.265 0.275 0.6069 0.282 0.449 0.268 0.899 
rs10878258 G 0.264 0.264 0.969 0.275 0.6284 0.251 0.5696 
rs7955902 A 0.479 0.421 0.0061 0.432 0.0599 0.413 0.0164 
rs2723264 T 0.173 0.177 0.8453 0.191 0.3478 0.17 0.8608 
rs17465912 T 0.151 0.171 0.2045 0.159 0.6468 0.191 0.0459 
rs10784462 C 0.481 0.48 0.9711 0.486 0.8211 0.458 0.3858 
rs11175784 C 0.509 0.507 0.953 0.503 0.6368 0.467 0.3652 
rs10784470 T 0.357 0.334 0.2276 0.338 0.4014 0.335 0.3922 
rs7308193 G 0.314 0.308 0.745 0.323 0.7012 0.295 0.4484 
rs10506150 T 0.122 0.112 0.4772 0.109 0.3962 0.122 0.9988 
rs7309197 T 0.49 0.493 0.8866 0.501 0.6498 0.469 0.4281 
rs17491061 C 0.157 0.168 0.4555 0.155 0.9366 0.191 0.0939 
rs10784499 T 0.337 0.363 0.1954 0.339 0.926 0.376 0.1255 
rs10878343 T 0.204 0.206 0.9234 0.223 0.333 0.201 0.8805 
rs11564128 T 0.147 0.17 0.1375 0.158 0.5423 0.191 0.0274 
rs2896975 G 0.33 0.326 0.8441 0.346 0.4654 0.311 0.4572 
rs10467144 A 0.432 0.436 0.8598 0.449 0.4939 0.422 0.6971 
rs11175985 T 0.147 0.137 0.4708 0.126 0.217 0.154 0.6984 
rs4768230 A 0.331 0.311 0.2862 0.313 0.4198 0.313 0.4582 
rs10878371 T 0.426 0.438 0.5586 0.451 0.2976 0.424 0.9485 
rs11176030 T 0.334 0.312 0.2465 0.315 0.3912 0.313 0.3998 
rs2404832 G 0.338 0.363 0.2128 0.341 0.9116 0.375 0.1557 
rs17444124 C 0.479 0.482 0.9213 0.473 0.7736 0.504 0.3659 
rs6581667 G 0.47 0.456 0.4991 0.462 0.7159 0.444 0.3264 
rs10506155 A 0.333 0.322 0.5985 0.326 0.784 0.324 0.741 
rs2162471 C 0.178 0.182 0.8049 0.197 0.3075 0.177 0.9683 
rs10459265 G 0.472 0.456 0.4418 0.462 0.6574 0.444 0.2925 
rs4767973 A 0.311 0.309 0.9227 0.326 0.5261 0.29 0.3795 
rs11835105 G 0.803 0.209 0.4811 0.199 0.9231 0.222 0.2556 
rs17466605 A 0.313 0.311 0.9046 0.327 0.5425 0.292 0.3807 
rs17520676  -  0 0  0  0   

















rs7973254 C 0.315 0.368 0.170 0.288 0.416 0.297 0.559 
rs12230685 T 0.119 0.153 0.197 0.112 0.754 0.129 0.626 
rs10878246 G 0.185 0.222 0.251 0.194 0.737 0.192 0.775 
rs6581622 C 0.265 0.318 0.145 0.277 0.715 0.269 0.895 
rs10878258 G 0.264 0.312 0.184 0.269 0.893 0.262 0.942 
rs7955902 A 0.479 0.360 0.004 0.439 0.276 0.467 0.728 
rs2723264 T 0.173 0.205 0.319 0.190 0.541 0.185 0.641 
rs17465912 T 0.151 0.182 0.302 0.153 0.952 0.147 0.851 
rs10784462 C 0.481 0.511 0.453 0.500 0.590 0.472 0.792 
rs11175784 C 0.509 0.517 0.528 0.517 0.478 0.496 0.878 
rs10784470 T 0.357 0.301 0.149 0.339 0.589 0.350 0.812 
rs7308193 G 0.314 0.341 0.481 0.306 0.800 0.329 0.641 
rs10506150 T 0.122 0.085 0.163 0.099 0.328 0.129 0.725 
rs7309197 T 0.490 0.517 0.512 0.508 0.617 0.500 0.774 
rs17491061 C 0.157 0.182 0.401 0.153 0.886 0.140 0.487 
rs10784499 T 0.337 0.364 0.493 0.347 0.769 0.325 0.703 
rs10878343 T 0.204 0.224 0.544 0.219 0.604 0.227 0.392 
rs11564128 T 0.147 0.182 0.240 0.153 0.829 0.147 0.982 
rs2896975 G 0.330 0.364 0.375 0.339 0.781 0.346 0.597 
rs10467144 A 0.432 0.476 0.282 0.440 0.837 0.446 0.680 
rs11175985 T 0.147 0.097 0.075 0.120 0.276 0.147 0.995 
rs4768230 A 0.331 0.273 0.124 0.314 0.604 0.325 0.842 
rs10878371 T 0.426 0.477 0.207 0.445 0.590 0.447 0.536 
rs11176030 T 0.334 0.278 0.146 0.314 0.553 0.325 0.780 
rs2404832 G 0.338 0.364 0.509 0.347 0.790 0.329 0.764 
rs17444124 C 0.479 0.455 0.540 0.467 0.725 0.476 0.906 
rs6581667 G 0.470 0.466 0.914 0.446 0.500 0.476 0.876 
rs10506155 A 0.333 0.310 0.562 0.322 0.758 0.339 0.837 
rs2162471 C 0.178 0.188 0.758 0.193 0.578 0.206 0.286 
rs10459265 G 0.472 0.466 0.877 0.446 0.466 0.476 0.921 
rs4767973 A 0.311 0.347 0.352 0.310 0.967 0.329 0.575 
rs11835105 G 0.803 0.227 0.360 0.215 0.539 0.168 0.261 
rs17466605 A 0.313 0.347 0.379 0.306 0.822 0.336 0.470 
rs17520676  -  0 0  0    0  
Table 8-6 LRRK2 CD sub phenotypic analysis: disease location, p-values<0.05 highlighted
 





MAF B1 MAF p-value B2 MAF p-value B3 MAF p-value 
rs7973254 C 0.315 0.294 0.419 0.316 0.991 0.385 0.149 
rs12230685 T 0.119 0.103 0.373 0.149 0.347 0.231 0.001 
rs10878246 G 0.185 0.193 0.704 0.228 0.263 0.194 0.808 
rs6581622 C 0.265 0.262 0.886 0.281 0.725 0.370 0.020 
rs10878258 G 0.264 0.245 0.418 0.333 0.116 0.361 0.032 
rs7955902 A 0.479 0.473 0.834 0.339 0.005 0.373 0.041 
rs2723264 T 0.173 0.167 0.773 0.219 0.225 0.287 0.004 
rs17465912 T 0.151 0.148 0.870 0.184 0.357 0.157 0.867 
rs10784462 C 0.481 0.470 0.697 0.500 0.697 0.565 0.096 
rs11175784 C 0.509 0.485 0.815 0.518 0.595 0.407 0.045 
rs10784470 T 0.357 0.369 0.659 0.289 0.150 0.250 0.026 
rs7308193 G 0.314 0.298 0.537 0.360 0.323 0.417 0.030 
rs10506150 T 0.122 0.116 0.750 0.114 0.813 0.065 0.080 
rs7309197 T 0.490 0.483 0.786 0.526 0.467 0.585 0.064 
rs17491061 C 0.157 0.144 0.524 0.184 0.446 0.852 0.818 
rs10784499 T 0.337 0.330 0.799 0.351 0.769 0.333 0.936 
rs10878343 T 0.204 0.208 0.854 0.246 0.299 0.292 0.034 
rs11564128 T 0.147 0.146 0.940 0.184 0.298 0.157 0.781 
rs2896975 G 0.330 0.330 0.971 0.377 0.305 0.417 0.068 
rs10467144 A 0.432 0.429 0.897 0.500 0.170 0.510 0.130 
rs11175985 T 0.147 0.131 0.408 0.158 0.756 0.065 0.019 
rs4768230 A 0.331 0.339 0.771 0.263 0.140 0.250 0.085 
rs10878371 T 0.426 0.433 0.817 0.500 0.135 0.509 0.098 
rs11176030 T 0.334 0.341 0.784 0.263 0.126 0.250 0.076 
rs2404832 G 0.338 0.330 0.771 0.360 0.645 0.333 0.920 
rs17444124 C 0.479 0.487 0.785 0.447 0.515 0.407 0.154 
rs6581667 G 0.470 0.444 0.347 0.482 0.805 0.528 0.255 
rs10506155 A 0.333 0.313 0.459 0.333 0.989 0.387 0.262 
rs2162471 C 0.178 0.179 0.957 0.219 0.277 0.278 0.011 
rs10459265 G 0.472 0.444 0.313 0.482 0.835 0.528 0.271 
rs4767973 A 0.311 0.305 0.798 0.360 0.292 0.407 0.042 
rs11835105 G 0.803 0.189 0.701 0.211 0.737 0.176 0.594 
rs17466605 A 0.313 0.307 0.806 0.360 0.312 0.407 0.046 
rs17520676  -  0  0  0   0  
Table 8-7 LRRK2 CD sub phenotypic analysis: disease behaviour, p-values<0.05 highlighted  
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MAF E3 MAF p-value E2 MAF p val E1 MAF p-value 
1 rs7973254 C 0.315 0.274 0.1977 0.395 0.044 0.444 0.1023 
2 rs12230685 T 0.119 0.121 0.908 0.134 0.5745 0.105 0.8 
3 rs10878246 G 0.185 0.246 0.0234 0.25 0.0497 0.263 0.2246 
4 rs6581622 C 0.265 0.25 0.6087 0.305 0.2892 0.289 0.7408 
5 rs10878258 G 0.264 0.243 0.4669 0.287 0.5501 0.237 0.7051 
6 rs7955902 A 0.479 0.42 0.0926 0.393 0.0512 0.389 0.2897 
7 rs2723264 T 0.173 0.165 0.7554 0.189 0.6263 0.105 0.2729 
8 rs17465912 T 0.151 0.206 0.0299 0.171 0.5224 0.184 0.5798 
9 rs10784462 C 0.481 0.441 0.2437 0.482 0.9829 0.5 0.8161 
10 rs11175784 C 0.509 0.452 0.2504 0.488 0.9307 0.5 0.9164 
11 rs10784470 T 0.357 0.337 0.5356 0.335 0.5857 0.316 0.5998 
12 rs7308193 G 0.314 0.294 0.5241 0.305 0.8113 0.289 0.7471 
13 rs10506150 T 0.122 0.132 0.6331 0.116 0.8324 0.053 0.1972 
14 rs7309197 T 0.49 0.452 0.2616 0.488 0.9507 0.5 0.9075 
15 rs17491061 C 0.157 0.204 0.0656 0.173 0.6006 0.184 0.647 
16 rs10784499 T 0.337 0.382 0.163 0.36 0.5703 0.395 0.4615 
17 rs10878343 T 0.204 0.195 0.7373 0.213 0.7819 0.132 0.2741 
18 rs11564128 T 0.147 0.206 0.019 0.171 0.4375 0.184 0.531 
19 rs2896975 G 0.33 0.294 0.266 0.329 0.9953 0.342 0.8711 
20 rs10467144 A 0.432 0.383 0.1456 0.468 0.4103 0.472 0.6341 
21 rs11175985 T 0.147 0.169 0.3655 0.134 0.6642 0.132 0.7917 
22 rs4768230 A 0.331 0.324 0.8053 0.311 0.6044 0.263 0.379 
23 rs10878371 T 0.426 0.386 0.2341 0.469 0.3055 0.474 0.561 
24 rs11176030 T 0.334 0.324 0.7446 0.311 0.5607 0.263 0.3624 
25 rs2404832 G 0.338 0.379 0.2106 0.36 0.5869 0.395 0.4693 
26 rs17444124 C 0.479 0.529 0.1432 0.482 0.958 0.447 0.6971 
27 rs6581667 G 0.47 0.401 0.0402 0.512 0.318 0.474 0.9673 
28 rs10506155 A 0.333 0.294 0.2267 0.384 0.1961 0.237 0.2169 
29 rs2162471 C 0.178 0.179 0.9624 0.183 0.8753 0.105 0.2478 
30 rs10459265 G 0.472 0.401 0.035 0.512 0.3407 0.474 0.9859 
31 rs4767973 A 0.311 0.276 0.256 0.311 0.9933 0.316 0.9532 
32 rs11835105 G 0.803 0.221 0.3947 0.207 0.7654 0.237 0.5487 
33 rs17466605 A 0.313 0.276 0.2319 0.317 0.9212 0.316 0.9732 
34 rs17520676  - 0 0  0  0  
Table 8-8 LRRK2 UC sub phenotypic analysis, p-values<0.05 highlighted   
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8.4.3 Haplotype analysis 
When corrected for multiple testing across the 43 haplotypes, a significant p-value 
was defined as being <0.00012. 
8.4.3.1 IBD, CD and UC overall 
Results of a haplotype analysis in CD and UC are shown in Table 8-9 and Table 
8-10.  Whilst none of the haplotypes reached statistical significance when corrected 
for multiple testing, there were haplotypes at the 5’ end of the gene (blocks 1 and 2) 
that approached significance.  In block 1, the TCT and TCG haplotypes were 
associated with UC (p = 0.02 and p =0.013, respectively).  In block 2, the TAA and 
TAC haplotypes were associated with both IBD and UC (TAA, IBD p = 0.018, UC p 
=0.039) and (TAC, IBD p =0.0224, UC p =0.0165).  None of the haplotypes were 
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Haplotype   Control IBD freq IBD p-value CD freq CD p-value UC freq UC p-value 
Block 1               
TCT 0.508 0.474 0.0924 0.494 0.5859 0.446 0.0201 
TCG 0.176 0.207 0.0506 0.193 0.3867 0.228 0.0134 
CCT 0.189 0.18 0.5771 0.174 0.4028 0.181 0.7559 
CTT 0.118 0.122 0.7721 0.129 0.5142 0.12 0.958 
CCG 0.009 0.016 0.1207     0.025 0.0157 
Block 2            
TAA 0.46 0.412 0.0178 0.42 0.0911 0.404 0.0393 
TAC 0.23 0.271 0.0224 0.254 0.236 0.286 0.0165 
CGC 0.208 0.218 0.5745 0.227 0.3385 0.205 0.9218 
CAC 0.043 0.053 0.2275 0.051 0.3962 0.057 0.1881 
TGC 0.045 0.043 0.8157 0.045 0.9871 0.041 0.7337 
Block 3               
CC 0.677 0.654 0.2393 0.651 0.2521 0.641 0.1516 
TC 0.172 0.176 0.816 0.19 0.329 0.168 0.8662 
CT 0.15 0.17 0.1857 0.158 0.6109 0.189 0.0432 
Block 4            
G 0.519 0.52 0.9711 0.514 0.8212 0.542 0.386 
C 0.481 0.48 0.9711 0.486 0.8212 0.458 0.386 
Block 5               
T 0.509 0.507 0.9531 0.497 0.638 0.533 0.3669 
C 0.491 0.493 0.9531 0.503 0.638 0.467 0.3669 
Block 6               
GC 0.331 0.363 0.1066 0.343 0.5977 0.374 0.0961 
TC 0.354 0.329 0.1915 0.334 0.3686 0.331 0.354 
GG 0.312 0.303 0.647 0.319 0.7563 0.291 0.3833 
Block 7               
A 0.878 0.888 0.4772 0.891 0.3962 0.878 0.9988 
T 0.122 0.112 0.4772 0.109 0.3962 0.122 0.9988 
Block 8               
TT 0.49 0.493 0.8812 0.502 0.6426 0.469 0.4281 
AT 0.354 0.338 0.4244 0.343 0.6297 0.34 0.5975 
AC 0.156 0.168 0.4084 0.155 0.9955 0.19 0.0825 
Block 9               
CC 0.459 0.432 0.1833 0.437 0.3707 0.423 0.1775 
TC 0.337 0.363 0.1954 0.339 0.926 0.376 0.1255 
CT 0.204 0.206 0.9156 0.223 0.326 0.201 0.8805 
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Haplotype   Control IBD freq IBD p-value CD freq CD p-value UC freq UC p-value 
Block 10               
CGACG 0.33 0.326 0.8441 0.346 0.4654 0.311 0.4572 
CTGCA 0.183 0.174 0.5688 0.187 0.8536 0.158 0.2233 
TTGCG 0.148 0.17 0.1565 0.158 0.5817 0.191 0.0315 
CTGTA 0.148 0.137 0.423 0.126 0.1943 0.154 0.7472 
CTACG 0.104 0.113 0.4809 0.105 0.9578 0.115 0.493 
CTGCG 0.087 0.081 0.5872 0.078 0.5115 0.07 0.2552 
Block 11               
TAAA 0.326 0.324 0.9191 0.343 0.4385 0.311 0.5288 
CTAC 0.332 0.311 0.2728 0.313 0.4158 0.312 0.4565 
CAGC 0.152 0.171 0.2126 0.158 0.7323 0.191 0.0458 
TAGA 0.102 0.113 0.409 0.105 0.8223 0.114 0.4924 
CAGA 0.084 0.08 0.7028 0.077 0.5757 0.069 0.318 
Block 12               
CGTA 0.53 0.544 0.4786 0.54 0.6138 0.556 0.2925 
GACG 0.176 0.181 0.7412 0.195 0.3104 0.178 0.9323 
GATG 0.156 0.142 0.3065 0.131 0.137 0.147 0.5921 
GGTG 0.138 0.133 0.7329 0.134 0.8165 0.12 0.3311 
Block 13            
GTGA 0.49 0.48 0.6146 0.474 0.5189 0.486 0.8841 
ATAA 0.311 0.309 0.9261 0.324 0.5378 0.29 0.3875 
GGGA 0.196 0.209 0.4401 0.198 0.9402 0.222 0.2264 
Table 8-10 LRRK2 Haplotype analysis in IBD, CD and UC, haplotype blocks 10-13, p-
values<0.05 highlighted   
8.4.3.2 CD sub phenotype 
An analysis on the CD phenotypic data is shown in Table 8-11/Table 8-12 (disease 
location) and Table 8-13/Table 8-14 (disease behaviour).  There were 3 haplotypes 
that demonstrated a non significant trend to association with L1 disease location, the 
strongest p-value being 0.015 for TAA in block 2.  When disease behaviour was 
analysed the results mirrored the single SNP analysis.  A few haplotypes showed a 
trend to association with B3 disease: the CTT haplotype in block 1 (p-value 0.0009, 
haplotype frequency 0.23 in patients with B3 disease, 0.12 in controls).  A further 10 
haplotypes across the gene also showed an association which approached statistical 
significance (p-value range 0.0036-0.0408). 
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 Haplotype 
Control 
freq L1 freq p-value L2 freq p-value L3 freq p-value 
Block 1              
TCT 0.506 0.417 0.0297 0.518 0.7483 0.522 0.661 
CCT 0.19 0.208 0.5919 0.176 0.6254 0.157 0.2049 
TCG 0.178 0.213 0.2645 0.185 0.7741 0.181 0.8707 
CTT 0.119 0.153 0.1968 0.112 0.7538 0.129 0.6264 
CCG 0.008             
Block 2              
TAA 0.459 0.361 0.0149 0.418 0.2396 0.453 0.8308 
TAC 0.231 0.285 0.1179 0.253 0.4433 0.23 0.9795 
CGC 0.208 0.274 0.049 0.213 0.8494 0.211 0.9048 
TGC 0.045 0.036 0.608 0.052 0.6382 0.047 0.8585 
CAC 0.041 0.041 0.9972 0.059 0.2524 0.053 0.4177 
CGA 0.012 0.002 0.2492 0.004 0.2495 0.004 0.2394 
Block 3              
CC 0.677 0.616 0.1088 0.659 0.5803 0.669 0.787 
TC 0.171 0.203 0.317 0.188 0.5316 0.185 0.6096 
CT 0.149 0.18 0.2969 0.151 0.9358 0.146 0.8915 
Block 4              
G 0.519 0.489 0.4532 0.5 0.5905 0.528 0.7924 
C 0.481 0.511 0.4532 0.5 0.5905 0.472 0.7924 
Block 5              
T 0.509 0.483 0.5282 0.484 0.4815 0.504 0.8782 
C 0.491 0.517 0.5282 0.516 0.4815 0.496 0.8782 
Block 6              
TC 0.356 0.301 0.1583 0.339 0.6174 0.345 0.758 
GC 0.33 0.358 0.4663 0.356 0.4504 0.326 0.8817 
GG 0.313 0.341 0.464 0.305 0.8244 0.324 0.6987 
Block 7              
A 0.878 0.915 0.1634 0.901 0.3278 0.871 0.7249 
T 0.122 0.085 0.1634 0.099 0.3278 0.129 0.7249 
Block 8              
TT 0.49 0.518 0.4975 0.508 0.6166 0.5 0.7737 
AT 0.354 0.3 0.1637 0.339 0.6499 0.36 0.8582 
AC 0.155 0.182 0.3767 0.153 0.926 0.14 0.5228 
Block 9              
CC 0.459 0.411 0.2404 0.434 0.4828 0.448 0.7348 
TC 0.337 0.364 0.4931 0.347 0.7685 0.325 0.7034 
CT 0.204 0.225 0.522 0.219 0.6041 0.227 0.3916 
Table 8-11 LRRK2 CD disease location haplotype analysis, haplotypes 1-9, p-values<0.05 
highlighted.  
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 Haplotype 
Control 
freq L1 freq p-value L2 freq p-value L3 freq p-value 
Block 10              
CGACG 0.33 0.364 0.3746 0.339 0.7809 0.346 0.5965 
CTGCA 0.183 0.176 0.8194 0.194 0.6944 0.178 0.8483 
TTGCG 0.148 0.182 0.2549 0.153 0.8586 0.147 0.9489 
CTGTA 0.148 0.097 0.0691 0.12 0.2575 0.147 0.9557 
CTACG 0.104 0.111 0.7686 0.106 0.9322 0.101 0.9091 
CTGCG 0.087 0.071 0.4749 0.089 0.9349 0.08 0.7249 
Block 11              
TAAA 0.326 0.358 0.4107 0.339 0.7103 0.325 0.8395 
CTAC 0.332 0.272 0.1186 0.314 0.5865 0.343 0.5894 
CAGC 0.152 0.182 0.3026 0.153 0.9451 0.147 0.8326 
TAGA 0.102 0.113 0.6587 0.107 0.8245 0.101 0.9635 
CAGA 0.084 0.068 0.4661 0.087 0.9173 0.081 0.8235 
Block 12              
CGTA 0.528 0.534 0.8767 0.554 0.4661 0.528 0.9907 
GACG 0.176 0.188 0.7125 0.195 0.4989 0.199 0.3711 
GATG 0.157 0.125 0.2798 0.128 0.2545 0.139 0.4562 
GGTG 0.137 0.153 0.5766 0.124 0.5823 0.134 0.8766 
Block 13              
GTGA 0.49 0.426 0.1145 0.479 0.7765 0.497 0.855 
ATAA 0.311 0.347 0.3468 0.306 0.8901 0.329 0.5674 
GGGA 0.196 0.227 0.3343 0.211 0.6136 0.168 0.2857 
Table 8-12 LRRK2 CD disease location haplotype analysis, haplotypes 10-13, p-values<0.05 
highlighted.   
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freq p val 
Block 1              
TCT 0.506 0.524 0.5616 0.46 0.3517 0.415 0.0723 
CCT 0.19 0.18 0.6896 0.163 0.4733 0.159 0.4254 
TCG 0.178 0.179 0.9038 0.224 0.2257 0.193 0.6963 
CTT 0.119 0.103 0.3729 0.149 0.3468 0.231 
9.00E-
04 
CCG 0.008 0.014 0.3101         
Block 2              
TAA 0.459 0.458 0.9389 0.33 0.0086 0.354 0.0361 
TAC 0.231 0.239 0.6662 0.316 0.0424 0.226 0.9291 
CGC 0.208 0.201 0.7637 0.257 0.2203 0.308 0.0158 
TGC 0.045 0.041 0.6929 0.073 0.1823 0.049 0.8442 
CAC 0.041 0.057 0.2231 0.02 0.2594 0.056 0.4652 
CGA 0.012     0.004 0.4128 0.004 0.4544 
Block 3              
CC 0.677 0.686 0.7442 0.598 0.089 0.557 0.0121 
TC 0.171 0.166 0.8034 0.218 0.2203 0.285 0.0036 
CT 0.149 0.147 0.9081 0.182 0.348 0.156 0.8593 
Block 4              
G 0.519 0.53 0.6968 0.5 0.697 0.435 0.0964 
C 0.481 0.47 0.6968 0.5 0.697 0.565 0.0964 
Block 5              
T 0.509 0.515 0.8161 0.482 0.5952 0.593 0.0452 
C 0.491 0.485 0.8161 0.518 0.5952 0.407 0.0452 
Block 6              
TC 0.356 0.366 0.6806 0.289 0.1571 0.25 0.0277 
GC 0.33 0.335 0.852 0.351 0.6505 0.334 0.9445 
GG 0.313 0.296 0.5085 0.359 0.3122 0.416 0.0283 
Block 7              
A 0.878 0.884 0.7499 0.886 0.8129 0.935 0.0795 
T 0.122 0.116 0.7499 0.114 0.8129 0.065 0.0795 
Block 8              
TT 0.49 0.483 0.7858 0.526 0.4665 0.585 0.0612 
AT 0.354 0.373 0.4798 0.289 0.1684 0.267 0.0691 
AC 0.155 0.144 0.5706 0.184 0.4238 0.148 0.8439 
Block 9              
CC 0.459 0.461 0.9265 0.404 0.2601 0.374 0.0906 
TC 0.337 0.33 0.7991 0.351 0.7689 0.333 0.9361 
CT 0.204 0.208 0.8543 0.246 0.299 0.293 0.0314 
Table 8-13 LRRK2 CD behaviour haplotype analysis, haplotypes 1-9, p-values<0.05 highlighted  
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freq p val 
Block 10              
CGACG 0.33 0.33 0.9705 0.377 0.3054 0.417 0.0682 
CTGCA 0.183 0.208 0.2577 0.105 0.0378 0.185 0.9623 
TTGCG 0.148 0.146 0.9015 0.184 0.3119 0.157 0.8019 
CTGTA 0.148 0.131 0.3789 0.158 0.7834 0.065 0.0177 
CTACG 0.104 0.101 0.8753 0.123 0.5304 0.093 0.7175 
CTGCG 0.087 0.083 0.8222 0.053 0.2094 0.083 0.8969 
Block 11              
TAAA 0.326 0.326 0.9867 0.377 0.2741 0.417 0.0585 
CTAC 0.332 0.339 0.7769 0.263 0.1356 0.25 0.0835 
CAGC 0.152 0.146 0.7665 0.185 0.3584 0.158 0.8717 
TAGA 0.102 0.103 0.9718 0.122 0.5023 0.092 0.7525 
CAGA 0.084 0.082 0.8469 0.053 0.2379 0.083 0.9608 
Block 12              
CGTA 0.528 0.556 0.3132 0.518 0.8354 0.472 0.2712 
GACG 0.176 0.179 0.8727 0.21 0.3607 0.278 0.0097 
GATG 0.157 0.134 0.2467 0.123 0.3368 0.112 0.2132 
GGTG 0.137 0.131 0.7339 0.14 0.928 0.138 0.9764 
Block 13              
GTGA 0.49 0.504 0.5945 0.43 0.2192 0.417 0.1444 
ATAA 0.311 0.303 0.7626 0.36 0.2881 0.407 0.0408 
GGGA 0.196 0.187 0.6605 0.211 0.7071 0.176 0.6194 
Table 8-14 LRRK2 CD disease behaviour haplotype analysis, haplotypes 10-13, p-values<0.05 
highlighted 
8.4.3.3 UC sub phenotype 
An analysis of the UC phenotypic data is shown in Table 8-15.  The CCG haplotype 
in block 1, which showed a statistically significant association with disease extent, 
also had very low carriage rates (carriage rates: E3 was not calculated, E2 0.043 and 
E1 0.063); therefore the levels of significance are uncertain (E2 p=0.0008; E1 
p=0.001).  A number of other haplotypes showed a trend to association with disease 
extent in blocks 1 and 2 but these did not reach overall statistical significance: in 
block 1, the TCT haplotype with E2 disease extent (p=0.0067) and the TCG 
haplotype with E3 disease (p=0.0156); in block 2, the TAC haplotype with E3 
disease extent (p=0.0397).  Three other haplotypes showed a trend to association 
with E3 disease extent: TTGCG in block 10 (p=0.0214), CAGC in block 11 
(p=0.0298) and CGTA in block 12 (p=0.035). 
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Haplotype  
Control 
freq E3 freq p-value E2 freq p-value E1 freq p-value 
Block 1        
TCT 0.506 0.48 0.4488 0.395 0.0067 0.345 0.0494 
TCG 0.178 0.243 0.0156 0.221 0.3137 0.287 0.1345 
CCT 0.191 0.153 0.1464 0.207 0.322 0.2 0.7078 
CTT 0.119 0.121 0.908 0.134 0.5745 0.105 0.8 
CCG 0.008   0.043 8.00E-04 0.063 0.001 
Block 2        
TAA 0.459 0.412 0.1699 0.38 0.0584 0.381 0.3388 
TAC 0.231 0.291 0.0397 0.27 0.264 0.3 0.3183 
CGC 0.207 0.19 0.5294 0.238 0.3668 0.203 0.9552 
TGC 0.045 0.047 0.9031 0.045 0.9857 0.03 0.6569 
CAC 0.042 0.052 0.4568 0.061 0.2698 0.08 0.2531 
CGA 0.012 0.006 0.3844 0.004 0.3321 0.004 0.6311 
Block 3        
CC 0.677 0.632 0.1534 0.641 0.361 0.711 0.6677 
TC 0.171 0.162 0.7314 0.188 0.6015 0.105 0.2863 
CT 0.149 0.203 0.0307 0.17 0.4941 0.184 0.5508 
Block 4        
G 0.519 0.559 0.2438 0.518 0.9829 0.5 0.8161 
C 0.481 0.441 0.2438 0.482 0.9829 0.5 0.8161 
Block 5        
T 0.509 0.548 0.2507 0.512 0.931 0.5 0.9164 
C 0.491 0.452 0.2507 0.488 0.931 0.5 0.9164 
Block 6        
TC 0.355 0.33 0.4454 0.335 0.6067 0.315 0.611 
GC 0.331 0.376 0.1646 0.36 0.4496 0.395 0.4044 
GG 0.312 0.286 0.4039 0.304 0.8292 0.289 0.7567 
Block 7        
A 0.878 0.868 0.6331 0.884 0.8324 0.947 0.1972 
T 0.122 0.132 0.6331 0.116 0.8324 0.053 0.1972 
Block 8        
TT 0.49 0.452 0.2616 0.488 0.9507 0.5 0.9075 
AT 0.354 0.343 0.7395 0.341 0.7499 0.316 0.6257 
AC 0.156 0.205 0.0529 0.171 0.615 0.184 0.6299 
Block 9        
CC 0.459 0.423 0.2877 0.427 0.4444 0.474 0.8566 
TC 0.337 0.382 0.163 0.36 0.5703 0.395 0.4615 
CT 0.204 0.195 0.7373 0.213 0.7819 0.132 0.2741 
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Haplotype 
Control 
freq E3 freq p-value E2 freq p-value E1 freq p-value 
Block 10        
CGACG 0.33 0.294 0.266 0.329 0.9953 0.342 0.8711 
CTGCA 0.183 0.154 0.2687 0.177 0.8427 0.132 0.4169 
TTGCG 0.148 0.206 0.0214 0.171 0.4587 0.184 0.543 
CTGTA 0.148 0.169 0.394 0.134 0.637 0.132 0.777 
CTACG 0.104 0.092 0.5765 0.14 0.1642 0.146 0.4037 
CTGCG 0.087 0.084 0.887 0.049 0.0983 0.064 0.6275 
Block 11        
CTAC 0.331 0.323 0.8062 0.311 0.5909 0.262 0.3799 
TAAA 0.327 0.294 0.3061 0.329 0.9418 0.342 0.8353 
CAGC 0.152 0.206 0.0298 0.171 0.5239 0.185 0.5796 
TAGA 0.102 0.092 0.6155 0.14 0.1498 0.131 0.5617 
CAGA 0.084 0.081 0.8529 0.049 0.1179 0.079 0.9055 
Block 12        
CGTA 0.528 0.599 0.035 0.488 0.3407 0.526 0.9859 
GACG 0.176 0.18 0.8652 0.183 0.8265 0.105 0.2584 
GATG 0.157 0.114 0.0737 0.201 0.1549 0.132 0.6717 
GGTG 0.137 0.107 0.1807 0.128 0.7474 0.237 0.0834 
Block 13        
GTGA 0.49 0.504 0.6966 0.476 0.7246 0.447 0.6022 
ATAA 0.311 0.276 0.2608 0.311 0.9993 0.316 0.9494 
GGGA 0.196 0.221 0.3631 0.207 0.73 0.237 0.532 
Table 8-16 LRRK2 UC disease extent haplotype analysis, haplotypes 10-13 p-values<0.05 
highlighted
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8.5 Discussion 
Mucins make attractive potential candidate genes in IBD susceptibility, as they are 
important constituents of the mucus layer and as such, are potentially involved in 
barrier function in the gut.  However, for MUC19 there are no data in the literature 
demonstrating MUC19 expression in the GI tract or in immune cells.  The MUC19 
data presented in this chapter had sufficient power to confidently rule out any 
potential genotypic association between IBD and this gene.  In addition, looking 
across all known SNPs in the MUC19 gene on available HapMap data, only one SNP 
has any LD with rs11175593.  Thus it is unlikely that the candidate gene for the 
rs11175593 locus is MUC19. 
Multiple SNPs within the LRRK2 gene, have D’ and r2 of 1 with rs11175593, thus it 
is more likely that LRRK2 represents the susceptibility gene for the rs11175593 
signal at this region. The complicated haplotypic structure and large gene size of 
LRRK2 makes it more difficult to study than the smaller MUC19 gene.  This has 
been borne out with the LRRK2 results presented here, which showed an association, 
the significance of which was lost when corrected for multiple testing.  However, the 
studied population of 639 patients (336 CD) and 539 controls had minimal power to 
detect differences, with a possibility of a type 2 statistical error.  For a single SNP 
analysis to have >80% power to detect a difference with an OR of 1.5, at least 384 
patients are required.  With correction for multiple testing, the number needed 
increases to at least 836 patients.  Therefore, these LRRK2 studies were inadequately 
powered to rule out an association between LRRK2 and the SNP rs11175593.  Given 
the fact that the MUC19 study was negative, and there was a high OR of 1.5 for 
rs11175593 in the meta-analysis, it is likely that the some of the SNP results are false 
negatives.  The SNPs that showed an association before multiple testing at least 
should be further investigated in a larger population. 
In this chapter, the results demonstrated that there are more potentially significant 
associations between LRRK2 and susceptibility to UC than to CD.  This is especially 
interesting as the SNP was associated with CD susceptibility in the CD meta-
analysis; in addition, other autophagy genes (ATG16L1 and IRGM) are also 
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associated with CD much more so than with UC.  UC GWAS have not found an 
association between UC and LRRK2.   
Intriguingly, the most significant association was between B3 disease in CD and a 
haplotype (CTT in haplotype block 1).  There were other LRRK2 SNPs and 
haplotypes associations with CD, even though significance was lost in CD when 
corrected for multiple testing.  This suggests that the gene may be involved in 
determining disease phenotype rather than susceptibility to CD.  This demonstrates 
why sub phenotypic studies are valuable, even with an overall lack of association of 
a gene with disease susceptibility. 
In order to fully understand the role of LRRK2 in CD susceptibility in the Scottish 
population, a larger cohort is required to provide more power.  In particular, SNPs at 
the 5’ end of the gene, especially in the first 2 haplotype blocks, should be 
genotyped, followed by replication in a further cohort.  In addition, exonic 
sequencing of the LRRK2 gene would be helpful to attempt to find a non 
synonymous SNP that may be associated with disease susceptibility. 
Functional studies of autophagy proteins (ATG16L1 and IRGM) associated with CD 
have suggested that mutations decrease autophagy103;323, resulting in defective 
intracellular processing of bacteria.  Thus, if LRRK2 is implicated in CD 
pathogenesis and functionally involved in autophagy, CD-associated LRRK2 
mutations would be expected to reduce autophagy.  In PD, the LRRK2 mutations 
prevent the negative regulation of autophagy, thus increasing autophagy.  Certainly, 
the PD autosomal dominant (AD) mutations are unlikely to be associated with CD as 
there is no known link between CD susceptibility and PD.  Alternatively, LRRK2 
pathogenicity in CD could be mediated by IFN-γ and its downstream effects, as 
argued by Gardet et al.322  Further functional studies to delineate the pathways 
involving LRRK2 are required. 
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Chapter 9 Future work 
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9.1 Crohn’s Disease Phenotype 
The studies presented indicate that the risk of disease progression in the Scottish 
cohort studied is lower than in other cohorts, yet the risk of resection is higher.  It 
consolidates existing knowledge that disease location is the most important clinical 
determinant of disease progression and the need for surgery.  The risk of further 
surgery also appears to be determined by the disease location, with colonic disease 
behaving in a more benign fashion than patients with ileal and/or UGI disease.  
Another important study would be to examine the risk of disease progression and 
surgery with respect to medication.  With increasing use of thiopurines and 
biologicals, conclusive evidence is still lacking that these medications actually 
change disease course.324  It would be important to factor these variables into a 
multivariate analysis.  An alternative way of considering this, possible with the 
currently available data, would be to complete an analysis of disease progression 
with respect to decade at diagnosis.  This could provide circumstantial evidence that 
immunosuppressants are changing the CD course, as thiopurines have only been used 
widely since the early 1990s.  It would also be useful to repeat the multivariate 
analysis of time to surgery including decade at diagnosis in the Cox proportional 
hazards model, as it would appear to be important, reflecting a change in surgical 
practices over time, and possibly reflecting a change in use of steroid-sparing agents 
– but this would be best done with the additional knowledge of medication history, 
which is not available in a substantial proportion of the Scottish cohort.  This could 
help to tease out whether surgical practices have changed, or whether steroid sparing 
agents are actually changing disease course. 
The analysis of patients with stricturing and penetrating disease indicates that the B2 
and B3 categories should be considered as completely separate disease progression 
categories, something that has implications for future CD classification.  This study 
should be extended to include all Scottish patients rather than just the Dundee subset 
which could provide a more robust confirmation of the findings presented.  In 
addition, a prospective study involving the pathologists who report the surgical 
resection specimens would be necessary to ensure that subtle details of the specimen 
are included that might not be documented on a standard pathology report but which 
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might affect the decision as to whether there are strictures or fistulae present in the 
pathology specimen.   
Of course, in the future, prospective studies of CD natural history that are population 
based will be important, although this will take some time to accumulate the relevant 
data.  In countries like the UK where there are no centralised hospital record systems, 
it can be hard to ensure that the entire disease population of an area has been 
accounted for.  Therefore clinic-based studies are the most realistic mode of 
recruitment for prospective studies in the UK for the time being.  Careful thought 
would need to be given as to which parameters should be collected from these 
patients.  Certainly details of all investigations, medications taken, microbiology, 
biochemistry and pathology results, disease activity index at predefined points (using 
the Crohn’s Disease Activity Index or Harvey Bradshaw Index) and the Endoscopic 
Index of Severity and Physician Global Assessment indices should be recorded.  In 
addition, blood for DNA extraction, serum extraction and stool samples should be 
taken from consenting patients. 
9.2 Crohn’s disease severity 
Predicting disease severity is fertile ground for future studies that could have 
important implications in CD patient care.  The disease severity score is a completely 
novel way of considering CD severity that has been shown to be correlated with long 
term disease progression.  It has been possible, with 3 clinical factors and 2 genetic 
factors at diagnosis, to build a model that can predict with reasonable accuracy 
whether a person is likely to have more severe disease.  This has important 
implications for choosing patients for early top-down therapy. 
The most important future work necessary for this study is confirmation of the 
findings in a separate cohort.  This confirmation cohort would need to have their 
novel severity score calculated.  In addition, the 5 variables from which the model 
has been produced (age <17 at diagnosis, ileal and/or UGI disease at diagnosis, 
rs13361189 and rs9286879 genotype) would also need to be obtained.  A further 
ROC curve would then be made from the sensitivities and specificities of the 
modelled probability to predict more severe disease. There are plans to complete this 
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in the Edinburgh cohort in the near future.  A separate cohort, geographically 
separate from Scotland would also be important if this formula is to have more 
widespread use. 
Additionally, it would be interesting to repeat the analyses with a different cut-off 
point for defining more severe disease.  This study has used a cut-off that divides the 
cohorts into two approximately equal halves.  Defining ‘more severe’ disease as a 
higher or lower severity score could produce a different set of variables.  This is 
likely in view of the Beaugerie234 variables which predict ‘disabling disease’.  These 
variables are different to the ones suggested in this thesis but this is unsurprising 
considering their definition encompasses a greater proportion of patients. 
A way to develop the formula further would be to use SNPs that appeared to 
differentiate between B1 and B2/B3 disease on GWAS, as had been initially planned 
in this study.  This could provide more relevant genotyping to enter into a 
multivariate analysis, and could increase the sensitivity and specificity of the model 
to predict more severe disease.  Any of the SNPs thus uncovered would be worth 
further detailed investigation as they might help to pin-point the molecular pathways 
involved in disease evolution – something that would be useful for future drug 
development.  Immune responses to microbial antigens have previously been shown 
to be associated with CD progression (e.g. anti-Saccharomyces antibodies19, anti-
OmpC325 and anti-I2 antibodies325); they are also likely to be correlated with the 
novel severity score.  All these factors could be considered for inclusion in the model 
with the aim of increasing the accuracy of the model for disease prediction. 
In schizophrenia, polygenic scoring across schizophrenia GWAS SNPs with p-values 
of <0.5 is positively associated with disease susceptibility.237  It would be interesting 
to do this with the WTCCC GWAS data and calculate the polygenic score, and 
compare CD patients with controls.  To take this one step further, using the 
polygenic score to look for differences between more and less severe patients would 
also be worthwhile, although this would require severity score calculation in all the 
WTCCC patients.  Whilst polygenic scoring would not have implications for patient 
care at the moment, in the future it could do so as genotyping costs come down. 
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9.3 GALNT2 genotype 
Any future genotyping work using the Illumina® platform in the Gastrointestinal 
Unit will benefit from lessons learnt from the GALNT2 genotyping work.  Indeed, it 
has highlighted the problems with automated genotyping, and demonstrates the need 
for stringent quality control as well as the importance of replication of any positive 
result. 
It has been demonstrated that rs7536663 in the GALNT2 gene is associated with CD 
susceptibility in the Edinburgh cohort with an OR of 1.38.  Although the MAF in CD 
and controls in the Dundee replication cohort were different and the differences in a 
similar direction to the Edinburgh cohort MAF, it was not statistically significant.  
The rs7536663 SNP and its associated haplotype should be genotyped in a larger 
cohort.  The rs7536663 SNP is currently being genotyped on the WTCCC 
immunochip with hopefully the results being available shortly.  Should this provide 
robust replication of the Edinburgh cohort findings, a more detailed examination of 
the GALNT2 gene should be completed, including further sequencing across the 
exons and important regulatory regions.  As the rs7536663 SNP lies within intron 1, 
this search should concentrate on exons 1 and 2, and the regulatory regions around it 
due to the large size of the gene.  Next-generation sequencing is making cost-
effective whole gene sequencing a reality thus it is more likely to represent the best 
way forward in discovering a mutation that has direct implications in the biological 
pathways of CD. 
9.4 GALNT2 expression 
It has been demonstrated convincingly that NOD2 and GALNT2 interact in 
mammalian cells.  This validates the initial yeast two-hybrid experiment that showed 
their interaction in yeast cells.  However the CoIP experiments need to be repeated to 
ensure that these results can be replicated.  It would be good to do this with 
densitometry on the western blot bands to quantitate the differing band intensities 
between the NOD2 mutants. 
Most important to the further development of the experiments in this chapter would 
be the development of a NOD2 antibody that works for both IHC and western 
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blotting.  In an ideal world, if the NOD2 protein could be produced in sufficient 
quantities it would be the preferred immunogen.  Failing that, further peptide 
sequences in the OMAP formation could be a better type of immunogen than KLH 
and might prove successful in antibody production.  Once a working NOD2 antibody 
is produced, IHC and immunofluorescence should be used on colonic and ileal 
tissues, to investigate the protein co-expression of NOD2 and GALNT2. Performing 
cell fractionation prior to CoIP could also help to prove that they are expressed in the 
same subcellular compartments. 
For the studies on mRNA expression, it would be useful to look at NOD2 and 
GALNT2 expression in tissue samples, including PBMCs as well as gastrointestinal 
tract tissue.  Microdissection of different cell types with subsequent qPCR could 
provide evidence of cellular co-localization of NOD2 and GALNT2.   
9.5 MUC2 and MUC3A genotyping 
In the first instance, the MUC2 SNP rs7942850 and its two-marker haplotype need 
full and formal replication in a large cohort that contains controls.  With MUC3A, a 
more detailed tagging SNP analysis, tagging for a lower haplotype frequency would 
be useful.  This was not completed in the study presented here due to the cost 
implications.  Improving knowledge of the full sequence of MUC3A would also help 
to provide an adequately genotyped study.  Interest in MUC3A was on the basis of a 
study using RFLP markers.286  However, the RLFP marker that was implicated in 
IBD susceptibility is actually >20Mbp upstream of the gene.  More recent UC 
GWAS has shown that a marker nearer this RFLP (rs7807999) is associated with UC 
susceptibility.  This SNP is in between the SMURF1 and KPNA7 genes.  Therefore 
further tagging SNP genotyping studies across these genes should also be completed. 
Mucins may be implicated in IBD pathogenesis without requiring germline variation 
in the underlying genes.  As already discussed, MUC2305and  MUC3A306 expression 
in colon cancer cell lines has been shown to be highly controlled by methylation and 
histone deacetylation.  Therefore epigenetic changes could affect the quantity of 
mucin produced.  Assessing human colonic tissue DNA methylation with bisulfite 
sequencing of extracted DNA with assessment of MUC2 and MUC3A mRNA 
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expression in the same tissues could be completed.  Given the literature suggesting 
that MUC2 expression is partly regulated by short-chain fatty acids (fermentation 
products of bacteria) via epigenetics307, it would be worthwhile to assess the 
corresponding bacteria present in the faeces and mucus using 16S rRNA technology. 
Further bacterial studies examining in more detail the effects of specific bacteria – 
for example adherent-invasive E. Coli – on mucin expression and production in cell 
lines would be useful. 
9.6 MUC19 and LRRK2 genotyping 
The results presented in this thesis indicate LRRK2 rather than MUC19 is likely to be 
responsible for the CD GWAS signal at the rs11175593 locus.  In order to definitely 
prove this, further genotyping in the Edinburgh cohort concentrating on SNPs at the 
5’ end of the LRRK2 gene would be necessary.  Should this prove an association with 
IBD, genotyping across the exons would be a further useful step in elucidating 
potentially ‘causative’ mutations.   
If a functioning LRRK2 antibody was available, IHC and immunofluorescence could 
be used to examine LRRK2 protein expression and localization in gastrointestinal 
biopsy samples, both with and without inflammation.  Quantitative PCR on patient 
samples would also be useful: given the potential role of LRRK2 in the IF-γ 
mediated immune response322, PBMCs isolated from CD patients and controls should 
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Chapter 10 Appendices 
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Research project into genetic factors in inflammatory bowel disease-  
Can you help? 
 
 
We would like to invite you to take part in our research project, which is aimed at 
identifying genetic factors that influence the severity of inflammatory bowel disease.  
It is well known that the outcome for patients with ulcerative colitis/Crohn’s disease 
is very variable - some patients have very mild disease with few if any symptoms 
throughout their life.  A proportion, however, develop severe symptoms, and require 
intensive hospital treatment, or even surgery.  At the present time there is a real need 
to identify factors which might predict the natural history of disease, and help 
identify those patients who are likely to develop severe symptoms. 
 
 
In recent years progress has been made in identifying genetic markers of severity of 
ulcerative colitis and Crohn’s disease. 
 
 
The study is outlined in the attached information sheet.  We ask that you would be 
prepared to give a blood or saliva sample for genetic analysis.  A Doctor or Nurse, 
who would also read carefully through your hospital notes, would take the blood.  
The blood/saliva sample would be used for studies of genetic markers, which may 
help predict the course of ulcerative colitis/Crohn’s disease.  
 
 
All data and DNA samples would be stored securely, and the data and samples would 
be coded and therefore anonymous. 
 
 
I hope that you are able to help with this research, which is promising to provide 
progress in understanding the cause of inflammatory bowel disease, and may lead to 





If you are prepared to take part, please contact our research nurse 
Shirley McLeod:             
tel: 01382 660111, extension 35302  or 
 
email: shirley.mcleod@nhs.net  or 
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approach Shirley directly at the out-patient clinic 
 
 
We could arrange to see you at a convenient time. Alternatively, we could see you at 
your next clinic appointment on_______________.  
 
Thank you very much for considering to help. 
 







Craig Mowat    Nigel Reynolds 
Consultant Gastroenterologist Consultant Gastroenterologist 
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10.2 Patient information sheet - Dundee IBD recruitment 
 
Patient / Volunteer Information Sheet  
AN INVESTIGATION INTO THE GENETIC DETERMINANTS OF 
SUSCEPTIBILITY AND PROGRESSION IN CHRONIC INFLAMMATORY 
BOWEL DISEASE.  
 
We would like to invite you to take part in a research project. We believe it to be of 
potential importance. However, before you decide whether or not you wish to 
participate, we need to be sure that you understand firstly why we are doing it, and 
secondly what it would involve if you agreed. We are therefore providing you with 
the following information. Read it carefully and be sure to ask any questions you 
have, and, if you want, discuss it with outsiders. We will do our best to explain and 
to provide any further information you may ask for now or later. You do not have to 
make an immediate decision. 
 
Background to the study 
The chronic inflammatory bowel diseases, Crohn’s disease and ulcerative colitis are 
common causes of gastrointestinal illness in Western Europe. They are particularly 
common in the North East of Scotland. The diseases cause considerable illness, 
particularly affecting quality of life in young people.  Genetic studies, examining 
twins and siblings, have provided strong evidence that both genetic and 
environmental factors are important in determining who develops the disease 
(susceptibility).  Genetic factors appear to be stronger in Crohn’s disease than in 
ulcerative colitis. In recent years considerable progress has been made in identifying 
regions of the human genome which are associated with susceptibility to 
inflammatory bowel disease and are therefore likely to contain true genes involved in 
determining disease susceptibility. The regions of the genome that have been 
identified to date are large, and now need to be narrowed down before the genes may 
be identified. A number of strategies are currently being applied in attempts to 
narrow these regions. The establishment of a DNA bank, created by taking blood 
from affected patients and healthy controls will allow further study of genetic 
markers with the overall objective of identifying susceptibility genes. 
The overall aims and objectives of this project are to identify genes involved in 
determining susceptibility and disease progression in the chronic inflammatory 
bowel diseases, Crohn’s disease and ulcerative colitis. We aim to do this by 
comparing the DNA of patients with ulcerative colitis/Crohn’s disease against the 
DNA of healthy volunteers, and by comparing the DNA of patients with mild forms 
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of ulcerative colitis/Crohn’s disease with the DNA of those patients with more severe 
disease. 
We hope that the results of this research will: 
increase our understanding of the cause of Crohn’s disease and ulcerative colitis. 
provide a better understanding of the natural course of Crohn’s disease and ulcerative 
colitis. 
Allow better use of medical and surgical therapy. 
 
The Tayside Committee on Medical Research Ethics, which has responsibility for 
scrutinising all proposals for medical research on humans in Tayside, has examined 
the proposal and has raised no objections from the point of view of medical ethics. If 
you agree to participate, monitors from the Committee may wish to examine your 
research records. 
 
You have been chosen as a possible participant because: (tick box) 
 
You have Crohn’s disease 
You have ulcerative colitis 




What are you asking me to do? 
To help with the research we would ask you to: 
Complete a brief questionnaire 
Donate a small blood sample (4 teaspoons, 20ml of blood) or saliva sample so that 
we can extract genetic material (DNA) from the blood.  The DNA would be used to 
search for genetic changes that might predict the development or progress of 
ulcerative colitis/Crohn’s disease.  We would arrange for the blood to taken at a 
convenient time. This carries no significant risk, although there may be a very small 
bruise. 
Sign a consent form for the study. 
 
What will happen to my blood sample? 
The blood/saliva sample will be given a code number so that laboratory personnel 
will not know your identity. 
The details of the genetic analysis will only be known to medically qualified 
investigators involved in the study and will not be available to anyone else. 
All data will be stored in secure databases. 
The research does not constitute "a genetic test" as defined by insurance companies. 
The genetic make-up of a patient with ulcerative colitis/Crohn’s disease is estimated 
to account for 20% of the underlying cause. Many genes are believed to be 
implicated and this area of research is at a very early stage. 
If, at a later date, we wished to contact your relatives, we would only do this with 
your permission. 
Your blood/saliva sample may be used again in the future if new tests become 
available to further investigate the genetic basis of ulcerative colitis/Crohn’s disease. 
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Future studies investigating the genetic basis of ulcerative colitis/Crohn’s disease 
may be performed in collaboration with commercial companies. Collaboration with 
commercial companies provides us with much needed resources required to develop 
our research and to develop new treatment for inflammatory bowel disease. Although 
such companies would have access to information provided by DNA samples, 
including your own, they will never be able to identify you or link you to such 
information. 
 
What will happen to the other information collected in the study? 
All information collected will be held on a secure database which can be accessed 
only by the researchers involved in the study.  
 
When is the research likely to benefit patients? 
There has been great progress in identifying genetic markers, and clinical factors, 
which predict the course of ulcerative colitis/Crohn’s disease.  We very much hope 
that within a few years, it will be possible to identify those patients who are likely to 
suffer severe forms, and adjust medical therapy accordingly. 
Will my GP know that I am involved in this study? 
Yes, we shall notify your GP about your participation.  
Who should I talk to if I have any questions or concerns? 
Please feel free to contact Dr Craig Mowat, Consultant Gastroenterologist, or Dr 
Nigel Reynolds, Consultant Gastroenterologist, Wards 5&6, Ninewells Hospital, 
Dundee DD1 9SY, Telephone Number: 01382 660111. 
 
Can I choose not to take part? 
Yes of course.  Participation in this study is entirely voluntary and you are free to 
refuse to take part or to withdraw from the study at any time without having to give a 
reason and without this affecting your future medical care or your relationship with 
medical staff looking after you. 
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10.3 Patient Questionnaire - Dundee IBD recruitment 
Patient Identification Number     
 












QUESTIONNAIRE FOR PATIENTS WITH CROHN’S DISEASE OR 
ULCERATIVE COLITIS 
 
Please fill in this questionnaire, and bring it with you to your next clinic visit.  Our 
Research Nurse in the clinic will answer any questions which you may have, and will 




Sex:  M/F           
(Please delete as appropriate) 
 
Date of Birth:     Diagnosis: (please delete as appropriate) 
      Ulcerative Colitis/Crohn’s disease 
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Have you ever had any trouble with your joints?  (delete as appropriate)   YES/NO 
 
Have you ever been admitted to hospital with a flare up of your ulcerative colitis?  















Have you ever smoked? (delete as appropriate) YES/NO 
 
 












1. In total, how many brothers           2. How many children do you and 
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3.  Do any family members (grandparents, parents, aunts, uncles, siblings or 
children) have: 
 
Crohn’s disease?  YES/NO 
 
Ulcerative colitis?  YES/NO  
 
Coeliac disease?  YES/NO 
 
Colon cancer?   YES/NO 
 
Please give details of affected relatives in the space provided including their age at 
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4.   Ethnic origin 
 
Which of the following best describes your ethnic origin? 
 
White European      Hispanic    
Jewish        Afro-Caribbean   
Japanese       Asian     




   
Have you had any operations due to your Crohn’s disease or ulcerative colitis? 
 
























     
Have you had your tonsils removed?      If yes, when?  (year)   
 
 
Have you had your appendix removed?  If yes, when? (year) 
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Medications 
   
Have you ever been treated with Azathioprine?    YES / NO /  Don’t know 
 
If yes,  were you tolerant          or intolerant        of this medication? 
    (please tick as appropriate) 
 
Are you taking Azathioprine at present?           YES / NO 
 
 
Have you ever been treated with Infliximab?             YES / NO   
    
 
Oral contraceptive status   Current      Never      Ex-  
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10.4 Consent form - Dundee IBD recruitment 
An investigation into the genetic determinants of susceptibility and progression in chronic 




Have you read and understood the Participant Information Sheet? Yes   No  
 
Have you been given the opportunity to ask questions & further discuss the study? 
Yes   No  
 
Have you received satisfactory answers to all of your questions? Yes   No  
 
Have you now received enough information about the study?  Yes   No  
 
Do you understand that your participation is entirely voluntary? Yes   No  
 
Do you understand that you are free to withdraw from this study: 
  
 At any time?      Yes   No  
 
 Without having to give a reason for withdrawing?  Yes   No  
 
 Without this affecting your present or future care?  Yes   No  
 
Do you agree to take part in this study?    Yes   No  
 
Do you agree to the DNA being used for future research?  Yes   No  
 
 
Note that it is a requirement that your research records and, if necessary, your medical records are 
available for scrutiny by monitors of the sponsor organisation and that by signing this document you 




Participant’s name in block capital letters___________________________________ 
 
Telephone contact (participant) Home__________________Work_______________ 
 
Signature witnessed by_____________________________Date________________ 
 
Witness name in block capital letters_______________________________________ 
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10.5 Crohn’s Disease Clinical Data Form 
 
 
Demographics      Lab Number 
 
 
     (In absence of sticky label please record 
patient’s       full name, sex, date of birth and 
hospital number.) 
 
         








Date of Onset of Symptoms 
 
 
Date of Diagnosis 
 
 
Oral contraceptive status 
Current Never  Ex  (please circle) 
 
Smoking status  Smoking at diagnosis      yes   no   ex   don’t know 
Current   Never    Ex    (please circle) 
 
Smoking amount  Smoking at follow-up       yes   no   ex   don’t know 
0-4      5-14    15-24     25+  (please circle)  Number of cigarettes per day = 
 
Family history of IBD 
Yes   No   (please circle) 
 





Form completed by 
 
Signature ……………………………………  Date ……………………  
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Investigations     UGIE     BaFT   Ba enema  Colonoscopy    Sigmoidoscopy 
 
 
Oral     OGD        Jejunal     Ileal      TI     Colonic       Rectal     Anal/Perianal  
 
Maximal extent prior to 1st  resection        Montreal  classification   (please circle) 
 
L1          L2          L3          L4          L1+L4          L2+L4          L3+L4    
 
At latest follow up   Date       Investigation 
 
Oral     OGD       Jejunal      Ileal      TI     Colonic      Rectal     Anal/Perianal  
 
Stoma   Ileal    Colonic  
 
 
Behaviour                  Montreal  classification   (please circle) 
 
 
At diagnosis   Inflammatory  B1      Stricturing  B2          Penetrating  B3 
 
Or any of these plus penetrating perianal disease  B1p      B2p       B3p     
 
If stricture/fistula, give site + evidence (? symptomatic, investigation, treatment) 
 
 
Date of 1st behaviour change                                                                                                                                
If stricture/fistula, give site, evidence (? symptomatic, investigation, treatment)      
                  
 




At 5 years of F-UP                 B1           B2         B3          B1p          B2p         B3p 
 
 
At 10 years of F-UP               B1           B2         B3          B1p          B2p         B3p 
 
 
At latest follow up              B1           B2         B3          B1p          B2p         B3p 
 
 
Behaviour  interim?  Yes / No  
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Extra-intestinal manifestations please tick 
 
Joints    large joint related to disease activity        Skin   Erythema nodosum 
   small joint unrelated to disease activity                     Pyoderma 
   AS             Psoriasis 
   Sacro-ilitis            Mouth ulcers 
 
Eyes    Uveitis            Liver   PSC 
   Episcleritis 
   Conjunctivitis           Cancer   Colon 
   Undiagnosed ocular inflammation              Other (specify) 
 







Surgical Details:  List date and operation details 
 
 




























Crohn’s Disease Behaviour Data Form 
 
DATE OF DIAGNOSIS: 
Disease Location 
Date Oral OgD Jej Ileal TI Colonic Rect Anal Notes? 
 
 





         
          














    





    
     
 
 
Date of Last Clinic:     Completed By: 
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10.6 Ulcerative Colitis Clinical Data Form 
 










Date of Onset of Symptoms: 
 
Date of Diagnosis: 
 
 
Oral contraceptive status 
Current Never  Ex  (please circle) 
 
Smoking status    Smoking at diagnosis      yes   no   ex   don’t know 
Current   Never    Ex    (please circle) 
 
Smoking amount    Smoking at follow-up       yes   no   ex   don’t 
know 
 
 0-4      5-14    15-24     25+   (please circle)       Number of cigarettes per day = 
 
Family history of IBD 
Yes   No   (please circle) 
 
Details of affected relatives, their diagnosis and age of onset. 
 
 
Form completed by 
 
Signature ……………………………………  Date ……………………  
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Extent of disease at diagnosis:  please circle 
 
Rectum only  Colonoscopic  Histological  Radiological 
 
Recto-sigmoid Colonoscopic  Histological  Radiological 
 
Splenic flexure Colonoscopic  Histological  Radiological 
 
Hepatic flexure Colonoscopic  Histological  Radiological 
 





If extent is unknown, please note why: 
 
 
Montreal Extent at Diagnosis         E1         E2             E3  
 
 
Montreal Maximal Extent During Follow-up E1       E2             E3 
 
 
Extent of disease at last follow-up investigation:       
 
 
Date of Investigation:   Type of Investigation: 
 
 
Rectum only  Colonoscopic  Histological  Radiological 
 
Recto-sigmoid Colonoscopic  Histological  Radiological 
 
Splenic flexure Colonoscopic  Histological  Radiological 
 
Hepatic flexure Colonoscopic  Histological  Radiological 
 
Total   Colonoscopic  Histological  Radiological 
 
 
Please note below,  if there have been no further investigations since diagnosis or if 
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Montreal Extent at Follow-up  E1  E2  E3 
Colectomy  Yes / No  Reason: Severe disease 
 
        Chronic continuous 
Date of Colectomy: 




Ileo-anal Pouch Yes / No Pouchitis      Yes ●  acute intermittent 
        ●   chronic 
               No 
 
Extra-intestinal manifestations please tick 
 
Joints    large joint related to disease activity  
   small joint unrelated to disease activity                          
   AS                
   Sacro-ilitis 
 
 
 Skin    Erythema nodosum 
  Pyoderma 
  Psoriasis 
 Mouth ulcers 
 
 
Eyes    Uveitis             
   Episcleritis 
   Conjunctivitis            
   Undiagnosed ocular inflammation              
 
 
Liver    PSC 
 
Cancer  Colon 
 
  Other(specify) 
 








Last Clinic Date: 
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10.7 Patient biopsy information letter 
 
GASTROINTESTINAL UNIT 
Molecular Medicine Centre 
The University of Edinburgh 
Western General Hospital  
Edinburgh EH4 2XU 
Telephone – 0131 651 1807 






Re: Research into the genetics of inflammatory bowel disease 
 
In the Gastrointestinal Unit we are researching the genetics of inflammatory bowel 
disease, and hope that you might be willing to take part in one of our studies.   
 
I understand that you are having a colonoscopy soon.  When you have your test, you 
will have a number of tiny samples of tissue (biopsies) taken from the lining of your 
bowel for your clinical care.  The number taken will depend on the reason for doing 
the colonoscopy, but could be up to 30.  Each of these samples is less than the size of 
a small grain of rice.  What we would like to do, with your permission, is take an 
extra 5-10 samples for research purposes.  Taking these extra samples would add less 
than 5 minutes to the procedure.  The aim of our study is to help us further our 
understanding of the processes that occur in both Crohn’s disease and ulcerative 
colitis, in the hope that in the future we might be able to develop more effective 
treatments or get better at using the ones we have. 
 
As you will be aware, a colonoscopy is generally an extremely safe procedure, but is 
not risk-free.  By taking a few more samples there could be a very slightly increased 
risk of minor problems, which would usually settle on their own without requiring 
any further action. 
 
If you agree to take part, I would be most grateful if you could fill in the enclosed 
form and bring it with you on the day.  If you choose not to participate then please 
rest assured that your medical care will not be affected in any way.   
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If you have any questions I would be happy to talk to you about the study - I can be 
e-mailed or phoned using the above details.  Alternatively, Dr Ian Arnott, who is the 






Dr Anne Phillips 
Clinical Research Fellow 
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Molecular Medicine Centre 
The University of Edinburgh 
Western General Hospital  
Edinburgh EH4 2XU 
Telephone – 0131 651 1807 
Fax – 0131 651 1085 
Email anne.phillips@ed.ac.uk 
 
Dear   , 
 
Re: Research into the genetics of inflammatory bowel disease 
 
In the Gastrointestinal Unit we are researching the genetics of inflammatory bowel 
disease (Crohn’s disease and ulcerative colitis) and hope that you might be willing to 
take part in one of our studies.  These diseases affect the gut and are a common cause 
of ill health in Scotland including weight loss, diarrhoea and the need for operations.  
The causes of Crohn’s disease and ulcerative colitis are not yet fully understood.   
 
I understand that you do not have inflammatory bowel disease and I would like to 
enter you into the control group for this study.  Control groups are vital for these 
studies so that we can compare people with and without inflammatory bowel disease. 
 
I am aware that you are having a colonoscopy soon.  When you have your test, you 
are likely to have a number of tiny samples of tissue (biopsies) taken from the lining 
of the bowel for your clinical care.  The number taken will depend on the reason for 
doing the colonoscopy, but could be up to 30.  Each of these samples is less than the 
size of a small grain of rice.  What we would like to do, with your permission, is take 
an extra 5-10 samples for research purposes.  Taking these extra samples would add 
less than 5 minutes to the procedure.  The aim of our study is to help us further our 
understanding of the processes that occur in both Crohn’s disease and ulcerative 
colitis, in the hope that in the future we might be able to develop more effective 
treatments or get better at using the ones we have. 
 
As you will be aware, a colonoscopy is generally an extremely safe procedure, but is 
not risk-free.  By taking a few more samples there could be a very slightly increased 
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risk of minor problems, which would usually settle on their own without requiring 
any further action. 
 
If you agree to take part, I would be most grateful if you could fill in the enclosed 
form and bring it with you on the day.  If you choose not to participate then please 
rest assured that your medical care will not be affected in any way.   
 
If you have any questions I would be happy to talk to you about the study - I can be 
e-mailed or phoned using the above details.  Alternatively, Dr Ian Arnott, who is the 






Dr Anne Phillips 
Research Registrar 
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10.9 Biopsy consent form 
Consent for colonoscopy: IBD patients 
 
Investigation of the expression of immune response genes in the gastro-intestinal 





I ___________________________ (please print your name in block capitals) have 
read and understood the patient information sheet. 
 
I understand that my participation in the research is entirely voluntary and does not 
affect my future medical care. 
 
I understand that that the research will involve: 
 
- allowing analysis of biopsies taken at colonoscopy 
- filling in a short questionnaire 
- allowing trained medical personnel to read my medical case notes 
 
 Participant     Witness 
 
Signed ……………………   Name ………………………… 
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